PN 75001
RN 00168
AN 75125193
AU Wheatley-B.
TI The fight against cystic fibrosis.
SO AARN-News-Lett. 1975 Jan. 31(1). P 1.
MJ CYSTIC-FIBROSIS: th.  LONG-TERM-CARE.
MN ADAPTATION-PSYCHOLOGICAL.  ADOLESCENCE.  ADULT.  CHILD.  FAMILY.
   HUMAN.  RESEARCH.
EX Cystic Fibrosis is a generalized hereditary disorder of children,
   adolescents, and young adults in which there is widespread
   dysfunction of mucus-secreting glands.  The patient's condition may
   be characterized by one or all of the following: chronic pulmonary
   disease, pancreatic enzyme deficiency and abnormally high sweat
   electrolytes.  Hence, each patient is treated on an individual basis.
   Parents tied to a rigid regime imposed by the disease must have help;
   volunteers are needed to support and assist them at home and at
   school.  Cystic Fibrosis still needs a lot of help, and knowledge
   and understanding on the part of the nursing profession helps a great
   deal.

PN 75002
RN 00169
AN 75221674
AU Holm-K.  Kessing-S-V.
TI Conjunctival goblet cells in patients with cystic fibrosis.
SO Acta-Ophthalmol (Kbh). 1975 Mar. 53(2). P 167-72.
MJ CONJUNCTIVA: pa.  CYSTIC-FIBROSIS: pa.
MN CHILD.  CHILD-PRESCHOOL.  EPITHELIUM.  HUMAN.  EPITHELIUM: cy
AB In five patients with cystic fibrosis of the pancreas the mucous
   glandular system of the conjunctiva was studied, as changes, if any,
   in the conjunctival goblet cells might be applicable as a diagnostic
   test in questionable cases. A whole-mount technique was used,
   specially developed for studying conjunctival goblet cells. In all
   five cases the qualitative as well as quantitative goblet-cell
   findings were in accordance with a previously reported normal
   material. In particular, there were no signs of stagnated secretion.
RF 001   BRUCE GM              ARCH OPHTHALMOL                 63   391 960
   002   DANES BS              AM J HUM GENET                  23   297 971
   003   GIBSON LE             PEDIATRICS                      23   545 959
   004   KESSING SV            ACTA OPTHAL SUPPL 95                     968
   005   KESSING SV            ACTA OPTHAL                     47   642 969
   006   NIELSEN EL            UGESKR LAEGER                  133  1017 971
   007   TYGSTRUP I            UGESKR LAEG TRANS DAN MED        1     6 972
   008   FLENSBORG EW          UGESKR LAEG TRANS DAN MED        1     2 972
CT   1   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982

PN 75003
RN 00170
AN 75221718
AU McWhirter-W-R.
TI Plasma tocopherol in infants and children.
SO Acta-Paediatr-Scand. 1975 May. 64(3). P 446-8.
MJ CELIAC-DISEASE: bl.  CYSTIC-FIBROSIS: bl.  GIARDIASIS: bl.
   VITAMIN-E: bl.
MN ADOLESCENCE.  AGE-FACTORS.  CHILD.  CHILD-PRESCHOOL.
   COMPARATIVE-STUDY.  HUMAN.  INFANT.
AB A study has been made of plasma tocopherol concentrations in normal
   children and in children with intestinal abnormalities. A positive
   correlation between plasma tocopherol and age is shown between the
   ages of 4 months and 10 years. Most patients with cystic fibrosis or
   coeliac disease were found to have markedly reduced plasma tocopherol
   concentrations in comparison with the normal children of similar age.
RF 001   FILER LJ JR           PEDIATRICS                       8   328 951
   002   GORDON HH             PEDIATRICS                      21   673 958
   003   HARRIES JT            ARCH DIS CHILD                  46   341 971
   004   HARRIS PL             AM J PUBLIC HEALTH              36   155 946
   005   HASSAN H              AM J CLIN NUTR                  19   147 966
   006   HORWITT MK            ANN NY ACAD SCI                203   223 972
   007   KERNER I              AM J DIS CHILD                  99   597 960
   008   MARTINEK RG           CLIN CHEM                       10  1078 964
   009   MULLER DPR            BIOCHEM J                      112   28P 969
   010   MULLER DPR            ARCH DIS CHILD                  45   715 970
   011   OSKI FA               J PEDIATR                       70   211 967
   012   RITCHIE JH            N ENGL J MED                   279  1185 968
   013   UNDERWOOD BA          PEDIATR RES                      6    26 972
   014   WRIGHT SW             PEDIATRICS                       7   386 951
CT   1   FARRELL PM            J CLIN INVEST                   60   233 977
     2   FARRELL PM            AM J CLIN NUTR                  31  1720 978
     3   BOHLES H              Z ERNAHRUNGSWISS                18    81 979
     4   OGUNMEKAN AO          AM J CLIN NUTR                  32  2269 979
     5   CORASH L              N ENGL J MED                   303   416 980
     6   SOLOMONS NW           NUTR REV                        39   149 981
     7   SOLOMONS NW           REV INFECT DIS                   4   859 982
     8   BIERI JG              N ENGL J MED                   308  1063 983
     9   ALVAREZ F             J PEDIATR GASTROENTEROL NUTR     3   390 984
    10   KEUSCH GT             J ENVIRON PATHOL TOXICOL ONCO    5   165 985
    11   OGUNMEKAN AO          TROP GEOGR MED                  37   175 985
    12   HAFEZ M               J PEDIATR                      108   558 986
    13   CYNAMON HA            J PEDIATR GASTROENTEROL NUTR     6    46 987

PN 75004
RN 00171
AN 75105999
AU Hultberg-B.  Sjoblad-S.  Ockerman-P-A.
TI Glycosidases in human skin fibroblast cultures.  Alpha-fucosidase,
   alpha-galactosidase, alpha-glucosidase, beta-mannosidase, and
   N-acetyl-alpha-glucosaminidase.
SO Acta-Paediatr-Scand. 1975 Jan. 64(1). P 123-31.
MJ FIBROBLASTS: en.  GLUCOSIDASES: me.  SKIN: cy.
MN ADOLESCENCE.  CELLS-CULTURED.  CHILD.  CHROMATOGRAPHY-ION-EXCHANGE.
   CYSTIC-FIBROSIS: en.  FEMALE.  GALACTOSIDASES: an.
   GLUCOSAMINIDASE: an.  GLUCOSIDASES: an.  GLYCOGENOSIS: en.   
   GLYCOSIDE-HYDROLASES: an.  HUMAN.  HYDROGEN-ION-CONCENTRATION.   
   ISOELECTRIC-FOCUSING.  MALE.  MUCOPOLYSACCHARIDOSIS: en.
   MYOCARDIAL-DISEASES: en.  SYNDROME.
AB Five glycosidases, alpha-fucosidase, alpha-galactosidase, alpha-
   glucosidase, beta-mannosidase and N-acetyl-alpha-glucosaminidase were
   studied in human skin fibroblast cultures. The pH-dependency, kinetic
   properties of the enzymes and results of isoelectric focusing and ion
   exchange chromatography are presented. Techniques suitable for
   diagnosing inborn lysosomal diseases in skin fibroblast cultures are
   defined.
RF 001   BARTHOLOMEW BA        BIOCHIM BIOPHYS ACTA           315   123 973
   002   BEUTLER E             AM J HUM GENET                  24   237 972
   003   ANON                  J BIOL CHEM                    247  7195 972
   004   BOSMANN HB            BIOCHIM BIOPHYS ACTA           258   265 972
   005   BRADY RO              N ENGL J MED                   276  1163 967
   006   CONCHIE J             BIOCHEM J                       87   354 963
   007   DREYFUS JC            BIOCHEM BIOPHYS RES COMMUN      48   914 972
   008   DURAND P              J PEDIATR                       75   665 969
   009   VON FIGURA K          BIOCHEM BIOPHYS RES COMMUN      48   262 972
   010   HAYFLICK L            EXP CELL RES                    37   614 965
   011   HERS HG               BIOCHEM J                       86    11 963
   012   HO MW                 AM J HUM GENET                  24   256 972
   013   HULTBERG B            ACTA PAEDIATR SCAND             62   474 973
   014   KINT JA               SCIENCE                        167  1268 970
   015   KILLBERG R            PROC EWGCF 1ST ANNU MTG               16 970
   016   LANGLEY TJ            ARCH BIOCHEM BIOPHYS           128   312 968
   017   LEVVY GA              BIOCHEM J                       80   435 961
   018   LOWRY OH              J BIOL CHEM                    193   265 951
   019   MURAMATSU T           J BIOCHEM (TOKYO)               62   700 967
   020   OBRIEN JS             PROC NAT ACAD SCI USA           69  1720 972
   021   ROBINSON D            CLIN CHIM ACTA                  47   403 973
   022   SALAFSKY IS           J LAB CLIN MED                  81   450 973
   023   WEISMANN B            BIOCHEMISTRY                     6   207 967
   024   WIEDERSCHAIN GY       CLIN CHIM ACTA                  46   305 973
   025   BORJESON M            NORD MED                        81   567 969
CT   1   HULTBERG B            BIOCHEM BIOPHYS RES COMMUN      67  1473 975
     2   HULTBERG B            BIOCHEM J                      155   599 976
     3   HULTBERG B            CLIN CHIM ACTA                  80    79 977
     4   HULTBERG B            HEREDITAS                       86   103 977
     5   HULTBERG B            BIOCHIM BIOPHYS ACTA           481   573 977
     6   ANDRIA G              CLIN GENET                      14    16 978
     7   PILZ H                FORTSCHR NEUROL PSYCHIAT        46   207 978
     8   HULTBERG B            HUM HERED                       29   250 979
     9   PILZ H                HUM GENET                       47   113 979
    10   HULTBERG B            CLIN CHIM ACTA                  93   221 979
    11   CHESTER MA            BIOCHIM BIOPHYS ACTA           627   244 980

PN 75005
RN 00172
AN 75106013
AU Rask-Madsen-J.  Schiotz-P-O.  Bartels-U.  Nielsen-M-D.
   Becher-Christensen-F.
TI Electrical polarization of rectal mucosa and excretion of
   tetrahydroaldosterone in patients with cystic fibrosis of pancreas
   and in normal subjects.
SO Acta-Paediatr-Scand. 1975 Jan. 64(1). P 81-86.
MJ ALDOSTERONE: ur.  CYSTIC-FIBROSIS: me.  INTESTINAL-MUCOSA: me.
   RECTUM: me.
MN ADOLESCENCE.  ADULT.  BIOLOGICAL-TRANSPORT.  CHILD.
   CYSTIC-FIBROSIS: ur.  ELECTROLYTES.  FIBROBLASTS.  HUMAN.   
   INTESTINAL-ABSORPTION.  MEMBRANE-POTENTIALS.  SODIUM: ur.
AB The electrical potential difference (PD) across the rectal wall was
   measured in 26 patients with cystic fibrosis of pancreas (CFP) and in
   18 healthy subjects. The PDs obtained in normal children were
   identical to those previously obtained in normal adults. A
   significantly greater dispersion of the values was observed in CFP.
   When the patients were divided into groups according to metachromasia
   in fibroblast cultures, the mean PD was increased only in the
   ametachromatic group. True enough, this observation suggests a
   difference between various forms of CFP, distinguished by
   metachromasia, and thus is a further indication of the heterogeneity
   of the disease. The greater abnormalities in metachromasia negative
   patients may, however, be due solely to the fact that these patients
   are more severely affected by the disease. The urinary excretion of
   tetrahydroaldosterone in patients was within the ranges obtained in
   controls, which excludes the possibility of secondary
   hyperaldosteronism as the source of increased PD. No evidence was
   provided in favour of a basic defect in the intestinal transport of
   Na+ or Cl minus, but K+ concentrations in faecal fluids of patients
   were significantly lower than in controls. The equilibrium
   concentration of K+ could be accounted for by simple passive
   diffusion, suggesting that the epithelium behaved inertly with
   respect to this ion in CFP.
RF 001   COFRE G               J PHYSIOL (LOND)               188   177 967
   002   CONOVER JH            LANCET                           1  1122 973
   003   COOPERSTEIN IL        J GEN PHYSIOL                   42   461 959
   004   DANES BS              AM J HUM GENET                  23   297 971
   005   DARBY CW              PROC EWGCF 1ST ANNU MTG                  970
   006   DEVROEDE GJ           GASTROENTEROLOGY                56   101 969
   007   EDMONDS CJ            LANCET                           2   624 970
   008   GRADY GF              GASTROENTEROLOGY                59   583 970
   009   GRAND RJ              J PEDIATR                       70   346 967
   010   GRAND RJ              J PEDIATR                       70   357 967
   011   KAISER D              LANCET                           1  1003 970
   013   MANGOS JA             SCIENCE                        158   135 967
   014   MANGOS JA             PEDIATR RES                      1   436 967
   015   NEW MI                J CLIN INVEST                   45   412 966
   016   NIELSEN MD            ACTA ENDOCRINOL                 71   498 972
   017   RASK MADSEN J         SCAND J GASTROENTEROL            8   327 973
   018   RASK MADSEN J         ACTA MED SCAND                 194   311 973
   019   RASK MADSEN J         SCAND J GASTROENTEROL            9   223 974
   020   RASK MADSEN J         SCAND J GASTROENTEROL            8   321 973
   021   RASK MADSEN J         SCAND J GASTROENTEROL            8   169 973
   022   SCHALES O             J BIOL CHEM                    140   879 941
   023   SIMOPOULOS AP         PEDIATR RES                      5   626 971
   024   SOLE J                ACTA ENDOCRINOL                 70   533 972
CT   1   PATTON CJ             PEDIATR RES                     16  1035 982
     2   WINGE P               DAN MED BULL                    29   358 982
     3   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982
     4   BOUCHER RC            LUNG                           161     1 983
     5   KNOWLES MR            PEDIATR RES                     19   676 985

PN 75006
RN 00173
AN 76036885
AU Darby-C-W.  Edmonds-C-J.
TI Letter: Measurement of electrical potential difference across
   colonic mucosa in cystic fibrosis patients.
SO Acta-Paediatr-Scand. 1975 Sep. 64(5). P 770.
MJ CYSTIC-FIBROSIS: pp.  INTESTINAL-MUCOSA: pp.  RECTUM.  SKIN: pp.
MN ACTION-POTENTIALS.  CHILD.  HUMAN.
EX By measuring potential difference between rectal mucosa and perianal
   skin using a reference electrode placed on the forearm, we
   demonstrated an altered potential difference in cystic children
   compared with control adults and normal children.  We suggested this
   might be due to an alteration in the rectal mucosa potential or
   altered skin potential, or both, in cystic fibrosis.  We measured
   skin and rectal charges directly by connecting our reference
   electrode to the blood stream through an intravenous line.  Using
   this technique we showed that the cystic fibrosis patients (C.F.)
   have an abnormal perianal skin potential difference compared with
   readings we obtained in normal children.  There was little
   difference in the transmural rectal potential difference between our
   cystic patients and previously reported values in normal adults.
   Thus the recent paper confirms our findings of normal polarity of
   the rectal mucosa surface and the increased skin polarisation in
   cystic fibrosis.
RF 001   ARCHAMPONG EQ         GUT                             13   559 972
   002   DARBY CW              PROC EWGCF 1ST ANNU MTG                  970
   003   DARBY CW              CF RESEARCH WORKERS CONF MAN             970
   004   RASK MADSEN J         ACTA PAEDIATR SCAND             64    81 975
CT   1   EDMONDS CJ            LANCET                           1   937 983

PN 75007
RN 00174
AN 75161694
AU Feigelson-J.  Pecau-Y.  Cathelineau-L.  Navarro-J.
TI Additional data on hepatic function tests in cystic fibrosis.
SO Acta-Paediatr-Scand. 1975 Mar. 64(2). P 337-44.
MJ CYSTIC-FIBROSIS: pp.  LIVER-FUNCTION-TESTS.  LIVER: pp.
MN ADOLESCENCE.  ADULT.  ALANINE-AMINOTRANSFERASE: bl.
   ALKALINE-PHOSPHATASE: bl.  CHILD.  CHILD-PRESCHOOL.
   CHOLINESTERASES: bl.  CYSTIC-FIBROSIS: bl, en.  FEMALE.   
   GAMMA-GLUTAMYLTRANSFERASE: bl.  HUMAN.  IGA.  IGG.  IGM.  INFANT.   
   LEUCINE-AMINOPEPTIDASE: bl.  LIVER-CIRRHOSIS: bl, en.  MALE.   
   ORNITHINE-CARBAMOYLTRANSFERASE: bl.  PROTHROMBIN: me.
   SERUM-ALBUMIN: me. TRANSFERRIN: me.  VITAMIN-B-12: bl.
AB Fifty cystic fibrosis (CF) patients, of whom 9 had multilobular
   cirrhosis, were observed regularly for a period of 3 years and
   various liver function tests, indicating cytolysis, cholestasis and
   cellular insufficiency were performed. Immunoglobulin and prothrombin
   were assayed. In 9 patients with cirrhosis, the tests were generally
   abnormal. Two distinct biochemical patterns of cirrhosis were
   distinguished, one clearly cholestatic and the other of a more
   cellular type. The distinction was made on the basis of the IgA :
   Transferrin ratio and of gamma-glutamyl-transpeptidase levels. In the
   non-cirrhotic patients, a temporary increase of cytolysis and
   cholestasis was observed in 50% of the cases.
RF 001   ARON E                ANN GASTROENTEROL HEPATOL        9     1 973
   002   BABSON AL             CLIN CHEM                       12     8 966
   003   BENHAMOU JP           PRESSE MED                      79   185 971
   004   BERG T                ACTA UNIV UPSALIENSIS                    969
   005   BODIAN M              FIBROCYSTIC DIS OF THE PANCRE            952
   006   CRAIG JM              AM J DIS CHILD                  93   357 957
   007   DOMINICK H            PROC EWGCF 4TH ANNU MTG                  973
   008   ELLMAN G              BIOCHEM PHARMACOL                7    88 961
   009   FEIGELSON J           ACTA PAEDIATR SCAND             59   539 970
   010   FEIGELSON J           ACTA PAEDIATR SCAND             61   337 972
   011   FEIGELSON J           NOUV PRESSE MED                  1  1899 972
   012   GAUDIER B             LILLE MED                       15  1391 970
   013   GEIGER H              Z KINDERHEILK                  109    22 970
   014   HALLEN J              SCAND J CLIN LAB INVEST SUPPL  124    97 972
   015   KATTWINKEL J          J PEDIATR                       82   234 973
   016   LELONG M              ARCH FR PEDIATR                  7   234 950
   017   LOGRIPPO GA           AM J GASTROENTEROL              54   357 971
   019   NAGEL W               KLIN WOCHENSCHR                 42   447 964
   020   REITMAN S             AM J CLIN PATHOL                28     1 957
   021   RITLAND S             SCAND J GASTROENTEROL SUPPL     19   113 973
   022   DI SANTAGNESE PA      PEDIATRICS                      18   387 956
   023   SITZMANN FC           ARCH KINDERHEILK               175   263 967
   024   SNODGRASS PJ          J LAB CLIN MED                  73   263 969
   025   SZASZ G               CLIN CHEM                       15   124 969
   026   TURLA B               RIV CLIN PEDIATR                78   485 966
   027   TYSON KRT             J PEDIATR SURG                   3   271 968
   028   WILROY RS JR          J PEDIATR                       68    67 966
CT   1   PECAU Y               BIOL GASTROENTEROL               8   193 975
     2   SCHWARZ HP            HELV PAEDIATR ACTA              33   351 978
     3   PECAU Y               PATHOL BIOL (PARIS)             28   575 980
     4   PECAU Y               SEM HOP PARIS                   57  1306 981
     5   PARK RW               GASTROENTEROLOGY                81  1143 981
     6   CORRIGAN JJ           J PEDIATR                       99   254 981
     7   ROY CC                J PEDIATR GASTROENTEROL NUTR     1   469 982
     8   MOWAT AP              CLIN GASTROENTEROL              11   171 982
     9   BERNARD O             CLIN GASTROENTEROL              14    33 985
    10   FEIGELSON J           ANN PEDIATR (PARIS)             32   218 985
    11   BAILEY DJ             PEDIATRICS                      79   281 987

PN 75008
RN 00175
AN 75221705
AU Kollberg-H.  Hellsing-K.
TI Screening for cystic fibrosis by analysis of albumin in meconium.
SO Acta-Paediatr-Scand. 1975 May. 64(3).
MJ ALBUMINS: an.  CYSTIC-FIBROSIS: di.  MECONIUM: an.
MN COMPARATIVE-STUDY.  GEL-DIFFUSION-TESTS.  HUMAN.  INFANT-NEWBORN.
   INFANT-PREMATURE.  MASS-SCREENING.
AB A clinical study of the albumin content in meconium was performed on
   two categories of newborn infants: a screening series of 8,830
   infants and a high-risk group for Cystic Fibrosis (CF) of 70 infants.
   A single radial immunodiffusion technique and test strips were used.
   Three CF infants were detected in the screening series (1:3,000) and
   16 in the high-risk group. The diagnostic accuracy for CF was fairly
   good. The specificity was 99.8% for the immunodiffusion technique and
   99.2% for test strips. A high concentration of albumin in meconium
   was found not only in CF but also in preterm babies and infants with
   gastrointestinal disturbances, such as atresias, malaena neonatorum
   and malabsorption syndromes. The sensitivity was 90% for the
   immunodiffusion technique and 78% for the test strip. False-negative
   results were probably due to proteolytic activity and might be
   avoided if the samples are stored at a low temperature before
   analysis. CF screening of all meconiums by the use of test strips
   followed by analysis of positive tests by the immunodiffusion
   technique is suggested.
RF 001   BENDER SW             MONATSSCHR KINDERHEILKD        119   632 971
   002   BERG T                NORTHERN PEDIATR CONG 15                 967
   003   BRAY PT               EWGCF SCREENING COMMITTEE                971
   004   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   005   EGGERMONT E           BIOL NEONATE                    10   266 966
   006   GEORGE L              ARCH DIS CHILD                  46   139 971
   007   GREEN MN              PEDIATRICS                      41   989 968
   008   HADORN B              LANCET                           1   812 969
   009   HELLSING K            SCAND J CLIN LAB INVEST         33   333 974
   010   HOBBS JR              PROTIDES BIOL FLUIDS            17   517 969
   011   HURWITT ES            AM J DIS CHILD                  64   443 942
   013   KOLLBERG H            ACTA PAEDIATR SCAND             63   411 974
   014   KOLLBERG H            ARCH DIS CHILD                  47   836 972
   015   LAWSON D              ARCH DIS CHILD                  47     1 972
   016   OPITZ JM              BIRTH DEF ORIG ART SER           2   144 969
   017   RULE AH               PEDIATRICS                      45   847 970
   018   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   019   SHWACHMAN H           PEDIATRICS                      46   335 970
   020   SHWACHMAN H           J PEDIATR                       65   645 964
   021   STEPHAN U             PADIATRISCHE PRAXIS             12   487 973
   023   THORNER RM            PUBLIC HEALTH MONOGRAPH NO 67            961
   024   WARWICK WJ            IN: LAWSON D PROC 5TH INT CF         320 969
   025   WILSON JMG            PUBLIC HEALTH PAPERS 45                  971
CT   1   PECAU Y               BIOL GASTROENTEROL               8   193 975
     2   ANON                  J PEDIATR                       88   711 976
     3   WOOD RE               AM REV RESPIR DIS              113   833 976
     4   CROSSLEY JR           LANCET                           2  1093 977
     5   KRAEMER R             SCHWEIZ MED WOCHENSCHR         107  1105 977
     6   CARAMELLO MTG         MINERVA PEDIATR                 30   989 978
     7   ARVANITAKIS C         GASTROENTEROLOGY                74   932 978
     8   SCHUTTRINGER G        CLIN CHIM ACTA                  83   109 978
     9   GURWITZ D             PEDIATR CLIN NORTH AM           26   603 979
    10   RYLEY HC              ARCH DIS CHILD                  54    92 979
    11   DOMINICI R            RIC CLIN LAB                    10   511 980
    12   MASTELLA G            RIV ITAL PEDIATR                 7   581 981
    13   PARK RW               GASTROENTEROLOGY                81  1143 981
    14   DODGE JA              ARCH DIS CHILD                  57   774 982
    15   HELLSING K            ACTA PAEDIATR SCAND             71   827 982
    16   ROSENSTEIN BJ         JOHNS HOPKINS MED J            150   113 982
    17   EGGERMONT E           ACTA PAEDIATR SCAND SUPPL 317 1985    16 985
    18   KOLLBERG H            J TROP PEDIATR                  32   293 986

PN 75009
RN 00176
AN 76084672
AU Bergan-T.  Hoiby-N.
TI Epidemiological markers for Pseudomonas aeruginosa.  6. Relationship
   between concomitant non-mucoid and mucoid strains from the
   respiratory tract in cystic fibrosis.
SO Acta-Pathol-Microbiol-Scand [Suppl]. 1975 Dec. 83(6). P 553-60.
MJ CYSTIC-FIBROSIS: mi.  PSEUDOMONAS-AERUGINOSA: ip.
   RESPIRATORY-SYSTEM: mi.
MN ADOLESCENCE.  ADULT.  BACTERIOPHAGE-TYPING.  CHILD.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: et.  FEMALE.  HUMAN.  MALE.  PHENOTYPE.  PYOCINS.
   SEROTYPING.
AB The simultaneously occurring mucoid (M) and non-mucoid (NM) variants
   of Pseudomonas aeruginosa frequently observed in cultures from the
   respiratory tract of chronically infected cystic fibrosis patients
   have been studied. M cultures in vitro were unstable and easily
   dissociated NM colonies. In a large proportion of the cases, M and NM
   variants occurring simultaneously in cultures from one and the same
   clinical specimen were of the same pyocine type, phage type, and
   serogroup. In some remaining cases there were small differences
   between the M and NM variants such that identity between the variants
   from one and the same specimen was possible, although not definite.
   The NM dissociants from M strains were of the same type as the M
   variant. The possible role of cross-infection and the interaction of
   bacteria and host response factors continuously tending to select the
   unstable M variant in vivo are discussed.
RF 001   BARTELL PF            INFECT IMMUN                     2   543 970
   002   BERGAN T              ACTA PATH MICROBIOL SCAND (B)   80   177 972
   003   BERGAN T              ACTA PATH MICROBIOL SCAND (B)   81    70 973
   004   BERGAN T              ACTA PATH MICROBIOL SCAND (B)   80    91 973
   005   BERGAN T              ACTA PATH MICROBIOL SCAND (B)   83     1 975
   007   BURNS MW              BR MED J                         3   382 973
   008   CARLSON DM            BIOCHEMISTRY                     5  2817 966
   009   DIAZ F                J INFECT DIS                   121   269 970
   010   DOGGETT RG            APPL MICROBIOL                  18   936 969
   011   DOGGETT RG            J PEDIATR                       68   215 966
   012   DOGGETT RG            INFECT IMMUN                     6   628 972
   013   GILLIES RR            J PATHOL BACTERIOL              91   339 966
   014   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   541 974
   015   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   551 974
   016   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   83   549 975
   017   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   81   298 973
   018   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   83   459 975
   019   JESSEN O              PSEUDOMONAS AERUGINOSA AND OT            965
   020   KAGAYAMA M            J GEN APPL MICROBIOL            16   531 970
   021   MARTIN DR             J MED MICROBIOL                  6   111 973
   022   SCHWARZMANN S         INFECT IMMUN                     3   762 971
CT   1   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   83   549 975
     2   HOIBY N               ACTA PATH MICROBIOL SCAND (C) S262     3 977
     3   HOIBY N               SCAND J RESPIR DIS              58    65 977
     4   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   85   107 977
     5   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   85   142 977
     6   MARKOWITZ SM          INFECT IMMUN                    22   530 978
     7   SEALE TW              J CLIN MICROBIOL                 9    72 979
     8   MAYBURY BA            ANTIMICROB AGENTS CHEMOTHER     15   494 979
     9   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   87   229 979
    10   THOMASSEN MJ          J INFECT DIS                   140   873 979
    11   ISKHAKOVA KI          ZH MIKROBIO EPIDEMIO IMMUNOBI 1979    98 979
    12   SAVITSKAYA KI         ZH MIKROBIO EPIDEMIO IMMUNOBI 1979    84 979
    13   DEMKO CA              CURRENT MICROBIOL                4    69 980
    14   MICHALSEN H           CHEMOTHERAPY                    26   135 980
    15   WOODS DE              INFECT IMMUN                    30   694 980
    16   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   88   125 980
    17   MICHALSEN H           SCAND J INFECT DIS            1981    92 981
    18   PUGASHETTI BK         J CLIN MICROBIOL                16   686 982
    19   MOLLER NE             EUR J RESPIR DIS                63   130 982
    20   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982
    21   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    33 982
    22   ISKHAKOVA KI          ZH MIKROBIO EPIDEMIO IMMUNOBI 1982    33 982
    23   ZIMAKOFF J            J HOSP INFECT                    4    31 983
    24   BRYAN LE              J CLIN MICROBIOL                18   276 983
    25   SANTINI G             BOLL IST SIEROTER MILAN         62   242 983
    26   PENKETH A             AM REV RESPIR DIS              127   605 983
    27   GOLD R                PEDIATR INFECT DIS               4   172 985
    28   PIER GB               J CLIN MICROBIOL                24   189 986
    29   ANASTASSIOU ED        J CLIN MICROBIOL                25   656 987
    30   OGLE JW               J INFECT DIS                   155   119 987

PN 75010
RN 00177
AN 76084671
AU Hoiby-N.
TI Prevalence of mucoid strains of Pseudomonas aeruginosa in
   bacteriological specimens from patients with cystic fibrosis and
   patients with other diseases.
SO Acta-Pathol-Microbiol-Scand [Suppl]. 1975 Dec. 83(6). P 549-52.
MJ CYSTIC-FIBROSIS: mi.  PSEUDOMONAS-AERUGINOSA: ip.
MN ADOLESCENCE.  ADULT.  AGED.  CHILD.  CHILD-PRESCHOOL.  FEMALE.
   HUMAN.  INFANT.  INFANT-NEWBORN.  MALE.  MIDDLE-AGE.  PHENOTYPE.
   RESPIRATORY-SYSTEM: mi.
AB The relative prevalence of mucoid strains compared with non-mucoid
   strains of Pseudomonas aeruginosa has been investigated in all
   routine bacteriological specimens received in a department of
   clinical microbiology during 1973. Pseudomonas aeruginosa was
   isolated from 1054 of the specimens (5.7 per cent) representing 53
   patients with cystic fibrosis (551 isolates) and 169 patients with
   other diseases (503 isolates). The relative prevalence of mucoid
   strains was significantly higher in specimens from patients with
   cystic fibrosis (80 per cent) than in specimens from patients with
   other diseases (3 per cent). Considering patients without cystic
   fibrosis, the relative prevalence of mucoid strains was low in
   specimens from all anatomical regions, and no special preference of
   these strains for the respiratory tract could be demonstrated in
   these patients, in contrast to the situation in patients with cystic
   fibrosis. Alternation between mucoid strains and non-mucoid strains
   in subsequent specimens was observed in 33 of the patients.
RF 001   BERGAN T              ACTA PATH MICROBIOL SCAND (B)   83   553 975
   002   BURNS MW              BR MED J                         3   382 973
   003   DIAZ F                J INFECT DIS                   121   269 970
   004   DOGGETT RG            J PEDIATR                       68   215 966
   005   DOGGETT RG            APPL MICROBIOL                  18   936 969
   006   DOGGETT RG            INFECT IMMUN                     6   628 972
   007   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   81   298 973
   008   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   541 974
   009   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   551 974
   010   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   83   459 975
   011   JESSEN O              THESIS                                61 965
   012   MARTIN DR             J MED MICROBIOL                  6   111 973
CT   1   BERGAN T              ACTA PATH MICROBIOL SCAND (B)   83   553 975
     2   HOIBY N               ACTA PATH MICROBIOL SCAND (C) S262     3 977
     3   HOIBY N               SCAND J RESPIR DIS              58    65 977
     4   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   85   107 977
     5   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   85   142 977
     6   MARKOWITZ SM          INFECT IMMUN                    22   530 978
     7   SCHIOTZ PO            HUM HERED                       28   293 978
     8   MARESZBABCZYSZYN J    ARCH IMMUNOL THER EXP           27   585 979
     9   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   88   125 980
    10   OHMAN DE              INFECT IMMUN                    33   142 981
    11   HOIBY N               SCAND J INFECT DIS            1981    27 981
    12   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982
    13   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    33 982
    14   DORING G              INFECT IMMUN                    42   197 983
    15   ADLER KB              JAMA                           249  1615 983
    16   WOODS DE              J INFECT DIS                   151   581 985
    17   PEDERSEN SS           ACTA PAEDIATR SCAND             75   840 986
    18   ADLER KB              AM J PATHOL                    125   501 986

PN 75011
RN 00178
AN 75221819
AU Hoiby-N.
TI The serology of Pseudomonas aeruginosa analysed by means of
   quantitative immunoelectrophoretic methods.  II.  Comparison of the
   antibody response in man against thirteen O groups of Ps.
   aeruginosa.
SO Acta-Pathol-Microbiol-Scand [B]. 1975 Aug. 83(4). P 328-34.
MJ ANTIBODIES-BACTERIAL.  ANTIGENS-BACTERIAL.  IMMUNOELECTROPHORESIS.
   PSEUDOMONAS-AERUGINOSA: im.  SEROTYPING.
MN ANTIBODY-SPECIFICITY.  COMPARATIVE-STUDY.  CYSTIC-FIBROSIS: im.
   HUMAN.  SEROTYPING: mt.
AB The occurrence of antibodies against antigens prepared from strains
   representing 13 O groups of Pseudomonas aeruginosa and against a
   polyvalent Ps. aeruginosa antigen (St-Ag) has been investigated in
   sera from 100 patients. By means of fused rocket
   immunoelectrophoresis with intermediate gel it was found that the
   humoral immune response against Ps. aeruginosa resulting in
   precipitating antibodies will be detected by St-Ag as well as by any
   other of the antigen samples investigated. Six of the sera contained
   group-specific antibodies which were revealed by only one of the
   antigen samples used and not by St-Ag. These six sera were further
   studied by means of various quantitative immunoelectrophoretic
   methods using St-Ag as well as antigens prepared from the infecting
   Ps. aeruginosa strain in the patient concerned. In all six sera, only
   one extra precipitin could be detected using antigens prepared from
   the homologous strain instead of St-Ag. This extra precipitin
   corresponded presumably to group-specific O-antigens not included in
   St-Ag. In sera from patients, these group-specific antibodies were
   always accompanied by antibodies against antigens common to all
   strains of Ps. aeruginosa.
RF 001   AXELSEN NH            SCAND J IMMUNOL SUPPL 2          1    71 973
   002   AXELSEN NH            SCAND J IMMUNOL SUPPL 2          1   101 973
   003   BOCK E                J IMMUNOL METH                   2    75 972
   004   BOCK E                SCAND J IMMUNOL SUPPL 1          2    95 973
   005   CROWDER JG            J LAB CLIN MED                  83   853 974
   006   DOGGETT RG            INFECT IMMUN                     6   628 972
   007   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   81   298 973
   008   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   551 974
   009   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   541 974
   010   HOIBY N               SCAND J IMMUNOL SUPPL 2          4   187 975
   011   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   83   321 975
   012   KROLL J               SCAND J IMMUNOL SUPPL                 79 973
   013   MIKKELSEN OS          ACTA PATH MICROBIOL SCAND       73   373 968
   014   MIKKELSEN OS          ACTA PATH MICROBIOL SCAND (B)   78   163 970
   015   SVENDSEN PJ           SCAND J IMMUNOL SUPPL                 69 973
CT   1   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   83   321 975
     2   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   83   433 975
     3   AXELSON NH            SCAND J IMMUNOL                  5   177 976
     4   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   84   372 976
     5   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   84   383 976
     6   HOIBY N               ACTA PATH MICROBIOL SCAND (C) S262     3 977
     7   CLARKE CW             CLIN ALLERGY                     7   527 977
     8   HOIBY N               SCAND J RESPIR DIS              58    65 977
     9   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982

PN 75012
RN 00179
AN 75221805
AU Hoff-G-E.  Hoiby-N.
TI Staphylococcus aureus in cystic fibrosis: antibiotic sensitivity and
   phage types during the latest decade.  Investigation of the
   occurrence of protein A and some other properties of recently
   isolated strains in relation to the occurrence of precipitating
   antibodies.
SO Acta-Pathol-Microbiol-Scand [B]. 1975 Jun. 83(3). P 219-25.
MJ CYSTIC-FIBROSIS: mi.  STAPHYLOCOCCUS: ip.
MN ANTIBIOTICS: pd, tu.  ANTIBODIES-BACTERIAL: an.
   BACTERIAL-PROTEINS: me.  BACTERIOPHAGE-TYPING.  CYSTIC-FIBROSIS: dt.
   DRUG-RESISTANCE-MICROBIAL.  HUMAN.  LIPASE: me.  MERCURY: pd.
   MICROBIAL-SENSITIVITY-TESTS.  PRECIPITATION.  STAPHYLOCOCCAL-PHAGES.
   STAPHYLOCOCCUS: im, de, me.
AB During the recent decade, 1651 isolates of Staphylococcus aureus from
   111 patients with cystic fibrosis have been tested for antibiotic
   sensitivity and half of the isolates have been phage typed. All the
   patients were followed in one clinic and the policy of antibiotic
   treatment was consistent during this period. The results show a
   dynamic situation where "epidemic" phage types during recent years
   have been gradually replaced by other types and, during the same
   period, the prevalence of strains resistant to more than one
   antibiotic decreased. Multiresistant strains including strains
   resistant to methicillin were infrequent in these patients. From 23
   per cent of the patients, the same strains were repeatedly isolated
   for more than 1 year despite an apparently successful chemotherapy.
   Recently isolated strains were found to produce cellbound as well as
   extracellular protein A. Ninety-one per cent of the strains produced
   extracellular lipase and only 8 per cent were resistant to mercury
   chloride. Eighty-one per cent of the patients produced precipitating
   antibodies against S. aureus as judged by crossed
   immunoelectrophoresis. The investigated properties of S. aureus were
   not significantly correlated with the occurrence of precipitating
   antibodies against these bacteria. The possible significance of
   protein A in the pathology of the respiratory tract infection is
   discussed.
RF 001   ANDERSEN DH           AM J DIS CHILD                  56   344 938
   002   BLAIR JE              BULL WHO                        24   771 961
   003   BROWN DFJ             J CLIN PATHOL                   27   420 974
   004   BULOW P               ANN NY ACAD SCI                182    21 971
   005   DIEM K                DOCUMENTA GEIGY SCIENTIFIC TA            962
   006   DOSSETT JH            J IMMUNOL                      103  1405 969
   007   EICHENWALD HF         IN: MCINTOSH R                        89 960
   008   FORSGREN A            INFECT IMMUN                     2   672 970
   009   FORSGREN A            J IMMUNOL                      112  1177 974
   010   GUSTAFSON GT          J IMMUNOL                       98  1178 967
   011   GUSTAFSON GT          J IMMUNOL                      100   530 968
   012   HALBERT SP            PEDIATRICS                      26   792 960
   013   HUANG NN              J PEDIATR                       59   512 961
   014   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   81   298 973
   015   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   541 974
   016   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   551 974
   019   IACOCCA VF            AM J DIS CHILD                 106   315 963
   020   IACOCCA VF            ARCH DIS CHILD                  43   220 968
   021   JENSEN K              THESIS                                   959
   022   JESSEN O              N ENGL J MED                   281   627 969
   023   KRONVALL G            INFECT IMMUN                     3    10 971
   024   LIND I                ACTA PATH MICROBIOL SCAND (B)   80   702 972
   025   MAY JR                ARCH DIS CHILD                  47   908 972
   026   MEARNS MB             ARCH DIS CHILD                  47   902 972
   027   PITTMAN FE            PEDIATRICS                      24    40 959
   029   ROSENDAL K            ACTA PATH MICROBIOL SCAND (B)   79   377 971
   030   STALENHEIM G          IMMUNOCHEMISTRY                 10   501 973
   031   WINBLAD S             ACTA PATH MICROBIOL SCAND (B)   81   150 973
CT   1   HOFF GE               ACTA PATH MICROBIOL SCAND (B)   83  U305 975
     2   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   83   459 975
     3   HOIBY N               ACTA PATH MICROBIOL SCAND (C) S262     3 977
     4   PIVETTA OH            PEDIATR RES                     11  1133 977
     5   HOIBY N               SCAND J RESPIR DIS              58       977
     6   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   85    57 977
     7   MAYANSKY AN           ZH MIKROBIO EPIDEMIO IMMUNOBI 1978    96 978
     8   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   87     1 979
     9   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   89   185 981
    10   CARRET G              ZENTRALBL BAKT MIKROB HYG (A)  249    32 981
    11   SZAFF M               ACTA PAEDIATR SCAND             71   821 982
    12   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982
    13   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    75 982
    14   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    33 982
    15   ESPERSEN F            DAN MED BULL                    34    59 987

PN 75013
RN 00180
AN 76133663
AU Winick-M.
TI Effects of malnutrition on the maturing central nervous system.
SO Adv-Neurol. 1975. 13. P 193-246. (REVIEW).
MJ CENTRAL-NERVOUS-SYSTEM: gd.  NUTRITION-DISORDERS: pp.
MN AGE-FACTORS.  AMINO-ACIDS: me.  ANIMAL.  BEHAVIOR-ANIMAL.
   BRAIN: gd, cy.  CENTRAL-NERVOUS-SYSTEM: pp, me, pa.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: co.  ENVIRONMENT.  GLUCOSE: me.  HUMAN.  INFANT.
   INFANT-NEWBORN.  LEARNING.  LIPIDS: me.  MENTAL-RETARDATION: et.
   MYELIN-SHEATH: me.  NERVE-TISSUE-PROTEINS: me.
   NUTRITION-DISORDERS: pa.  RATS.  REVIEW.
EX During recent years, more and more data have been accumulated
   implicating early malnutrition in subsequent small stature and
   behavioral abnormalities.  These studies can be divided into two
   large categories: one dealing with cellular and biochemical changes
   at a tissue level and one dealing with functional changes within the
   nervous system as measured by changes in various modes of behavior.
   This chapter will attempt to review the studies in both of these
   broad categories, which have led to the present concept that
   malnutrition during the growing period will permanently retard
   growth, resulting in a stunted individual, and markedly retard
   psychologic development, resulting in an individual with permanently
   altered behaviors.  We shall first consider the normal cellular and
   biochemical development of the central nervous system; second, we
   shall examine how malnutrition alters these cellular and biochemical
   processes; and finally, we shall review the evidence that implicates
   early malnutrition with alterations in later behavior and ability to
   learn.
RF 001   MANDEL P              IN: RICHTER D                            964
   002   FISH I                PEDIATR RES                      3   407 969
   003   ALTMAN J              J COMP NEUROL                  128   431 974
   004   ALTMAN J              J COMP NEUROL                  126   337 966
   005   WINICK M              FED PROC                        29  1510 970
   006   DAVISON AN            IN: DAVISON AN                           968
   007   WINICK M              PEDIATR RES                      2   352 968
   008   DOBBING J             NATURE                         226   639 970
   009   HOWARD E              BRAIN RES                       14   697 969
   010   DOBBING J             ARCH DIS CHILD                  48   757 973
   011   BRASEL JA             DEVELOP BIOL                    23   424 970
   012   WINICK M              EXP NEUROL                      26   393 970
   013   DUCKETT S             PROC INT CONG OF NEUR 5TH            738 966
   014   DUCKETT S             REV CAN BIOL                    26   173 967
   015   DUCKETT S             J ANAT                         102   183 968
   016   DUCKETT S             ANAT REC                       163    59 969
   017   NACHMANSOHN D         IN: BARRON ESG                           952
   018   AUGUSTINSSON KB       IN: SUMNER JB                    1       950
   019   IM HS                 FED PROC ABST                   31   697 972
   020   HOLSTEIN IJ           J LIPID RES                      7   364 966
   021   KRITCHEVSKY D         BIOCHEM BIOPHYS RES COMMUN       7   128 962
   022   ADAMS CWM             J NEUROCHEM                      4   282 959
   023   ROUSER G              IN: LAJTHA A                     1       969
   024   SVENNERHOLM L         J LIPID RES                      9   570 968
   025   WIEGARDT H            J NEUROCHEM                     14   671 967
   027   LE BARON F            IN: LAJTHA A                     3       970
   028   SPERRY WM             IN: ELLIOTT KAC                          962
   029   BRANTE G              ACTA PHYSIOL SCAND SUPPL 63     18     1 949
   030   CUMINGS JN            J NEUROCHEM                      2   289 958
   031   TINGEY AH             J MENT SCI LOND                102   429 956
   032   HOWARD E              J NUTR                          95   111 968
   033   ALTMAN J              IN: LAJTHA A                     2       969
   034   BUNGE RP              PHYSIOL REV                     48   197 968
   035   ROSSO P               AM J CLIN NUTR                  23  1275 970
   036   PORCELLATI G          BIBL NUTR DIETA                 17    16 972
   037   MUZZO SJ              IN: GARDNER LI                   1       973
   038   CULLEY WJ             FED PROC ABST                   30   459 971
   039   ROBERTS E             IN: KOREY SR                     1       956
   040   LAJTHA A              J NEUROCHEM                      3   322 959
   041   MACHIYAMA Y           BIOCHEM J                       96    68 965
   042   TSUKADA Y             IN: ROBERTS E                            960
   044   NEAME DK              J NEUROCHEM                     11   655 964
   045   TSUKADA Y             J NEUROCHEM                     10   241 963
   046   GUROFF G              J BIOL CHEM                    236  1773 961
   047   WURTMAN RJ            FED MTGS REPORT                          972
   048   HASLAM RJ             BIOCHEM J                       88   566 963
   049   STRECKER HJ           IN: RICHTER D                            957
   050   CRAVIOTO RO           PROC SOC EXP BIOL MED           78   856 951
   051   DAWSON RMC            BIOCHEM J                       47   386 950
   052   DE ROFF PS            SCIENCE                        133  1072 961
   053   TALLAN HH             J BIOL CHEM                    219   257 956
   054   CURATOLA A            J NEUROCHEM                     12   339 965
   055   APRISON MH            IN: LAJTHA A                     3       970
   056   BRIDGERS WF           J BIOL CHEM                    240  4591 965
   057   SERENI F              BIOL NEONATE                    10   254 966
   058   SHOEMAKER WJ          SCIENCE                        171  1017 971
   059   ROBERTS S             J NEUROCHEM                     12   373 965
   060   HARPER AE             CITED IN: MUNRO HN               2       964
   061   CLARK HE              IN: ALBANESE AA                  2       965
   062   RICHTER D             J BIOL CHEM                    176  1199 948
   063   LAJTHA A              J NEUROCHEM                      1   289 957
   064   ROBERTS S             IN: LAJTHA A                             970
   065   PORCELLATI G          J NEUROCHEM                      5   277 960
   066   ANSELL GB             BIOCHIM BIOPHYS ACTA            13    92 954
   067   SCHAIN RJ             SCIENCE                        156   984 967
   068   ABDEL-LATIF AA        J NEUROCHEM                     13  1189 966
   069   OJA SS                ANN ACAD SCI FENN              131     1 967
   070   ORREGO F              J BIOL CHEM                    242   665 967
   071   WUNNER WH             BIOCHEM J                      101   417 966
   072   MILLER SA             IN: MUNRO HN                             969
   073   WIDDOWSON EM          PROC R SOC LOND BIOL           152    88 960
   074   DICKERSON JWT         PROC R SOC LOND BIOL           166   396 966
   075   JACKSON CM            J EXP ZOOL                      30    97 920
   076   PLATT BS              PROC R SOC LOND BIOL           156   337 962
   077   WINICK M              J NUTR                          89   300 966
   078   WINICK M              J NUTR                          95   623 968
   079   CULLEY WJ             J NUTR                          96   375 968
   080   DAVISON AN            BR MED BULL                     22    40 966
   081   CHASE HP              PEDIATRICS                      40   551 967
   084   ALLEYNE GAO           IN: WINICK M                     1       972
   085   WINICK M              IN: WINICK M                     1       972
   086   SHOEMAKER WJ          SCIENCE                        171  1017 971
   087   IM HS                 FED PROC ABST                   31   697 972
   088   FISH I                EXP NEUROL                      25   534 969
   089   CULLEY WJ             FED MTGS REPORT                          971
   090   PLATT BS              IN: MUNRO HR                     2       964
   091   ZEMAN FJ              FED MTGS REPORT                          972
   092   ZEMAN FJ              FED MTGS REPORT                          973
   093   MANOCHA SL            MALNUTRITION AND RETARDED HUM            972
   094   WINICK M              PEDIATR CLIN NORTH AM           17    69 970
   095   WINICK M              PEDIATR RES                      3   181 969
   097   CRAVIOTO J            AM J ORTHOPSYCHIATRY            35   449 965
   098   COWLEY JJ             J GENET PSYCHOL                 95   187 959
   099   COWLEY JJ             J GENET PSYCHOL                103   233 963
   100   COWLEY JJ             J GENET PSYCHOL                104    89 964
   101   COWLEY JJ             ANIM BEHAV                      14   506 966
   102   LEVITSKY DA           IN: KALLEN DJ                            970
   103   LEVITSKY DA           NATURE                         225   468 970
   104   GRIFFITHS WJ          J COMP PHYSIOL PSYCHOL          47    41 954
   105   BAIRD A               BR J NUTR                       25   391 971
   106   BARNES RH             J NUTR                          89   399 966
   107   COWLEY JJ             PSYCHOL ANGLICANA                9   216 962
   108   STROBEL DA            PSYCHONOMIC SCI                 24    19 971
   109   KERR RR               CITED IN: HARRIS RS                      970
   110   CALDWELL DF           NEUROLOGY (MINN)                17    95 967
   111   FRANKOVA S            J NUTR                          96   485 968
   112   SIMONSON M            J NUTR                         100   685 970
   113   BARNES RH             J NUTR                         100   149 970
   114   SIMONSON M            J NUTR                         101   331 971
   115   LAT J                 PROC R SOC LOND BIOL           153   347 961
   116   ALTMAN J              DEVELOP PSYCHOBIOL               4    97 971
   117   FRANKOVA S            J NUTR                          96   477 968
   118   GUTHRIE HA            PHYSIOL BEHAV                    3   619 968
   119   BARNETT SA            DEVELOP PSYCHOBIOL               4     1 971
   120   ZIMMERMANN RR         J ABNORM PSYCHOL                80   125 972
   121   STROBEL DA            PSYCHONOMIC SCI                 24    19 971
   122   STROBEL DA            DEVELOP PSYCHOBIOL               5   291 972
   123   AAKRE B               PERCEPT MOT SKILLS              36   787 973
   124   GEIST CR              LAB ANIM SCI                    22   369 972
   125   WISE LA               PERCEPT MOT SKILLS              36   674 973
   126   PEREGOY PL            PERCEPT MOT SKILLS              35   495 972
   128   WISE LA               BEHAV BIOL                       9    77 973
   129   ZIMMERMANN RR         PROC ANN CONV AM PSYCHOL ASSO        187 970
   130   LEVITSKY DA           SCIENCE                        176    68 972
   131   BARNES RH             IN: MOORE WM                             973
   132   CANOSA CA             IN: MOORE WM                             973
   133   GIBSON EJ             CITED IN: PRIN PERCEPTUAL LEA            967
   134   STOLLNITZ F           PSYCHOL REV                     72   247 965
   135   GUETZKOW HS           CITED IN: MEN AND HUNGER                 946
   136   SMART JL              BRAIN RES                       28    85 971
   137   SEITZ PFD             AM J PSYCHIATRY                110   916 954
   138   LEVINE S              IN: AMBROSE A                            969
   139   DENENBERG VH          SCIENCE                        130   629 959
   140   DENENBERG VH          ENDOCRINOLOGY                   81  1047 967
   141   ADER R                PHYSIOL BEHAV                    3   327 968
   142   ADER R                PHYSIOL BEHAV                    4   303 969
   143   ADER R                PHYSIOL BEHAV                    5   837 970
   144   DENENBERG VH          PSYCHOL REV                     71   335 964
   145   KRECH D               PHYSIOL BEHAV                    1    99 966
   146   TAPP JJ               SCIENCE                        140   486 963
   147   LEVINE S              CAN J PSYCHOL                   12   103 958
   148   SCHAPIRO S            SCIENCE                        167   292 970
   149   ALTMAN J              IN: SCRIMSHAW NS                         968
   150   ROSENZWEIG MR         J COMP PHYSIOL PSYCHOL          55   429 962
   151   ROSENZWEIG MR         PHYSIOL BEHAV                    3   819 968
   152   ADER R                PSYCHOSOM MED                   30   277 968
   153   WINICK M              J NUTR                          89   300 966
   154   CULLEY WJ             J NUTR                          96   375 968
   155   BENTON JW             PEDIATRICS                      38   801 966
   156   DOBBING J             BRAIN                           88   357 965
   157   GUTHRIE HA            J NUTR                          94   419 968
   158   EAYRS JT              ANAT REC                       121    53 955
   159   SERENI F              BIOL NEONATE                    10   254 966
   160   ADLARD BPF            BRAIN RES                       28    97 971
   161   ADLARD BPF            BRAIN RES                       30   198 971
   162   IM HS                 THESIS                                   971
   163   FRANKOVA S            IN: SCRIMSHAW NS                         968
   164   LEVITSKY DA           SCIENCE                        176    68 972
   165   CINES B               SYMP ON NUTRITION AND REPORT             972
   167   FRANKOVA S            SYMP ON EARLY MALNUTRI REPORT            973
   168   CABAK V               ARCH DIS CHILD                  40   532 965
   169   CHASE HP              PROC AM PEDIATR SOC ANNU MTG             969
   170   GARROW JS             LANCET                           1     1 967
   171   GRAHAM GG             FED PROC                        26   139 967
   172   CRAVIOTO J            BOL MED HOSP INFANTIL MEX       24   217 967
   173   CRAVIOTO J            PEDIATRICS PART 2 SUPPL         38   319 966
   174   KUGELMASS IN          AM J MED SCI                   208   631 944
   175   LIANG PH              AM J CLIN NUTR                  20  1290 967
   176   CHAMPAKAM S           AM J CLIN NUTR                  21   844 968
   177   BHATIA CM             CITED IN: PERFORMANCE TESTS O            958
   178   STOCH MB              S AFR MED J                     41  1027 967
   179   STOCH MB              ARCH DIS CHILD                  38   546 963
   180   HERTZIG ME            PEDIATRICS                      49   814 972
   181   CRAVIOTO J            J SPECIAL EDUCATION              2    75 967
   182   LATHAM MC             IN: SCRIMSHAW NS                         968
   183   STEIN Z               SCIENCE                        178   708 972
   184   LLOYD-STILL JD        PROC INT CONF ON NUTRI 9TH               972
   185   MCKAY H               PROC SYMP SWED NUTR FOUND       12       974
   186   CANOSA CA             PAN AM HEALTH ORG REPORT                 968
   188   RUSH D                IN: WINICK M                     2       974
   189   DELICARDIE ER         PROC SYMP SWED NUTR FOUND       12       974
   190   ZIMMERMANN RR         PROC SYMP SWED NUTR FOUND       12   115 974
CT   1   FIGLEWICZ DA          EXP NEUROL                      67   315 980
     2   HAMBERGER A           RES EXP MED                    180    41 982
     3   CONRADI NG            ACTA NEUROPATH (BERL)           60   159 983
     4   BAKER H               J NEUROSCI RES                  11   419 984
     5   BHARGAVA P            LIPIDS                          19   179 984
     6   PRENSKY AL            N ENGL J MED                   310  1527 984

PN 75014
RN 00181
AN 75125824
AU Berry-H-K.  Kellogg-F-W.  Hunt-M-M.  Ingberg-R-L.  Richter-L.
   Gutjahr-C.
TI Dietary supplement and nutrition in children with cystic fibrosis.
SO Am-J-Dis-Child. 1975 Feb. 129(2). P 165-71.
MJ CHILD-NUTRITION.  CYSTIC-FIBROSIS: dh.  DIETARY-CARBOHYDRATES.
   DIETARY-FATS.  DIETARY-PROTEINS.
MN ADOLESCENCE.  AMINO-ACIDS: bl.  BLOOD-PROTEINS: an.
   BLOOD-UREA-NITROGEN.  BODY-HEIGHT.  BODY-WEIGHT.  CHILD.
   CHILD-PRESCHOOL.  CHOLESTEROL: bl.  CLINICAL-TRIALS.  FEMALE.
   GLUCOSE: tu.  HEMOGLOBINS: an.  HUMAN.  INFANT.  MALE.
   PROTEIN-HYDROLYSATES: tu.  SERUM-ALBUMIN: an.  TRANSFERRIN: an.
   TRIGLYCERIDES: tu.
AB Assessment of nutritional status of patients with cystic fibrosis of
   the pancreas (CFP) showed that poor growth was associated with low
   concentrations of albumin, urea nitrogen, and cholesterol in serum
   and with elevated white blood cell (WBC) counts. Patients with CFP
   maintained weight approximately 1 standard deviation below the mean
   until 8 years, after which there was a progressive decline in growth
   rate compared to normal. A complete dietary supplement consisting of
   a beef serum hydrolysate, a glucose polymer, and medium-chain
   triglycerides was given to 15 patients for a year. Patients who
   received the diet showed significant gains in weight, significant
   increase in clinical score, significant increase in serum albumin
   level, and a significant drop in the WBC count compared to control
   patients who did not receive the supplement.
RF 001   WEIHOFEN DM           J AM DIET ASSOC                 54   206 969
   002   SHOHL AT              J PEDIATR                       23   267 943
   003   WEST CD               AM J DIS CHILD                  72   251 946
   004   GRACEY M              ARCH DIS CHILD                  44   401 969
   005   ALLAN JD              LANCET                           1   785 970
   006   ALLAN JD              AM J DIS CHILD                 126    22 973
   007   KUMAR V               PEDIATRICS                      49   736 972
   008   RANANATHAN MK         INDIAN J MED RES                43   517 955
   009   MCFARLANE H           LANCET                           1   392 969
   010   SIMMONS WK            BULL WHO                        42   480 970
   011   ANON                  RECOMMENDED DIETARY ALLOWANCE            968
   012   SONTAG LW             J PEDIATR                       26   327 945
   013   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   014   DOERSHUK CF           J PEDIATR                       65   677 964
   015   ARROYAVE G            AM J CLIN NUTR                  23   703 970
   016   GREULICH WW           RADIOGRAPHIC ATLAS OF SKELETA            959
   017   SPROUL A              J PEDIATR                       65   664 964
   018   POLLACK JD            CF CLUB ABST                    13    46 972
CT   1   BERRY HK              FED PROC                        34  2134 975
     2   WOOD RE               AM REV RESPIR DIS              113   833 976
     3   MAASER R              MONATSSCHR KINDERHEILKD        124   373 976
     4   DAUM F                PEDIATR RES                     12    24 978
     5   YASSA JG              ARCH DIS CHILD                  53   777 978
     6   BRADLEY JA            BR MED J                         1   167 979
     7   KAISER D              AKTUEL ERNAHRUNGSMED             4    26 979
     8   CHASE HP              PEDIATRICS                      64   207 979
     9   WOOD RE               SOUTH MED J                     72   189 979
    10   MOSS TJ               J PEDIATR                       94    32 979
    11   CHASE HP              J PEDIATR                       95   337 979
    12   SHEPHERD R            J PEDIATR                       97   351 980
    13   KERZNER B             PEDIATR RES                     15   250 981
    14   SOLOMONS NW           AM J CLIN NUTR                  34   462 981
    15   BELL L                J CAN DIET ASSOC                42    62 981
    16   PARK RW               GASTROENTEROLOGY                81  1143 981
    17   BEDDOES V             PRACTITIONER                   225   557 981
    18   PENCHARZ PB           J PEDIATR GASTROENTEROL NUTR     2   400 983
    19   SHEPHERD RW           J PEDIATR GASTROENTEROL NUTR     2   439 983
    20   DREHER ML             CRC CRIT REV FOOD SCI NUTR      20    47 984
    21   HODGES P              J AM DIET ASSOC                 84   664 984
    22   BERTRAND JM           J PEDIATR                      104    41 984
    23   MANSELL AL            J PEDIATR                      104   700 984
    24   CANCIANI M            J PEDIATR GASTROENTEROL NUTR     4   735 985
    25   LEVY LD               J PEDIATR                      107   225 985
    26   DODGE JA              ACTA PAEDIATR SCAND SUPPL 317 1985    31 985
    27   NEIJENS HJ            ACTA PAEDIATR SCAND SUPPL 317 1985    38 985
    28   LEVY L                J PEDIATR GASTROENTEROL NUTR     5    97 986
    29   KOHLER JA             J CLIN HOSP PHARM               11    21 986
    30   SOUTTER VL            CLIN GASTROENTEROL              15   137 986
    31   PUMARIEGA AJ          J AM ACAD CHILD PSYCHIAT        25   269 986
    32   MAHANEY MC            ARCH ORAL BIOL                  31   363 986
    33   BUSTAMANTE SA         AM J CLIN NUTR                  43   891 986
    34   OLOUGHLIN E           AM J CLIN NUTR                  43   732 986
    35   MOORE MC              AM J CLIN NUTR                  44    33 986
    36   DODGE JA              J ROY SOC MED                   79    27 986

PN 75015
RN 00182
AN 75125836
AU Wood-R-E.  Herman-C-J.  Johnson-K-W.  di-SantAgnese-P-A.
TI Pneumatosis coli in cystic fibrosis: clinical, radiological, and
   pathological features.
SO Am-J-Dis-Child. 1975 Feb. 129(2). P 246-8.
MJ CYSTIC-FIBROSIS: co.  PNEUMATOSIS-CYSTOIDES-INTESTINALIS: et.
MN ADOLESCENCE.  BARIUM-SULFATE: du.  CASE-REPORT.  CYSTIC-FIBROSIS: pa.
   HUMAN.  INTESTINE-LARGE: pa.  MALE.
   PNEUMATOSIS-CYSTOIDES-INTESTINALIS: ra, pa.  RECTAL-PROLAPSE: et.
   RESPIRATORY-FUNCTION-TESTS.
AB A patient with cystic fibrosis was found to have pneumatosis coli
   associted with rectal prolapse.  In cystic fibrosis there are
   several factors predisposing to pneumatosis, yet it is rarely
   reported.  Symptoms are nonspecific, and the diagnosis should be
   considered in patients with cystic fibrosis or other chronic lung
   disease and vague abdominal complaints.
RF 001   ECKER JA              AM J GASTROENTEROL              56   125 971
   002   KOSS LG               ARCH PATHOL                     53   523 952
   003   DOUB HP               JAMA                           172  1238 960
   004   KEYTING WS            RADIOLOGY                       76   733 961
   005   CREEVEY K             N ENGL J MED                   259   912 958
   006   MARSHAK RH            AM J DIG DIS                     1    99 956
   007   SMITH WF              GASTROENTEROLOGY                35   528 958
   008   WHITE H               RADIOL CLIN NORTH AM             1   539 963
   009   KULCZYCKI LL          N ENGL J MED                   259   409 958
   010   NELSON SW             AM J ROENTG RAD THER NUCL MED  115   225 972
CT   1   OLMSTED WW            GASTROINTEST RADIOL              1   177 976
     2   EIMOTO T              ACTA PATHOL JAP                 28   481 978
     3   KLEINMAN PK           AM J DIS CHILD                 134  1149 980
     4   DORSTEN JF            J AM OSTEOPATH ASSOC            81   123 981
     5   WALL LL               J PEDIATR                      101   745 982
     6   BALI A                BR MED J                       287  1011 983
     7   KLIEGMAN RM           N ENGL J MED                   310  1093 984
     8   HUBBARD VS            SEM RESPIR MED                   6   299 985
     9   PIETERSE AS           HUM PATHOL                      16   683 985
    10   AMMONS MA             TRANSPLANTAT PROC               18  1868 986
    11   HERNANZSCHULMAN M     RADIOLOGY                      160   497 986
    12   YEAGER AM             PEDIATR RADIOL                  17    18 987

PN 75016
RN 00183
AN 75181297
AU Athreya-B-H.  Borns-P.  Rosenlund-M-L.
TI Cystic fibrosis and hypertrophic osteoarthropathy in children.
   Report of three cases.
SO Am-J-Dis-Child. 1975 May. 129(5). P 634-7.
MJ CYSTIC-FIBROSIS: co.  OSTEOARTHROPATHY-SECONDARY-HYPERTROPHIC: co.
MN ADOLESCENCE.  ASPIRIN: tu.  CHILD.  CHRONIC-DISEASE.  FEMALE.  HUMAN.
   JOINT-DISEASES: dt.  MALE.
   OSTEOARTHROPATHY-SECONDARY-HYPERTROPHIC: ra.  PERIOSTEUM: pa.
   SYNOVITIS: pa.
AB Three patients with cystic fibrosis were noted to have swelling of
   knee and ankle joints during exacerbation of their lung disease.
   Synovial fluid was analyzed in one patient and the synovium underwent
   biopsy in another. These studies excluded other causes of arthritis
   but did not contribute any new information on the nature of secondary
   hypertrophic osteoarthropathy. Radiological examination of long bones
   confirmed the diagnosis of hypertrophic osteoarthropathy in all three
   patients. Since many patients with cystic fibrosis survive longer,
   more instances of hypertrophic osteoarthropathy are expected in the
   future.
RF 001   CAVANAUGH JJA         J PEDIATR                       66    27 965
   002   GROSSMAN H            AM J DIS CHILD                 107     1 964
   003   VAN LEERSUM HG        J BELGE RADIOL                  49    65 966
   004   BRUSILOW SW           ANNU REV MED                    21    99 970
   005   TOMASHEFSKI JF        CHEST                           57    28 970
   006   HOWELL DS             IN: HOLLANDER JL                    1120 966
   007   MENDLOWITZ M          MEDICINE                        21   269 942
   008   HOLLING HE            JAMA                           178   977 961
   009   GREENFIELD GB         AM J ROENTG RAD THER NUCL MED  101   927 967
   010   GALL EA               AM J PATHOL                     27   349 951
   011   ROPES MW              SYNOVIAL FLUID CHANGES IN JOI         89 953
   012   RACOCEANU SN          ANN INTERN MED                  75   933 971
   013   GINSBURG J            LANCET                           2  1274 961
   014   STEINER H             LANCET                           1   783 968
CT   1   WOOD RE               AM REV RESPIR DIS              113   833 976
     2   NATHANSON I           RADIOLOGY                      135   649 980
     3   BELUFFI G             EUR J PEDIATR                  139   199 982
     4   DELUMLEY L            ARCH FR PEDIATR                 40   723 983
     5   LESTER LA             SEM RESPIR MED                   6   285 985
     6   RUSH PJ               SEM ARTHRITIS RHEUM             15   213 986
     7   PITTSTUCKER TJ        ARCH DIS CHILD                  61   576 986
     8   PHILLIPS BM           J ROY SOC MED                   79    44 986
     9   COHEN AM              AM J DIS CHILD                 140    74 986

PN 75018
RN 00184
AN 76059172
AU Meyers-A.  Dolan-T-F-Jr.  Mueller-D.
TI Compliance and self-medication in cystic fibrosis.
SO Am-J-Dis-Child. 1975 Sep. 129(9). P 1011-3.
MJ ANTIBIOTICS: ur.  CYSTIC-FIBROSIS: dt.  PATIENT-COMPLIANCE.
   SELF-MEDICATION.
MN ADOLESCENCE.  ADULT.  ANTIBIOTICS: tu.  BIOLOGICAL-ASSAY.  CHILD.
   CHILD-PRESCHOOL.  FEMALE.  HUMAN.  MALE.
AB Sixty-one patients with cystic fibrosis were studied to determine the
   relationship between degree of compliance with taking antibiotics and
   severity of the disease. The compliance rate was high in these
   patients, suggesting that perception of the severity of the disease
   and the potential consequences of discontinuing medication is a
   principal factor.
RF 001   FRANCIS V             N ENGL J MED                   280   535 969
   002   DAVIS MS              AM J PUBLIC HEALTH              58   274 968
   003   CHARNEY E             PEDIATRICS                      40   188 967
   004   COLCHER IS            JAMA                           222   657 972
   005   LEISTYNA JA           AM J DIS CHILD                 111    22 966
   006   CHARNEY E             PEDIATR CLIN NORTH AM           19   263 972
   007   WATKINS JD            AM J PUBLIC HEALTH              57   452 967
   008   CARON H               AM J MED SCI                   261    61 971
   009   GORDIS L              J PEDIATR                       75   957 969
   010   DONABEDIAN A          J CHRON DIS                     17   847 964
   011   BECKER MH             J PEDIATR                       81   843 972
   012   GROVE DC              ASSAY METH OF ANTIBIOTICS                955
   013   MARKOWITZ M           PEDIATRICS                      41   151 968
   014   SHWACHMAN H           AM J DIS CHILD                  96     6 958
CT   1   WOOD RE               AM REV RESPIR DIS              113   833 976
     2   STAPLETON FB          N ENGL J MED                   295   246 976
     3   SHWACHMAN H           MEDICINE                        56   129 977
     4   SUBLETT JL            ANN ALLERGY                     43    95 979
     5   KUMAR A               POSTGRAD MED                    65   165 979
     6   ASHBURN FS            SURV OPHTHALMOL                 24   237 980
     7   LITT IF               PEDIATR CLIN NORTH AM           27     3 980
     8   KAUFFMAN RE           PEDIATR PHARMACOL                1   231 981
     9   PASSERO MA            CLIN PEDIATR                    20   264 981
    10   GOYAN J               WEST J MED                     134   463 981
    11   LITT IF               AM J DIS CHILD                 135   434 981
    12   SLEATOR EK            CLIN PEDIATR                    21   474 982
    13   MARKELLO JR           PEDIATR INFECT DIS               4   579 985
    14   WOOD PR               ANN ALLERGY                     54   400 985
    15   FRIEDMAN IM           PEDIATR CLIN NORTH AM           33   955 986
    16   NOLAN T               PEDIATRICS                      77   229 986

PN 75019
RN 00185
AN 76059148
AU Lober-C-W.
TI Letter: Nutritional supplementation in cystic fibrosis.
SO Am-J-Dis-Child. 1975 Oct. 129(10). P 1239.
MJ CYSTIC-FIBROSIS: dh.
MN ADOLESCENCE.  CHILD.  HUMAN.
EX Duke Medical Center and the National Institutes of Health have
   analyzed the maximum achieved heights and weights of 60 persons with
   CF over 20 years old.  Both parameters were markedly skewed toward
   the lower percentile bands.  No significant differences were found
   among patients whose condition was diagnosed early in life, in those
   with more severe pulmonary or gastrointestinal impairment, or among
   those in whom pancreatic enzyme and/or nutritional supplementation
   had been employed.  Nutritional supplementation has yet to be proven
   a significant long-term influence on the morbidity or mortality of
   CF. - Lober reported data on 60 persons with cystic fibrosis (CF)
   over 20 years of age, while our population of 63 individuals
   contained only three who were over 15 years old.  The median age of
   death in patients with CF is 12 years.  It is not realistic to
   compare patients who have survived to adulthood with a younger
   group.  He did not state the type of nutritional supplementation
   that was of no significance among his patients.  Our experience with
   nutritional supplements other than the amino acid-glucose polymer
   mixture has been equally poor.  Our data on growth rates were
   similar to those of Lober in that both heights and weights were
   skewed toward the lower end, and height was less affected than
   weight.  Increased rates of linear growth were observed in eight of
   13 children under 12 years of age at the time the dietary supplement
   was begun.  Patients who continue to take the nutritional supplement
   have not shown further deterioration in pulmonary status.
RF 001   BERRY HK              AM J DIS CHILD                 129   165 975
   002   LOBER CW              PROC AM COLL CHEST 40TH AN MT            974
   003   VAUGHAN VC III        IN: NELSON WE                         15 969
   004   MONTOYE HJ            AM J CLIN NUTR                  16   417 965
CT   1   YASSA JG              ARCH DIS CHILD                  53   777 978
     2   PARSONS HG            J PEDIATR GASTROENTEROL NUTR     2    44 983

PN 75020
RN 00186
AN 76059140
AU Perman-J.  Breslow-L.  Ingal-D.
TI Nonoperative treatment of meconium ileus equivalent.
SO Am-J-Dis-Child. 1975 Oct. 129(10). P 1210-1.
MJ CYSTIC-FIBROSIS: co.  FECES.  INTESTINAL-OBSTRUCTION: et.
MN ACETYLCYSTEINE.  CASE-REPORT.  CHILD.  ENEMA.  FEMALE.  HUMAN.
   INTESTINAL-OBSTRUCTION: th.  LIPASE: tu.  MECONIUM.
AB Intraluminal bowel obstruction secondary to inspissated feces is a
   known complication of cystic fibrosis. When seen in the older child,
   it is termed "meconium ileus equivalent." We studied a case in which
   nonsurgical resolution of the obstruction was obtained with N-
   acetylcysteine enemas and pancreatic replacement enzymes given orally
   and by enema. The pathogenesis of this disorder and the basis for the
   treatment are described. Recognition of this complication and
   familiarity with its medical management are important in caring for
   the older child with cystic fibrosis.
RF 001   JENSEN KG             ACTA PAEDIATR SCAND             51   344 962
   002   MULLINS F             JAMA                           192   741 965
   003   JAFFE BF              ARCH SURG                       92   337 966
   004   SHEFFNER AL           ANN NY ACAD SCI                106   298 963
   005   MEEKER IA             SURGERY                         56   419 964
   006   SIMPSON TE            MAYO CLIN PROC                  43   725 968
   007   SIGLER RM             MAYO CLIN PROC                  40   477 965
   008   LILLIBRIDGE CB        J PEDIATR                       71   887 967
   009   GRACEY M              ARCH DIS CHILD                  44   404 969
   010   SHAW A                J PEDIATR SURG                   4   119 969
   011   GRAND RJ              CLIN PEDIATR                     9   588 970

PN 75021
RN 00187
AN 76059130
AU Bardana-E-J-Jr.  Sobti-K-L.  Cianciulli-F-D.  Noonan-M-J.
TI Aspergillus antibody in patients with cystic fibrosis.
SO Am-J-Dis-Child. 1975 Oct. 129(10). P 1164-7.
MJ ANTIBODIES-FUNGAL: an.  ASPERGILLUS-FUMIGATUS: im.
   CYSTIC-FIBROSIS:  im.
MN ADOLESCENCE.  ADULT.  ASPERGILLUS-FUMIGATUS: ip.
   BINDING-SITES-ANTIBODY.  CHILD.  CHILD-PRESCHOOL.  CROSS-REACTIONS.
   HUMAN.  IGE: an.  INFANT.  PRECIPITINS: an.  RESPIRATORY-SYSTEM: mi.
   SUPPORT-U-S-GOVT-P-H-S.
AB The respiratory flora of patients with cystic fibrosis (CF)
   frequently includes Aspergillus, and 30% of their serum samples have
   been observed to contain precipitating antibody to this fungus. Serum
   from 61 CF patients, 60 healthy persons, and three patients with CF
   and allergic bronchopulmonary aspergillosis was studied, using a
   quantitative assay for antibody to A fumigatus. Although CF patients
   had significantly higher levels of Aspergillus antibody, some
   antibody was found in all serum samples from normal individuals.
   Binding was immunologically specific for A fumigatus. Serum IgE
   levels and dermal reactivity to Aspergillus were similar in both CF
   and normal subjects. Increased levels of Aspergillus antibody in CF
   patients probably reflect pulmonary colonization, which only rarely
   causes infection or sensitization.
RF 001   FEIGELSON J           MOD PROBL PEDIATR               10   214 967
   002   RIDDELL RW            IN: LAWSON D PROC 5TH INT CF         189 969
   003   HUGHES WT             MYCOPATHOL MYCOL APPL           50   261 973
   004   MEARNS MB             LANCET                           1   538 967
   005   HALBERT SP            MOD PROBL PEDIATR               10   144 967
   006   SCHWARTZ RH           AM J DIS CHILD                 120   432 970
   007   DOGGETT RG            INFECT IMMUN                     6   628 972
   008   MEARNS MB             THORAX                          20   385 965
   009   BATTEN JC             MOD PROBL PEDIATR               10   227 967
   010   MCCARTHY DS           IN: LAWSON D PROC 5TH INT CF         194 969
   011   BARDANA EJ JR         J ALLERGY CLIN IMMUNOL          50   222 972
   012   BARDANA EJ JR         ANN NY ACAD SCI                221    64 974
   013   BARDANA EJ JR         J ALLERGY CLIN IMMUNOL          50   208 972
   014   FARR RS               J INFECT DIS                   103   239 958
   015   COOMBS RRA            IN: GELL PGH                         317 964
   016   HEINER DC             J ALLERGY                       45    30 970
   017   PATTERSON R           AM J MED                        54    16 973
   018   BARDANA EJ JR         AM REV RESPIR DIS              109   724 974
   019   BAZARAL M             J IMMUNOL                      107   794 971
   020   WALDMANN TA           J IMMUNOL                      109   304 972
   021$  POLMAR SH             J IMMUNOL                      110  1253 970
   022   YOUNG RC              MEDICINE (BALTIMORE)            49   147 970
   023   BOWMAN BH             SCIENCE                        164   325 969
   024   BOXERBAUM B           AM REV RESPIR DIS              108   777 973
   025   CAUDILL M             LANCET                           2   307 973
   026   MINDEN P              INFECT IMMUN                     6   574 972
   027   MINDEN P              J IMMUNOL                       96   180 966
   028   LINDBLAD JH           J ALLERGY                       32   392 961
   029   SAFIRSTEIN BH         AM REV RESPIR DIS              108   450 973
CT   1   BARDANA EJ            AM REV RESPIR DIS              112   799 975
     2   GALANT SP             AM REV RESPIR DIS              114   325 976
     3   HOIBY N               ACTA PATH MICROBIOL SCAND (C) S262     3 977
     4   OSVATH P              MONATSSCHR KINDERHEILKD        125   220 977
     5   SANDHU RS             MYCOPATHOLOGIA                  63    21 978
     6   NELSON LA             AM REV RESPIR DIS              120   863 979
     7   TOBIN MJ              THORAX                          35   807 980
     8   ANDERSON CJ           J ALLERGY CLIN IMMUNOL          65   140 980
     9   HARGIS JL             AM J MED                        68   389 980
    10   MOSS RB               J PEDIATR                       99   215 981
    11   PITCHERWILMOTT RW     ARCH DIS CHILD                  57   582 982
    12   VOSS MJ               J ALLERGY CLIN IMMUNOL          69   536 982
    13   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    33 982
    14   LAUFER P              J ALLERGY CLIN IMMUNOL          73    44 984
    15   SCHONHEYDER H         ACTA PATH MICROB IMMU SCA (B)   93   105 985

PN 75022
RN 00188
AN 75162186
AU Pennington-J-E.  Reynolds-H-Y.  Wood-R-E.  Robinson-R-A.  Levine-A-S.
TI Use of a Pseudomonas Aeruginosa vaccine in pateints with acute
   leukemia and cystic fibrosis.
SO Am-J-Med. 1975 May. 58(5). P 629-36.
MJ BACTERIAL-VACCINES.  LEUKEMIA: im.  PSEUDOMONAS-AERUGINOSA: im.
   PSEUDOMONAS-INFECTIONS: pc.
MN ADOLESCENCE.  ADULT.  BACTERIAL-VACCINES: ad, ae.  CHILD.
   CLINICAL-TRIALS.  CYSTIC-FIBROSIS: im.  DRUG-ADMINISTRATION-SCHEDULE.
   DRUG-EVALUATION.  FEMALE.  HUMAN.  INJECTIONS-INTRAMUSCULAR.  MALE.
   MIDDLE-AGE.
AB A heptavalent lipopolysaccharide Pseudomonas vaccine was evaluated in
   22 patients with acute leukemia and 12 patients with cystic fibrosis
   during an 18 month interval at the Clinical Center of the National
   Institutes of Health. Of the 34 patients, 32 had an excellent serum
   hemagglutinating (HA) antibody response to immunization. In
   comparison to the patients with cystic fibrosis, the patients with
   leukemia had a smaller HA antibody response, which lasted a shorter
   period of time, and also}i experienced greater toxicity from the
   vaccine. The mixing of adrenal corticosteroids with vaccine greatly
   decreased side reactions among the patients with leukemia without
   significantly inhibiting antibody production. Previous antineoplastic
   chemotherapy had little influence on antibody response in patients
   with leukemia, with the exception of methortrexate. Vaccinated
   patients with leukemia had 1 Pseudomonas infection of 14 bacterial or
   fungal infections, whereas 2 pseudomonas infections of 5 bacterial or
   fungal infections occurred in a control group of 20 patients with
   acute leukemia. Of the 12 patients with cystic fibrosis, 4 had a
   Pseudomonas infection after vaccination.
RF 001   MARKLEY K             ANN SURG                       145   175 957
   002   RABIN ER              N ENGL J MED                   265  1225 961
   003   DI SANTAGNESE PA      N ENGL J MED                   277  1399 967
   004   ROSE HD               AM REV RESPIR DIS              107   416 973
   005   TILLOTSON JR          ANN INTERN MED                  68   295 968
   006   LEVINE AS             SEMIN HEMATOL                    9   141 972
   007   LEVINE AS             SEMIN HEMATOL                   11   141 974
   008   SCHIMPFF SC           ANN INTERN MED                  77   707 972
   009   PENNINGTON JE         AM J MED                        55   155 973
   010   REYES MP              MEDICINE (BALTIMORE)            52   173 973
   011   MARKLEY K             ANN INTERN MED                  74   140 971
   012   HANESSIAN S           NATURE NEW BIOL                229   209 971
   013   FISHER MW             J BACTERIOL                     98   835 969
   014   ALEXANDER JW          J TRAUMA                        10   565 970
   015   YOUNG LS              ANN INTERN MED                  79   518 973
   016   HAGHBIN M             CANCER                          32   761 973
   017   WOLFF SM              J INFECT DIS                   128   243 973
   018   YOUNG LS              J INFECT DIS                   126   257 972
   019   BJORNSON AB           INFECT IMMUN                     2   453 970
   020   YOUNG LS              INFECT IMMUN                     2   495 970
   021   SANTOS GW             FED PROC                        26   907 967
   022   LEVENTHAL BG          ISR J MED SCI                   10   866 974
   023   GUMP DW               ARCH INTERN MED                132   847 973
   024   BODEY GP              AM J MED SCI                   260    82 970
   025   DALE DC               J CLIN INVEST                   54   664 974
   026   UFFELMAN JA           CLIN CHIM ACTA                  28   185 970
CT   1   ANON                  LANCET                           2   168 975
     2   LEVINE AS             CANCER                          36   813 975
     3   WOOD RE               AM REV RESPIR DIS              113   833 976
     4   DISANTAGNESE PA       N ENGL J MED                   295   597 976
     5   HOIBY N               ACTA PATH MICROBIOL SCAND (C) S262     3 977
     6   PENNINGTON JE         CANCER                          39  1345 977
     7   KAZMIEROWSKI JA       J INFECT DIS                   135   438 977
     8   HORTOBAGYI GN         CANCER IMMUNOL IMMUNOTHER        4   201 978
     9   MOODY MR              INFECT IMMUN                    21   905 978
    10   GEDDES AM             S AFR MED J                     53   121 978
    11   BERGERON MG           SCAND J INFECT DIS            1978   189 978
    12   PENNINGTON JE         INFECT IMMUN                    25  1029 979
    13   POLLACK M             J CLIN INVEST                   63   276 979
    14   WOOD RE               SOUTH MED J                     72   189 979
    15   PENNINGTON JE         J INFECT DIS                   140    73 979
    16   NETER E               ZENTRALBL BAKT PARA INFEK HYG  243   349 979
    17   LEPRAT R              ANN MICROBIOL (PARIS)         B131   209 980
    18   PASKO M               J MED                           11   303 980
    19   FICK RB               J IMMUNOL METH                  38   103 980
    20   RAMSEY PG             MEDICINE                        59   206 980
    21   BALTIMORE RS          J INFECT DIS                   141   238 980
    22   PENNINGTON JE         J INFECT DIS                   142   191 980
    23   FICK RB               J CLIN INVEST                   68   899 981
    24   PENNINGTON JE         J CLIN INVEST                   68  1140 981
    25   PIZZO PA              J PEDIATR                       98   524 981
    26   SEID RC               J BIOL CHEM                    256  7305 981
    27   BODEY GP              SEM HEMATOL                     19   193 982
    28   OHMAN DE              INFECT IMMUN                    37   662 982
    29   HOOKE AM              INFECT IMMUN                    38   136 982
    30   PIER GB               J CLIN INVEST                   69   303 982
    31   PIER GB               J INFECT DIS                   145   217 982
    32   PINCHING AJ           CLIN IMMUNOL ALLERGY             3   305 983
    33   BODEY GP              REV INFECT DIS                   5   279 983
    34   PENNINGTON JE         REV INFECT DIS                   5  S852 983
    35   PIER GB               REV INFECT DIS                   5  S950 983
    36   TEGTMEIER BR          REV INFECT DIS                   5  S963 983
    37   BRYAN LE              J CLIN MICROBIOL                18   276 983
    38   FICK RB               BULL EUR PHYSIOPATH RESP        19   151 983
    39   CRYZ SJ               INFECT IMMUN                    39  1067 983
    40   KLINGER JD            INFECT IMMUN                    39  1377 983
    41   CRYZ SJ               INFECT IMMUN                    40   659 983
    42   PIZZO PA              CANCER TREAT REP                67   223 983
    43   MORRISON AJ           REV INFECT DIS                   6  S627 984
    44   YOUNG LS              REV INFECT DIS                   6  S769 984
    45   SPEERT DP             PEDIATR RES                     18   431 984
    46   CRYZ SJ               INFECT IMMUN                    44   508 984
    47   TSAY GC               INFECT IMMUN                    45   217 984
    48   GONGGRIJP R           ANT V LEEUW J MICROBIOL         50   285 984
    49   FICK RB               J CLIN INVEST                   74   236 984
    50   YOUNG LS              AM J MED                        76   664 984
    51   WHEELER WB            J PEDIATR                      104   695 984
    52   OLSON B               J INFECT DIS                   150   808 984
    53   GOULD IM              LANCET                           2  1224 985
    54   SPEERT DP             SURV SYNTH PATHOL RES            4    14 985
    55   MISCHLER EH           SEM RESPIR MED                   6   271 985
    56   SHRYOCK TR            CURRENT MICROBIOL               12    91 985
    57   BANNISTER P           J BIOL STANDARD                 13   321 985
    58   PODNOS SD             WEST J MED                     143   622 985
    59   OLSON B               J INFECT DIS                   152   769 985
    60   PENNINGTON JE         REV INFECT DIS                   8  S426 986
    61   CLASENER HAL          REV INFECT DIS                   9   295 987

PN 75023
RN 00189
AN 76085352
AU Burnette-B-A.
TI Family adjustment to cystic fibrosis.
SO Am-J-Nurs. 1975 Nov. 75(11). P 1986-9.
MJ ADAPTATION-PSYCHOLOGICAL.  CYSTIC-FIBROSIS.  FAMILY.
MN CYSTIC-FIBROSIS: di.  FEMALE.  HUMAN.  INFANT.  LUNG-DISEASES: pc.
   SOCIAL-ADJUSTMENT.
EX A nurse and mother describes the clinical effects of cystic fibrosis
   on patients and the long-term demands the disease places on her own
   and other children and families.  Diagnosis is mainly accomplished
   with an analysis of sweat for sodium and chloride ions.  CF is
   transmitted as a Mendelian recessive trait.  It is a generalized
   dysfunction of the endocrine glands.  The abnormalities, seemingly
   unrelated, appear as loss of electrolytes through the sweat and
   salivary glands and as unusually thick, sticky mucus secretions that
   obstruct and damage the patient's pancreas, lungs, gallbladder,
   intestines, and liver.  The objective of pulmonary therapy are to
   decrease viscosity of the pulmonary secretions and to improve and
   maintain pulmonary hygiene.  Financial cost is only one of many
   burdens on the family.
RF 001   JEANS PC              ESSENTIALS OF PEDIATRICS             714 954
   002   DI SANTAGNESE PA      TODAY'S HEALTH                  47    38 969
   003   ANON                  GUIDE TO DIAGNOSIS AND MANAGE            971

PN 75024
RN 00190
AN 76016602
AU Changus-J-E.  Quissell-D-O.  Sukup-M-R.  Pitot-H-C.
TI Studies on the synthesis of plasma membrane proteins of fibroblasts
   from patients with cystic fibrosis.
SO Am-J-Pathol. 1975 Aug. 80(2). P 317-28.
MJ CELL-MEMBRANE: me.  CYSTIC-FIBROSIS: me.  PROTEINS: bi.
MN BIOPSY.  CARBON-RADIOISOTOPES.  CELLS-CULTURED.
   CYSTIC-FIBROSIS: pa, fg.  DENSITOMETRY.
   ELECTROPHORESIS-POLYACRYLAMIDE-GEL.  FIBROBLASTS:  me, ul.  GENOTYPE.
   HUMAN.  IN-VITRO.  LEUCINE: me.  SKIN: pa.  TRITIUM.
   SUPPORT-U-S-GOVT-P-H-S.
AB The characteristic increased salinity of sweat and other
   abnormalities of exocrine secretions in patients with cystic fibrosis
   (CF) suggest the possibility of a disturbed functioning of the plasma
   membrane in this disease. Several lines of evidence indicate that
   fibroblasts express the presence of the CF genotype. Therefore these
   cells were used in an in vitro study directed at determining whether
   the manifestations of CF might be related to an alteration of one or
   more of the protein components of the plasma membrane. In order to
   evaluate the synthesis of these components, growing fibrosblasts from
   patients with CF and normal subjects were briefly exposed to either
   14C- or 3-H-leucine. Their plasma membranes were then isolated and
   subjected to analysis in a nondetergent acrylamide gel system.
   Coelectrophoresis of differentially labeled preparations revealed the
   absence of a detectable abnormality in the synthetic rates of any of
   the more than 30 resolved protein species.
RF 001   FARBER S              ARCH PATHOL                     37   238 944
   002   GIBSON LE             PEDIATRICS                      23   545 959
   003   DI SANTAGNESE PA      PEDIATRICS                      12   549 953
   004   MCCOMBS ML            TEX REP BIOL MED                31   615 973
   005   POTTER JL             ANN NY ACAD SCI                106   692 963
   006   MANDEL ID             AM J DIS CHILD                 113   431 967
   007   DISCHE Z              PEDIATRICS                      24    74 959
   008   ROELFS RE             AM J DIS CHILD                 113   419 967
   009   LOBECK CC             IN: STANBURY JB                     1605 972
   010   BALFE JW              SCIENCE                        162   689 968
   011   HORTON CR             BIOCHEM BIOPHYS RES COMMUN      40   505 970
   012   HADDEN JW             PROC SOC EXP BIOL MED          142   577 973
   013   FITZPATRICK DF        NATURE NEW BIOL                235   173 972
   014   FEIG SA               PEDIATR RES                      8   594 974
   015   DANES BS              LANCET                           1  1061 968
   016   MATALON R             LANCET                           2   838 969
   017   REED GB               J PATHOL                       101   251 970
   018   DANES BS              J EXP MED                      137  1538 973
   019   BERATIS NG            PEDIATR RES                      7   958 973
   020   BOWMAN BH             PROC NAT ACAD SCI USA           70   548 973
   021   DANES BS              J EXP MED                      129   775 969
   022   PALLAVICINI JC        J PEDIATR                       77   280 970
   023   HOUCK JC              PROC SOC EXP BIOL MED          135   369 970
   024   FLETCHER DS           CLIN CHIM ACTA                  44     5 973
   025   BAIG MM               J PEDIATR                       86    72 975
   027   BARLAND P             J CELL BIOL                     45   662 970
   028   TERMAN SA             PROC NAT ACAD SCI USA           65   985 970
   029   SHWACHMAN H           BIRTH DEF ORIG ART SER           8   102 972
   030   DANES BS              LANCET                           2   765 973
   031   ROBERTS RM            BIOCHEMISTRY                    13  4846 974
   032   WARREN L              J CELL BIOL                     37   729 968
   033   BERGSMA D             BIRTH DEF ORIG ART SER           9    11 973
   034   SHAW CR               SCIENCE                        149   936 965
   035   CAPECCHI MR           PROC NAT ACAD SCI USA           71  4732 974
   036   DERN RJ               J LAB CLIN MED                  68   560 966
   037   PITOT HC              PROC SYMP MOLE BASIS HUM              14 972
   038   BENKE PJ              LANCET                           1   182 972
   039   MARSDEN JC            BIOCHEM SOC TRANS                2   326 974
   040   QUISSELL DO           NATURE                         247   115 974
CT   1   WARD JB               TEX REP BIOL MED                34    11 976
     2   WOOD RE               AM REV RESPIR DIS              113   833 976
     3   SANTAGNESE PAD        N ENGL J MED                   295   481 976
     4   YOKOYAMA M            PEDIATR RES                     11   765 977
     5   QUISSELL DO           ANAL BIOCHEM                    79   240 977
     6   OWEN E                J MOL MED                        3   203 978
     7   PENA SDJ              PEDIATR RES                     12   887 978
     8   PEARSON RD            PEDIATR RES                     13   834 979
     9   MALER T               BIOCHIM BIOPHYS ACTA           598     1 980
    10   HARRIS A              CLIN CHIM ACTA                 128    41 983
    11   KARLSSON S            J MED GENET                     21   441 984

PN 75025
RN 00191
AN 75089105
AU Lieberman-J.
TI Carboxypeptidase B-like activity and C3 in cystic fibrosis.
SO Am-Rev-Respir-Dis. 1975 Jan. 111(1). P 100-2.
MJ CARBOXYPEPTIDASES: bl.  COMPLEMENT.  CYSTIC-FIBROSIS: di.
MN COMPLEMENT: an.  CYSTIC-FIBROSIS: im, en.  FEMALE.
   GEL-DIFFUSION-TESTS.  HUMAN.  MALE.  SUPPORT-U-S-GOVT-NON-P-H-S.
AB Assays of carboxypeptidase B-like activity and C3 in serum from
   patients with cystic fibrosis and appropriate control subjects failed
   to demonstrate a deficiency of carboxypeptidase B-like activity or a
   consistent increase in C3, as was suggested by Conover and
   associates. Differences between men and women with cystic fibrosis
   were apparent, in that women with cystic fibrosis had higher
   concentrations of both serum carboxypeptidase B-like activity and C3
   than either men with cystic fibrosis or control subjects.
RF 001   CONOVER JH            LANCET                           2  1501 973
   002   CONOVER JH            LIFE SCI                        14   253 974
   003   CUSHMAN DW            BIOCHEM PHARMACOL               20  1637 971
   004   NEURATH H             IN: BOYER PD                     4    11 960
   005$  FOLK JE               METHODS ENZYMOL                      504 970
   006   ERDOS EG              BIOCHEM PHARMACOL               16  1287 967
CT   1   ALTLAND K             HUM GENET                       28   207 975
     2   HARPER BL             TEX REP BIOL MED                34    73 976
     3   CORBIN NC             ANAL BIOCHEM                    73    41 976
     4   ANON                  J PEDIATR                       88   711 976
     5   WOOD RE               AM REV RESPIR DIS              113   833 976
     6   DISANTAGNESE PA       N ENGL J MED                   295   534 976
     7   MARCHI AG             HELV PAEDIATR ACTA              33   517 978
     8   GOTZ M                EUR J PEDIATR                  127   133 978
     9   SCHIOTZ PO            MONOGR PAEDIATR                 10   131 979
    10   STRAUSS RG            HELV PAEDIATR ACTA              34   429 979
    11   BUTTERWORTH J         CLIN CHIM ACTA                  97    39 979
    12   HODSON ME             THORAX                          35   801 980
    13   PLUMMER TH            ANAL BIOCHEM                   108   348 980
    14   MOSS RB               AM REV RESPIR DIS              121    23 980
    15   MCCORMICK JR          AM J PATHOL                    109   283 982
    16   SCHIOTZ PO            ACTA PAEDIATR SCAND SUPPL 301 1982    55 982
    17   SCHWEISFURTH H        DTSCH MED WSCHR                109  1254 984
    18   CICARDI MGM           INT J ARTIF ORGANS               8   135 985
    19   MATHEWS KP            PROG ALLERGY                    39   344 986
    20   BOGART BI             J CHROMATOGR                   381    29 986

PN 75026
RN 00192
AN 76086198
AU Corbet-A.  Ross-J.  Popkin-J.  Beaudry-P.
TI Relationship of arterial-alveolar nitrogen tension to
   alveolar-arterial oxygen tension, lung volume, flow measurements,
   and diffusing capacity in cystic fibrosis.
SO Am-Rev-Respir-Dis. 1975 Oct. 112(4). P 513-9.
MJ CYSTIC-FIBROSIS: pp.  NITROGEN.  OXYGEN.  RESPIRATION.
MN ADOLESCENCE.  CARBON-DIOXIDE.  CARBON-MONOXIDE.  CHILD.
   CHILD-PRESCHOOL.  FEMALE.  HUMAN.  LUNG-VOLUME-MEASUREMENTS.  MALE.
   NITROGEN: bl.  OXYGEN: bl.  PULMONARY-ALVEOLI.  PULMONARY-ARTERY.
   PULMONARY-DIFFUSING-CAPACITY.  VENTILATION-PERFUSION-RATIO.
AB Pulmonary function in children with cystic fibrosis was assessed by
   the arterial-alveolar PN2 difference adjusted to sublingual
   temperature. The resulting values were compared with the alveolar-
   arterial PO2 difference, arterial PCO2, and standard measurements of
   lung volume, flow, and diffusing capacity. The arterial-alveolar PN2
   difference was nearly one half of the PO2 difference, both early in
   the disease and at a more advanced stage. Analysis taking into
   account the O2 dissociation curve and the possibility that alveolar
   temperature is higher than sublingual temperature suggested that all
   of the PO2 difference could be explained in terms of ventilation-
   perfusion imbalance in gas-filled units of the lung. Reduction of
   fractional CO uptake with increasing PN2 difference suggested that
   the decrease in diffusing capacity in cystic fibrosis may be
   explained by ventilation-perfusion inequality. A significant
   relationship between arterial PCO2 and the PN2 difference supported
   the view that ventilation-perfusion inequality is the cause of CO2
   retention when present. The PN2 and PO2 differences were abnormal
   before the standard tests of lung volume and flow, but in general,
   the correlation was excellent. Because the PN2 difference was not
   superior to the PO2 difference in detecting early disease, and
   because the technical problems in its measurement are considerable,
   it is not recommended as a routine measurement.
RF 001   MELLINS RB            PEDIATRICS                      44   315 969
   002   LANDAU LI             AM REV RESPIR DIS              108   593 973
   003   RILEY RL              J APPL PHYSIOL                   4    77 951
   004   CANFIELD RE           J APPL PHYSIOL                  10   165 957
   005   KABE J                CAN J PHYSIOL PHARMACOL         46   795 968
   006   FARHI LE              J APPL PHYSIOL                  18    97 963
   007   KLOCKE FJ             MEASURE TRACE AMOUNTS INERT G         75 967
   008   CORBET A              J APPL PHYSIOL                  36    74 974
   009   WINQUIST RA           J PEDIATR                       76   455 970
   010   RAHN H                GRAPH ANALYSIS RESPIR GAS EXC            955
   011   BERNSTEIN L           THORAX                           7   255 952
   012   LEUALLEN EC           AM REV TUBERC PULM DIS          72   783 955
   013   MENEELY GR            J CLIN INVEST                   28   129 949
   014   BATES DV              RESPIRATORY FUNCTION IN DISEA            971
   015   BATES DV              J PHYSIOL (LOND)               129   237 955
   016   BEAUDRY PH            IN: POLGAR G                          87 971
   017   ARMITAGE P            STATISTICAL METHODS IN MEDICA            971
   018   FEATHERBY EA          AM REV RESPIR DIS              102   737 970
   019   WARING WW             AM REV RESPIR DIS               91    77 965
   020   ABERNATHY JD          PHYSIOLOGIST                     9   128 966
   021   CORBET A              CAN J PHYSIOL PHARMACOL         52    63 975
   022   LAMARRE A             PEDIATRICS                      50   291 972
   023   DEMUTH GR             AM J DIS CHILD                 103   129 962
   024   MARKELLO R            ANESTHESIOLOGY                  37     4 972
   025   LENFANT C             J APPL PHYSIOL                  18  1090 963
   026   EDWARDS AWT           J APPL PHYSIOL                  18   107 963
   027   SEVERINGHAUS JW       IN: FENN WO                      2  1475 965
   028   MOSS AJ               PEDIATRICS                      41   438 968
   029   WAGNER PD             J APPL PHYSIOL                  33    62 972
   030   WEST JB               RESPIR PHYSIOL                   7    88 969
   031   MACKLEM PT            J APPL PHYSIOL                  22   395 967
   032   MEAD J                J APPL PHYSIOL                  22    95 967
   033   FOX WW                PEDIATRICS                      54   293 974
CT   1   MILLIS RM             CHEST                           71   508 977
     2   MILLIS RM             CHEST                           72   217 977

PN 75027
RN 00193
AN 75163031
AU Stowe-S-M.  Boat-T-F.  Mendelsohn-H.  Stern-R-C.  Tucker-A-S.
   Doershuk-C-F.  Matthews-L-W.
TI Open thoracotomy for pneumothorax in cystic fibrosis.
SO Am-Rev-Respir-Dis. 1975 May. 111(5). P 611-7.
MJ CYSTIC-FIBROSIS: co.  PLEURA: su.  PNEUMOTHORAX: su.
MN CYSTIC-FIBROSIS: mo.  EVALUATION-STUDIES.  HUMAN.  LENGTH-OF-STAY.
   PNEUMOTHORAX: et, dt, pp, mo.  POSTOPERATIVE-COMPLICATIONS.
   RECURRENCE.  SCLEROSING-SOLUTIONS: tu.  SUPPORT-U-S-GOVT-P-H-S.
   VITAL-CAPACITY.
AB The results of open thoractomy and pleurectomy or pleural abrasion
   for 17 episodes of pneumothorax in patients with cystic fibrosis were
   compared with the results of observation, closed thoracostomy, and
   closed thoracostomy with sclerosing agents. Open thoracotomy had the
   advantage of insuring prompt resolution of the pneumothorax. A small
   incision minimized postoperative morbidity. The average hospital stay
   was 15 days after open thoracotomy and 19 days after closed
   thoracostomy, with or without sclerosing agents. Complications of all
   treatments were infrequent. A limited symptomatic recurrence was
   observed in 2 of 17 pneumothoraces successfully treated with open
   thoracotomy. Recurrence also occurred in 1 of 8 treated with
   observation, 3 of 9 treated with closed thoracostomy, and 1 of 14
   treated with closed thoracostomy and sclerosing agents. A loss of
   vital capacity was usually noted 4 to 18 months after resolution,
   regardless of treatment. Forty per cent of patients in both operative
   and nonoperative groups survived 3 years. In our experience, open
   thoracotomy can be used safely for treatment of unresolved or
   recurrent pneumothorax and warrants further evaluation as a primary
   therapy for pneumothorax in patients with cystic fibrosis.
RF 001   LIFSCHITZ MI          AM J DIS CHILD                 116   633 968
   002   BOAT TF               JAMA                           209  1498 969
   003   MITCHELL-HEGGS PF     THORAX                          25   165 970
   004   HOLSCLAW DS           CLIN PEDIATR                     9   346 970
   005   SMITH WG              THORAX                          17   342 962
   006   ALDER RH              ANN THORAC SURG                  5   474 968
   007   ANDERSEN I            DIS CHEST                       54   230 968
   008   CATTANEO SM           J THORAC CARDIOVASC SURG        66   467 973
   009   KATTWINKEL J          JAMA                           226   557 973
   010   ANON                  BR MED J                         1   720 968
   011   HORNE NW              BR MED J                         1   281 966
   012   ANON                  AM REV RESPIR DIS               88   275 963
   013   ROUSDELL HT JR        ARCH SURG                       87   161 963
   014   YOUMANS CR            AM J SURG                      120   644 970
   015   SEREMETIS MG          CHEST                           57    65 970
   016   COLLINS HA            AM SURGEON                      29   844 963
   017   INOUYE WY             DIS CHEST                       51    67 967
   018   HICKOK DF             SURG GYNECOL OBSTET            120   499 965
   019   THOMAS PA             J THORAC CARDIOVASC SURG        39   194 960
   020   GOBBEL WG             J THORAC CARDIOVASC SURG        46   331 963
   021   CLARK TA              AM J SURG                      124   728 972
   022   MATTHEWS LW           J PEDIATR                       65   558 964
   023   MATTHEWS LW           PEDIATRICS                      39   176 967
   024   BERNHARD WF           DIS CHEST                       42   403 962
   025   KLASSEN KP            JAMA                           182   111 962
CT   1   STERN RC              J PEDIATR                       89   406 976
     2   WOOD RE               AM REV RESPIR DIS              113   833 976
     3   LUCK SR               J THORAC CARDIOVASC SURG        74   834 977
     4   RICH RH               J PEDIATR SURG                  13   237 978
     5   SCHEELE J             CHIRURG                         49   236 978
     6   FINK RJ               CHEST                           74   643 978
     7   LARRIEU AJ            ANN THORAC SURG                 28   146 979
     8   WOOD RE               SOUTH MED J                     72   189 979
     9   STERN RC              AM J DIS CHILD                 134   267 980
    10   MCLOUD TC             RADIOLOGY                      135   313 980
    11   GELFAND ET            CAN J SURG                      24   458 981
    12   TABACHNIK NF          SURG GYNECOL OBSTET            152   837 981
    13   KISTLER I             HELV PAEDIATR ACTA              36   495 982
    14   PENKETH ARL           THORAX                          37   850 982
    15   MCLAUGHLIN FJ         J PEDIATR                      100   863 982
    16   SCHUSTER SR           J PEDIATR SURG                  18   492 983
    17   WEEDEN D              THORAX                          38   737 983
    18   DAVIS PB              CHEST                           85   802 984
    19   SEGERER H             KLIN PAEDIATR                  196    44 984
    20   LESTER LA             SEM RESPIR MED                   6   285 985
    21   TOMASHEFSKI JF        HUM PATHOL                      16   253 985
    22   FERNALD GW            SEM ROENTGENOL                  22    87 987

PN 75028
RN 00194
AN 75181879
AU Landau-L-I.  Taussig-L-M.  Macklem-P-T.  Beaudry-P-H.
TI Contribution of inhomogeneity of lung units to the maximal
   expiratory flow-volume curve in children with asthma and cystic
   fibrosis.
SO Am-Rev-Respir-Dis. 1975 Jun. 111(6). P 725-31.
MJ ASTHMA: pp.  CYSTIC-FIBROSIS: pp.  RESPIRATION.
MN ADOLESCENCE.  ADULT.  AGE-FACTORS.  ANTHROPOMETRY.  CHILD.  HUMAN.
   MAXIMAL-EXPIRATORY-FLOW-VOLUME-CURVES.
   MAXIMAL-MIDEXPIRATORY-FLOW-RATE.  VITAL-CAPACITY.
AB Normal children as well as those with asthma and cystic fibrosis were
   studied to assess the contribution of lung zones emptying at
   different rates to the curvilinearity of the maximal expiratory flow-
   volume curve. Lung volumes, maximal expiratory flow-volume curves
   breathing air and then breathing a helium-oxygen mixture, and single-
   breath nitrogen washouts were measured. Forced expiratory maneuvers
   from lung volumes near functional residual capacity were performed to
   produce transients of flow exceeding maximal flow defined by the full
   flow-volume curve. Normal children and those with asthma and mild
   cystic fibrosis had small or no transients. Those with severe cystic
   fibrosis had large transients as well as increased phase I on the
   nitrogen washout curves. These large transients were associated with
   increased curvilinearity of the maximal expiratory flow-volume curve
   and smaller than normal flow response breathing helium. In severe
   cystic fibrosis, the large transients suggest sequential emptying of
   fast and slow spaces, which influences the shape of the maximal
   expiratory flow-volume curve. The fast space could be due to
   compression of an enlarged anatomic dead space. Any time constant
   inequality between parenchymal units present in asthma and mild
   cystic fibrosis does not appear to contribute significantly to the
   shape of the maximal expiratory flow-volume curve.
RF 001   FRY DL                AM J MED                        16    80 954
   002   HYATT RE              J APPL PHYSIOL                  13   331 958
   003   FRY DL                AM J MED                        29   672 960
   004   MEAD J                J APPL PHYSIOL                  22    95 967
   005   MACKLEM PT            J APPL PHYSIOL                  25   159 968
   006   TAKISHIMA TG          SCAND J RESPIR DIS              48   384 967
   007   DUBOIS AB             J CLIN INVEST                   35   322 956
   008   MEAD J                J APPL PHYSIOL                  15   736 960
   009   WENG TR               AM REV RESPIR DIS               99   879 969
   010   BEAUDRY PH            AM REV RESPIR DIS               95   248 967
   011   POLGAR G              PULMONARY FUNCTION TESTING IN            971
   012   ZAPLETAL A            J APPL PHYSIOL                  26   308 969
   013   DESPAS PJ             J CLIN INVEST                   51  3235 972
   014   FOX WW                PEDIATRICS                      54   293 974
   015   ANTHONISEN NR         RESPIR PHYSIOL                   8    58 969
   016   KNUDSON RJ            J APPL PHYSIOL                  36   653 974
   017   ZUELZER WW            PEDIATRICS                       4    53 949
   018   ESTERLY JR            JOHNS HOPKINS MED J            122    94 968
   019   FRY DL                COMPUT BIOMED RES                2   111 968
   020   PRIDE NB              J APPL PHYSIOL                  23   646 967
   021   HILL DJ               AM REV RESPIR DIS              106   873 972
   022   LANDAU LI             AM REV RESPIR DIS              108   593 973
   023   LANDAU LI             AUST NZ J MED                    3   557 973
   024   MACKLEM PT            PHYSIOL REV                     51   368 971
   025   FRASER RG             BRONCHIAL DYNAMICS HEALTH OBS         76 970
   026   FOWLER WS             AM J PHYSIOL                   154   405 948
   027   ZAPLETAL A            PEDIATRICS                      48    64 971
   028   MELLINS RB            PEDIATRICS                      41   560 968
   029   MANSELL A             AM REV RESPIR DIS              109   190 974
CT   1   ANCIC P               REV MED CHIL                   104   513 976
     2   CERECEDA J            REV MED CHIL                   104   519 976
     3   WOOD RE               AM REV RESPIR DIS              113   833 976
     4   LIGAS JR              J APPL PHYSIOL                  42   607 977
     5   PROCTOR DF            AM REV RESPIR DIS              115    97 977
     6   WEBSTER PM            AM REV RESPIR DIS              115   805 977
     7   KEENS TG              AM REV RESPIR DIS              116   853 977
     8   KRAEMER R             HELV PAEDIATR ACTA              34   417 979
     9   MELISSINOS CG         J APPL PHYSIOL                  47  1043 979
    10   KRAEMER R             SCHWEIZ MED WOCHENSCHR         109    39 979
    11   KATTAN M              THORAX                          35   531 980
    12   JANSEN JM             AM REV RESPIR DIS              122   221 980
    13   MARAZZINI L           RESPIRATION                     42    88 981
    14   HOLZER FJ             ARCH DIS CHILD                  56   455 981
    15   LOUGHLIN GM           CHEST                           79   206 981
    16   PESLIN R              BULL EUR PHYSIOPATH RESP        18   679 982
    17   LEMEN RJ              J APPL PHYSIOL                  53   977 982
    18   REDDING GJ            AM REV RESPIR DIS              126    31 982
    19   VANPELT W             BULL EUR PHYSIOPATH RESP        19   P83 983
    20   TECULESCU DB          BULL EUR PHYSIOPATH RESP        21   193 985
    21   VANPELT W             METH INF MED                    24    91 985
    22   PEDERSEN OF           J APPL PHYSIOL                  58  1305 985
    23   PYSZCZYNSKI D         J APPL PHYSIOL                  59    28 985
    24   ZACH MS               AM REV RESPIR DIS              131   537 985
    25   DARGA LL              PEDIATR PULMONOL                 2    82 986
    26   OBERWALDNER B         PEDIATR PULMONOL                 2   358 986
    27   ODONNELL CR           J APPL PHYSIOL                  61  2243 986

PN 75029
RN 00195
AN 75181880
AU Wood-R-E.  Wanner-A.  Hirsch-J.  Farrell-P-M.
TI Tracheal mucociliary transport in patients with cystic fibrosis and
   its stimulation by terbutaline.
SO Am-Rev-Respir-Dis. 1975 Jun. 111(6). P 733-8.
MJ CYSTIC-FIBROSIS: pp.  MUCUS.  TERBUTALINE: pd.  TRACHEA: pp.
MN ADOLESCENCE.  ADULT.  AIRWAY-OBSTRUCTION: dt.  BRONCHOSCOPY.
   CILIA:  de.  CYSTIC-FIBROSIS: co.  FEMALE.  HUMAN.  MALE.
   MUCOUS-MEMBRANE:  pp, de.  STIMULATION-CHEMICAL.  TERBUTALINE: tu.
   TRACHEA:  de.
AB Tracheal mucous velocity was measured by observing the motion of
   teflon discs across the tracheal mucosa through a fiberoptic
   bronchoscope. The average rate of movement in 14 adult patients with
   cystic fibrosis was 2.6 mm per min plus or minus 3.3 SD, compared
   with 20.1 mm per min plus or minus 6.3 in 20 normal subjects of the
   same age (P less than 0.001). This failure of mucociliary transport
   may play a role in the pathogenesis of the pulmonary disease in
   cystic fibrosis. Administration of a beta-adrenergic agent,
   terbutaline, increased the average mucous velocity in the patients
   with cystic fibrosis (to 5.5 mm per min plus or minus 3.6 SD, P less
   than 0.001) but not in control subjects. This observation has
   potential therapeutic significance.
RF 001   SANCHIS J             N ENGL J MED                   288   651 973
   002   NEWHOUSE M            IN: MANGOS JA                        319 973
   003   SACKNER MA            J APPL PHYSIOL                  34   495 973
   004   TAUSSIG LM            J PEDIATR                       82   380 973
   005   SANTA CRUZ R          AM REV RESPIR DIS              109   458 974
   006   SACKNER MA            ANN INTERN MED                  82    40 975
   007   WARING WW             N ENGL J MED                   288   681 973
   008   MORROW PE             IN: BOUHUYS A                        299 970
   009   CAMNER P              SCAND J RESPIR DIS              54   272 973
   010   THOMSON ML            N ENGL J MED                   289   749 973
   011   ASMUNDSSON T          AM REV RESPIR DIS              102   388 970
   012   HILDING AC            AM J PHYSIOL                   191   404 957
   013   ADLER KB              ARCH ENVIRON HEALTH             27   364 973
   015$  EWERT G               ANN OTOLARYNGOL                 76   359 967
   016   CHARMAN J             BIORHEOLOGY                      9   185 972
   017   MAGID SL              ARCH OTOLARYNGOL                86   212 967
   018   SPOCK A               PEDIATR RES                      1   173 967
   019   BOWMAN BH             SCIENCE                        164   325 969
   020   ESTERLY JR            JOHNS HOPKINS MED J            122    94 968
   021   SPENCER H             PATHOLOGY OF THE LUNG                    968
   022   HILDING AC            MED THORAC                      22   329 965
   023   LOURENCO RV           J CLIN INVEST                   50  1411 971
   024   HINDS L               ANESTHESIOLOGY                  34   445 971
   025   LEEGAARD J            ARCH DIS CHILD                  48   229 973
   026   LAURENZI GA           N ENGL J MED                   279   333 968
   027   ASMUNDSSON T          IN: DULFANO MJ                       107 973
   028   BOYD EM               RESPIRATORY TRACT FLUID                  972
CT   1   BOWMAN BH             LIFE SCI                        19  1289 976
     2   BOWMAN BH             TEX REP BIOL MED                34     1 976
     3   DULFANO MJ            ANN ALLERGY                     37   357 976
     4   MOSSBERG B            SCAND J RESPIR DIS              57   119 976
     5   SACKNER MA            CHEST                           69   593 976
     6   ANON                  J PEDIATR                       88   711 976
     7   DISANTAGNESE PA       N ENGL J MED                   295   597 976
     8   CLARKE CW             CLIN ALLERGY                     7   527 977
     9   SORENSEN RU           INFECT IMMUN                    18   735 977
    10   GEUMEI AM             CHEST                           72   267 977
    11   ROSSMAN CM            J PEDIATR                       90   579 977
    12   FRIEDMAN M            AM REV RESPIR DIS              115    67 977
    13   SHIH CK               AM REV RESPIR DIS              115   989 977
    14   KNIGHT RK             PRACTITIONER                   218   286 977
    15   GUERRIN F             LILLE MED                       23   368 978
    16   MARIN MG              J APPL PHYSIOL                  44   900 978
    17   KOLLBERG H            SCAND J RESPIR DIS              59   297 978
    18   SACKNER MA            CHEST                           73   958 978
    19   GIORDANO A            ANN OTOL RHINOL LARYNGOL        87   484 978
    20   SACKNER MA            ANN OTOL RHINOL LARYNGOL        87   474 978
    21   WILSON GB             J LAB CLIN MED                  92   463 978
    22   GOTZ M                EUR J PEDIATR                  127   133 978
    23   NAGY EC               PEDIATR RES                     13   729 979
    24   SACKNER MA            BULL EUR PHYSIOPATH RESP        15   505 979
    25   AFZELIUS BA           INT REV EXP PATHOL              19     1 979
    26   STURGESS JM           PEDIATR CLIN NORTH AM           26   481 979
    27   MOSSBERG B            ACTA PHARMACOL TOXICOL          44    41 979
    28   WANNER A              AM J MED                        67   477 979
    29   WOOD RE               SOUTH MED J                     72   189 979
    30   DAVIS B               AM REV RESPIR DIS              120   547 979
    31   CLARKE SW             BR J CLIN PHARMACOL              9   537 980
    32   PAVIA D               CLIN RESP PHYSIOL               16   335 980
    33   AFZELIUS BA           THORAX                          35   401 980
    34   SVENONIUS E           RESPIRATION                     40   226 980
    35   WELLER PH             RESPIRATION                     40    53 980
    36   CAMNER P              CLIN SCI                        59    79 980
    37   MOSSBERG B            EUR J RESPIR DIS                61    51 980
    38   DAVIS PB              J LAB CLIN MED                  96    75 980
    39   SORENSEN RU           PEDIATR RES                     15    14 981
    40   BATEMAN JRM           THORAX                          36   683 981
    41   RUTLAND J             THORAX                          36   654 981
    42   SADOUL P              CHEST                           80   885 981
    43   SORENSEN RU           AM REV RESPIR DIS              123    37 981
    44   ANON                  LANCET                           1   203 982
    45   SCHLESINGER RB        BIOSCIENCE                      32    45 982
    46   KANG SB               ANESTH ANALG CLEVE              61   793 982
    47   VOSS MJ               J ALLERGY CLIN IMMUNOL          69   536 982
    48   BATEMAN JRM           BR J CLIN PHARMACOL             15   695 983
    49   DAVIS PB              J CHRON DIS                     36   269 983
    50   PAVIA D               EUR J RESPIR DIS                64   304 983
    51   DAVIS PB              J PEDIATR                      102   177 983
    52   GAIL DB               AM REV RESPIR DIS              127   366 983
    53   RUTLAND J             AM REV RESPIR DIS              128  1030 983
    54   BOUCHER RC            LUNG                           161     1 983
    55   OHASHI Y              ACTA OTOLARYNGOL STOCKH SUPPL  397    49 983
    56   BRIDGES MA            ANN NY ACAD SCI                421   360 983
    57   KATZ S                CELL CALC                        5   421 984
    58   CAMNER P              ATEMWEGS LUNGENKRANKH           10   237 984
    59   WEISS T               ATEMWEGS LUNGENKRANKH           10   383 984
    60   MATTHEWS LW           PEDIATR CLIN NORTH AM           31   133 984
    61   REDDING GJ            PEDIATR CLIN NORTH AM           31   891 984
    62   STUART BO             ENVIRON HEALTH PERSPECT         55   369 984
    63   LURIE A               REV MALAD RESPIR                 2   117 985
    64   DAVIS PB              SEM RESPIR MED                   6   261 985
    65   MISCHLER EH           SEM RESPIR MED                   6   271 985
    66   REYNOLDS HY           DISEASE A MONTH                 31     1 985
    67   RONCORONI AJ          MED (BUENOS AIRES)              45   183 985
    68   GREENSTONE M          BR J DIS CHEST                  79     9 985
    69   SOSULSKI R            PEDIATR PULMONOL                 2   269 986
    70   VITTING C             J VET MED (A)                   33   706 986
    71   WILSON R              THORAX                          41   453 986
    72   VERBOON JML           EUR J RESPIR DIS                69   169 986
    73   SYKES DA              THORAX                          42   256 987

PN 75030
RN 00196
AN 76059953
AU Rossman-C-M.  Dolovich-M.  Dolovich-J.  Wilson-W.  Newhouse-M.
TI Mucociliary clearance.
SO Am-Rev-Respir-Dis. 1975 Nov. 112(5). P 744.
MJ CYSTIC-FIBROSIS: pp.  NASAL-MUCOSA: pp.
MN COUGH.  HUMAN.
EX Mucociliary clearance data obtained by our group in relatively
   healthy cystic fibrosis subjects was not affected by cough.  The
   majority of subjects mentioned in the original article did not cough
   during the study and indeed were chosen because they were relatively
   healthy at the time.  It was possible to study them over fairly long
   periods without interference from cough and thus the relatively
   normal clearance times demonstrated were presumably due to
   mucociliary transport.  Reference was made to nasal mucociliary
   clearance studies in patients with cystic fibrosis and normal
   subjects which indicated that clearance was similar in both groups
   until mild inflammation of the nasal mucosa was produced.  We would
   like to point out that the work was performed in our Laboratory,
   since no reference was given in the discussion.
RF 001   SANCHIS J             N ENGL J MED                   288   651 973
   002   ROSSMAN CM            PEDIATR RES                      8   469 974

PN 75031
RN 00197
AN 75223179
AU Brown-B-R-Jr.  Walson-P-D.  Taussig-L-M.
TI Congenital metabolic diseases of pediatric patients: anesthetic
   implications.
SO Anesthesiology. 1975 Aug. 43(2). P 197-209.
MJ ANESTHESIA.
MN ACIDOSIS: pc.  DYSAUTONOMIA-FAMILIAL.  CHILD.  CYSTIC-FIBROSIS.
   GLUCOSEPHOSPHATASE-DEFICIENCY.  GLYCOGENOSIS-5.  HOMOCYSTINURIA: me.
   HUMAN.  HYPERINSULINISM.  HYPOGLYCEMIA: pc.
   METABOLISM-INBORN-ERRORS.  MUSCULAR-DISEASES: cn.
   MYOTONIA-ATROPHICA.  MYOTONIA-CONGENITA.  SUCCINYLCHOLINE: ae.
   SUPPORT-U-S-GOVT-P-H-S.
EX The large number of congenital metabolic disorders makes a complete
   discussion of the biochemical problems, hazards, pharmacologic
   implications, and anesthetic recommendations for each impossible.
   This review is confined to discussion of certain aspects of several
   genetically acquired diseases of metabolism which the
   anaesthesiologist may be called upon to manage in the pediatric
   patient.  Every genetic metabolic disease is the result of a specific
   enzyme defect (or defects) in function or in amount.  In this review,
   diseases in which defects are known (e.g., homocystinuria), suspected
   (e.g., myotonia congenita), and unknown (e.g., cystic fibrosis) are
   discussed.  Therapeutic approaches to genetic metabolic disease
   include: supplying the missing product; preventing substrate
   accumulation; preventing alternate product synthesis; enzyme
   induction; enzyme replacement; increasing deficient function with
   cofactor administration; and compensatory therapy.  Obviously, the
   ideal way to treat the consequences of a genetic disease is to
   normalize the patient biochemically.  For diseases where the
   pathophysiology is clear, this goal is approachable; for conditions
   where the pathophysiology is unknown, only compensatory therapy is
   possible.
RF 001   SCHIMKE RN            AMINO ACID METAB GENET VARIAT        297 967
   002   CUSWORTH DC           BR MED BULL                     25    42 969
   003   HARKER LA             N ENGL J MED                   291   537 974
   004   MUDD SH               J CLIN INVEST                   49  1762 970
   005   HOLLOWELL JG JR       PROC SOC EXP BIOL MED          129   327 968
   006   CARSON NAJ            ARCH DIS CHILD                  44   387 969
   007   CHASE HP              ARCH DIS CHILD                  42   514 967
   008   HAMBRAEUS L           CLIN SCI                        35   457 968
   009   PERRY TL              LANCET                           2   474 968
   010   WONG PWK              PEDIATR RES                      2   149 968
   011   GAULL GE              PEDIATR RES                      5   265 971
   012   WONG PWK              PEDIATR RES                      6   172 972
   013   STURMAN JA            BIOCHEM MED                      5   404 971
   014   CAREY MC              IR J MED SCI                     6   488 966
   015   CAREY MC              AM J MED                        45    26 968
   016   MUDD SH               BIOCHEM BIOPHYS RES COMMUN      46   905 972
   017   GOODMAN SI            BIOCHEM MED                      4   500 970
   018   TALLAN HH             BIOCHEM MED                      9    90 974
   019   STURMAN JA            SCIENCE                        169    74 970
   020   FINKELSTEIN JD        METABOLISM                      23   387 974
   021   HOLLOWELL JG JR       LANCET                           2  1428 969
   022   RITCHIE JWK           J OBSTET GYNAECOL BR COMMONW    80   664 973
   023   HOLMGREN G            UPSALA J MED SCI                78   215 973
   024   RATNOFF OD            SCIENCE                        162  1007 968
   025   CROOKE JW             BR J ANAESTH                    43    96 971
   026   HARKER LA             PROC AM SOC HEMATOL 15TH ANN          46 972
   027   CROSS HE              AM J OPHTHALMOL                 75   405 973
   028   SCHIMKE RN            JAMA                           193   711 965
   029   BECKER PE             ACTA NEUROL SCAND               49   480 973
   030   BAXTER DW             J CAN MED ASSOC                 85   113 961
   031   THRUSCH DC            BRAIN                           95   537 972
   032   KIM C                 HAWAII MED J                    33    15 974
   033   WINTERS JL            J BONE JOINT SURG               52  1345 970
   034   CAUGHEY JE            DYSTROPHIA MYOTONICA                     963
   035   HARVEY JC             AM J MED                        39    81 965
   036   WELSH JD              ARCH INTERN MED                114   669 964
   037   FEARRINGTON EL        AM HEART J                      67   599 964
   038   FISCH C               N ENGL J MED                   251   527 954
   039   ROSENTHAL G           NY STATE J MED                  67   940 967
   040   WATTERS GV            ARCH NEUROL                     17   137 967
   041   KOHN NN               N ENGL J MED                   271  1179 964
   042   BOURKE TD             BR J ANAESTH                    29    35 957
   043   COBHAM IG             ANESTH ANALG CLEVE              43    22 964
   045   DI SANTAGNESE PA      PEDIATRICS                      18   387 956
   046   SCHUSTER SR           J THORAC CARDIOVASC SURG        48   750 964
   047   HOLSCLAW DS           MINN MED                        52  1547 969
   048   DOERSHUK CF           ANESTH ANALG CLEVE              51   413 972
   049   SALANITRE E           ANESTHESIOLOGY                  25   801 964
   050   KATTWINKEL J          J PEDIATR                       82   234 973
   051   BONDY PK              DISORDERS CARBOHYD METAB DUNC            974
   052   CORI GT               J BIOL CHEM                    199   661 952
   053   FIELD JB              J CLIN INVEST                   44  1240 965
   054   SCHWARTZ R            PEDIATRICS                      19   585 957
   055   LOWE CU               J CLIN INVEST                   39  1007 960
   056   HOWELL RR             IN: STANBURY JB                      149 972
   057   COX JM                ANESTHESIOLOGY                  29  1221 968
   058   JACKSON SH            IN: KATZ J                               973
   059   ZUPPINGER K           HELV MED ACTA                   35   496 969
   060   MCARDLE B             CLIN SCI                        10    13 951
   061   MOMMAERTS WFHM        PROC NAT ACAD SCI USA           45   791 959
   062   SCHMID R              J CLIN INVEST                   38  2044 959
   063   DANCIS J              N ENGL J MED                   274   207 966
   064   FILLER J              J PEDIATR                       66   509 965
   065   DANCIS J              ANN NY ACAD SCI                151   876 968
   066   HENKIN RI             LIFE SCI                         3  1319 964
   067   SMITH AA              N ENGL J MED                   270   704 964
   068   SMITH AA              N ENGL J MED                   268   705 963
   069   GITTOW SE             PEDIATRICS                      46   513 970
   070   WEINSHILBOUM RM       N ENGL J MED                   285   938 971
   071   MASON DT              AM J MED                        41   898 966
   072   KRICHMAN MM           JAMA                           170   529 959
   073   MCCAUGHEY TJ          CAN ANAESTH SOC J               12   558 965
   074   MERIDY HW             CAN ANAESTH SOC J               18   563 971
CT   1   CAMPBELL RL           J ORAL MAXILLOFAC SURG          40   497 982
     2   LYNN A                CLIN ANAESTHESIOL                3   739 985
     3   KEON TP               INT ANESTHESIOL CLIN            23    87 985

PN 75032
RN 00198
AN 76060265
AU Lamm-L-U.  Thorsen-I-L.  Petersen-G-B.  Jorgensen-J.  Henningsen-K.
   Bech-B.  Kissmeyer-Nielsen-F.
TI Data on the HL-A linkage group.
SO Ann-Hum-Genet. 1975 May. 38(4). P 383-90.
MJ HISTOCOMPATIBILITY-ANTIGENS.  HLA-ANTIGENS.  LINKAGE-GENETICS.
MN BLOOD-GROUPS.  COMPUTERS.  CYSTIC-FIBROSIS: fg.  GENE-FREQUENCY.
   GENOTYPE.  HUMAN.  PHOSPHOGLUCOMUTASE: bi.  RECOMBINATION-GENETIC.
AB Lod scores from a study in 229 families of the linkage relations of
   HL-A-PGM3 to 19 marker loci and cystic fibrosis are reported. The
   data exclude that ADA belongs to this linkage group while they give
   weak support for the inclusion of P. There is weak evidence for
   linkage of cystic fibrosis to PGM3, but none for linkage to HL-A. No
   new suggestive linkages appeared.
RF 001   AZEN EA               BIOCHEM GENET                    3   215 969
   002   BACH FH               AM J HUM GENET                  25   208 973
   003   CHEN SH               SCIENCE                        173   148 971
   004   CREAGAN RP            LANCET                           2  1449 973
   005   DANES BS              J EXP MED                      129   775 969
   006   DANES BS              AM J HUM GENET                  23   297 971
   007   DAUSSET J             HISTOCOMPATIBILITY TESTING               972
   008   EDWARDS JH            CLIN GENET                       3   371 972
   009   EDWARDS JH            HISTOCOMPATIBILITY TESTING               972
   010   FELLOUS M             EUR J IMMUNOL                    3   543 973
   011   JONGSMA A             HUMANGENETIK                    20   195 973
   012   LAMM LU               HUM HERED                       24   273 974
   013   LAMM LU               HUM HERED                       20   305 970
   014   LAMM LU               TISSUE ANTIGENS                  2   205 972
   015   LAMM LU               NATURE NEW BIOL                231   109 971
   016   MAYNARD-SMITH S       MATH TABLES RES WORKERS IN HU            961
   017   MIDDLETON J           TISSUE ANTIGENS                  4   366 974
   018   RENWICK JH            BR MED BULL                     25    65 969
   019   ROBSON EB             ANN HUM GENET                   36   393 973
   021   SVEJGAARD A           TISSUE ANTIGENS                  1    81 971
CT   1   JONES EA              SOMATIC CELL GENET               2   483 976
     2   BIJNEN AB             J IMMUNOGENET                    3   171 976
     3   WEITKAMP LR           TISSUE ANTIGENS                  7   273 976
     4   GOODCHILD MC          J MED GENET                     13   417 976
     5   BODMER WF             CYTOGENET CELL GENET            16    24 976
     6   LEWIS M               CYTOGENET CELL GENET            16   317 976
     7   SIMON M               GUT                             17   332 976
     8   DAY NK                VOX SANG                        31    96 976
     9   JERSILD C             TRANSPLANTAT REV                32    43 976
    10   RAUM D                J CLIN INVEST                   58  1240 976
    11   ROTTHAUWE HW          DTSCH MED WSCHR                101   849 976
    12   MUNRO A               NATURE                         264   145 976
    13   HOIBY N               ACTA PATH MICROBIOL SCAND (C) S262     3 977
    14   BOMFORD A             LANCET                           1   327 977
    15   KOMPF J               SCAND J IMMUNOL                  6   453 977
    16   FELLOUS M             EUR J IMMUNOL                    7    22 977
    17   GIRALDO G             CLIN IMMUNOL IMMUNOPATHOL        8   377 977
    18   OHELA K               TISSUE ANTIGENS                  9    90 977
    19   SAFWENBERG J          TISSUE ANTIGENS                 10   287 977
    20   BREUNING MH           HUM GENET                       37   131 977
    21   ROSENFELD SI          J IMMUNOL                      119   604 977
    22   SIMON M               N ENGL J MED                   297  1017 977
    23   HENNEQUET A           TISSUE ANTIGENS                 12   159 978
    24   LEWIS M               CYTOGENET CELL GENET            22   452 978
    25   WEITKAMP L            CYTOGENET CELL GENET            22    92 978
    26   BODMER WF             PROC R SOC LOND (B)            202    93 978
    27   BODMER WF             HARVEY LECTURES               1978    91 978
    28   CUZNER ML             MOL ASP MED                      2   147 979
    29   BERGER R              CLIN GENET                      15   245 979
    30   HAUPTMANN G           REV FR TRANSFUS IMMUNOHEMATOL   22   587 979
    31   PEPPER B              HUM HERED                       29   279 979
    32   BENDER K              HUM GENET                       49   159 979
    33   RAUM  D               J CLIN INVEST                   64   858 979
    34   HERROD HG             J PEDIATR                       94   676 979
    35   RUBINSTEIN P          J IMMUNOL                      122  2584 979
    36   TACIEREUGSTER H       HELV PAEDIATR ACTA              35    31 980
    37   NAKAO Y               CLIN EXP IMMUNOL                42    20 980
    38   PEDERSEN L            HUM GENET                       54   371 980
    39   LOPEZLARREA C         HUM GENET                       57   317 981
    40   PLATZ P               DIABETOLOGIA                    23    16 982
    41   NIELSEN OH            ACTA PAEDIATR SCAND             71   339 982
    42   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982
    43   MARDER HK             KIDNEY INT                      23   749 983
    44   ROBSON EB             ANN HUM GENET                   48   347 984
    45   REGUEIRO JR           HUM GENET                       67   437 984
    46   EIBERG H              CLIN GENET                      27   206 985
    47   EIBERG H              CLIN GENET                      28   265 985
    48   PEDERSEN  EB          Q J MED                         57   883 985
    49   SCHMIEGELOW K         CLIN GENET                      29   374 986
    50   WERDELIN L            ACTA NEUROL SCAND               73     1 986

PN 75033
RN 00199
AN 75181965
AU Lieberman-J.  Rodbard-S.
TI Low blood pressure in young adults with cystic fibrosis: an effect
   of chronic salt loss in sweat?.
SO Ann-Intern-Med. 1975 Jun. 82(6). P 806-8.
MJ BLOOD-PRESSURE.  CYSTIC-FIBROSIS: pp.  SWEATING.
   WATER-ELECTROLYTE-BALANCE.
MN ADOLESCENCE.  ADULT.  BLOOD-PRESSURE-DETERMINATION.
   CYSTIC-FIBROSIS: me.  EXERTION.  FEMALE.  HUMAN.  MALE.  SEX-FACTORS.
AB Young adults with cystic fibrosis have lower blood pressures than
   control subjects of similar age and sex. The low blood pressure may
   be related to the excessive loss of salt in the sweat of these
   patients. A beneficial effect of the cystic fibrosis gene may be
   protection against developing hypertension in both the homozygous and
   heterozygous states, especially if the heterozygote has borderline
   elevation of sweat electrolytes.
RF 001   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   002   JOHANSEN PG           LANCET                           1   455 968
   003   RODBARD S             AM HEART J                      53   205 957
   004   DI SANTAGNESE PA      ANN INTERN MED                  50  1321 959
   005   SHWACHMAN H           PEDIATRICS                      36   689 965
   006   COATES EO JR          DIS CHEST                       49   195 966
   007   TOMASHEFSKI JF        CHEST                           57    28 970
   008   ROSENLUND ML          ANN INTERN MED                  78   959 973
   009   MOSS AJ               PROBLEMS OF BLOOD PRESSURE IN            962
   010   HULL DH               PRACTITIONER                   210   195 973
   011   QUINTERO-ATENCIO J    N ENGL J MED                   274  1224 966
   012   LEVI J                ISR J MED SCI                    6   665 970
   013   LIEBERMAN J           AM J MED SCI                   246   537 963
   014   HOLMAN RL             PEDIATRICS                      24    34 959
   015   HALLETT WY            AM REV RESPIR DIS               92   714 965
CT   1   BEDROSSIAN CWM        AM J CLIN PATHOL                70   244 978
     2   LEMEN RJ              AM REV RESPIR DIS              117   639 978
     3   BARRY MM              J AM DIET ASSOC                 75   446 979
     4   LAKE CR               CLIN CHIM ACTA                  92   141 979
     5   STALCUP SA            J CLIN INVEST                   67   201 981
     6   MOSS AJ               PEDIATRICS                      70   728 982
     7   MELLINS RB            AM J ROENTGENOL                138   999 982
     8   DAVIS PB              J CHRON DIS                     36   269 983
     9   MITCHELL EA           AUST PAEDIATR J                 21   127 985
    10   DAVIS PB              HORM METAB RES                  18   217 986

PN 75034
RN 00200
AN 75181973
TI Pseudomonas aeruginosa infections: persisting problems and current
   research to find new therapies.
SO Ann-Intern-Med. 1975 Jun. 82(6). P 819-31.
MJ PSEUDOMONAS-AERUGINOSA.  PSEUDOMONAS-INFECTIONS: th.
MN ADULT.  AGRANULOCYTOSIS: co, th.  ANIMAL.  ANTIBIOTICS.
   ANTIBODIES-BACTERIAL: bi.  BLOOD-TRANSFUSION.  BONE-MARROW: de.
   CHILD.  CYSTIC-FIBROSIS: co.  DOGS.  GRANULOCYTES.  HUMAN.
   IMMUNOSUPPRESSIVE-AGENTS: ae.  IN-VITRO.  LEUKEMIA: co.
   LYMPHOMA: co.  PSEUDOMONAS-AERUGINOSA: ip.
   PSEUDOMONAS-INFECTIONS: mi, im.  IMMUNOTHERAPY.  BONE-MARROW: cy.
AB Despite the availability of specific antibiotics, Pseudomonas
   aeruginosa bacteria still cause troublesome infections in patients
   with a variety of illnesses: extensive thermal injury, leukopenia
   from antineoplastic chemotherapy and other forms of immunosuppressive
   treatment, chronic pulmonary disease such as cystic fibrosis, or
   intravenous narcotic use. The use of antibiotics has improved the
   prognosis of pseudomonas infections considerably. However, patients
   with marginal or defective host immunity may need more extensive
   therapy to master the infection. By evaluating additional modalities
   of treatment such as granulocyte replacement, improved usage of
   antibiotics, and active (prophylaxis) or passive antibody
   administration, the optimal combination may be found.
RF 001   LEVINE AS             SEMIN HEMATOL                   11   141 974
   002   LEVINE AS             SEMIN HEMATOL                    9   141 972
   003   BODEY GP              ANN INTERN MED                  64   328 966
   004   LEVINE AS             N ENGL J MED                   288   477 973
   005   BODEY GP              EUR J CANCER                     9   435 973
   006   SCHIMPFF SC           EUR J CANCER                     9   445 973
   007   ANDRIOLE VT           J INFECT DIS                   129   124 974
   008   PENNINGTON JE         J INFECT DIS SUPPL             130   159 974
   010   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   011   BIGGAR WD             PROC NAT ACAD SCI USA           68  1716 971
   012   BOXERBAUM B           AM REV RESPIR DIS              108   777 973
   013   DOGGETT RG            APPL MICROBIOL                  18   936 969
   014$  SHIONOYA H            JAPAN J EXP MED                 37   359 972
   015   NITO T                TROP MED                        14     1 972
   016   PAVLATOU M            ANN INST PASTEUR PARIS         102   300 962
   017   FISHER MW             J BACTERIOL                     98   835 969
   018   HOMMA JY              JAPAN J EXP MED                 41    89 971
   019   HOMMA JY              JAPAN J EXP MED                 42   171 972
   020   ZIERDT CH             J BACTERIOL                     87  1003 964
   021   SONNENSCHEIN C        ZENTRALBL BAKTERIOL            104   365 927
   022   SCHIMPFF SW           N ENGL J MED                   284  1061 971
   023   TATTERSALL MHN        LANCET                           1   162 972
   024   STRUMIA MH            AM J MED SCI                   187   527 934
   025   BOGGS DR              N ENGL J MED                   290  1055 974
   026   GRAW RG JR            TRANSFUSION                     11    94 971
   027   GRAW RG JR            N ENGL J MED                   287   367 972
   028   MCCREDIE KB           TRANSPLANT PROC                  5   128 973
   029   BENBUNAN M            NOUV REV FR HEMATOL             13   469 973
   030   DALE DC               J CLIN INVEST                   54   664 974
   031   BUCKNER DR            BLOOD                           31   653 968
   032   HERZIG GP             BLOOD                           39   554 972
   033   TILLOTSON JR          ANN INTERN MED                  68   295 968
   034   PENNINGTON JE         AM J MED                        55   155 973
   035   HANESSIAN S           NATURE NEW BIOL                229   209 971
   036   YOUNG LS              J INFECT DIS                   126   257 972
   037   ALEXANDER JW          J TRAUMA                        10   565 970
   038   YOUNG LS              ANN INTERN MED                  79   518 973
   039   HAGHBIN M             CANCER                          32   761 973
   040   BJORNSON AB           INFECT IMMUN                     2   453 970
   041   YOUNG LS              INFECT IMMUN                     2   495 970
   042   ALEXANDER JW          ARCH SURG                      102    31 971
   043   JONES CE              J SURG RES                      14    87 973
   044   GREEN GM              AM REV RESPIR DIS              102   691 970
   045   REYNOLDS HY           J IMMUNOL                      111   358 973
   046   REYNOLDS HY           J LAB CLIN MED                  84   559 974
   047   REYNOLDS HY           J IMMUNOL                      111   358 973
   048   REYNOLDS HY           J CLIN INVEST                   53  1351 974
   049   HAND WL               J CLIN INVEST                   53   354 974
   050   REYNOLDS HY           CLIN RES                        22   427 974
   051   GOLDE DW              N ENGL J MED                   290   875 974
   052   COHN EJ               J AM CHEM SOC                   72   465 950
   053   BUCKLEY RH            AM J DIS CHILD                 124   376 972
CT   1   NEU HC                CLIN HAEMATOL                    5   449 976
     2   DALE DC               BLOOD                           47   869 976
     3   PAREDES L$            REV MED CHIL                   104   615 976
     4   PAREDESP L$           REV MED CHIL                   104   538 976
     5   WOOD RE               AM REV RESPIR DIS              113   833 976
     6   REYNOLDS HY           JAMA                           236  2190 976
     7   HOIBY N               ACTA PATH MICROBIOL SCAND (C) S262     3 977
     8   SENSAKOVIC JW         INFECT IMMUN                    18   304 977
     9   LAVERDIERE M          CURR THER RES CLIN EXP          21   464 977
    10   HARANAKA K            JAP J EXP MED                   47    35 977
    11   KAZMIEROWSKI JA       J INFECT DIS                   135   438 977
    12   BALTCH AL             AM J MED SCI                   274   119 977
    13   KROPINSKI AMB         ANTIMICROB AGENTS CHEMOTHER     13   494 978
    14   MARKOWITZ SM          INFECT IMMUN                    22   530 978
    15   LIM DT                ANN ALLERGY                     41    30 978
    16   PENNINGTON JE         J INFECT DIS                   137   764 978
    17   KULCZYCKI LL          JAMA                           240    30 978
    18   VANFURTH R            NETH J MED                      22   123 979
    19   DIMITRACOPOULOS G     INFECT IMMUN                    23    87 979
    20   PENNINGTON JE         INFECT IMMUN                    25  1029 979
    21   HOLLOWAY BW           MICROBIOL REV                   43    73 979
    22   LOENINGBAUCKE VA      J PEDIATR                       95   630 979
    23   SOTER NA              J PEDIATR                       95   197 979
    24   PENNINGTON JE         J INFECT DIS                   139   396 979
    25   PENNINGTON JE         J INFECT DIS                   140   881 979
    26   PENNINGTON JE         J INFECT DIS                   140    73 979
    27   THOMASSEN MJ          J INFECT DIS                   140   873 979
    28   MCCARTHY MM           CLIN PEDIATR                    19   746 980
    29   KAMIMURA T            INFECT IMMUN                    29    13 980
    30   FICK RB               J IMMUNOL METH                  38   103 980
    31   RAMSEY PG             MEDICINE                        59   206 980
    32   SIEBERT WT            SOUTH MED J                     73    75 980
    33   CRYZ SJ               PROC NAT ACAD SCI USA           77  7199 980
    34   RAINES JM             LARYNGOSCOPE                    90   369 980
    35   PENNINGTON JE         J INFECT DIS                   142   191 980
    36   ROSENSTEIN BJ         JOHNS HOPKINS MED J            147   188 980
    37   FICK RB               CLIN CHEST MED                   2    91 981
    38   CARLONE S             MICROBIOLOGICA                   4   215 981
    39   LANDAU Z              SCAND J INFECT DIS              13   227 981
    40   BLACKWOOD LL          INFECT IMMUN                    32   443 981
    41   CRYZ SJ               INFECT IMMUN                    32   759 981
    42   KOEPP LH              INFECT IMMUN                    33   788 981
    43   LONG GG               AM J VET RES                    42  2129 981
    44   MASHIMO K             JAP J EXP MED                   51   271 981
    45   PENNINGTON JE         J CLIN INVEST                   68  1140 981
    46   MOSS RB               J PEDIATR                       99   215 981
    47   MACONE AB             N ENGL J MED                   304  1445 981
    48   FROLAND SS            SCAND J INFECT DIS            1981    72 981
    49   MOROZ AF              ZH MIKROBIO EPIDEMIO IMMUNOBI 1981     6 981
    50   JANDA JM              MICROB ECOL                      8   335 982
    51   PUGASHETTI BK         J CLIN MICROBIOL                16   686 982
    52   DAVIDSON S            ISR J MED SCI                   18   859 982
    53   PENNINGTON JE         ANTIMICROB AGENTS CHEMOTHER     22   406 982
    54   SATO K                ANTIMICROB AGENTS CHEMOTHER     22   548 982
    55   OTANI T               MICROBIOL IMMUNOL               26    67 982
    56   OHMAN DE              INFECT IMMUN                    37   662 982
    57   WEINER RN             EXP MOL PATH                    37   249 982
    58   PIER GB               J CLIN INVEST                   69   303 982
    59   LAMBRIS J             J INFECT DIS                   145    78 982
    60   LONG GG               J AM VET MED ASSOC             181  1343 982
    61   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    33 982
    62   CRYZ SJ               REV INFECT DIS                   5  S992 983
    63   PATT LM               INT J TISS REACT EXP CLIN ASP    5   135 983
    64   PENNINGTON JE         REV INFECT DIS                   5  S852 983
    65   NEU HC                J ANTIMICROB CHEMOTHER          11     1 983
    66   HOOGKAMPKORSTANJE JAA J ANTIMICROB CHEMOTHER          12   175 983
    67   FICK RB               BULL EUR PHYSIOPATH RESP        19   151 983
    68   URBACH J              ISR J MED SCI                   19   992 983
    69   MARESZBABCZYSZYN J    ARCH IMMUNOL THER EXP           31   199 983
    70   BLACKWOOD LL          INFECT IMMUN                    39   198 983
    71   MARKHAM RB            INFECT IMMUN                    41   232 983
    72   LAL S                 J GEN MICROBIOL                129    93 983
    73   PIER GB               J INFECT DIS                   148   206 983
    74   CONKLIN JJ            SURG GYNECOL OBSTET            156   809 983
    75   ROSE HD               JAMA                           250  2027 983
    76   MACKOWIAK PA          REV INFECT DIS                   6   649 984
    77   PENNINGTON JE         REV INFECT DIS                   6  S657 984
    78   KEREN G               J INFECT                         9    22 984
    79   SPEERT DP             PEDIATR RES                     18   431 984
    80   SCHIFF JB             ANTIMICROB AGENTS CHEMOTHER     25    49 984
    81   SCHIFF JB             ANTIMICROB AGENTS CHEMOTHER     26     1 984
    82   OTANI T               MICROBIOL IMMUNOL               28  1077 984
    83   CRYZ SJ               INFECT IMMUN                    43   795 984
    84   SPEERT DP             INFECT IMMUN                    43  1006 984
    85   PIER GB               J IMMUNOL                      133   734 984
    86   RUSNAK MG             J INFECT DIS                   149   980 984
    87   ELNIMA EI             ZENTRALBL BAKT MIKROB HYG (A)  258   120 984
    88   CRYZ SJ               EUR J CLIN MICROBIOL             4   153 985
    89   LIEBERMAN MM          SURV SYNTH PATHOL RES            4   312 985
    90   SPEERT DP             SURV SYNTH PATHOL RES            4    14 985
    91   MARTY N               MED MALAD INFECT                15   604 985
    92   SUTTORP N             MED WELT                        36  1238 985
    93   KOMIYAMA K            ORAL SURG                       59   590 985
    94   SUTTORP N             J CELL PHYSIOL                 123    64 985
    95   SAMYKINA TD           ZH MIKROBIO EPIDEMIO IMMUNOBI         21 986
    96   PENNINGTON JE         REV INFECT DIS                   8  S426 986
    97   KRIEG DP              J CLIN MICROBIOL                24   986 986
    98   SALERNO RA            MED (BUENOS AIRES)              46   377 986
    99   SEEGER W              INFECT IMMUN                    52   846 986
   100   PENNINGTON JE         INFECT IMMUN                    54   239 986
   101   PIER GB               J CLIN INVEST                   77   491 986
   102   FICK RB               AM REV RESPIR DIS              133   418 986
   103   SPEERT DP             J HOSP INFECT                    9    11 987
   104   KHARAZMI A            TRANS R SOC TROP MED HYG        81    49 987
   105   PENNINGTON JE         J INFECT DIS                   155   973 987

PN 75035
RN 00201
AN 75203428
AU Adshead-P-C.  Martinez-J-R.  Kilburn-K-H.  Hess-R-A.
TI Ciliary inhibition and axonemal microtubule alterations in
   freshwater mussels.
SO Ann-NY-Acad-Sci. 1975 Jun 30. 253. P 192-212.
MJ CILIA: de.  MICROTUBULES: de.  MUSSELS: ul.
MN ANIMAL.  BLOOD.  CILIA: ph.  CYSTIC-FIBROSIS: bl.  HETEROZYGOTE.
   HOMOZYGOTE.  HUMAN.  MALE.  MICROSCOPY-ELECTRON.  MOVEMENT.
   MUSSELS:  de, ph.  RATS.  RESERPINE: pd.  SALIVA: de.
EX A phenomenon associated with the genetic disease of cystic fibrosis
   (CF) is the presence of a serum factor that stops or discoordinates
   ciliary beating.  This effect has been demonstrated by exposing
   freshwater mussel or oyster gill cilia, or rabbit tracheal cilia, to
   sera from homozygous or heterozygous cystic fibrosis subjects.  Assay
   reproducibility is unsatisfactory, however, and the mechanism of the
   effect is not understood.  Nor do we know why there may be
   considerable differences between the activity of tested heterozygotes
   and of homozygotes.  Because the ciliary assay is capricious, there
   is a need to understand how ciliary beating is disturbed or stopped.
   Since microtubules are important in the mechanism of ciliary motion,
   they could conceivably show alterations during the response to
   inhibitory substances.  There has been no ultrastructural study,
   however, of the effects of ciliary inhibition on the axonemal
   components.  Therefore, this study was designed to examine ciliary
   structure during the different stages of ciliary inhibition.  Rapid
   microtubular disappearance and reappearance occurs in the terminal
   cilia of the freshwater mussel Unio when exposure to CF serum causes
   a shock-stop reaction, and return to water allows resumption of
   normal ciliary beating.  In contrast, a slow-stop reaction causes
   distortion of cilia, asynchronous beating, and ejection of cells from
   the distal gill filament, but ciliary axonemal structure is
   preserved.  Slow-stopped cilia do not resume their beating in water.
   Saliva from reserpine-treated rats causes ciliary inhibition similar
   to that induced by CF serum.
RF 001   SPOCK A               PEDIATR RES                      1   173 967
   002   BOWMAN BH             SCIENCE                        164   325 969
   003   BOWMAN BH             SCIENCE                        167   871 970
   004   BESLEY GTN            J MED GENET                      6   278 969
   005   CONOVER JH            PEDIATR RES                      7   220 973
   006   CHERRY JD             J PEDIATR                       79   937 971
   007   MARTINEZ JR           PEDIATR RES                      9   463 975
   008   MARTINEZ JR           PEDIATR RES                      9   463 975
   009   SATIR P               J CELL BIOL                     18   345 963
   010   SATIR P               J GEN PHYSIOL                   50   241 967
   011   SATIR P               J CELL BIOL                     39    77 968
   012   AIELLO EL             J CELL BIOL                     54   493 972
   013   WARNER FD             J CELL SCI                      12   313 973
   014   SHIGENAKA Y           J CELL SCI                       8   127 971
   015   GIBBONS IR            J BIOPHYS BIOCHEM CYTOL         11   179 961
   016$  MILLONIG G            J APPL PHYS                     32  1637 961
   017   SATO T                STAIN TECHNOL                   48   223 973
   018   REYNOLDS ES           J CELL BIOL                     17   208 963
   019   ADSHEAD PC            CF CLUB ABST                    15    25 974
   020   HOPKINS JM            J CELL SCI                       7   823 970
   021   COSTELLO DP           BIOL BULL                      145   292 973
   022   CONOVER JH            LANCET                           1  1194 973
   023   BEHNKE O              INT REV EXP PATH                 9     1 970
   024   WILSON L              FED PROC                        33   151 974
   025   WILSON L              FED PROC                        33   158 974
   026   WILSON L              J CELL BIOL                     58   709 973
   027   GOSS RJ               ADV CELL BIOL                    1   233 970
   028   BOVEE EC              ARCH PROSTISTENK               104   503 960
   029   BARDELE CF            Z ZELLFORSCH MIKROSK ANAT      130   219 972
   030   WITMAN GB             J CELL BIOL                     54   507 972
   031   MARTINEZ JR           CF CLUB ABST                    15     3 974
   032   VOLLET JJ             J CELL BIOL                     55  269A 972
CT   1   BAUR PS               TEX REP BIOL MED                34   155 976
     2   CZEGLEDYNAGY E        LAB INVEST                      35   588 976
     3   MARTINEZ JR           MO MED                          73   173 976
     4   WOOD DL               PEDIATR RES                     11   827 977
     5   KILBURN KH            J ULTRASTRUCT RES               60    34 977
     6   BOGART BI             PEDIATR RES                     12    15 978
     7   MARTINEZ JR           PEDIATR RES                     13  1156 979
     8   NAGY EC               PEDIATR RES                     13   729 979
     9   KENNEDY JR            PEDIATR RES                     14  1173 980
    10   SILLERS PJ            CAN J BIOCHEM                   59   777 981

PN 75036
RN 00202
AN 75163543
AU McDougal-W-S.  Izant-R-J-Jr.  Zollinger-R-M-Jr.
TI Primary peritonitis in infancy and childhood.
SO Ann-Surg. 1975 Mar. 181(3). P 310-3.
MJ PERITONITIS: di.
MN ABDOMEN: ra.  ABDOMEN-ACUTE: di.  ADRENAL-HYPERPLASIA-CONGENITAL: co.
   AGE-FACTORS.  CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: co.
   DIAGNOSIS-DIFFERENTIAL.  FEMALE.  BACTERIA: ip.  BACTERIA: ip.
   HUMAN.  HYALINE-MEMBRANE-DISEASE: co.  HYDRONEPHROSIS: co.  INFANT.
   INFANT-NEWBORN.  MALE.  NEPHROTIC-SYNDROME: co.  PERITONITIS: et, mi.
   PNEUMONIA: co.  SEX-FACTORS.  TIME-FACTORS.
   URINARY-TRACT-INFECTIONS: co.
AB Primary peritonitis, rarely diagnosed preoperatively, is an uncommon
   disease accounting for 2.1% of all pediatric abdominal emergencies.
   It is often associated with urinary or hepatic pathology, the former
   the source of the infecting organism in the majority of cases, and
   presents with characteristic symptoms depending upon whether it
   occurs in infancy or childhood. The symptoms and signs which allow
   for a positive prospective diagnosis are illustrated by comparing
   this disease to those entities with which it is most often confused,
   e.g. diffuse peritonitis of other etiologies, and include a short
   duration of symptoms, associated urinary tract infection and an
   absence of free air on abdominal roentgenograms. In the past, gram
   positive organisms were the most common infecting agent; however, in
   this series gram negative bacteria accounted for 69% or the
   organisms. Antibiotics with a gram negative spectrum and exploratory
   laparotomy with appendectomy are the hallmarks of therapy, the latter
   replaced by abdominal tap only in the patient who satisfies the
   criteria for primary peritonitis and in whom an associated disease
   makes the risk of surgery prohibitive.
RF 001   EPSTEIN M             N ENGL J MED                   278    69 968
   002   FOWLER R JR           AUST NZ J SURG                  26   204 957
   003   FOWLER R JR           AUST PAEDIATR J                  7    73 971
   004   FRIEDLAND JA          AM J SURG                      119   737 970
   005   GOLDEN GT             SURG GYNECOL OBSTET            135   513 972
   006   LADD WE               JAMA                           113  1455 939
   007   LADD WE               ABDOMINAL SURGERY INFANCY CHI        188 941
   008   SCHWEINBURG FB        N ENGL J MED                   242   747 959
CT   1   PRIGOGINE T           ACTA CLIN BELG                  33   143 978
     2   MATTHEWS P            BR MED J                         2   903 979
     3   TAYLOR L              J PEDIATR                       95   556 979
     4   UDALL DA              J UROL                         125   750 981
     5   KRENSKY AM            AM J DIS CHILD                 136   732 982
     6   GORSKI J              CLIN PEDIATR                    22   183 983
     7   HOFFMANN S            DAN MED BULL                    30   265 983
     8   JENNY P               Z KINDERCHIRURGIE               38    36 983
     9   VANRIJSSEN H          BR J SURG                       70   446 983
    10   MOORE JL              J PEDIATR SURG                  19   594 984
    11   NOHR CW               CAN J SURG                      27   179 984
    12   CLARK JH              J PEDIATR                      104   495 984
    13   FREIJ BJ              AM J DIS CHILD                 138  1058 984
    14   STEVENSON RJ          SURG CLIN NORTH AM              65  1181 985
    15   SERLO W               ANN CHIR GYNAECOL               74   183 985
    16   BASART MAG            MED CLIN                        84   207 985

PN 75037
RN 00203
AN 76110493
AU Childs-B.
TI Genetic screening.
SO Annu-Rev-Genet. 1975. 9. P 67-89. (REVIEW).
MJ HEREDITARY-DISEASES: pc.  INFANT-NEWBORN-DISEASES: di.
   MASS-SCREENING.  PRENATAL-DIAGNOSIS.
MN ADENOSINE-DEAMINASE: df.  ADULT.  LIPOIDOSIS: pc.  AMNIOCENTESIS.
   CHILD.  CHROMOSOME-ABNORMALITIES: pc.  CYSTIC-FIBROSIS.
   DOWNS-SYNDROME: pc.  HEMOGLOBINOPATHIES: pc.  HUMAN.
   HYPERLIPIDEMIA:  pc.  INFANT-NEWBORN.  METABOLISM-INBORN-ERRORS: pc.
   MUSCULAR-DYSTROPHY: pc.  PHENYLKETONURIA: pc.  POLYMORPHISM-GENETICS.
   REVIEW.  THALASSEMIA: pc.  SUPPORT-U-S-GOVT-P-H-S.
EX The recent proliferation of genetic knowledge has been accompanied by
   speculation about its uses in the pursuit of both medical and social
   goals, as well as by fear and concern about possible misuses.  These
   speculations have appeared in the proceedings of numerous symposia
   and in many books and papers.  A review of this literature reveals
   that the nonmedical participants in this debate were preoccupied with
   those aims of genetics that might benefit (or threaten) society,
   while the physicians were concerned with the accomplishment of
   standard medical missions in which social aims figure only
   incidentally.  These missions are diagnosis, management, and
   prevention of disease.  The specific uses of genetic knowledge most
   frequently mentioned were advances in the taxonomy of disease that
   lead to improvements in diagnosis and treatment of individual
   patients and their relatives, genetic counseling, and genetic
   screening.  The latter two, particularly screening, are preventive
   and represent the interface between medical genetics, especially
   population genetics, and society.  This review focuses on
   developments in genetic screening, defined as the search in a
   population, generally for medical reasons, for individuals possessing
   particular genotypes.
RF 001   MOTULSKY AG           SCIENCE                        185   653 974
   002   CHILDS B              YALE J BIOL MED                 46   297 973
   003   ANON                  GENETIC SCREENING PROG PRIN A            975
   004   POWLES J              SCI MED MAN                      1     1 973
   005   CARTER CO             GREAT ORMOND ST J               11    65 968
   006   ROBERTS DF            ARCH DIS CHILD                  45    33 970
   007   CHILDS B              IN: SUTTON HE                          3 972
   008   SCRIVER CR            CAN MED ASSOC J                108  1111 973
   009   DAY N                 AM J HUM GENET                  25   237 973
   010   LA DU BN              IN: MCKUSICK VA                       91 973
   011   JICK H                N ENGL J MED                   291   824 974
   012   STOCKINGER HE         J OCCUP MED                     15   564 973
   013   THOMAS L              BIOSCIENCE                      24    99 974
   014   WHITE K               SCI AM                         229    23 973
   015   HARRIS H              ANN HUM GENET                   36     9 972
   016   HUTCHINSON J          PEDIGREE OF DISEASE                      881
   017   ROLLESTON H           IDIOSYNCRACIES                           927
   018   GARROD AE             INBORN FACTORS IN DISEASE            157 931
   019   RIMOIN DL             MED CLIN NORTH AM               55   807 971
   020   BECKER MA             ANNU REV MED                    25    15 974
   021   WYNGAARDEN JB         AM J MED                        56   651 974
   022   MURPHY EA             CIRC RES SUPPL                  32   129 973
   023   SWIFT M               AM J HUM GENET                  26   304 974
   024   BESSMAN SP            J PEDIATR                       81   834 972
   025   CHILDS B              ANNU REV MED                    23   374 972
   026   SWIFT M               SCIENCE                        178   308 972
   027   COHEN C               MED CLIN NORTH AM               58    25 974
   028   LEVINE BB             CLIN IMMUNOL ALLERGY IN PAEDI         49 973
   029   MARSH DG              SCIENCE                        179   691 973
   030   MCDEVITT HO           LANCET                           1  1269 974
   031   GUTHRIE R             US DHEW CHILDRENS BUREAU PUBL            965
   032   BLASKOVICS ME         ARCH DIS CHILD                  49   835 974
   033   HOLTZMAN NA           JAMA                           229   667 974
   034   HOLTZMAN NA           J PEDIATR                       85   175 974
   035   HANSEN H              AM J MENT DEFIC                 75    22 970
   036   HOWELL RR             SOC BIOL SUPPL 19               18    29 971
   037   PERRY TL              N ENGL J MED                   289   395 973
   039   LEVY HL               ADV HUM GENET                    4     1 973
   040   RAINE DN              LANCET                           2   966 974
   041   ANON                  ACTA PAEDIATR SCAND             63   413 973
   042   KOMROWER GM           PEDIATRICS                      53   182 974
   043   LEVY HL               N ENGL J MED                   288  1299 973
   044   KOMROWER GM           LANCET                           1  1047 974
   045   ANON                  LANCET                           1   710 974
   046   POPKIN JS             LANCET                           1   721 974
   047   LEVY HL               N ENGL J MED                   291  1214 974
   048   BEUTLER E             J LAB CLIN MED                  68   137 966
   049   ANON                  N ENGL J MED                   291  1414 974
   050   CLOW CL               PROG MED GENET                   9   159 973
   051   GOLDSTEIN JL          J CLIN INVEST                   52  1533 973
   052   GOLDSTEIN JL          J CLIN INVEST                   52  1544 973
   053   GOLDSTEIN JL          J LAB CLIN MED                  85    15 975
   054   KWITEROVICH PO JR     PEDIATRICS                      53   455 974
   055   MOTULSKY AG           IN: MILUNSKY A                       306 975
   057   MITTMAN C             ARCH ENVIRON HEALTH             27   201 973
   058   MITTMAN C             ISR J MED SCI                    9  1311 973
   059   KUEPPERS F            ANN INTERN MED                  80   209 974
   060   COOPER DM             AM REV RESPIR DIS              110   708 974
   061   MORSE JO              N ENGL J MED                   292   278 975
   062   MORIN T               LANCET                           1   250 975
   063   GIBSON LE             CLIN PEDIATR                    12   450 973
   064   SCHUTT WH             ARCH DIS CHILD                  43   178 968
   065   BRIMBLECOMBE FSW      LANCET                           2  1428 973
   066   STEPHAN U             PEDIATRICS                      55    35 975
   067   MEUWISSEN HJ          J PEDIATR                       86   169 975
   068   MOORE EC              J PEDIATR                       85   802 974
   069   ZELLWEGER H           PEDIATRICS                      55    30 975
   070   MOTULSKY AG           ISR J MED SCI                    9  1341 973
   071   JACKSON RE            ARCH INTERN MED                133   533 974
   072   WHITTEN CF            N ENGL J MED                   288   318 973
   073   WHITTEN CF            ARCH INTERN MED                133   681 973
   074   YOUNG WI              OHIO MED J                      70    27 930
   075   KELLON DB             JAMA                           227    71 974
   076   HAMPTON ML            AM J DIS CHILD                 128    58 974
   077   STAMATOYANNOPOULOS G  IN: MOTULSKY AG                          973
   078   ANON                  S HEMOGLOBINOPATHIES: EVAL ST            973
   079   PEARSON HA            N ENGL J MED                   288   351 973
   080   KAZAZIAN HH JR        ANN NY ACAD SCI                241   691 974
   081   HOBBINS JC            N ENGL J MED                   290  1065 974
   082   CHANG H               N ENGL J MED                   290  1067 974
   083   KABACK MM             PROG MED GENET                  10   103 974
   085   MILUNSKY A            PRENATAL DIAGNOSIS OF HEREDIT            973
   086   HARRIS H              PRENATAL DIAG SELECTIVE ABORT            974
   087   BLUMBERG B            AM J HUM GENET                  26   15A 974
   088   CARTER CO             J BIOSOCIAL SCI                  1    71 969
   089   MILUNSKY A            J PEDIATR                       84   889 974
   090   BROCK DJH             LANCET                           2   923 973
   091   ANON                  BR MED J                         1   414 975
   092   JACOBS PA             ANN HUM GENET                   37   359 974
   093   HAMERTON JL           CAN MED ASSOC J                106   776 972
   094   LUBS HA               IN: JACOBS PA                        119 970
   095   GERALD PS             IN: JACOBS PA                        143 970
   096   MACHIN GA             LANCET                           1   549 974
   097   GARVEY M              ARCH DIS CHILD                  48   937 973
   098   LEONARD MF            PEDIATRICS                      54   208 974
   099   ROBINSON AM           LANCET                           1  1343 974
   100   BORGAONKAR DS         PROG MED GENET                  10   135 974
   101   TENNES K              AM J HUM GENET                  27    71 975
   102   MELLMAN WJ            BIRTH DEF ORIG ART SER          10   123 974
   103   BECK E                N ENGL J MED                   291  1166 974
   105   KABACK MM             ETHICAL SOCIAL LEGAL DIMEN SC            974
   106   CHILDS B              AM J HUM GENET                  26   120 974
   107   ROSENSTOCK IM         MILBANK MEM FUND Q              44    94 966
CT   1   SCRIVER CR            SCIENCE                        200   946 978
     2   ANON                  CAN MED ASSOC J                121  1193 979
     3   KHOURY MJ             AM J PUBLIC HEALTH              75  1204 985

PN 75038
RN 00204
AN 78143452
AU Goodchild-M-C.  Banks-A-J.  Drolc-Z.  Anderson-C-M.
TI Liver scans in cystic fibrosis.
SO Arch-Dis-Child. 1975 Oct. 50(10). P 813-5.
MJ CYSTIC-FIBROSIS: ri.  LIVER: ri.
MN ADOLESCENCE.  CHILD.  COMPARATIVE-STUDY.  FEMALE.  HUMAN.
   LIVER-FUNCTION-TESTS.  MALE.
AB Liver scans were performed on 16 cystic fibrosis patients. Most scans
   were considered abnormal. In most patients, the results of
   serological liver function tests were normal. Liver scanning in
   cystic fibrosis is unlikely to make a significant contribution to an
   assessment of prognosis.
RF 001   BODIAN M              FIBROCYSTIC DIS OF THE PANCRE            952
   002   COLOMBETTI LG         J NUCL MED                      10   597 969
   003   DI SANTAGNESE PA      PEDIATRICS                      18   387 956
   004   FEIGELSON J           ACTA PAEDIATR SCAND             61   337 972
   005   KATTWINKEL J          J PEDIATR                       82   234 973
   006   LIEWENDAHL K          ACTA MED SCAND                 192   395 972
   007   LUDBROOK J            GASTROENTEROLOGY                62  1013 972
   008   SHWACHMAN H           AM J DIS CHILD                  96     6 958
CT   1   SMITH AL              ARCH DIS CHILD                  52   633 977
     2   SCHWARZ HP            HELV PAEDIATR ACTA              33   351 978
     3   GIUNTA A              RIV ITAL PEDIATR                 9   171 983

PN 75039
RN 00205
AN 78143443
AU Goodchild-M-C.  Murphy-G-M.  Howell-A-M.  Nutter-S-A.  Anderson-C-M.
TI Aspects of bile acid metabolism in cystic fibrosis.
SO Arch-Dis-Child. 1975 Oct. 50(10). P 769-78.
MJ BILE-ACIDS-AND-SALTS: me.  CYSTIC-FIBROSIS: me.  FECES: an.
MN ADOLESCENCE.  ADULT.  BILE-ACIDS-AND-SALTS: bl.  BODY-FLUIDS: me.
   CHILD.  CHILD-PRESCHOOL.  DUODENUM: me.  FEMALE.  HUMAN.  INFANT.
   LIPIDS: me.  MALE.  PANCREATIC-DISEASES: me.
AB Previous reports have indicated that cystic fibrosis (CF) patients
   with pancreatic enzyme insufficiency have a raised faecal bile acid
   output.  In this study, 18 out of 29 CF patients and 2 out of the 4
   non-CF patients with pancreatic enzyme insufficiency had raised
   faecal bile acid levels.  In the CF patients no correlation was
   found between faecal bile acid and faecal fat excretion, but an
   inverse relation was shown between faecal bile acid values and age.
   Those CF patients with overt liver disease tended to have the lowest
   faecal bile acid values.  Duodenal spiration in 5 CF patients and in
   one non-CF patient with pancreatic enzyme insufficiency
   (Shwachman-Diamond syndrome), produced very small fluid volumes.
   Duodenal fluid mean total bile acid concentrations were within
   normal limits.  Estimation of serum bile acids in these 6 patients
   showed that 3 patients had raised serum bile acid values.  It is
   suggested that excessive faecal bile acid loss may produce a
   contraction of the bile acid pool, and lead eventually to a
   reduction of intraduodenal bile acid concentrations.  Measures which
   curtail faecal bile acid loss may have a particular significance in
   the management of CF.
RF 001   ANDERSON CM           LANCET                           1   836 952
   002   BODIAN M              FIBROCYSTIC DIS OF THE PANCRE            952
   003   BURKE V               BR MED J                         2  1050 966
   004   CAREY JB JR           GASTROENTEROLOGY                56  1249 969
   005   DI SANTAGNESE PA      PEDIATRICS                      18   387 956
   006   DOWLING RH            GASTROENTEROLOGY                62   122 972
   007   DRASAR BS             GASTROENTEROLOGY                56    71 969
   008   GATZIMOS CD           AM J DIS CHILD                  89   182 955
   009   GRACEY M              AUSTRALAS ANN MED               18    91 969
   010   HADORN B              CAN MED ASSOC J                 98   377 968
   011   HADORN B              J PEDIATR                       73    39 968
   012   HEATON KW             BILE SALTS IN HEALTH AND DISE            972
   013   KAPLOWITZ N           GASTROENTEROLOGY                62   768 972
   014   LAPEY A               J PEDIATR                       84   328 974
   015   LEYLAND C             ARCH DIS CHILD                  45   714 970
   016   MATTHEWS LW           PEDIATRICS                      27   351 961
   017   MOORE RB              J CLIN INVEST                   47  1517 968
   018   MURPHY GM             ANN CLIN BIOCHEM                 9    67 972
   019   MURPHY GM             J CLIN PATHOL                   23   594 970
   020   MURPHY GM             CLIN CHIM ACTA                  54    81 974
   021   POLEY JR              J LAB CLIN MED                  63   838 964
   022   RUDMAN D              J CLIN INVEST                   36   530 957
   023   SCHAFFNER F           LANCET                           2   355 969
   024   SHWACHMAN H           J PEDIATR                       65   645 964
   025   TAYLOR WF             AM J DIS CHILD                 123   161 972
   026   TURNBERG LA           GUT                             11   126 970
   027   TYSON KRT             J PEDIATR SURG                   3   271 968
   028   VALMAN HB             ARCH DIS CHILD                  46   805 971
   029   VAN DEEST BW          J CLIN INVEST                   47  1314 968
   030   VAN DE KAMER JH       J BIOL CHEM                    177   347 949
   031   WEBER A               PEDIATRICS                      50    73 972
   032   WEBER A               N ENGL J MED                   289  1001 973
   033   WEBER AM              CLIN CHIM ACTA                  39   524 972
   034   WEBER A               CLIN RES                        20   257 972
   035   WEBSTER R             ARCH DIS CHILD                  28   343 953
   036   WIGGINS HS            GUT                              8   415 967
CT   1   HUANG CTL             AM J CLIN NUTR                  29  1196 976
     2   ROY CC                CLIN GASTROENTEROL               6   377 977
     3   ROLLER RJ             GASTROENTEROLOGY                72   661 977
     4   KERN F                GASTROENTEROLOGY                73   631 977
     5   ROY CC                GASTROENTEROLOGY                73   631 977
     6   WATKINS JB            GASTROENTEROLOGY                73  1023 977
     7   BALISTRERI WF         J PEDIATR                       90    21 977
     8   ROY CC                N ENGL J MED                   297  1301 977
     9   SCHWARZ HP            HELV PAEDIATR ACTA              33   351 978
    10   SMALLEY CA            ARCH DIS CHILD                  53   477 978
    11   BENNION LJ            N ENGL J MED                   299  1221 978
    12   KAISER D              AKTUEL ERNAHRUNGSMED             4    26 979
    13   FEIGELSON J           NOUV PRESSE MED                  8  3029 979
    14   STARKEY BJ            MONOGR PAEDIATR                 10    12 979
    15   HARRIES JT            ARCH DIS CHILD                  54    19 979
    16   LLOYDSTILL JD         AM J CLIN PATHOL                71   444 979
    17   REGAN PT              GASTROENTEROLOGY                77   285 979
    18   CHASE HP              J PEDIATR                       95   337 979
    19   ROY CC                PROC SOC EXP BIOL MED          161   105 979
    20   DAVIDSON GP           J CLIN PATHOL                   33   390 980
    21   EKLUND A              SCAND J CLIN LAB INVEST         40   595 980
    22   BOYLE BJ              GASTROENTEROLOGY                78   950 980
    23   BALISTRERI WF         J PEDIATR                       96   582 980
    24   PARK RW               GASTROENTEROLOGY                81  1143 981
    25   TABACHNIK NF          SURG GYNECOL OBSTET            152   837 981
    26   COLOMBO C             RIV ITAL PEDIATR                 8    77 982
    27   HILDEBRAND H          GUT                             23   243 982
    28   ABDULKARIM FW         GASTROENTEROLOGY                82   758 982
    29   BALISTRERI WF         J PEDIATR GASTROENTEROL NUTR     2   105 983
    30   ISENBERG JN           J PEDIATR GASTROENTEROL NUTR     2   447 983
    31   ROY CC                J PEDIATR GASTROENTEROL NUTR     2   152 983
    32   COLOMBO C             DIG DIS SCI                     28   306 983
    33   DOHERTY DE            SOUTH MED J                     76  1580 983
    34   BASS S                GASTROENTEROLOGY                84  1592 983
    35   MASOERO G             AM J DIS CHILD                 137   167 983
    36   NIESSEN KH            GUT                             25    26 984
    37   ZENTLERMUNRO PL       GUT                             25   500 984
    38   ABRAMS CK             J CLIN INVEST                   73   374 984
    39   MCKENNA MC            J PEDIATR GASTROENTEROL NUTR     4    45 985
    40   ROBB TA               GUT                             26  1246 985
    41   ZENTLERMUNRO PL       GUT                             26   892 985
    42   SETCHELL KDR          CLIN CHIM ACTA                 151   101 985
    43   WEBER AM              ACTA PAEDIATR SCAND SUPPL 317 1985     9 985
    44   WEIZMAN Z             GUT                             27  1043 986
    45   LEROY C               DIG DIS SCI                     31   911 986
    46   DUTTA SK              GASTROENTEROLOGY                91  1243 986

PN 75040
RN 00206
AN 76110779
AU Jones-R-S.
TI Letter: Bronchial lability in cystic fibrosis.
SO Arch-Dis-Child. 1975 Nov. 50(11). P 909.
MJ BRONCHI: pp.  CYSTIC-FIBROSIS: pp.
MN HUMAN.  RESPIRATORY-FUNCTION-TESTS: mt.
EX It has always seemed to me that the use of the Exercise Lability
   Index (ELI) distorts results and may be misleading because a falsely
   high value for lability is obtained when the PEF at rest is low.  It
   is incorrect to compare percentage values from such patients with
   percentage values from those with figures at rest which are near to
   normal.  The Jones Liability Index avoids this distortion.  I do not
   suggest that a proportion of CF patients do not have abnormal
   lability but would maintain that the ELI introduces inaccuracy which
   may blur the distinction between CF and other respiratory conditions
   and may lead to the postulation of problems concerning lability in
   CF which do not necessarily exist.  Failure to use a bronchodilator
   agent to reinforce brief exercise may also cause distortion but in
   the opposite direction.
RF 001   COUNAHAN R            ARCH DIS CHILD                  50   477 975
   002   DAY G                 ARCH DIS CHILD                  48   355 973
   003   JONES RS              BR MED J                         2   972 966
CT   1   SILVERMAN M           ARCH DIS CHILD                  53   873 978

PN 75041
RN 00207
AN 75145262
AU Elliott-R-B.  Robinson-P-G.
TI Unusual clinical course in a child with cystic fibrosis treated with
   fat emulsion.
SO Arch-Dis-Child. 1975 Jan. 50(1). P 76-8.
MJ CYSTIC-FIBROSIS.  OILS: tu.
MN CYSTIC-FIBROSIS: dt, di.  EMULSIONS.  FEMALE.  HUMAN.  ILEOSTOMY.
   INFANT.  INFANT-NEWBORN.  INFUSIONS-PARENTERAL.
   INTESTINAL-OBSTRUCTION: su.  MECONIUM.  PANCREATIC-EXTRACTS: tu.
   SOY-BEANS.  SURGICAL-WOUND-INFECTION.  SWEAT: an.
AB A child diagnosed as having cystic fibrosis by customary criteria has
   been given regular parenteral soya oil emulsion from near birth.
   Sweat tests have improved, pancreatic achylia was relieved, and the
   child at present remains entirely well. Correction of the essential
   fatty acid deficiency found in cystic fibrosis may prevent some of
   the manifestations of the disease.
RF 001   AHLUWALIA B           J NUTR                          92   205 967
   002   CUTHBERT MF           IN: CUTHBERT MF                          973
   003   HANSEN AE             J NUTR                          66   565 958
   004   HAVERBACK BJ          GASTROENTEROLOGY                44   588 963
   005   HOPKINS DT            PROC SOC EXP BIOL MED          114    82 963
   006   KUO PT                J PEDIATR                       60   394 962
   007   MORRISON WR           J LIPID RES                      5   600 964
   008   SCHWARTZ IL           J CLIN INVEST                   35   114 956
CT   1   DODGE JA              BR MED J                         2   192 975
     2   MCEVOY FA             LANCET                           2   236 975
     3   RIVERS JPW            LANCET                           2   642 975
     4   ROBINSON PG           LANCET                           2   919 975
     5   THOMPSON G            LANCET                           2   769 975
     6   DODGE JA              ARCH DIS CHILD                  50   578 975
     7   WARNER JO             PEDIATRE                        12   243 976
     8   CAMPBELL IM           PEDIATRICS                      57   480 976
     9   CHASE HP              PEDIATRICS                      57   441 976
    10   ELLIOTT RB            PEDIATRICS                      57   474 976
    11   HUBBARD VS            LANCET                           2  1302 977
    12   CHAZALETTE JP         PEDIATRE                        13   303 977
    13   DALE G                ADV CLIN CHEM                   19   207 977
    14   GALABERT C            LANCET                           2   903 978
    15   DAVIDSON GP           AUST PAEDIATR J                 14    80 978
    16   PHELAN PD             AUST PAEDIATR J                 14    61 978
    17   BERG U                MONOGR PAEDIATR                 10     1 979
    18   BOHLES H              Z ERNAHRUNGSWISS                18    81 979
    19   LLOYDSTILL JD         PEDIATRICS                      64    50 979
    20   ROGIERS V             PEDIATR RES                     14  1088 980
    21   HUBBARD VS            AM J CLIN NUTR                  33  2281 980
    22   LLOYDSTILL JD         AM J CLIN NUTR                  34     1 981
    23   SOLOMONS NW           AM J CLIN NUTR                  34   462 981
    24   KUSOFFSKY E           J PEDIATR GASTROENTEROL NUTR     2   434 983
    25   COLLINS JE            ACTA PAEDIATR SCAND             74   423 985
    26   DODGE JA              ACTA PAEDIATR SCAND SUPPL 317 1985    31 985
    27   GIBSON RA             J PEDIATR GASTROENTEROL NUTR     5   408 986

PN 75042
RN 00208
AN 76038708
AU Dodge-J-A.  Prosser-R.  Yassa-J.
TI Letter: Essential fatty acids in cystic fibrosis.
SO Arch-Dis-Child. 1975 Jul. 50(7). P 578-9.
MJ CYSTIC-FIBROSIS: dh.  FATTY-ACIDS-ESSENTIAL: tu.
MN FATTY-ACIDS-ESSENTIAL: ad.  HUMAN.
EX We have read with interest the report by Elliott and Robinson
   concerning the apparent beneficial effects of intravenous fat
   infusions in a child with cystic fibrosis.  We question whether the
   increase in essential fatty acids brought about by soya oil can
   account for the favourable course of the disease in this patient.
   Our own observations confirm that essential fatty acids levels are
   often below normal in cystic fibrosis, but they do not correlate
   with the clinical condition of the patient.  It seems unlikely that
   minor degrees of essential fatty acid deficiency would impair
   prostaglandin synthesis, or give rise to the usual clinical features
   of cystic fibrosis. - Our own more recent research in platelet
   aggregation, prostaglandin, and cyclic nucleotide production, makes
   us aware that simple EFA deficiency per se cannot be the origin of
   the symptoms of CF.  The possibility that some other agent in the
   infusion mixture (which, for example, contains about 12% tocopherol)
   may be a contributing factor, is also under investigation.  This
   does not, however, invalidate a possible therapeutic effect of EFA
   in the disease, and in particular, a partial correlation of a
   possible disorder of prostaglandin synthesis.
RF 001   DODGE JA              BR MED J                         2   192 975
   002   ELLIOTT RB            ARCH DIS CHILD                  50    76 975
   003   FLENSBORG EW          PROC EWGCF 1ST ANNU MTG                  970
   004   FORSTROM L            PROSTAGLANDINS                   7   459 974
   005   GRIFFITHS AD          ARCH DIS CHILD                  47   132 972
   006   HANSEN AE             PEDIATRICS                      31   171 963

PN 75043
RN 00209
AN 75204146
AU Kjellman-N-I.  Larsson-Y.
TI Insulin release in cystic fibrosis.
SO Arch-Dis-Child. 1975 Mar. 50(3). P 205-9.
MJ CYSTIC-FIBROSIS: pp.  GLUCOSE-TOLERANCE-TEST.  INSULIN: se.
MN BLOOD-GLUCOSE: an.  BODY-HEIGHT.  BODY-WEIGHT.  CATHETERIZATION.
   CHILD.  CHILD-PRESCHOOL.  COLORIMETRY.  FEMALE.  HUMAN.  INFANT.
   MALE.  RADIOIMMUNOASSAY.
AB Early insulin response to rapid intravenous injection of glucose was
   studied in 7 cases of cystic fibrosis aged 8 months to 9 1/2 years.
   Plasma insulin was measured with a radioimmunological method. Blood
   glucose values were determined and the glucose disappearance rate
   (kG) calculated. In all children except the youngest one the early
   insulin response values were low compared with normal children. The
   kG-values were normal and correlated neither to the duration of
   clinical symptoms, nor to the patients' actual clinical condition
   measured by means of the Shwachman score. The explanation of the
   decreased insulin response is probably the progressive fibrosis of
   the pancreas. This may also explain the reported increased incidence
   of diabetes mellitus in cystic fibrosis. Comparison is made with the
   condition in pancreatic fibrosis in rabbits, produced through duct
   ligation.
RF 001   BEARDMORE M           BR MED J                         2  1383 966
   002   BROWN RE              ARCH PATHOL                     92    53 971
   003   CARROLL JJ            BIOCHEM MED                      4   171 971
   004   CERASI E              ACTA ENDOCRINOL                 55   278 967
   005   CERASI E              ACTA ENDOCRINOL                 55   330 967
   006   EDSTROM C             UMED UNIV MED DISSERTATIONS     10       972
   007   VON EULER U           SCAND J CLIN LAB INVEST SUPPL   64    62 962
   008   GRACEY M              MED J AUST                       1   212 971
   009   HANDWERGER S          N ENGL J MED                   281   451 969
   010   IKKOS D               ACTA ENDOCRINOL                 25   312 957
   011   KAISER G              HELV PAEDIATR ACTA              25   135 970
   012   LARSSON Y             ACTA PAEDIATR SCAND SUPPL       45   106 956
   013   LARSSON Y             PEDIATRICS                      21   893 958
   014   MEISSNER H            BEITR PATHOL ANAT              114   192 954
   015   MILNER AD             ARCH DIS CHILD                  44   351 969
   016   MILUNSKY A            AM J DIS CHILD                 121    15 971
   017   NOSSLIN B             LAKARTIDNINGEN                  69  5225 972
   018   ROSAN RC              AM J DIS CHILD                 104   625 962
   019   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   020   SHWACHMAN H           PEDIATRICS                      46   335 970
   021   STERKY G              ACTA PAEDIATR SCAND SUPPL       52   144 963
   022   WALPOLE AL            BR J PHARMACOL                   1   174 946
   023   WEBER B               ARCH KINDERHEILK SUPPL 65                971
CT   1   WOOD RE               AM REV RESPIR DIS              113   833 976
     2   CEDER O               ACTA PAEDIATR SCAND SUPPL 309 1983     1 983
     3   IANNUCCI A            HUM PATHOL                      15   278 984
     4   GEFFNER ME            AM J DIS CHILD                 138   677 984

PN 75044
RN 00210
AN 75204201
AU Sarsfield-J-K.  Davies-J-M.
TI Negative sweat tests and cystic fibrosis.
SO Arch-Dis-Child. 1975 Jun. 50(6). P 463-6.
MJ CYSTIC-FIBROSIS: di.  SWEAT: an.
MN AMYLASES: an.  BICARBONATES: an.  CHILD.  CHILD-PRESCHOOL.
   CHRONIC-DISEASE.  CYSTIC-FIBROSIS: co, bl, ra.  FEMALE.  HUMAN.
   LUNG-DISEASES: co.  MALE.  PNEUMONIA: co.  SPUTUM: mi.
   STAPHYLOCOCCUS.  TRYPSIN: an.
AB Two brothers are described with chronic suppurative pulmonary
   disease. One has classical cystic fibrosis with complete pancreatic
   involvement and abnormal sweat test. The other had incomplete
   pancreatic disease with repeatedly normal sweat tests. The
   implications of a negative sweat test in patients with cystic
   fibrosis are discussed.
RF 001   COGSWELL JJ           ARCH DIS CHILD                  49   520 974
   002   DI SANTAGNESE PA      JAMA                           172  2065 960
   003   GIBSON LE             J PEDIATR                       81   193 972
   004   HADORN B              CAN MED ASSOC J                 98   377 968
   005   HADORN B              J PEDIATR                       73    39 968
   006   SHWACHMAN H           IN: KENDIG EL JR                 1   524 972
CT   1   STERN RC              JAMA                           239  2676 978
     2   HUFF DS               J PEDIATR                       94   237 979
     3   DAVIS PB              AM J MED                        69   643 980
     4   LITTLEWOOD JM         PRACTITIONER                   224   305 980
     5   SCHWACHMAN H          J PEDIATR                       98   576 981
     6   STERN RC              LANCET                           1  1401 982
     7   WONG LTK              GUT                             23   744 982
     8   LITTLEWOOD JM         LANCET                           1   183 983
     9   TAL A                 CLIN PEDIATR                    24   460 985
    10   NIELSEN OH            CURR THER RES CLIN EXP          41   367 987

PN 75045
RN 00211
AN 75204203
AU Counahan-R.  Mearns-M-B.
TI Prevalence of atopy and exercise-induced bronchial lability in
   relatives of patients with cystic fibrosis.
SO Arch-Dis-Child. 1975 Jun. 50(6). P 477-81.
MJ BRONCHIAL-SPASM: co.  CYSTIC-FIBROSIS: fg.  HYPERSENSITIVITY: co.
MN ADOLESCENCE.  ADULT.  ALLERGENS.  CHILD.  CHILD-PRESCHOOL.
   CLINICAL-TRIALS.  CYSTIC-FIBROSIS: co, pp.  EXERCISE-TEST.  FAMILY.
   FEMALE.  HUMAN.  MALE.  MIDDLE-AGE.  PARENTS.
   PEAK-EXPIRATORY-FLOW-RATE: mt.  SKIN-TESTS.
AB Skin tests and exercise tests were performed on children with cystic
   fibrosis (CF) and first-degree relatives of CF children. Positive
   skin tests were found in 56% of patients and 19% of relatives, but
   the prevalence of atopy in CF patients bore no relationship to its
   prevalence in their relatives. Increased 0ronchial lability, mainly
   due to bronchoconstriction, was present in 54% of patients and 27% of
   relatives. The results showed that increased prevalence of bronchial
   lability, but not atopy, is found in first-degree relatives of CF
   children, and that the abnormal lability and atopy found in CF
   children does not indicate a familial allergic background.
RF 001   ANDERSON SD           THORAX                          26   396 971
   002   CONNOLLY NM           J ASTHMA RES                     8    31 970
   003   DANES BS              LANCET                           1  1061 968
   004   DAY G                 ARCH DIS CHILD                  48   355 973
   005   GIMENO F              THORAX                          29    16 974
   006   HEIMLICH EM           J ALLERGY CLIN IMMUNOL          37   103 966
   007   JONES RHT             BR MED J                         2   976 966
   008   KONIG P               ARCH DIS CHILD                  48   513 973
   009   KONIG P               ARCH DIS CHILD                  48   942 973
   010   MCCARTHY DS           IN: LAWSON D PROC 5TH INT CF         194 969
   011   MEARNS MB             LANCET                           1   538 967
   012   NAIRN JR              ARCH DIS CHILD                  36   253 961
   013   SILVERMAN M           ARCH DIS CHILD                  47   882 972
   014   SPOCK A               PEDIATR RES                      1   173 967
CT   1   JONES RS              ARCH DIS CHILD                  50   909 975
     2   WARNER JO             LANCET                           1   990 976
     3   TWAROG FJ             J ALLERGY CLIN IMMUNOL          59    35 977
     4   SILVERMAN M           ARCH DIS CHILD                  53   873 978
     5   MELLIS CM             PEDIATRICS                      61   446 978
     6   MITCHELL I            J PEDIATR                       93   744 978
     7   ANON                  LANCET                           1   708 979
     8   BURDON JGW            MED J AUST                       2    77 980
     9   VANASPEREN PP         AUST PAEDIATR J                 16    53 980
    10   HODSON ME             THORAX                          35   801 980
    11   ORMEROD LP            THORAX                          35   768 980
    12   TOBIN MJ              THORAX                          35   807 980
    13   HOLZER FJ             ARCH DIS CHILD                  56   455 981
    14   CLARKE CW             BR J DIS CHEST                  75    15 981
    15   GEORGITIS JW          ANN ALLERGY                     48   175 982
    16   MURPHY MB             THORAX                          39   179 984
    17   BIRX DL               ANN ALLERGY                     53   124 984
    18   WONNE R               CLIN ALLERGY                    15   455 985
    19   MITCHELL I            ANN ALLERGY                     54   233 985

PN 75046
RN 00212
AN 75204208
AU Barclay-R-P.  Shannon-R-S.
TI Trial of artificial diet in treatment of cystic fibrosis of pancreas.
SO Arch-Dis-Child. 1975 Jun. 50(6). P 490-3.
MJ CYSTIC-FIBROSIS: dh.
MN BODY-HEIGHT.  BODY-WEIGHT.  CHILD.  CHILD-PRESCHOOL.
   CLINICAL-TRIALS.  CYSTIC-FIBROSIS: co.  FEMALE.  GROWTH.  HUMAN.
   INFANT.  MALE.  RESPIRATORY-TRACT-INFECTIONS: co.
EX Twelve patients with cystic fibrosis were started on an artificial
   diet of Albumaid and Caloreen, together with a supplement of medium
   chain triglyceride oil, vitamins, and minerals.  Growth velocity and
   general health were assessed over a period of a full year for each
   child.  Patients who were only mildly affected by the disease showed
   improvement in stool frequency and growth rate when the diet
   represented the major part of their nutritional intake.  Patients who
   were severely affected showed no improvement in growth, general
   clinical status, or frequency of respiratory infections.
RF 001   ALLAN JD              AM J DIS CHILD                 126    22 973
   002   DARBY CW              ARCH DIS CHILD                  46   866 971
   003   MEARNS MB             ARCH DIS CHILD                  47     5 972
   004   TANNER JM             ARCH DIS CHILD                  41   613 966
CT   1   WOOD RE               AM REV RESPIR DIS              113   833 976
     2   SOLOMONS NW           AM J CLIN NUTR                  34   462 981
     3   PARSONS HG            J PEDIATR GASTROENTEROL NUTR     2    44 983
     4   OLOUGHLIN E           AM J CLIN NUTR                  43   732 986

PN 75047
RN 00213
AN 76111670
TI Letter: Management of children with cystic fibrosis.
SO Aust-Paediatr-J. 1975 Jun. 11(2). P 89-92.
MJ CYSTIC-FIBROSIS: th.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: mo.
   FEMALE.  HUMAN.  INFANT.  PHYSICAL-THERAPY.
EX Reports of children with cystic fibrosis living well whilst on
   intensive treatment can be covered by allegations that their disease
   must be basically mild.  More revealing evidence comes from the
   longterm survival studies done by Professor Warren Warwick, of the
   University of Minnesota.  The introduction of antibiotics have
   allowed the children to live loner, but 3/4 were dead by aged 10
   years.  Physiotherapy given after infections prolonged lives so that
   half were still alive at 10 years - but still faced a relentless
   death rate.  Prophylactic - daily - physiotherapy produced a
   doubling of survival at 20 years from under 30% to over 60%.  I do
   not deny for a moment that daily physiotherapy with inhalations is a
   great strain on the family, but it is not as great as the strain of
   watching the slow and relentless decline of the child which, with
   racking cough and persistent dyspnoea, is anything but peaceful.
RF 001   PHELAN PD             AUST PAEDIATR J                  9   302 973
   002   WARWICK WJ            MINN MED                        52  1476 969

PN 75048
RN 00214
AN 75183463
AU Bowman-B-H.  Lankford-B-J.  Fuller-G-M.  Carson-S-D.  Kurosky-A.
   Barnett-D-R.
TI Cystic fibrosis: the ciliary inhibitor is a small polypeptide
   associated with immunoglobulin G.
SO Biochem-Biophys-Res-Commun. 1975 Jun 16. 64(4). P 1310-5.
MJ CILIA: pp.  CYSTIC-FIBROSIS: bl.  IGG: ph.
MN ANIMAL.  CYSTIC-FIBROSIS: pp.  GILLS: ph.  HETEROZYGOTE.  HOMOZYGOTE.
   HUMAN.  MOLECULAR-WEIGHT.  OYSTERS: ph.  PEPTIDES: bl.
   SUPPORT-U-S-GOVT-P-H-S.
AB A small polypeptide within the molecular weight range of 6,000 to
   11,000 was found in immunoglobulin fractions from sera of cystic
   fibrosis homozygotes and heterozygotes.  This factor appears to be
   responsible for interfering with ciliary activity in oyster gills.
   Since it can be dissociated from IgG without reductive cleavage it
   must be bound in a non-covalent manner.  After its dissociation the
   IgG fractions from cystic fibrosis sera no longer inhibited ciliary
   activity.  This finding explains the differences previously observed
   in the molecular weights of the ciliary inhibitor synthesized by
   cultured cells and that of sera from cystic fibrosis genotypes.
RF 001   SPOCK A               PEDIATR RES                      1   173 967
   002   BOWMAN BH             SCIENCE                        164   325 969
   003   BESLEY GTN            J MED GENET                      6   278 969
   004   BARNETT DR            TEX REP BIOL MED                31   709 973
   005   HERZBERG V            J CLIN INVEST                   52  2732 973
   006   DANES BS              J EXP MED                      136  1313 972
   007   BOWMAN BH             PROC NAT ACAD SCI USA           70   548 973
   008   CONOVER JH            PEDIATR RES                      7   224 973
   009   BERATIS NG            PEDIATR RES                      7   958 973
   010   BARNETT DR            TEX REP BIOL MED                31   703 973
   011   BOWMAN BH             SCIENCE                        167   871 970
   012   MCCOMBS ML            CLIN GENET                       1   171 970
   013   PALACIOS R            J BIOL CHEM                    247  2316 972
   014   SWANK RT              ANAL BIOCHEM                    39   462 971
CT   1   LEE TJ                CLIN RES                        23  A655 975
     2   GILLARD BK            PEDIATR RES                     10   907 976
     3   BOWMAN BH             LIFE SCI                        19  1289 976
     4   BAUR PS               TEX REP BIOL MED                34   113 976
     5   BAUR PS               TEX REP BIOL MED                34   155 976
     6   BOWMAN BH             TEX REP BIOL MED                34     1 976
     7   CARSON SD             TEX REP BIOL MED                34   209 976
     8   HARPER BL             TEX REP BIOL MED                34    73 976
     9   WARD JB               TEX REP BIOL MED                34    83 976
    10   WOOD RE               AM REV RESPIR DIS              113   833 976
    11   DISANTAGNESE PA       N ENGL J MED                   295   534 976
    12   CONOD EJ              PEDIATR RES                     11    45 977
    13   THOMAS JM             PEDIATR RES                     11  1148 977
    14   YOKOYAMA M            PEDIATR RES                     11   765 977
    15   BOWMAN BH             CLIN GENET                      12   333 977
    16   ROSSMAN CM            J PEDIATR                       90   579 977
    17   CONOVER JH            BIOCHEM BIOPHYS RES COMMUN      83  1595 978
    18   GUY GJ                CLIN CHIM ACTA                  87    63 978
    19   WILSON GB             J LAB CLIN MED                  92   463 978
    20   BOAT TF               ACS SYMPOSIUM SERIES          1978   108 978
    21   NAGY EC               PEDIATR RES                     13   729 979
    22   PIVETTA OH            PEDIATR RES                     13  1160 979
    23   TUCKER RD             PEDIATR RES                     13  1371 979
    24   STRAUSS RG            HELV PAEDIATR ACTA              34   429 979
    25   BOWMAN BH             TEX REP BIOL MED                38    47 979
    26   BOGART BI             BIOCHEM BIOPHYS RES COMMUN      88  1398 979
    27   KURLANDSKY LE         PEDIATR RES                     14  1263 980
    28   BOWMAN BH             FED PROC                        39  3195 980
    29   MARTINEZ JR           PEDIATR RES                     15  1439 981
    30   SANDERSON MJ          PEDIATR RES                     15   219 981
    31   FLEMING N             EXPERIENTIA                     37   139 981
    32   TEGNER H              ACTA PAEDIATR SCAND             70   629 981
    33   CARSON SD             BIOCHIM BIOPHYS ACTA           667    23 981
    34   BLITZER MG            PEDIATR RES                     16   203 982
    35   CARSON SD             PEDIATR RES                     16    13 982
    36   MCNEELY MC            PEDIATR RES                     16    21 982
    37   WOODS DE              INFECT IMMUN                    36  1223 982
    38   BUCHANAN KD           SCAND J GASTROENTEROL           18   155 983
    39   HERMANS CO            OCEANOGR MARINE BIOL            21   283 983
    40   SHAPIRA E             ANN NY ACAD SCI                421   352 983
    41   ROOMANS GM            SCANN ELECTRON MICROSC        1983   697 983
    42   BLITZER MG            PEDIATR RES                     18   540 984

PN 75049
RN 00215
AN 76000549
AU Wilson-J-D.  Goldstein-J-L.
TI Classification of hereditary disorders of sexual development.
SO Birth-Defects. 1975. 11(4). P 1-16. (REVIEW).
MJ SEX-DIFFERENTIATION-DISORDERS: cl.
MN ANDROGENS: bi, me.  CYSTIC-FIBROSIS.  FEMALE.  GENES.  GENITALIA: em.
   HERMAPHRODITISM.  HUMAN.  MALE.  OVARY: em.  PHENOTYPE.
   PSEUDOHERMAPHRODITISM.  REVIEW.  SEX-DETERMINATION.
   SEX-DIFFERENTIATION.  SEX-REVERSAL-GONADAL.  TESTIS: em, ab.
   TESTOSTERONE: me.  TURNERS-SYNDROME.  SUPPORT-U-S-GOVT-P-H-S.
   UTERUS: ab.  VAGINA: ab.
EX We have recently proposed a classification of the disorders of sexual
   development based upon the presumed site of action of the abnormal
   gene during embryogenesis.  These disorders, which may be either
   genetic or nongenetic in nature, are the result of disturbances in
   the physiology of sexual differentiation during embryogenesis.  The
   purpose of this review is to summarize the current physiologic
   concepts of normal sexual differentiation, to review the known
   hereditary disorders of sexual development, and to consider briefly
   the implications that these mutations have for the understanding of
   normal sexual differentiation.  The translation of genetic sex into
   phenotypic sex is a complex process.  Since some 19 hereditary,
   single-gene determined disorders of sexual development are currently
   recognized that involve loci on both the autosomes and the X
   chromosome, it can be inferred that at a minimum 19 genes and hence
   19 discrete biochemical steps are involved in this process.  At least
   10 mutations result in male pseudohermaphroditism, whereas only 2
   mutations are known to cause female pseudohermaphroditism.  The
   predominance of male type of mutation is the result of the fact that
   the formation of the male phenotype is actively induced by the
   secretions of the fetal testis whereas the formation of the female
   phenotype does not require secretion from the fetal ovary.  The end
   result of these mutations that involve the formation and action of
   testosterone can be similar, and it requires anatomic,
   endocrinologic, and genetic study of individual patients to identify
   the mutant genes involved.  Undoubtedly, many more as yet
   unidentified genes must participate in sexual differentiation.  The
   identification of these genes will depend on the continued
   delineation of new simply inherited clinical syndromes.  Any
   fundamental understanding of the programming of events in phenotypic
   differentiation will require not only the identification of the genes
   involved but the elucidation of the molecular mechanisms by which
   each of these genes is expressed.
RF 001   GOLDSTEIN JL          IN: MOTULSKY AG                      165 974
   002   JOST A                ARCH ANAT MICROSC MORPHOL EXP   36   271 946
   003   JOST A                RECENT PROGR HORM RES            8   379 953
   004   JOST A                HARVEY LECTURES SER 55               201 959
   005   JOST A                JOHNS HOPKINS MED J            130    38 972
   006   PATTEN BM             HUMAN EMBRYOLOGY                         953
   007   BEATTY RA             PHIL TRANS R SOC LOND BIOL     259     3 970
   008   WILSON KM             CONTRIBUTIONS EMBRYOL           18    25 926
   009   GILLMAN J             CONTRIBUTIONS EMBRYOL           32    83 948
   010   FEDERMAN DD           ABNORMAL SEXUAL DEVELOPMENT              967
   011   JOSSO N               J CLIN ENDOCRINOL METAB         32   404 971
   012   JOSSO N               J CLIN ENDOCRINOL METAB         34   265 972
   013   JOSSO N               BIOL NEONATE                    20   368 972
   014   WILSON JD             ENDOCRINOLOGY                   92  1182 973
   015   SIITERI PK            J CLIN ENDOCRINOL METAB         38   113 974
   016   WILSON JD             ENDOCRINOLOGY                   89   659 971
   017   WILSON JD             ENDOCRINOLOGY                   92  1192 973
   018   SCHULTZ FM            ENDOCRINOLOGY                   94   979 974
   019   CLAYTON GW            J CLIN ENDOCRINOL METAB         18  1349 958
   020   MILNER WA             J UROL                          79  1003 958
   021   ROSENBERG HS          J CLIN ENDOCRINOL METAB         23   203 963
   022   MORI Y                JAPAN J UROL                    59    10 968
   023   HAMERTON JL           J REPROD FERTIL SUPPL            7    25 969
   024   CATTANACH BM          CYTOGENETICS                    10   318 971
   025   DE LA CHAPELLE A      AM J HUM GENET                  24    71 972
   026   KASDAN R              N ENGL J MED                   288   539 973
   027   BOCZKOWSKI K          CLIN GENET                       2   379 971
   028   JOSSO N               BULL SOC MED PARIS ANN PEDIAT   39   775 963
   029   GUISTI G              ACTA GENET MED GEMELLOL ROMA    15    51 966
   030   SIMPSON JL            OBSTET GYNECOL SURV             24   580 969
   031   CHRISTAKOS AC         AM J OBSTET GYNECOL            104  1027 969
   032   SIMPSON JL            BIRTH DEF ORIG ART SER           7   215 971
   033   COHEN MM              N ENGL J MED                   272  1083 965
   034   STERNBERG WH          N ENGL J MED                   278   695 968
   035   CHEMKE J              J MED GENET                      7   105 970
   036   ESPINER EA            N ENGL J MED                   283     6 970
   037$  FEDERMAN DD           IN: STEINBERG AG                 9   215 973
   038   HALL JG               BIRTH DEF ORIG ART SER          11   115 975
   039   PRADER A              HELV PAEDIATR ACTA              10   397 955
   040   PRADER A              HELV PAEDIATR ACTA              12   569 957
   041   CAMACHO AM            J CLIN ENDOCRINOL METAB         28   153 968
   042   BONGIOVANNI AM        J CLIN ENDOCRINOL METAB         21   860 961
   043   BONGIOVANNI AM        J CLIN INVEST                   41  2086 962
   044   BONGIOVANNI AM        RECENT PROGR HORM RES           23   375 967
   045   KOGUT MD              AM J DIS CHILD                 110   562 965
   046   JANNE O               J CLIN ENDOCRINOL METAB         31   162 970
   047   ZACHMANN M            J CLIN ENDOCRINOL METAB         30   719 970
   048   BONGIOVANNI AM        IN: STANBURY JB                      857 972
   049   BIGLIERI EG           J CLIN INVEST                   45  1946 966
   050   NEW MI                J CLIN ENDOCRINOL METAB         27   300 967
   051   MALLIN SR             ANN INTERN MED                  70    69 969
   052   GOLDSMITH O           N ENGL J MED                   277   673 967
   053   MIURA K               J CLIN ENDOCRINOL METAB         28  1807 968
   054   LINQUETTE M           ANN ENDOCRINOL PARIS            32   574 971
   055   MANTERO F             SCHWEIZ MED WOCHENSCHR         101    38 971
   056   NEW MI                J CLIN INVEST                   49  1930 970
   057   BRICAIRE H            J CLIN ENDOCRINOL METAB         35    67 972
   058   ALVAREZ MN            PEDIATR RES                      7   325 973
   059   ZACHMANN M            ACTA ENDOCRINOL SUPPL          155    65 971
   060   ZACHMANN M            CLIN ENDOCRINOL TOKYO            1   369 972
   061   SAEZ JM               J CLIN ENDOCRINOL METAB         32   604 971
   062   SAEZ JM               J CLIN ENDOCRINOL METAB         34   598 972
   063   GOEBELSMANN U         J CLIN ENDOCRINOL METAB         36   867 973
   064   MORRIS JM             AM J OBSTET GYNECOL             65  1192 953
   065   MORRIS JM             AM J OBSTET GYNECOL             87   731 963
   066   HAUSER GA             IN: OVERZIER C                       255 963
   067   SOUTHREN AL           IN: LEVINE R                     2   227 965
   068   WILKINS L             DIAG TREATMENT ENDOCRINE DISO        278 957
   069   SOUTHREN AL           J CLIN ENDOCRINOL METAB         25   518 965
   070   JUDD HL               J CLIN ENDOCRINOL METAB         34   229 972
   071   WILSON JD             N ENGL J MED                   290  1097 974
   072   GOLDSTEIN JL          J CLIN INVEST                   51  1647 972
   073   WINTERBORN MH         ARCH DIS CHILD                  45   811 970
   074   PHILIP J              AM J OBSTET GYNECOL             93  1076 965
   075   KHOO SK               AUST NZ J OBSTET GYNAECOL       12     1 972
   076   ROSENFIELD RL         J CLIN ENDOCRINOL METAB         32   625 971
   077   LUBS HA               J CLIN ENDOCRINOL METAB         19  1110 959
   078   GILBERT-DREYFUS S     ANN ENDOCRINOL PARIS            18    93 957
   079   REIFENSTEIN EC        CLIN RES                         3    86 947
   080   BOWEN P               ANN INTERN MED                  62   252 965
   081   BOCZKOWSKI K          AM J OBSTET GYNECOL            112   192 972
   082   ROSEWATER S           ANN INTERN MED                  63   377 965
   083   WALKER AC             MED J AUST                       1   156 970
   084   RIMOIN DL             GENET DISORDERS ENDOCRINE            279 971
   085   SIMPSON JL            BIRTH DEF ORIG ART SER           7   140 971
   086   OPITZ JM              CLIN GENET                       3     1 972
   087   IMPERATO-MCGINLEY J   J CLIN INVEST                   53   35A 974
   089   NILSEN O              ACTA CHIR SCAND                 83   231 939
   090   MORILLO-CUCCI G       BIRTH DEF ORIG ART SER           7   229 971
   091   DAVID L               ACTA PAEDIATR SCAND             61   249 972
   092   BROOK CGD             BR MED J                         1   771 973
   093   GUELL-GONZALEZ JR     REV ROUN ENDOCRINOL              7   343 970
   094   BRYAN AL              SURG GYNECOL OBSTET             88    79 949
   095   WHARTON LR            AM J OBSTET GYNECOL             53    37 947
   096   BLOCH P               GYNAECOLOGIA                   151   113 961
   097   HAUSER GA             GYNAECOLOGIA                   151   111 961
   098   LEDUC B               AM J OBSTET GYNECOL            100   512 968
   099   HAUSER GA             SCHWEIZ MED WOCHENSCHR          91   381 961
   100   VAN CAMPENHOUT J      LANCET                           2   928 971
   101   ANGER D               BULL FED SOC GYNECOL OBSTET L   18   229 966
   102   JONES HW JR           AM J OBSTET GYNECOL            114  1100 972
   103   HOLSCLAW DS           J UROL                         106   568 971
   104   KAPLAN E              N ENGL J MED                   279    65 968
CT   1   SCHWEIKERT HU         J CLIN ENDOCRINOL METAB         43   785 976
     2   GRIFFIN JE            J CLIN INVEST                   57  1342 976
     3   MOREIRAFILHO CA       REV BRASIL PESQUISAS MED BIOL   10   345 977
     4   GRIFFIN JE            J CLIN ENDOCRINOL METAB         45  1137 977
     5   SIMPSON JL            AM J OBSTET GYNECOL            128   137 977
     6   KOO GC                SCIENCE                        196   655 977
     7   GRIFFIN JE            CLIN OBSTET GYNAECOL             5   457 978
     8   WILSON JD             ANNU REV PHYSIOL                40   279 978
     9   SIMPSON JL            HUM GENET                       44     1 978
    10   WEISS EB              PEDIATRICS                      61   797 978
    11   RAJFER J              J UROL                         119   525 978
    12   BERNSTEIN R           J MED GENET                     17   291 980
    13   GRIFFIN JE            N ENGL J MED                   302   198 980
    14   WILSON JD             SCIENCE                        211  1278 981
    15   GRIFFIN JE            AM J PHYSIOL                   243  E 81 982
    16   WILSON JD             AUST J BIOL SCI                 36   101 983
    17   PEREIRA RR            HELV PAEDIATR ACTA              39   255 984
    18   SAENGER P             J PEDIATR                      104     1 984
    19   WILSON JD             HARVEY LECTURES                 79   145 985
    20   GREENE RA             HUM PATHOL                      17    88 986
    21   PAGE DC               COLD SPRING HARBOR SYMP Q BIO   51   229 986
    22   GYORKI S              J STEROID BIOCHEM               26     7 987

PN 75050
RN 00216
AN 76000814
AU Zaidi-Z-H.
TI Letter: Serum alpha-fetoprotein in cystic fibrosis.
SO Br-Med-J. 1975 Aug 23. 3(5981). P 491.
MJ CYSTIC-FIBROSIS: di.
MN ALPHA-FETOPROTEINS: an.  CARRIER-STATE: di.  CYSTIC-FIBROSIS: fg.
   FEMALE.  HETEROZYGOTE.  HUMAN.  MALE.
EX Professor R. K. Chandra and others suggest that estimation of serum
   alpha-fetoprotein (AFP) might help in detecting carriers in families
   at risk for cystic fibrosis.  Observers in the U.K. have been unable
   to confirm these findings, whereas Dr. J. A. Smith of New York
   supports them.  Perhaps the crux of the matter lies in the technique
   of estimating serum AFP.  if a small number of families is analysed
   the proportion of affected individuals may differ from the expected.
   By chance some families may have all normal children whereas some
   may have all affected children.  For example, nowadays, since
   families tend to be small, the appearance of an autosomal recessive
   condition is often sporadic with only one affected person in the
   family.  This could well apply to cystic fibrosis.
RF 001   CHANDRA RK            BR MED J                         1   714 975
   002   SMITH JA              BR MED J                         2   392 975
   003   DANKS DM              ANN HUM GENET                   28   323 965
   004   EMERY AEH             IN: FORFAR JO                         66 973
   005   CARTER CO             IN: HARRIS M                          22 970

PN 75051
RN 00217
AN 76019895
AU Fitzsimmons-J-S.  Smith-N.  Hiller-E-J.  Wynne-J.
TI Letter: Serum alpha-fetoprotein in cystic fibrosis.
SO Br-Med-J. 1975 Aug 30. 3(5982). P 544.
MJ ALPHA-FETOPROTEINS: an.  CYSTIC-FIBROSIS: bl.  FETAL-PROTEINS: an.
MN CYSTIC-FIBROSIS: fg.  HETEROZYGOTE.  HUMAN.
EX Professor R. K. Chandra and others found raised serum levels of
   alpha-fetoprotein (AFP) in a heterozygote carrier of the gene for
   cystic fibrosis and in patients with the disease and some of the
   siblings.  Our results do not show any significant difference in AFP
   levels in patients, siblings, parents, or control children.
   Probably the discrepancy in the findings will be explained by more
   detailed examination of the technique used.
RF 001   CHANDRA RK            BR MED J                         1   714 975
   002   BROCK DJH             BR MED J                         2   392 975
   003   ADINOLFI A            J MED GENET                     12   138 975
CT   1   BELANGER  L           BR MED J                         4   759 975
     2   BISWAS S              CLIN CHIM ACTA                  69   541 976
     3   KNOPFLE G             EUR J PEDIATR                  122   241 976
     4   KNOPFLE G             KLIN PAEDIATR                  189   207 977
     5   ALHADEFF JA           CLIN GENET                      14   189 978
     6   BROCK DJH             CLIN CHIM ACTA                  82   101 978
     7   ADINOLFI M            ADV HUM GENET                    9   165 979

PN 75052
RN 00218
AN 76063497
AU Knopple-G.  Rotthauwe-H-W.  Lehmann-F-G.
TI Letter: Serum alpha-fetoprotein in cystic fibrosis.
SO Br-Med-J. 1975 Nov 22. 4(5994). P 459.
MJ ALPHA-FETOPROTEINS: an.  CYSTIC-FIBROSIS: bl.  FETAL-PROTEINS: an.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: fg.
   HUMAN.  INFANT.
EX Professor R. K. Chandra and others reported significantly increased
   levels of alpha-fetoprotein (AFP) in the serum of patients with
   cystic fibrosis (CF), in the parents of the patients, and in some of
   their siblings in Newfoundland, Canada.  The serum AFP levels in our
   38 patients with CF were not different from those in healthy adults.
   In our opinion, genetic differences cannot explain the different
   results concerning the serum AFP levels in patients with CF.
RF 001   CHANDRA RK            BR MED J                         1   714 975
   002   SMITH JA              BR MED J                         2   392 975
   003   BROCK DJH             BR MED J                         2   392 975
   004   NISHI S               GANN MOGR CANCER RES            14    79 973
   005   ISHII M               GANN MOGR CANCER RES            14    89 973
   006   LEHMANN FG            CLIN CHIM ACTA                  33   197 971
   007   LEHMANN FG            Z KLIN CHEM KLIN BIOCHEM         9   309 971
   008   MANCINI G             COLLOQ PROTIDES BIOL FLUIDS     11   370 965
   009   LEHMANN FG            Z KLIN CHEM KLIN BIOCHEM        11   399 973
   010   SIZARET P             J BIOL STANDARDS                 3   201 975
CT   1   BISWAS S              CLIN CHIM ACTA                  69   541 976
     2   KNOPFLE G             EUR J PEDIATR                  122   241 976
     3   KNOPFLE G             KLIN PAEDIATR                  189   207 977
     4   ALHADEFF JA           CLIN GENET                      14   189 978

PN 75053
RN 00219
AN 75165793
TI Letter: Serum alpha-fetoprotein in cystic fibrosis.
SO Br-Med-J. 1975 May 17. 2(5967). P 392.
MJ ALPHA-FETOPROTEINS: an.  CYSTIC-FIBROSIS: bl.  FETAL-PROTEINS: an.
MN CHILD.  COUNSELING.  CYSTIC-FIBROSIS: fg.  HUMAN.
   RADIOIMMUNOASSAY.
EX Over the past 12 months we have examined by both
   counterimmunoelectrophoresis and radioimmunoassay sera from (a) 37
   patients with cystic fibrosis (age 6 months to 17 years), (b) 10 of
   their siblings, and (c) 24 of their parents for the presence of
   raised serum levels of AFP.  By counterimmunoelectrophoresis we were
   unable to detect an increased serum concentration of AFP in any of
   the cystic fibrosis patients or their relatives.  In addition, the
   results from the radioimmunoassay method showed that all of the
   cystic fibrosis patients and their relatives had normal
   concentrations of AFP in their serum. - Using a double antibody
   radioimmunoassay we found the mean serum AFP for seven children with
   cystic fibrosis to be little different from that of controls, while
   all seven values fell within the normal range for this series. - In
   seven patients considered to have cystic fibrosis on the basis of a
   sweat chloride level above 65 mmol/l the mean serum
   alpha-fetoprotein (AFP level was 1825 (range 130 - 2360) microg/l.
   The corresponding level in the patients was 433 (range 80 - 1055)
   microg/l.  Drug therapy given to these patients may have a subtle
   hepatoxic influence, thereby causing a rise in AFP levels.  The
   severity of the disease does not influence the degree of elevation.
   There is a corresponding rise in carcinoembryonic antigen levels
   also, but the latter is related to the degree of tissue damage and
   results from the sero-cross-reactivity between mucus-producing
   respiratory mucosa and fetal tissues.
RF 001   CHANDRA RK            BR MED J                         1   714 975
   002   BROCK DJH             LANCET                           1   767 974
   003   RUOSLAHTI E           NATURE                         235   161 972
CT   1   FITZSIMMONS JS        BR MED J                         3   544 975
     2   ZAIDI ZH              BR MED J                         3   491 975
     3   BELANGER  L           BR MED J                         4   759 975
     4   BELANGER  L           BR MED J                         4   759 975
     5   KNOPFLE G             BR MED J                         4   459 975
     6   KNOPFLE G             BR MED J                         4   459 975
     7   GRENIER A             CLIN CHEM                       22  1001 976
     8   BISWAS S              CLIN CHIM ACTA                  69   541 976
     9   BISWAS S              CLIN CHIM ACTA                  69   541 976
    10   KNOPFLE G             EUR J PEDIATR                  122   241 976
    11   KNOPFLE G             EUR J PEDIATR                  122   241 976
    12   DISANTAGNESE PA       N ENGL J MED                   295   597 976
    13   DISANTAGNESE PA       N ENGL J MED                   295   597 976
    14   RAMIREZ P             N ENGL J MED                   295  1381 976
    15   CHANDRA RK            INT ARCH ALLERGY APPL IMMUNOL   53   180 977
    16   KNOPFLE G             KLIN PAEDIATR                  189   207 977
    17   ALHADEFF JA           CLIN GENET                      14   189 978
    18   ALHADEFF JA           CLIN GENET                      14   189 978
    19   BROCK DJH             CLIN CHIM ACTA                  82   101 978
    20   MIZEJEWSKI GJ         PEDIATR RES                     17    47 983

PN 75054
RN 00220
AN 75147772
AU Dodge-J-A.  Salter-D-G.  Yassa-J-G.
TI Letter: Essential fatty acid deficiency due to artificial diet in
   cystic fibrosis.
SO Br-Med-J. 1975 Apr 26. 2(5964). P 192-3.
MJ CYSTIC-FIBROSIS: dh.  FATTY-ACIDS-ESSENTIAL: df.
   INFANT-NUTRITION.
MN CHILD-PRESCHOOL.  FEMALE.  HUMAN.  INFANT.  NUTRITIONAL-REQUIREMENTS.
   SKIN-MANIFESTATIONS.
EX We wish to draw the attention of your readers to a possible hazard
   of feeding infants with an elemental diet.  Considerable interest is
   currently being shown in the use of the artificial diet in cystic
   fibrosis.  It may be used as a supplement to ordinary food or to
   supply all the nutritional needs of the child.  In the latter event
   we believe that it is particularly important to emphasize to the
   parents the need for an additional source of dietary fat.  Clinical
   evidence and animal experiments suggest that infants, because of
   their rapid growth rate, are particularly at risk and that in the
   absence of dietary E.F.A. they will develop deficiency symptoms in
   about two months.
RF 001   ALLAN JD              AM J DIS CHILD                 126    22 973
   002   HANSEN AE             PEDIATRICS                      31   171 963
   003   WARWICK WJ            AM J DIS CHILD                  98   317 959
   004   PAULSRUD JR           AM J CLIN NUTR                  25   897 972
   005   CALDWELL MD           J PEDIATR                       81   894 972
   006   COLLINS FD            NUTR METAB                      13   150 971
   007   PRESS M               BR MED J                         2   247 974
   008   ELLIOTT RB            ARCH DIS CHILD                  50    76 975
   009   LOVE WC               BIOCHEM SOC TRANS                1   141 973
CT   1   RIVERS JPW            LANCET                           2   642 975
     2   DODGE JA              ARCH DIS CHILD                  50   578 975
     3   WOOD RE               AM REV RESPIR DIS              113   833 976
     4   OHALLORAN ET          IR MED J                        71   184 978
     5   DODGE JA              LANCET                           2  1256 980
     6   LLOYDSTILL JD         AM J CLIN NUTR                  34     1 981
     7   SOLOMONS NW           AM J CLIN NUTR                  34   462 981
     8   DODGE JA              ACTA PAEDIATR SCAND SUPPL 317 1985    31 985
     9   PARSONS HG            BIOCHIM BIOPHYS ACTA           860   420 986

PN 75055
RN 00221
AN 75147682
AU Chandra-R-K.  Madhavankutty-K.  Way-R-C.
TI Serum alpha - fetoprotein levels in patients with cystic fibrosis
   and their parents and siblings.
SO Br-Med-J. 1975 Mar 29. 1(5960). P 714-6.
MJ ALPHA-FETOPROTEINS: an.  CYSTIC-FIBROSIS: bl.  FETAL-PROTEINS: an.
MN BRONCHIECTASIS: bl.  CELIAC-DISEASE: bl.  CHLORIDES: an.
   CYSTIC-FIBROSIS: fg, me.  GEL-DIFFUSION-TESTS.  GENETIC-COUNSELING.
   HETEROZYGOTE.  HUMAN.  IMMUNOELECTROPHORESIS.  INFANT.  LIVER: me.
   SWEAT: an.
AB Patients with cystic fibrosis (C.F.) showed raised serum levels of
   alpha-fetoprotein (AFP). A moderate but significant increase in serum
   AFP was present in their parents and some siblings. There was no
   correlation between the clinical severity of the disease and serum
   AFP concentration. Samples from control groups with gluten-induced
   malabsorption and bronchiectasis had normal levels. Persistent
   synthesis of AFP may be an associated marker of C.F. genes, and
   estimation of serum AFP might help in detecting heterozygote carriers
   in families at risk.
RF 001   ABELEV GI             ADV CANCER RES                  14   295 971
   002   ALLAN LD              LANCET                           2   522 973
   003   BESLEY GTN            J MED GENET                      6   278 969
   004   BROCK DJH             LANCET                           2   197 972
   005   BROCK DJH             LANCET                           2   923 973
   006   BRUNECKY Z            J MED GENET                      9    33 972
   007   CHANDRA RK            ARCH DIS CHILD                  48   157 973
   008   CHANDRA RK            MED CHIR DIG                     3    63 974
   010   CHERRY JD             J PEDIATR                       79   937 971
   011   DANES BS              LANCET                           1  1061 968
   012   DANES BS              J EXP MED                      129   775 969
   013   DANKS DM              ANN HUM GENET                   28   323 965
   014   GITLIN D              J CLIN INVEST                   45  1826 966
   015   LEEK AE               LANCET                           2   385 973
   016   LOCKHART LH           SOUTH MED J                     61  1356 968
   017   MASOPUST J            INT J CANCER                     3   364 968
   018   NAYAK NC              LANCET                           1    86 972
   019   RENNERT OM            CLIN PEDIATR                    11   351 972
   020   RUOSLAHTI E           INT J CANCER                     8   374 971
   021   SPOCK A               PEDIATR RES                      1   173 967
   022   WALDMANN TA           LANCET                           2  1112 972
   023   WRIGHT SW             HAWAII MED J                    27   229 968
CT   1   BROCK DJH             BR MED J                         2   392 975
     2   SMITH JA              BR MED J                         2   392 975
     3   WALLWORK JC           BR MED J                         2   392 975
     4   FITZSIMMONS JS        BR MED J                         3   544 975
     5   ZAIDI ZH              BR MED J                         3   491 975
     6   BELANGER  L           BR MED J                         4   759 975
     7   KNOPFLE G             BR MED J                         4   459 975
     8   LEHMANN FG            LEBER MAGEN DARM                 5   144 975
     9   ADINOLFI A            J MED GENET                     12   138 975
    10   BROCK DJH             CHILDS BRAIN                     2     1 976
    11   BERNAUDIN F           NOUV PRESSE MED                  5   643 976
    12   GRENIER A             CLIN CHEM                       22  1001 976
    13   LUCKING T             KLIN WSCHR                      54   391 976
    14   BISWAS S              CLIN CHIM ACTA                  69   541 976
    15   NORGAARDPEDERSEN B    CLIN CHIM ACTA                  71   343 976
    16   KNOPFLE G             EUR J PEDIATR                  122   241 976
    17   DISANTAGNESE PA       N ENGL J MED                   295   597 976
    18   RAMIREZ P             N ENGL J MED                   295  1381 976
    19   NORGAARDPEDERSEN B    SCAND J IMMUNOL               1976     7 976
    20   CRUIKSHANK DP         SEM PERINATOL                    1   135 977
    21   BROCK DJH             PROG MED GENET                   2     1 977
    22   SIZARET P             DIGESTION                       15    97 977
    23   CHANDRA RK            INT ARCH ALLERGY APPL IMMUNOL   53   180 977
    24   OLSSON M              J EXP MED                      145   819 977
    25   KNOPFLE G             KLIN PAEDIATR                  189   207 977
    26   DELPRE G              GASTROENTEROL CLIN BIOL          2   193 978
    27   ALHADEFF JA           CLIN GENET                      14   189 978
    28   BROCK DJH             CLIN CHIM ACTA                  82   101 978
    29   ADINOLFI M            ADV HUM GENET                    9   165 979
    30   BROCK DJH             MOL ASP MED                      3   431 980
    31   BOYE NP               EUR J RESPIR DIS                61   227 980
    32   SCAMBLER  P           HUM GENET                       69   250 985

PN 75056
RN 00222
AN 76115710
AU Belanger-L.  Hamel-D.  Aubin-G.  Belanger-M.  Bigonesse-P.  Dorval-J.
   Sell-S.  Stillman-D.  Skelly-H.  Scott-J.  Harwood-I.  Olmsted-N.
TI Letter: Serum alpha-fetoprotein in cystic fibrosis.
SO Br-Med-J. 1975 Dec 27. 4(5999). P 759.
MJ ALPHA-FETOPROTEINS: an.  CYSTIC-FIBROSIS: bl.  FETAL-PROTEINS: an.
MN HUMAN.
EX Sera from 40 well-confirmed cystic fibrosis patients and 60 of their
   parents were obtained through two Canadian (Chicoutimi and Quebec)
   and one United States (San Diego) cystic fibrosis clinics.  AFP was
   measured by two methods: a double antibody enzyme immunoassay and a
   sodium sulphate precipitation radioimmunoassay.  Our results thus
   confirm that serum AFP levels are normal in cystic fibrosis.
RF 001   CHANDRA RK            BR MED J                         1   714 975
   002   WALLWORK JC           BR MED J                         2   392 975
   003   BROCK DJH             BR MED J                         2   392 975
   004   FITZSIMMONS JS        BR MED J                         3   544 975
   005   SMITH JA              BR MED J                         2   392 975
   007   SELL S                IMMUNOCHEMISTRY                 10   439 973
CT   1   GRENIER A             CLIN CHEM                       22  1001 976
     2   KNOPFLE G             EUR J PEDIATR                  122   241 976
     3   KNOPFLE G             KLIN PAEDIATR                  189   207 977
     4   BROCK DJH             CLIN CHIM ACTA                  82   101 978

PN 75057
RN 00223
AN 75110215
AU McFarlane-H.  Holzel-A.  Brenchley-P.  Allan-J-D.  Wallwork-J-C.
   Singer-B-E.  Worsley-B.
TI Immune complexes in cystic fibrosis.
SO Br-Med-J. 1975 Feb 22. 1(5955). P 423-8.
MJ CYSTIC-FIBROSIS: im.
MN ADSORPTION.  ADULT.  ANTIBODIES.  ANTIGEN-ANTIBODY-COMPLEX: an.
   AUTORADIOGRAPHY.  CHILD.  CHILD-PRESCHOOL.  COMPLEMENT: an.  FEMALE.
   FLUORESCENT-ANTIBODY-TECHNIC.  GASTROINTESTINAL-SYSTEM: im.
   CHROMATOGRAPHY-GEL.  HEMOLYSINS: ip.  HUMAN.  IGA.  IGG: ip.  IGM.
   IMMUNOELECTROPHORESIS.  INFANT.  LUNG: im.  MALE.  PRECIPITIN-TESTS.
   RESPIRATORY-SYSTEM: im.  SERUM-ALBUMIN-BOVINE: im.  SPUTUM: im.
   STAPHYLOCOCCUS.
AB Circulating immune complexes were detected in serum and sputum of
   patients with cystic fibrosis (C.F.).  There were extensive deposits
   of immunoglobulins and complement immune complexes in several of the
   C.F. organs, especially the respiratory and gastrointestinal tracts,
   but not in the kidneys.  Significant concentrations of IgG and of
   complement complexes could be eluted from the lungs of the C.F.
   patients but not from those of controls.  Studies involving
   immunoabsorption, autoradiography, and molecular sieving through
   Sephadex G-200 columns identified both bovine serum albumin and
   staphylococcal alpha-haemolysin as two of the antigens present in
   the immune complexes.  The sedimentation constant of the immune
   complexes was about 8S to 11S.  The clinical significance of these
   immune complexes and the wide variety of antibodies detected in C.F.
   patients are discussed.
RF 001   ALLISON AC            LANCET                           1  1232 969
   002   BURNS MW              LANCET                           1   354 967
   003   CRACCO G              PROC EWGCF 5TH ANNU MTG               16 974
   004   DIXON FJ              HARVEY LECTURES                 58    21 963
   005   GRABAR P              IN: GRABAR P                           3 964
   006   GULCHARD Y            PROC EWGCF 5TH ANNU MTG                  974
   007   JOHANSSON SGO         IMMUNOLOGY                      10   265 968
   008   KILBURN KH            IN: MANGOS JA                        129 973
   009   MCCARTHY DS           IN: LAWSON D PROC 5TH INT CF         194 969
   010   MANCINI G             IMMUNOCHEMISTRY                  2   235 965
   011   MERCOLA KE            EXP MOL PATH                    19   230 973
   012   MURRAY MJ             ANN INTERN MED                  53   548 960
   013   PEPYS J               IN: SERAFINI U                       136 971
   014   SOOTHILL JF           CLIN EXP IMMUNOL                 2    83 967
   015   SOOTHILL JF           LANCET                           2   929 967
   016   STEIN AA              J PEDIATR                       65   495 964
   017   WALLWORK JC           CLIN EXP IMMUNOL                18   303 974
   018   WARREN CPW            AM REV RESPIR DIS              109   672 974
CT   1   ALLAN JD              CLIN ALLERGY                     5   255 975
     2   GIBBONS A             BR MED J                         1   120 976
     3   MCFARLANE H           LANCET                           1  1241 976
     4   WALLWORK JC           CLIN ALLERGY                     6   349 976
     5   STEPHAN U             INTERNIST                       17   336 976
     6   VISCONTI A            ANN SCLAVO                      18   308 976
     7   WEEKE B               DAN MED BULL                    23   155 976
     8   CLARKE CW             THORAX                          31   702 976
     9   ANON                  NUTR REV                        34   210 976
    10   GALANT SP             AM REV RESPIR DIS              114   325 976
    11   DISANTAGNESE PA       N ENGL J MED                   295   597 976
    12   GENIN C               ARCH FR PEDIATR                 34   717 977
    13   STRUNK RC             ARCH DIS CHILD                  52   687 977
    14   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   85    57 977
    15   ZUBLER RH             PROG ALLERGY                    24     1 978
    16   HILTON AM             CLIN EXP IMMUNOL                31   237 978
    17   SMITH WR              CHEST                           73   471 978
    18   GOTZ M                EUR J PEDIATR                  127   133 978
    19   HOIBY N               MONOGR PAEDIATR                 10   138 979
    20   SCHIOTZ PO            MONOGR PAEDIATR                 10   131 979
    21   HOWIE AD              SCOTT MED J                     24   193 979
    22   HOIBY N               ACTA PAEDIATR SCAND             68   495 979
    23   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   87   229 979
    24   SOTER NA              J PEDIATR                       95   197 979
    25   BERDISCHEWSKY M       PEDIATR RES                     14   830 980
    26   HODSON ME             THORAX                          35   801 980
    27   CARR RI               CLIN EXP IMMUNOL                39   562 980
    28   MIELIVERGANI G        ARCH DIS CHILD                  55   696 980
    29   MOSS RB               AM REV RESPIR DIS              121    23 980
    30   MATTHEWS WJ           N ENGL J MED                   302   245 980
    31   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C) S276     1 981
    32   FICK RB               CLIN CHEST MED                   2    91 981
    33   HOLLAND EJ            J CLIN LAB IMMUNOL               6   137 981
    34   PENNINGTON JE         J CLIN INVEST                   68  1140 981
    35   CHURCH JA             CHEST                           80   405 981
    36   MARKS MI              J PEDIATR                       98   173 981
    37   MOSS RB               J PEDIATR                       99   215 981
    38   DANIELE RP            AM REV RESPIR DIS              124   738 981
    39   FROLAND SS            SCAND J INFECT DIS            1981    72 981
    40   COX KL                J PEDIATR GASTROENTEROL NUTR     1   345 982
    41   ABRAMOWSKY CR         HUM PATHOL                      13   934 982
    42   MARGOLIES R           PEDIATR RES                     16   181 982
    43   MOSS RB               CLIN EXP IMMUNOL                47   301 982
    44   PITCHERWILMOTT RW     ARCH DIS CHILD                  57   577 982
    45   MANTHEI U             AM REV RESPIR DIS              126   253 982
    46   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    63 982
    47   SCHIOTZ PO            ACTA PAEDIATR SCAND SUPPL 301 1982    55 982
    48   ANON                  LANCET                           2   257 983
    49   MARGOLIES R           PEDIATR RES                     17   931 983
    50   BRYAN LE              J CLIN MICROBIOL                18   276 983
    51   KLINGER JD            INFECT IMMUN                    39  1377 983
    52   WALLACE JM            AM REV RESPIR DIS              128  1077 983
    53   DORING G              J INFECT DIS                   147   744 983
    54   DAVIS CA              HUM PATHOL                      15   244 984
    55   BOSSO JA              DRUG INTEL CLIN PHARM           18   825 984
    56   SPEERT DP             PEDIATR RES                     18   431 984
    57   HODSON ME             POSTGRAD MED J                  60   225 984
    58   DORING G              ACTA PATH MICROB IMMU SCA (C)   92   307 984
    59   WHEELER WB            J PEDIATR                      104   695 984
    60   MICHALSEN H           PATHOL RES PRACT               178   261 984
    61   AUERBACH HS           LANCET                           2   686 985
    62   SPEERT DP             SURV SYNTH PATHOL RES            4    14 985
    63   MISCHLER EH           SEM RESPIR MED                   6   271 985
    64   HODSON ME             CLIN ALLERGY                    15   363 985
    65   WISNIESKI JJ          AM REV RESPIR DIS              132   770 985
    66   GOTZ M                MONATSSCHR KINDERHEILKD        133   718 985
    67   PIER GB               J INFECT DIS                   151   575 985
    68   WOODS DE              J INFECT DIS                   151   581 985
    69   DISIS ML              PEDIATR RES                     20   385 986
    70   HOIBY N               ANNU REV MICROBIOL              40    29 986
    71   PHILLIPS BM           J ROY SOC MED                   79    44 986
    72   MOSS RB               AM REV RESPIR DIS              133   648 986
    73   BOSSO JA              PEDIATR INFECT DIS J             6   393 987
    74   DASGUPTA MK           J CLIN IMMUNOL                   7    51 987

PN 75058
RN 00224
AN 75147969
AU Blenkarn-G-D.  Lanning-C-F.  Kylstra-J-A.
TI Anaesthetic management of volume controlled unilateral lung lavage.
SO Can-Anaesth-Soc-J. 1975 Mar. 22(2). P 154-63.
MJ ANESTHESIA-GENERAL: mt.  CYSTIC-FIBROSIS: th.  DIAZEPAM.  HALOTHANE.
   IRRIGATION: mt.  PULMONARY-ALVEOLAR-PROTEINOSIS: th.
MN ANESTHESIA-INTRATRACHEAL: mt.  ANESTHESIA-INTRAVENOUS: mt.
   BLOOD-PRESSURE: de.  CARBON-DIOXIDE: bl.  COMPARATIVE-STUDY.
   DIAZEPAM: ad.  HALOTHANE: ad.  HEART-RATE: de.  HUMAN.
   HYDROGEN-ION-CONCENTRATION.  IRRIGATION: ae.  KETAMINE: ad.
   OXYGEN-CONSUMPTION.  OXYGEN: bl.  THIOPENTAL: ad.
AB Conventional means to facilitate clearance of inspissated material
   obstructing gas exchange in the alveoli and finer airways of
   patients with alveolar proteinosis, asthma, and mucoviscidosis, are
   often not very effective.  The mechanical removal of such materials
   by volume controlled unilateral lung lavage with saline has been of
   benefit in selected patients refractory to conventional therapy
   (particularly those with alveolar proteinosis or accidentally
   inhaled radioactive particles).  This report describes the
   anaesthetic and lavage techniques currently used in managing
   patients with alveolar proteinosis and mucoviscidosis and in whom
   lung lavage repeated at approximately six-month intervals has
   resulted in both subjective and objective improvements.  In 14
   lavages in four different patients (10 lavages in two patients with
   alveolar proteinosis and four lavages in two patients with
   mucoviscidosis) certain physiologic responses to lung lavage,
   particularly those related to oxygen transport, were measured
   quantitatively in an attempt to evaluate and to optimize anaesthetic
   and lavage techniques.  The maintenance anaesthetic during lavage
   was selected randomly, so that each patient received light
   anaesthesia with ketamine/diazepam during one lavage and light
   halothane anaesthesia during lavage of the contralateral lung.
RF 001   KYLSTRA JA            AM REV RESPIR DIS              103   651 971
   002   RAMIREZ RJ            DIS CHEST                       50   581 966
   003   ROGERS RM             MED CLIN NORTH AM               54   755 970
   004   MCCLELLAN RO          ANN REP FISSION PRODUCT INHAL        287 972
   005   LYNCH CC              ANESTHESIOLOGY                  18   138 957
   006$  KELMAN GR             J APPL PHYSIOL                  24  1375 966
   007   WASSERMAN K           AM J MED                        44   611 968
   008   SMITH JD              ANESTHESIOLOGY                  33   401 970
   009   ROGERS RM             N ENGL J MED                   286  1230 972
   010   PERMUTT S             J APPL PHYSIOL                  18   924 963
   011   COPPEL D              ANAESTHESIA                     28   293 973
   012   PRICE HL              J APPL PHYSIOL                   6   517 954
   013   MEAD J                J APPL PHYSIOL                  22    95 967
CT   1   BRADFIELD HGC         ANAESTHESIA                     34  1032 979
     2   ALFERY DD             ANESTHESIOLOGY                  55   376 981
     3   ROTHMANN BF           ANN OTOL RHINOL LARYNGOL        91   641 982
     4   KARIMAN K             LUNG                           162   223 984
     5   HUDES ET              CAN ANAESTH SOC J               33   662 986

PN 75059
RN 00225
AN 76001068
AU Forstner-G.  Crozier-D-N.  Sturgess-J-M.
TI Cystic fibrosis: present status and future prospects in detection of
   patients and carriers.
SO Can-Med-Assoc-J. 1975 Sep 20. 113(6). P 550-6.
MJ CARRIER-STATE: di.  CYSTIC-FIBROSIS: di.
MN BIOLOGICAL-ASSAY.  BLOOD-PROTEINS: an.  COMPARATIVE-STUDY.
   CYSTIC-FIBROSIS: fg, bl.  FEMALE.  HETEROZYGOTE.  HOMOZYGOTE.  HUMAN.
   MALE.  MECONIUM: an.  PREGNANCY.  PRENATAL-DIAGNOSIS.  SWEAT: an.
AB Development of a sensitive, easily performed, reliable test would be
   an important advance in detecting cystic fibrosis, improving genetic
   counselling and providing early effective treatment. The sweat
   chloride test, which is reliable in diagnosis, is technically too
   difficult for a screening program, and only reliably detects
   homozygotes. In contrast, the meconium test for detecting homozygote
   newborns is simple, inexpensive, reasonably specific but its general
   application has yet to be evaluated. Detection of serum components is
   the basis of two new tests to distinguish patients with cystic
   fibrosis and carriers. The effect of these serum components on
   ciliary activity is the principle of one test, an extremely difficult
   procedure that is subjective and lacks sufficient specificity for
   routine use. The second test, in which serum components are separated
   by isoelectric focusing, may provide an objective biochemical means
   of detecting both homozygotes and heterozygotes.
RF 001   KRAMM ER              AM J PUBLIC HEALTH              52  2041 962
   002   SULTZ HA              AM J PUBLIC HEALTH              56  1461 966
   003   MERRITT AD            J LAB CLIN MED                  60   998 962
   004   MILUNSKY A            ANNU REV MED                    23    57 972
   005   DI SANTAGNESE PA      ANN NY ACAD SCI                 93   555 962
   006   SPROUL A              J PEDIATR                       69   759 966
   007   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   008   STRACHAN PG           ANN R COLL PHYS SURG CAN         3    23 970
   009   SARLES H              GUT                              6   545 965
   010   CROZIER DN            PEDIATR CLIN NORTH AM           21   935 974
   011   MACLEAN WC JR         J PEDIATR                       83    86 973
   012   FLEISHER DS           J PEDIATR                       64   349 964
   013   VINK CLJ              IN: DE REUCK AVS                     310 962
   014   SEKELJ P              AM REV RESPIR DIS              108   603 973
   015   SCHWARZ V             ARCH DIS CHILD                  43   695 968
   016   GIBSON LE             PEDIATRICS                      23   545 959
   017   MAUER AM              AM J DIS CHILD                  92   160 956
   018   BUCHANAN DJ           PEDIATRICS                       9   304 952
   019   SCHACHTER H           CAN J BIOCHEM                   43   381 965
   020   SCHUTT WH             ARCH DIS CHILD                  43   178 968
   021   HELLSING K            SCAND J CLIN LAB INVEST         34   333 974
   022   STEPHAN U             KLIN PAEDIATR                  186    79 974
   023   STEPHAN U             CF CLUB ABST                    15       974
   024   DI SANTAGNESE PA      PEDIATRICS                      24   313 959
   025   SPOCK A               PEDIATR RES                      1   173 967
   026   BOWMAN BH             SCIENCE                        164   325 969
   027   SCHMOYER IR           BIOCHEM BIOPHYS RES COMMUN      46  1923 972
   028   BARNETT DR            TEX REP BIOL MED                31   703 973
   029   DANES BS              J EXP MED                      137  1538 973
   030   CONOVER JH            LIFE SCI                        14   253 974
   031   BARNETT DR            TEX REP BIOL MED                31   697 973
   032   BARNETT DR            TEX REP BIOL MED                31   691 973
   033   BOWMAN BH             CLIN GENET                       4   461 973
   034   CONOVER JH            LANCET                           1  1194 973
   035   WOOD RE               LANCET                           2  1452 973
   036   WILSON GB             CLIN CHIM ACTA                  49    79 973
CT   1   CZEGLEDYNAGY E        LAB INVEST                      35   588 976
     2   FORSTNER G            CLIN CHIM ACTA                  70   459 976
     3   GABRIDGE MG           PEDIATR RES                     13    31 979
     4   BELL L                J CAN DIET ASSOC                42    62 981

PN 75060
RN 00226
AN 76064099
AU Marcotte-A-A.
TI Cystic fibrosis.
SO Can-Nurse. 1975 Jul. 71(7). P 33-7.
MJ CYSTIC-FIBROSIS.
MN CASE-REPORT.  CHILD.  CYSTIC-FIBROSIS: th.  FEMALE.  HUMAN.
   PATIENT-CARE-PLANNING.  PATIENT-CARE-TEAM.
AB Cystic fibrosis, whether it is called fibrocystic disease of the
   pancreas, mucoviscidosis, of simply C.F., is a condition that
   currently afflicts one in every 2,500 children.  A glimpse of this
   disease is gained through the experience of Amelia, one of its
   victims.
RF 001   GARDNER LI            ENDOCRINE GENET DIS CHILDH           991 969
   002   BELMONTE MM           CF MOST SERIOUS LUNG PROB CAN          1    
   003   BELMONTE MM           FIBROSE KYSTIQUE UN MANUEL A             968
   004   BELMONTE MM           FIBROSE KYSTIQUE UN MANUEL A             968
   005   STEINSCHNEIDER R      SOINS ET OBSERVATIONS           18    25 973
   006   STEINSCHNEIDER R      SOINS ET OBSERVATIONS           18    25 973
   007   BELMONTE MM           FIBROSE KYSTIQUE UN MANUEL A             968
   008   GILLY R               ANN PEDIATR (PARIS)             20     5 973
   009   TROPAUER A            AM J DIS CHILD                 119   424 970
   010   TROPAUER A            AM J DIS CHILD                 119   424 970
   011   MCCOLLUM AT           J PEDIATR                       77   571 970
   012   BELMONTE MM           UNION MED CAN                   98  1944 969

PN 75061
RN 00227
AN 76002502
AU Lober-C-W.  Saltzman-H-A.  Kylstra-J-A.
TI Volume-controlled lung lavage in a woman with cystic fibrosis.
SO Chest. 1975 Sep. 68(3). P 382-3.
MJ CYSTIC-FIBROSIS: th.  IRRIGATION.  LUNG.
MN ADULT.  CASE-REPORT.  FEMALE.  HUMAN.  REMISSION-SPONTANEOUS.
   RESPIRATORY-FUNCTION-TESTS.
AB A 22-year-old woman with cystic fibrosis was treated by volume-
   controlled lavage of each of her lungs on two occasions. Following
   the first lavages, the patient's vital capacity increased by 1.03
   liters and her 1-sec forced expiratory volume increased by 0.70
   liters/second. Similar improvements, although less pronounced, were
   noted after both lungs has been lavaged a second time. It is
   concluded that volume-controlled lung lavage can be of benefit as an
   adjunct in the treatment of patients with cystic fibrosis.
RF 001   KYLSTRA JA            AM REV RESPIR DIS              103   651 971
   002   BRAUNSTEIN MS         CHEST                           66    96 974
   003   ROGERS RM             CHEST SUPPL                     62    95 972
CT   1   MILLIS RM             CHEST                           71   508 977
     2   EWING CW              CHEST                           73   750 978
     3   ROTHMANN BF           ANN OTOL RHINOL LARYNGOL        91   641 982

PN 75062
RN 00228
AN 85177317
AU Warren-C-P.  Tai-E.  Batten-J-C.  Hutchcroft-B-J.  Pepys-J.
TI Cystic fibrosis--immunological reactions to A. fumigatus and common
   allergens.
SO Clin-Allergy. 1975 Mar. 5(1). P 1-12.
MJ ASPERGILLUS-FUMIGATUS: im.  CYSTIC-FIBROSIS: im.
MN ASPERGILLOSIS: im.  ASTHMA: im.  EOSINOPHILS: im.  HAY-FEVER: im.
   HUMAN.  HYPERSENSITIVITY: im.  IGE: an.  IMMUNOGLOBULINS: an.
   LEUKOCYTE-COUNT.  PRECIPITIN-TESTS.  SKIN-TESTS.
AB Immunological studies of forty-three patients with cystic fibrosis
   showed that positive prick tests to at least one common allergen were
   obtained in 70%, to multiple allergens in 28% and to A. fumigatus in
   50%. Specific IgE antibodies against these allergens were found in
   the appropriate subjects. In spite of this evidence of type 1, IgE,
   sensitization none of the patients had a history of infantile eczema.
   Intracutaneous tests with A. fumigatus extract gave types 1 and 3
   reactions in sixteen patients (37%), only seven of whom were among
   the sixteen (37%) who gave positive precipitin tests. Raised levels
   of total serum IgG and IgA were found as compared with healthy
   controls and asthmatic subjects. No differences were found in total
   serum IgM and IgD levels. The high incidence of allergy to A.
   fumigatus in cystic fibrosis is confirmed.
RF 001   BATTEN JC             MOD PROBL PEDIATR               10   227 967
   002   COCHRANE CG           J EXP MED                      134   75S 971
   003   CURRAN WS             ANN INTERN MED                  55   777 961
   004   DOLOVICH J            J ALLERGY                       46   127 970
   005   DOLOVICH J            J ALLERGY CLIN IMMUNOL          52    38 973
   006   KATZ RM               N ENGL J MED                   288   233 973
   007   LESKOWITZ S           CLIN ALLERGY                     2   237 972
   008   LONGBOTTOM JL         J PATHOL BACTERIOL              88   141 964
   009   MCCARTHY DS           IN: LAWSON D PROC 5TH INT CF         194 969
   010   MCCARTHY DS           CLIN ALLERGY                     1   415 971
   011   MEARNS MB             THORAX                          20   385 965
   012   MEARNS MB             LANCET                           1   538 967
   013   PEPYS J               IN: GELL PGH                             968
   014   PEPYS J               PROC INT CONG ALLERGOLOGY        6   221 968
   015   PEPYS J               CLIN ALLERGY SUPPL               3   491 973
   016   PEPYS J               CLIN ALLERGY                     3   143 973
   017   ROWE DS               BULL WHO                        40   613 969
   018   SALVAGGIO JE          CLIN ALLERGY                     3    43 973
   019   SCADDING JG           SCAND J RESPIR DIS              48   372 967
   020   SIMON G               TEACH IN ON CF                           970
   021   TADA T                J IMMUNOL                      104   377 970
   022   TAYLOR B              LANCET                           2   111 973
   023   WIDE L                LANCET                           2  1105 967
CT   1   WARNER JO             LANCET                           1   990 976
     2   MULLINS J             CLIN ALLERGY                     6   209 976
     3   MITCHELLHEGGS P       Q J MED                         45   479 976
     4   CLARKE CW             CLIN ALLERGY                     7   527 977
     5   WARNER JO             CLIN ALLERGY                     7   385 977
     6   SAKULA A              BR J DIS CHEST                  71   295 977
     7   TURNER MW             ARCH DIS CHILD                  53   631 978
     8   ZAMBIE MF             ANN ALLERGY                     42   290 979
     9   HODSON ME             THORAX                          35   801 980
    10   TOBIN MJ              THORAX                          35   807 980
    11   PRIOR J               BR J DIS CHEST                  74    84 980
    12   MATTHEWS WJ           N ENGL J MED                   302   245 980
    13   CROMWELL O            LANCET                           2   164 981
    14   REEN DJ               CLIN ALLERGY                    11   571 981
    15   CLARKE CW             BR J DIS CHEST                  75    15 981
    16   MOSS RB               J PEDIATR                       99   215 981
    17   ZETTERSTROM O         BR MED J                       283  1215 981
    18   SCHIOTZ PO            ACTA PAEDIATR SCAND SUPPL 301 1982    55 982
    19   ANON                  LANCET                           2   257 983
    20   BIRX DL               ANN ALLERGY                     53   124 984
    21   HODSON ME             POSTGRAD MED J                  60   225 984
    22   LAUFER P              J ALLERGY CLIN IMMUNOL          73    44 984
    23   AUERBACH HS           LANCET                           2   686 985
    24   STARKE ID             BR J DIS CHEST                  79   295 985
    25   GORDON IJ             J ROY COLL PHYSICIANS LOND      20   206 986
    26   PIEDRA P              J PEDIATR                      108   817 986

PN 75063
RN 00229
AN 76042250
AU Allan-J-D.  Moss-A-D.  Wallwork-J-C.  McFarlane-H.
TI Immediate hypersensitivity in patients with cystic fibrosis.
SO Clin-Allergy. 1975 Sep. 5(3). P 255-61.
MJ CYSTIC-FIBROSIS: im.  HYPERSENSITIVITY-IMMEDIATE: im.
MN ALLERGENS: ad.  CHILD.  CHILD-PRESCHOOL.  GEL-DIFFUSION-TESTS.
   HUMAN.  IGE: an.  INFANT.  PRECIPITIN-TESTS.  SKIN-TESTS.
AB Twenty-three out of thirty patients with cystic fibrosis gave strong
   immediate skin hypersensitivity reaction to a wide variety of
   allergens. Seventy-five per cent of these had a markedly elevated
   serum IgE concentration whereas those patients who had negative Type
   1 immediate skin reactions also had normal levels of serum IgE. The
   sputum of those patients with immediate skin reactivity also had
   positive precipitins to a variety of antigens.
RF 001   JOHANSSEN SGO         IMMUNOLOGY                      10   265 968
   002   MANCINI G             IMMUNOCHEMISTRY                  2   235 965
   003   MCCARTHY DS           IN: LAWSON D PROC 5TH INT CF         194 969
   004   MCFARLANE H           BR MED J                         1   423 975
   005   MEARNS MB             THORAX                          20   385 965
   006   MEARNS MB             LANCET                           1   538 967
   007   SHWACHMAN H           PEDIATRICS                      30   389 962
   008   WALLWORK JC           CLIN EXP IMMUNOL                18   303 974
   009   YOHE RM               ANN ALLERGY                     30   627 972
CT   1   MCFARLANE H           LANCET                           1  1241 976
     2   WARNER JO             LANCET                           1   990 976
     3   SHAKIB F              CLIN ALLERGY                     6   237 976
     4   WALLWORK JC           CLIN ALLERGY                     6   349 976
     5   CLARKE CW             CLIN ALLERGY                     7   527 977
     6   MCFARLANE H           CLIN ALLERGY                     7   279 977
     7   WARNER JO             CLIN ALLERGY                     7   385 977
     8   RAEBURN JA            PROC NUTR SOC                   36    77 977
     9   SILVERMAN M           ARCH DIS CHILD                  53   873 978
    10   TURNER MW             ARCH DIS CHILD                  53   631 978
    11   GANIER M              CLIN ALLERGY                     9   125 979
    12   PRICE JF              CLIN ALLERGY                     9   563 979
    13   CARSWELL F            MONOGR PAEDIATR                 10   144 979
    14   CARSWELL F            CLIN EXP IMMUNOL                35   141 979
    15   LARSEN GL             AM REV RESPIR DIS              119   399 979
    16   NELSON LA             AM REV RESPIR DIS              120   863 979
    17   THEOHARIDES TC        LIFE SCI                        27   703 980
    18   HODSON ME             THORAX                          35   801 980
    19   TOBIN MJ              THORAX                          35   807 980
    20   MIELIVERGANI G        ARCH DIS CHILD                  55   696 980
    21   MOSS RB               AM REV RESPIR DIS              121    23 980
    22   LARSEN GL             AM J DIS CHILD                 134  1143 980
    23   HARPER TB             LUNG                           157   219 980
    24   REEN DJ               CLIN ALLERGY                    11   571 981
    25   HOLZER FJ             ARCH DIS CHILD                  56   455 981
    26   CLARKE CW             BR J DIS CHEST                  75    15 981
    27   MOSS RB               J PEDIATR                       99   215 981
    28   VOSS MJ               J ALLERGY CLIN IMMUNOL          69   536 982
    29   SCHIOTZ PO            ACTA PAEDIATR SCAND SUPPL 301 1982    55 982
    30   ANON                  LANCET                           2   257 983
    31   SPEERT DP             SURV SYNTH PATHOL RES            4    14 985
    32   WONNE R               CLIN ALLERGY                    15   455 985
    33   LAUFER P              CUTIS                           35   557 985
    34   LAUFER P              CUTIS                           36   245 985

PN 75064
RN 00230
AN 75207948
AU Lundgren-D-W.  Farrell-P-M.  Di-SantAgnese-P-A.
TI Polyamine alterations in blood of male homozygotes and heterozygotes
   for cystic fibrosis.
SO Clin-Chim-Acta. 1975 Jul 23. 62(2). P 357-62.
MJ CYSTIC-FIBROSIS: bl.  HOMOZYGOTE.  SPERMIDINE: bl.  SPERMINE: bl.
MN FEMALE.  HETEROZYGOTE.  HUMAN.  MALE.  SEX-FACTORS.
AB The polyamines, spermidine and spermine, have been measured in whole
   blood extracts from control volunteers, patients with cystic
   fibrosis, and obligate cystic fibrosis heterozygotes. Male homo- and
   heterozygotes for cystic fibrosis exhibit a consistent and
   significant decrease in blood spermine resulting in an elevated
   spermidine/spermine ratio when compared to control males. In
   contrast, control females exhibited reduced spermidine and spermine
   levels as compared to control males. Blood from female cystic
   fibrosis homo- and heterozygotes showed similar results. The sex
   difference is probably due to fluctuations of blood polyamines during
   the menstrual cycle. Abnormal polyamine levels are the first
   observation of an alteration of a low molecular weight metabolite
   characteristic of both male homo- and heterozygotes for cystic
   fibrosis.
RF 001   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   002   RENNERT OM            IN: MANGOS JA                         41 973
   003   TAUSSIG LM            J PEDIATR                       82   380 973
   004   TABOR H               ANAL BIOCHEM                    55   457 973
   005   ROSENTHAL SM          J PHARMACOL EXP THER           116   131 956
   006   RUSSELL DH            ENDOCRINOLOGY                   88  1397 971
   007   RUSSELL DH            BIOCHEM J                      128  1109 972
   008   COHEN HI              CF CLUB ABST                     6     1 965
   009   WARWICK WJ            J ASTHMA RES                     5   277 968
   010   RUSSELL DH            PROC NAT ACAD SCI USA           60  1420 968
   011   RUSSELL DH            CANCER RES                      31  1555 971
   013   BAKER AP              FED PROC                        33  1300 974
   014   MUNRO GF              J BIOL CHEM                    247  1272 972
CT   1   RENNERT O             LIFE SCI                        19   257 976
     2   TABOR CW              ANNU REV BIOCHEM                45   285 976
     3   COHEN LF              BLOOD                           48   469 976
     4   CHUN PW               BIOCHEM BIOPHYS RES COMMUN      69  1095 976
     5   WOOD RE               AM REV RESPIR DIS              113   833 976
     6   LUNDGREN DW           PROC SOC EXP BIOL MED          152    81 976
     7   SANTAGNESE PAD        N ENGL J MED                   295   481 976
     8   KELLY JC              BIOCHEM GENET                   15   695 977
     9   SULLIVAN JL           BIOCHEM GENET                   15  1125 977
    10   BURDICK AB            HUM HERED                       27   366 977
    11   LUNDGREN DW           J PEDIATR                       90  1034 977
    12   ALHADEFF JA           CLIN GENET                      14   189 978
    13   ROSENBLUM MG          SCIENCE                        200  1496 978
    14   LUNDGREN DW           AM J PHYSIOL                   234  E451 978
    15   SAVORY J              LANCET                           2  1136 979
    16   RUSSELL DH            PEDIATR RES                     13  1137 979
    17   JAKEL HP              BIOL ZENTRALBL                  98    55 979
    18   BAYLIN SB             PEDIATR RES                     14   921 980
    19   THEOHARIDES TC        LIFE SCI                        27   703 980
    20   BENINATI S            BIOMEDICINE EXPRESS             33   182 980
    21   NAHAS N               BIOCHEM BIOPHYS RES COMMUN     109  1035 982
    22   CHENG PW              J BIOL CHEM                    257  6251 982
    23   RUSSELL DH            CRC CRIT REV CLIN LAB SCI       18   261 983
    24   EKSTROM J             ACTA PHYSIOL SCAND             119   287 983
    25   CHAYEN R              CELL BIOCHEM FUNCT               2    15 984
    26   RAM BP                CRC CRIT REV BIOCHEM            17   257 985
    27   KAMOUN PP             CLIN CHIM ACTA                 154   219 986

PN 75065
RN 00231
AN 75129766
AU van-Stekelenburg-G-J.  van-de-Laar-AJB.  van-der-Laag-J.
TI Copper analysis of nail clippings.  An attempt to differentiate
   between normal children and patients suffering from cystic fibrosis.
SO Clin-Chim-Acta. 1975 Mar 10. 59(2). P 233-40.
MJ COPPER: me.  CYSTIC-FIBROSIS: di.  NAILS: me.
MN CHILD.  COPPER: an.  CYSTIC-FIBROSIS: me.  DIAGNOSIS-LABORATORY.
   FINGERS.  HUMAN.  METHODS.  SPECTROPHOTOMETRY-ATOMIC-ABSORPTION.
   TOES.
AB From 39 normal children and 36 patients, suffering from cystic
   fibrosis (C/F), the copper content of finger nail clippings and toe
   nail clippings were determined. From this study it can be concluded
   that, although the patients with cystic fibrosis (C/F) have a higher
   copper content, the determination of copper in nail samples cannot be
   used in order to differentiate between normal children and patients.
   Also higher mean copper concentrations were found in finger nail
   clippings in comparison with toe nails. This difference was
   significant for patients with cystic fibrosis.
RF 001   DI SANTAGNESE PA      PEDIATRICS                      12   549 953
   002   GIBSON LE             PEDIATRICS                      23   545 959
   003   BENDER SW             MUCOVISCIDOSE CYSTISCHE FIBR             970
   004   STEPHAN U             PADIATRISCHE PRAXIS             12   487 973
   005   WISER WC              PEDIATRICS                      33   115 964
   006   GREEN MN              PEDIATRICS                      41   989 968
   007   BABB AL               TRANS AM NUCL SOC                9   591 966
   008   FITE LE               PROC SYMP BLED INT AT ENE                972
   009   BARNETT WB            ATOMIC ABSORP APPL STUDY 474             971
   010   KOLLBERG H            ACTA PAEDIATR SCAND             63   405 974
   011   KOLLBERG H            ACTA PAEDIATR SCAND             63   411 974
   012   HARRISON GM           CF CLUB ABST                    11    26 970
   013   MARTIN GM             NATURE                         202   903 964
   014   KANABROCKI E          J NUCL MED                       9   478 968
   015   HARRISON WW           CLIN CHIM ACTA                  31    63 971
   016   BARNETT WB            CLIN CHEM                       18   923 972
   017   DIXON WJ              BIOMETRICS                       9    74 953
CT   1   SOHLER A              CLIN CHIM ACTA                  70   391 976
     2   SOLOMONS NW           AM J CLIN NUTR                  32   856 979
     3   LANGMYHR FJ           ANALYST                        104   993 979
     4   SOLOMONS NW           AM J CLIN NUTR                  34   462 981
     5   LANGMYHR FJ           PROG ANALYT ATOM SPECTR          8   193 985

PN 75066
RN 00232
AN 75129741
AU Kyaw-Myint-T-O.  Howell-A-M.  Murphy-G-M.  Anderson-C-M.
TI Alpha-1-antitrypsin in duodenal fluid and gallbladder bile.
SO Clin-Chim-Acta. 1975 Feb 22. 59(1). P 51-4.
MJ ALPHA-1-ANTITRYPSIN: an.  DUODENUM: an.  GALLBLADDER: an.
MN BILE: an.  CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: me.  FEMALE.
   HUMAN.  INFANT.  INFANT-NEWBORN.  LIVER-DISEASES: me.  MALE.
   MEGACOLON: me.  TRYPSIN-INHIBITORS: an.
AB Using the immunoelectrophoretic method alpha-1-antitrypsin was
   detected in all but 6 of 26 samples of duodenal fluid obtained from
   16 patients with various gastroenterological problems. The
   concentrations (mg/100 ml) of alpha-1-antitrypsin in duodenal
   aspirates from children with liver disease (7.32 plus or minus 6.1)
   were less than those from children with cystic fibrosis, Shwachman
   Diamond syndrome, or Hirschsprung's disease (16.7 plus or minus 11.9;
   p smaller than 0.02). Alpha-1-antitrypsin was detected in all but one
   of 6 samples of gallbladder bile, the exception being that from a
   patient with extrahepatic biliary atresia. No significant correlation
   was found between the alpha-1-antitrypsin concentration in the
   samples studied and the corresponding total antitrypsin activity.
RF 001   BEARN AG              IN: STANBURY JB                     1637 972
   002   TALAMO RC             AM J DIS CHILD                 125   845 973
   003   TALAMO RC             J PEDIATR                       79    20 971
   004   GLASGOW JFT           AM J MED                        54   181 973
   005   AAGENAES O            ACTA PAEDIATR SCAND             61   632 972
   006   LEIBERMAN J           SCIENCE                        175    63 972
   007   BELL OF               NATURE                         243   410 973
   008   NELSON R              GUT                             14   427 973
   009   WIGGINS HS            GUT                              8   415 967
   010   HADORN B              J PEDIATR                       73    39 968
   011   MURPHY GM             J CLIN PATHOL                   23   594 970
   012   LAURELL CB            SCAND J CLIN LAB INVEST         15   132 963
   013   LASKOWSKI M           IN: ANSON ML                     9   203 954
CT   1   MORSE JO              N ENGL J MED                   299  1045 978
     2   AROOR AR              INDIAN J EXP BIOL               17   503 979
     3   GRILL BB              J PEDIATR GASTROENTEROL NUTR     2    95 983
     4   MISZCZUKJAMSKA B      HOPPE SEYLERS Z PHYSIOL CHEM   364   509 983
     5   CALLEA F              HISTOPATHOLOGY                   9    99 985
     6   THEAKER JM            J CLIN PATHOL                   39    58 986

PN 75067
RN 00233
AN 75207931
AU Robinson-P-G.  Smith-P-A.  Elliott-R-B.
TI A simple method for the quantitative determination of stool trypsin
   and chymotrypsin.
SO Clin-Chim-Acta. 1975 Jul 23. 62(2). P 225-9.
MJ CHYMOTRYPSIN: an.  FECES: en.  TRYPSIN: an.
MN CHILD.  CHYMOTRYPSIN: me.  CYSTIC-FIBROSIS: en.  DUODENUM: en.
   HETEROZYGOTE.  HUMAN.  HYDROGEN-ION-CONCENTRATION.  INFANT.  METHODS.
   TRYPSIN: me.
AB A simple method for the determination of the activity of trypsin and
   chymotrypsin in stool and duodenal aspirations is described.  The
   method is based on that described by Barbero et al. (Am. J. Dis.
   Child., 112 (1966) 536) [1] but utilizes the time for a drop of 0.1
   pH unit in the solution, instead of a constant pH titration, to
   determine enzyme activity.  Results for a number of cystic fibrosis
   patients and normals compare favorably with the literature.
RF 001   BARBERO GJ            AM J DIS CHILD                 112   536 966
   002   SHWACHMAN H           AM J DIS CHILD                  66   418 943
   003   SHWACHMAN H           PEDIATRICS                       4   222 949
   004   JOHNSTONE DE          PEDIATRICS                       7   483 951
   005   GORDON I              BR MED J                         1   463 952
   006   HORSFIELD A           J MED LAB TECH                  10    18 952
   007   JOHNSTONE DE          AM J DIS CHILD                  84   191 952
   008   NEURATH H             CHEM REV                        46    69 950
   009   RICHMOND RC           PEDIATRICS                      16   207 955
   010   LUNDH G               SCAND J CLIN LAB INVEST          9   229 957
   011   GROSSMAN MI           PROC SOC EXP BIOL MED          110    41 962
   012   HAVERBACK BJ          GASTROENTEROLOGY                44   588 963
   013   DYCK WP               AM J DIG DIS                    10   530 965
   014   ROBINSON PG           NZ MED J                        79  1024 974
CT   1   ROBINSON PG           ARCH DIS CHILD                  51   301 976
     2   CROSSLEY JR           LANCET                           2  1093 977
     3   DURR HK               DIGESTION                       17   396 978
     4   CONGDON PJ            POSTGRAD MED J                  57   453 981
     5   VARIYAM EP            GASTROENTEROLOGY                81   751 981
     6   MITCHELL EA           AUST PAEDIATR J                 18   118 982
     7   KASPAR P              CLIN CHEM                       30  1753 984
     8   LAMI F                AM J GASTROENTEROL              79   697 984
     9   JUNGE W               CLIN BIOCHEM                    19   323 986

PN 75068
RN 00234
AN 76042342
AU Ryley-H-C.  Neale-L-M.  Brogan-T-D.  Bray-P-T.
TI Screening for cystic fibrosis by analysis of meconium for albumin
   and protease inhibitors.
SO Clin-Chim-Acta. 1975 Oct 15. 64(2). P 117-25.
MJ ALBUMINS: an.  ALPHA-1-ANTITRYPSIN: an.  CHYMOTRYPSIN: ai.
   CYSTIC-FIBROSIS: di.  INFANT-NEWBORN-DISEASES: di.  MECONIUM: an.
MN ALBUMINS: im.  COMPARATIVE-STUDY.  FECES: an.  HUMAN.
   IMMUNOELECTROPHORESIS.  INFANT-NEWBORN.  MASS-SCREENING.  METHODS.
AB A qualitative method of detecting elevated meconium protein
   concentration was compared with a method of determining meconium
   albumin concentration by electroimmunoassay since elevated meconium
   protein levels can indicate pancreatic insufficiency caused by cystic
   fibrosis. Between 5 and 10 per 1000 healthy infants passed meconium
   specimens that gave a false positive reaction with the Boehringer
   Mannheim test strip and contained a greater than expected
   concentration of albumin.  It was possible to exclude pancreatic
   insufficiency in all of these children by determining the ratio,
   albumin : alpha1-antitrypsin in meconium and subsequent faecal
   specimens, since it was found that values of this ratio in excess of
   2.0 suggested pancreatic insufficiency of the type associated with
   cystic fibrosis. Three of 14 neonates with subsequently proven cystic
   fibrosis yielded meconium specimens giving negative test strip
   results and low albumin concentrations. In two of these patients, the
   ratio, albumin : alpha1-antitrypsin in the meconium was within normal
   limits but, within two months of birth, the albumin : alpha1-
   antitrypsin ratio in the faeces of both children was greater than 3.0
   suggesting that pancreatic insufficiency had developed.
RF 001   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   002   GEORGE L              ARCH DIS CHILD                  46   139 971
   003   WARWICK WJ            MINN MED                        52  1567 969
   004   DI SANTAGNESE PA      N ENGL J MED                   277  1344 967
   005   DI SANTAGNESE PA      N ENGL J MED                   277  1399 967
   006   BUCHANAN DJ           PEDIATRICS                       9   304 952
   007   WISER WC              PEDIATRICS                      33   115 964
   008   GREEN MN              PEDIATRICS                      21   635 958
   009   ROULET DLA            SCHWEIZ MED WOCHENSCHR          91    74 961
   010   PRITCHARD JA          OBSTET GYNECOL                  25   289 965
   011   HIGA Y                AM J OBSTET GYNECOL            119   932 974
   012   RYLEY HC              ARCH DIS CHILD                  49   901 974
   013   DAVIDSON AG           BR MED J                         4   362 971
   014   STEPHAN U             PADIATRISCHE PRAXIS             12   487 973
   015   HELLSING K            SCAND J CLIN LAB INVEST         33   333 974
   016   BULL FE               ARCH DIS CHILD                  49   602 974
   017   RYLEY HC              J CLIN PATHOL                   26   852 973
   018   CRAWFORD IP           ARCH BIOCHEM BIOPHYS           156   215 973
   019   ROSEBAUM T            SCIENCE TOOLS APPL NOTE 87               973
   020   AVRAMEAS S            IMMUNOCHEMISTRY                  6    53 969
   021   FAGERHOL MK           IN: MITTMAN C                        145 972
   022   SIEGAL S              NONPARAMETRIC STATISTICS                 956
   023   PROSSER R             ARCH DIS CHILD                  49   597 974
CT   1   RYLEY HC              LANCET                           2   365 976
     2   GRIFFITHS AD          ARCH DIS CHILD                  51   901 976
     3   RYLEY HC              ARCH DIS CHILD                  51   641 976
     4   ANON                  BR MED J                         1   596 977
     5   CROSSLEY JR           BR MED J                         1   428 977
     6   CROSSLEY JR           LANCET                           2  1093 977
     7   KRAEMER R             SCHWEIZ MED WOCHENSCHR         107  1105 977
     8   STARK JM              J CLIN PATHOL                   31  1177 978
     9   EVANS TJ              ARCH DIS CHILD                  53   239 978
    10   RYLEY HC              MONOGR PAEDIATR                 10   151 979
    11   STEPHAN U             MONOGR PAEDIATR                 10    41 979
    12   UXA F                 MINERVA PEDIATR                 31   831 979
    13   RYLEY HC              ARCH DIS CHILD                  54    92 979
    14   DOYLE EE              IR MED J                        72    93 979
    15   MASTELLA G            RIV ITAL PEDIATR                 7   581 981
    16   MORRIS TJ             CLIN ALLERGY                    11   561 981
    17   EVANS RT              J CLIN PATHOL                   34   911 981
    18   RYLEY HC              J CLIN PATHOL                   34   179 981
    19   THOMAS DW             GASTROENTEROLOGY                80   776 981
    20   PARK RW               GASTROENTEROLOGY                81  1143 981
    21   DODGE JA              ARCH DIS CHILD                  57   774 982
    22   PEDERZINI F           RIV ITAL PEDIATR                 9   445 983
    23   HEELEY AF             CLIN CHEM                       29  2011 983
    24   RYLEY HC              CLIN CHIM ACTA                 135    49 983
    25   NAYLOR EW             SEM PERINATOL                    9   232 985

PN 75069
RN 00235
AN 75167100
AU Danes-B-S.
TI Cystic fibrosis heterozygote detection: a study on a normal
   population.
SO Clin-Genet. 1975 Feb. 7(2). P 128-33.
MJ CYSTIC-FIBROSIS: fg.  HETEROZYGOTE.
MN ADOLESCENCE.  ADULT.  BIOLOGICAL-ASSAY.  CELLS-CULTURED.  CILIA: me.
   CULTURE-MEDIA.  CYSTIC-FIBROSIS: me.  FEMALE.  FIBROBLASTS.
   GENETICS-POPULATION.  HUMAN.  LEUKOCYTES.  MALE.  MIDDLE-AGE.
   OYSTERS.  SKIN.
AB Detection of the cystic fibrosis (CF) heterozygote by testing for
   cystic fibrosis factor activity (CFFA) in serum samples using
   bioassays had been reported to give unreliable results. The present
   study was undertaken to find whether the use of medium from short
   term white blood cell or skin fibroblast cultures, rather than serum,
   as the test sample would eliminate such inconsistencies. Short term
   white blood cell cultures were established from 107 normal, healthy
   individuals. Cultures from 97 had no CFFA, six (No. 1-6) showed
   variable results and four (No. 7-10) had activity in all four tests
   done on a single sample. When the assays were repeated 3 months later
   on new cultures from these four positive CFFA individuals, two showed
   activity (Nos. 7 & 9) and two did not (Nos. 8 & 10). All 10
   individuals whose cultures showed CFFA has histories of allergies.
   The association of CFFA in the culture medium derived from
   individuals having allergies with the intermittent presence of this
   activity suggested that environmental factors induced a CFF-like
   activity in such white blood cell cultures. The oyster ciliary assay,
   using medium from white blood cell cultures, cannot be used for
   screening for the CF heterozygote since the substitution of culture
   medium for serum did not eliminate inconsistent results and CFFA was
   not specific by this assay for the CF gene. Of the fibroblast lines
   established from the four persons whose initial white blood cell
   cultures consistently showed CFFA, only one (No. 7) showed the CF
   culture phenotype (CFFA positive and metachromasia).
RF 001   BOWMAN BH             PROC NAT ACAD SCI USA           70   548 973
   002   BOWMAN BH             CLIN GENET                       4   461 973
   003   BOWMAN BH             SCIENCE                        164   325 969
   004   BOWMAN BH             SCIENCE                        167   871 970
   005   CONOVER JH            PEDIATR RES                      7   220 973
   006   CONOVER JH            PEDIATR RES                      7   224 973
   007   CONOVER JH            LANCET                           1  1194 973
   008   CONOVER JH            LANCET                           2  1501 973
   009$  DANES BS              BIRTH DEF ORIG ART SER           7   141 971
   010   DANES BS              BIRTH DEF ORIG ART SER           8   114 972
   011   DANES BS              LANCET                           2   765 973
   013   DANES BS              J EXP MED                      123     1 966
   014   DANES BS              J EXP MED                      129   775 969
   016   DANES BS              J EXP MED                      137  1538 973
   017   DANES BS              J EXP MED                      132   765 970
   018   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   019   HIRSCHHORN K          IN: MANGOS JA                         11 973
   020   SPOCK A               PEDIATR RES                      1   173 967
   021   WOOD RE               LANCET                           2  1452 973
CT   1   DANES BS              CLIN GENET                       8    85 975
     2   GILLARD BK            PEDIATR RES                     10   907 976
     3   DANES BS              TEX REP BIOL MED                34   135 976
     4   DANES BS              CLIN GENET                      11    83 977
     5   IMPERO JE             PEDIATR RES                     12   108 978
     6   DANES BS              CLIN GENET                      13   327 978
     7   WILSON GB             J LAB CLIN MED                  92   463 978

PN 75070
RN 00236
AN 75208046
AU Danes-B-S.  Beck-B.  Flensborg-E-W.
TI Cystic fibrosis heterozygote detection: a family study.
SO Clin-Genet. 1975 Jul. 8(1). P 85-91.
MJ CYSTIC-FIBROSIS: fg.  HETEROZYGOTE.
MN CELLS-CULTURED.  CHROMOSOME-MAPPING.  FEMALE.  FIBROBLASTS: cy.
   GENES.  HOMOZYGOTE.  HUMAN.  LEUKOCYTES: cy.  MALE.  PEDIGREE.
   PHENOTYPE.
AB Family studies have been done to determine if the phenotypes
   described for the cystic fibrosis (CF) cultured cell reliably
   detected the CF gene. Two culture phenotypes were studied in culture
   derived from consecutive generations in four CF families: (1) cystic
   fibrosis factor (CFF) in the medium of short-term white blood cell
   cultures assayed by a modified oyster ciliary test and (2) the three
   characteristics of cultured skin fibroblasts (metachromasia without
   alcianophilia at 0.3 M MgCl2, CFF in the culture medium and metabolic
   cooperation with normal fibroblasts). As CF is an autosomal recessive
   disorder, the family offered a test unit for determining the
   specificity of these cell phenotypes for the CF gene. On the basis of
   detecting the CF culture phenotypes in the homozygote and obligatory
   heterozygotes, the parents, and their segregation in consecutive
   generations, detection of the CF gene was not possible in the white
   blood cell cultures, but was possible in the skin fibroblast
   cultures.
RF 001   BERATIS NG            PEDIATR RES                      7   958 973
   002   BOWMAN BH             PROC NAT ACAD SCI USA           70   548 973
   003   BOWMAN BH             SCIENCE                        164   325 969
   004   BOWMAN BH             SCIENCE                        167   871 970
   005   CONOVER JH            PEDIATR RES                      7   220 973
   006   CONOVER JH            PEDIATR RES                      7   224 973
   007   CONOVER JH            LANCET                           1  1194 973
   008$  DANES BS              BIRTH DEF ORIG ART SER           7   141 971
   009   DANES BS              BIRTH DEF ORIG ART SER           8   114 972
   010   DANES BS              LANCET                           2   765 973
   011   DANES BS              CLIN GENET                       7   128 975
   012   DANES BS              J EXP MED                      123     1 966
   013   DANES BS              J EXP MED                      129   775 969
   014   DANES BS              AM J HUM GENET                  23   297 971
   015   DANES BS              J EXP MED                      137  1538 973
   016   DANES BS              J EXP MED                      132   765 970
   017   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   018   SPOCK A               PEDIATR RES                      1   173 967
   019   WOOD RE               LANCET                           2  1452 973
CT   1   GILLARD BK            PEDIATR RES                     10   907 976
     2   DANES BS              TEX REP BIOL MED                34   135 976
     3   WARD JB               TEX REP BIOL MED                34    11 976
     4   DANES BS              CLIN GENET                      11    83 977
     5   IMPERO JE             PEDIATR RES                     12   108 978
     6   NIELSEN HE            ACTA PAEDIATR SCAND             67   443 978
     7   PEDERSEN PS           ACTA PAEDIATR SCAND             70   507 981
     8   WINGE P               DAN MED BULL                    29   358 982
     9   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982

PN 75071
RN 00237
AN 75167122
AU Ho-Shin-Y.  Glass-L.  Evans-H-E.
TI Pulmonary diseases in childhood.
SO Clin-Notes-Respir-Dis. 1975 Summer. 14(1). P 3-12.
MJ LUNG-DISEASES.
MN ASTHMA.  ATELECTASIS.  BRONCHI.  BRONCHIOLITIS-VIRAL.  CHILD.
   CHILD-PRESCHOOL.  CYSTIC-FIBROSIS.  FEMALE.  FOREIGN-BODIES.
   HEMOPTYSIS.  HUMAN.  INFANT.  INFANT-NEWBORN.  MALE.
   MEDIASTINAL-EMPHYSEMA.  PNEUMONIA.  PNEUMOTHORAX.  PREGNANCY.
   RESPIRATORY-DISTRESS-SYNDROME.  TUBERCULOSIS-IN-CHILDHOOD.
   TUBERCULOSIS-PULMONARY.
EX Many types of lung disease are seen in the pediatric age group.
   These range all the way from disorders of the neonate that are
   closely related to parturition, to acute infectious diseases seen in
   infancy and early childhood, to chronic disorders such as cystic
   fibrosis and bronchial asthma.  Management of the conditions
   described involves cooperation between the primary care physician and
   the specialist.  A variety of organizations offers aid to both
   physicians and patients' families.
RF 001   MILLER HC             J PEDIATR                       72   628 968
   002   GLUCK L               PEDIATR RES                      6    81 972
   003   GLUCK L               AM J OBSTET GYNECOL            109   440 971
   004   CLEMENTS JA           N ENGL J MED                   286  1077 972
   005   KATTWINKEL J          PEDIATRICS                      52   131 973
   006   WILSON MG             AM J DIS CHILD                  99   489 960
   007   ANDERSON WR           ARCH PATHOL                     91   506 971
   008   ELDERKIN FM           BR MED J                         2   722 965
   009   RAPKIN RH             CLIN PEDIATR                    10   312 971
   010   GERBEAUX J            AM J DIS CHILD                 110   507 965
   011   DURFEE ML             AM REV RESPIR DIS               99   304 969
   012   MARKS MB              CLIN PEDIATR                    13   225 974
   013   FRANKLIN W            N ENGL J MED                   290  1469 974
   014   GIBBS GE              PAEDIATRICIAN                    1   133 972

PN 75072
RN 00238
AN 76065031
AU Shwachman-H.  Khaw-K-T.  Kowalski-S-M.
TI The management of cystic fibrosis.  Observations on gentamycin when
   used with other antibiotics in pulmonary infections associated with
   cystic fibrosis.
SO Clin-Pediatr (Phila). 1975 Dec. 14(12). P 1115-8.
MJ ANTIBIOTICS: tu.  CYSTIC-FIBROSIS: dt.  GENTAMICINS: tu.
   LUNG-DISEASES: dt.
MN CYSTIC-FIBROSIS: co.  DRUG-THERAPY-COMBINATION.  FEMALE.  HUMAN.
   LUNG-DISEASES: et.  MALE.  PSEUDOMONAS-INFECTIONS: dt.
EX From 1971 to 1973, we hospitalized 41 symptomatic patients with
   cystic fibrosis for intensive pulmonary therapy.  The more severely
   ill patients were admitted more than once during this period.  Our
   study included 100 courses of such intensive treatment.  Garamycin
   pediatric injectable, containing 10 mg/ml of the active ingredient,
   was administered intravenously to all patients in divided doses of
   3.0 to 5.0 mg/kg/day.  The purpose of the study was to evaluate the
   tolerance, pharmacokinetics, and efficacy of garamycin when
   administered parenterally to cystic fibrosis patients with serious
   infections.  During the 100 courses of treatment, clinical
   improvement was rated as follows: significant or definite
   improvement, 39; moderate improvement, 50; slight improvement, 9; and
   no change, 2.  The use of garamycin pediatric injectable is safe and
   can be helpful in the management of the pulmonary infectious
   complications of cystic fibrosis when employed along with other
   well-established modalities of therapy.
RF 001   ANDERSEN DH           AM J DIS CHILD                  56   344 938
   002   GREEN MN              PEDIATRICS                      41   989 968
   003   STEPHAN U             IN: MANGOS JA                        281 973
   004   STEPHAN U             PADIATRISCHE PRAXIS             12   487 973
   005   SHWACHMAN H           ANN NY ACAD SCI                 93   600 962
   006   SHWACHMAN H           CF IN PEDIATRIC THERAPY              573 972
   007   GINGELL JC            J INFECT DIS                   119   396 969
   008   KULCZYCKI LL          CLIN PEDIATR                     9   390 970
CT   1   HOIBY N               ACTA PATH MICROBIOL SCAND (C) S262     3 977
     2   SHWACHMAN H           MEDICINE                        56   129 977
     3   SCHIOTZ PO            HUM HERED                       28   293 978
     4   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    75 982
     5   HOOGKAMPKORSTANJE JAA J ANTIMICROB CHEMOTHER          12   175 983

PN 75073
RN 00239
AN 76002085
AU Grossman-M-L.
TI The psychosocial approach to the medical management of patients with
   cystic fibrosis.
SO Clin-Pediatr (Phila). 1975 Sep. 14(9). P 830-3.
MJ ADAPTATION-PSYCHOLOGICAL.  CYSTIC-FIBROSIS: th.
MN ADOLESCENCE.  AMBULATORY-CARE.  ANXIETY-SEPARATION.
   ATTITUDE-TO-DEATH.  ATTITUDE-TO-HEALTH.  CHILD-PSYCHIATRY.  CHILD.
   CHILD-HOSPITALIZED.  CHILD-PRESCHOOL.  DEFENSE-MECHANISMS.  HUMAN.
   IDENTITY-CRISIS.  INFANT.  INFANT-NEWBORN.  LIFE-STYLE.
   PARENT-CHILD-RELATIONS.  PROFESSIONAL-PATIENT-RELATIONS.
   REFERRAL-AND-CONSULTATION.  STRESS-PSYCHOLOGICAL.
EX It is most important to deal with the feelings of the child and his
   family in regard to cystic fibrosis.  Genuine recognition of feelings
   by the pediatric staff can go a long way toward reassuring family
   members that their long-standing burden and suffering are being
   validated and understood.  When a family manifests early signs of
   difficulty in coping with the emotional and physical stress imposed
   by cystic fibrosis, it is helpful to refer them to a child
   psychiatrist for consultation.  It is primarily the families at high
   risk for breakdown which most require early prevention and
   intervention.  The role of the pediatrician as the primary clinician
   is crucial.  It is he who must provide the support and understanding
   that are integral parts of the primary prevention of emotional
   decompensation in this disorder.
RF 001   BOWLBY J              MATERNAL CARE AND MENTAL HEAL            952
   002   BOWLBY J              INT J PSYCHOANAL                41    89 960
   003   TISZA VB              J AM ACAD CHILD PSYCHIAT         9   515 970
   004   SPITZ RA              PSYCHOANALYT STUDY CHILD         2   313 946
   005   BERGMANN T            CHILDREN IN THE HOSPITAL                 965
   006   PRUGH DG              AM J ORTHOPSYCHIATRY            23    70 953
   007   PIAGET J              SIX PSYCHOLOGICAL STUDIES                967
   008   ERIKSON EH            IDENTITY AND THE LIFE CYCLE              959
   009   MCCOLLUM AT           J PEDIATR                       77   571 970
   010   LEVY DM               MATERNAL OVERPROTECTION                  943
   011   PRUGH DG              IN: FREEDMAN AM                      181 971
   012   CAPLAN G              PRINCIPLES OF PREVENTIVE PSYC            964

PN 75074
RN 00240
AN 76002091
AU Dolan-T-F-Jr.  Meyers-A.
TI Mild cystic fibrosis presenting as an asymptomatic distended
   appendiceal mass: A case report.
SO Clin-Pediatr (Phila). 1975 Sep. 14(9). P 862-3.
MJ APPENDICITIS: di.  CYSTIC-FIBROSIS: di.
MN APPENDECTOMY.  APPENDIX: pa.  CASE-REPORT.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: pa.  DIAGNOSIS-DIFFERENTIAL.  FEMALE.  HUMAN.
   PALPATION.
AB A case of cystic fibrosis presenting as a right lower quadrant mass
   in a five-year-old white female is presented. At laparotomy, a
   mucoid, impacted appendix was found which microscopically suggested
   the diagnosis of cystic fibrosis. Cystic fibrosis must be added to
   conditions presenting with abdominal masses.
RF 001   BECK AR               GASTROENTEROLOGIA              106    84 966
   002   HOLSCLAW DS           PEDIATRICS                      48    51 971
   003   SHWACHMAN H           N ENGL J MED                   286  1300 972
   004   SNYDER WH JR          PEDIATRICS                      34    72 964
CT   1   STERN RC              J PEDIATR                       89   412 976
     2   WOOD RE               AM REV RESPIR DIS              113   833 976
     3   LOBER CW              JAMA                           235  1140 976
     4   ROSENSTEIN BJ         JOHNS HOPKINS MED J            150   113 982
     5   MCCARTHY VP           GASTROENTEROLOGY                86   564 984

PN 75075
RN 00241
AN 75130315
AU Monset-Couchard-M.  Mason-C-V.  Moss-A-J.
TI Cor pulmonale in children.
SO Curr-Probl-Pediatr. 1975 Feb. 5(4). P 3-31. (REVIEW).
MJ PULMONARY-HEART-DISEASE.
MN ACUTE-DISEASE.  CHILD.  CHILD-PRESCHOOL.  CHRONIC-DISEASE.
   CYSTIC-FIBROSIS: co.  DIGOXIN: tu.  ELECTROCARDIOGRAPHY.  FEMALE.
   HEART-CATHETERIZATION.  HEART-ENLARGEMENT: co.  HUMAN.
   HYPERTENSION-PULMONARY: co.  INFANT.  INFANT-NEWBORN.  LUNG: bs.
   MALE.  PULMONARY-HEART-DISEASE: pa, cl, pp, et, ra, co, dt.  REVIEW.
   VECTORCARDIOGRAPHY.
EX According to the World Health Organization, chronic cor pulmonale is
   defined as "hypertrophy of the right ventricle resulting from
   diseases affecting the function and/or the structure of the lung,
   except when these pulmonary alterations are the result of diseases
   that primarily affect the left side of the heart or of congenital
   heart disease."  Cor pulmonale has been extensively studied and
   reported in adults, but it has received relatively little attention
   in the pediatric age group.  Although some parts of knowledge gained
   from adult studies can be used, chronic cor pulmonale in children and
   infants is quite a different entity from that usually seen in adults.
   This review is primarily an attempt to clarify some of the confusion
   surrounding this subject and to focus on the pediatric aspects.
   Pathophysiology, etiology, diagnosis, and treatment are discussed.
RF 001   ANON                  CIRCULATION                     27   594 963
   002   YATER WM              AM J MED SCI                   191   474 936
   003   NAEYE RL              AM J PATHOL                     38   561 961
   004   YEPEZ CG              AM J CARDIOL                    10    30 962
   005   MOUSA AH              J EGYPT MED ASSOC               47   270 964
   006   TURINO GM             BULL NY ACAD MED                41   959 965
   007   HOSONO K              JAPAN HEART J                    6   318 965
   008   HICKAM JB             BULL NY ACAD MED                41   994 965
   009   GOUGH J               BULL NY ACAD MED                41   927 965
   010   FERRER MI             BULL NY ACAD MED                41   942 965
   011   DEXTER L              BULL NY ACAD MED                41   981 965
   012   FUKUDA M              JAPAN CIRC J                    30   693 966
   013   OSTREA EM JR          ACTA MED PHILIP                  2    68 965
   014   PARKER JO             CIRCULATION                     33    17 966
   015   SASAHARA AA           PROG CARDIOVASC DIS              9   259 966
   016   TORRANCE DJ           PROG CARDIOVASC DIS              9   275 966
   017   DINES DE              TUBERCULOLOGY                   24    17 967
   018   LEE J                 AM REV RESPIR DIS               96  1173 967
   019   OAKLEY CM             AM J CARDIOL                    20   842 967
   020   ABRAHAM AS            CIRC RES                        24    51 969
   021   BUCHANAN WM           J TROP MED HYG                  73   218 970
   022   MORET P               ACTA CARDIOL BRUX               27   596 972
   023   LUCAS RV              MINN MED                        52  1537 969
   024   THOMAS AJ             BR HEART J                      34   653 972
   025   BARNARD PJ            AM J DIS CHILD                  92   115 956
   026   ROSENBERG HS          PEDIATRICS                      20   408 957
   027   HUSSON GS             PEDIATRICS                      23   493 959
   028   THILENIUS OG          PEDIATRICS                      36    75 965
   029   NOONAN JA             N ENGL J MED                   269    70 963
   030   SPERLING DR           AM J DIS CHILD                 107   308 964
   031   FRIEDMAN S            J PEDIATR                       64   305 964
   032   FAVARA BE             JAMA                           199   668 967
   033   RAO PS                J NEUROSURG                     33   221 970
   034   SINHA RP              J S CAROLINA MED ASSOC          67   421 971
   035   AL NAAMAN YD          ANGIOLOGY                       17    40 965
   036   ANDERSON G            PROC R SOC MED                  65   824 972
   037   CHESNEY CF            AM J PATHOL                     70   489 973
   038   SIMMONS DH            DIS CHEST                       48   347 965
   039   VON EULER US          ACTA PHYSIOL SCAND              12   301 946
   040   HARVEY RM             AM J MED                        10   719 951
   041   FISHMAN AP            HOSP PRACT                       6   101 971
   042   DOYLE JT              CIRCULATION                      5   263 952
   043   FISHMAN AP            CIRCULATION                     22   204 960
   044   ABRAHAM AS            CARDIOVASC RES                   5    95 971
   045   JAMES WRL             CARDIOVASC RES                   2   278 968
   046   HEATH D               THORAX                          28    24 973
   047   SIME F                AM J CARDIOL                    11   143 963
   048   PENALOZA D            AM J CARDIOL                    11   150 963
   049   GROVER RF             AM J CARDIOL                    18   928 966
   050   VOGEL JHK             AM HEART J                      72    50 966
   051   KILBURN KH            CIRCULATION                     39   639 969
   052   LILJESTRAND G         ACTA PHYSIOL SCAND              44   216 958
   053   BERGOFSKY EH          J CLIN INVEST                   41  1492 962
   054   DOWNING SE            AM J PHYSIOL                   208   237 965
   055   HERLES F              CARDIOVASC RES                   6   641 972
   056   ENSON Y               J CLIN INVEST                   43  1146 964
   057   LLOYD TC JR           J APPL PHYSIOL                  21   358 966
   058   RUDOLPH AM            J CLIN INVEST                   45   399 966
   059   HARVEY RM             CIRCULATION                     35  1019 967
   060   NOONAN JA             PEDIATR CLIN NORTH AM           18  1255 971
   061   BERGOFSKY EH          MEDICINE (BALTIMORE)            38   263 959
   062   SYMCHYCH PS           ARCH PATHOL                     92   409 971
   063   SWIGART RH            CIRC RES                        17    30 965
   064   NAEYE RL              AM J PATHOL                     50  1027 967
   065   VOGEL JHK             CIRC RES                        13   557 963
   066   LAKS MM               AM J PHYSIOL                   222   578 972
   067   MALAMANI V            BULL PHYSIOPATH RESPIR NANCY     8  1397 972
   068   BAROLDI G             BULL PHYSIOPATH RESPIR NANCY     8  1406 972
   069   WILLIAMS JF JR        J CLIN INVEST                   47  1143 968
   070   FRANK MJ              CIRCULATION                     47   798 973
   071   BAUM GL               N ENGL J MED                   285   361 971
   072   LOCKHART A            BULL PHYSIOPATH RESPIR NANCY     8  1448 972
   073   RAO BS                AM J MED                        45   229 968
   074   FISHMAN AP            N ENGL J MED                   285   402 971
   075   HARRIS P              BULL PHYSIOPATH RESPIR NANCY     8  1408 972
   076   BERGLUND E            BULL PHYSIOPATH RESPIR NANCY     8  1417 972
   077   BLOUNT SG             MOD CONCEPTS CARDIOVASC DIS     36    61 967
   078   GROVER RF             AM HEART J                      66     1 963
   079   FOWLER KT             J APPL PHYSIOL                  18   244 963
   080   VOGEL JHK             AM J DIS CHILD                 113   576 967
   081   MORGAN AD             AM HEART J                      73   550 967
   082   WALCOTT G             AM J MED                        49    70 970
   083   HOOD WB JR            BR HEART J                      30   336 968
   084   THOMPSON P            BR HEART J                      32   758 970
   085   WAGENVOORT CA         CIRCULATION                     42  1163 970
   086   BLOUNT SG             MOD CONCEPTS CARDIOVASC DIS     36    67 967
   087   BURNELL RH            AM J DIS CHILD                 123   167 972
   088   LEVINE OR             J PEDIATR                       83   964 973
   089   MALLORY TB            N ENGL J MED                   217  1045 937
   090   LE TAN VINH           ARCH FR PEDIATR                 31   187 974
   091   EMERY JL              ARCH DIS CHILD                  37   591 962
   092   HABER SL              J PEDIATR                       61   759 962
   093   GOOTMAN N             PEDIATRICS                      34   861 964
   094   SYMCHYCH PS           AM J DIS CHILD                 110   636 965
   095   STREEPER RB           DIS CHEST                       46    61 964
   096   EMERY JL              SURGERY                         50   309 961
   097   MOSER KM              AM J MED                        22   561 957
   098   OPPENHEIMER EH        AM REV RESPIR DIS              103   858 971
   099   PEARSON HA            PEDIATRICS                      48   629 971
   100   MOTULSKY AG           N ENGL J MED                   288    31 973
   101   PEARSON HA            J PEDIATR                       81  1201 972
   102   DIGGS LW              CLIN PEDIATR                    10   697 971
   103   RANNEY HM             BLOOD                           39   433 972
   104   KENAWY MR             AM HEART J                      39   678 950
   105   GIRGIS B              AM HEART J                      43   606 952
   106   TURNER PP             BR HEART J                      26   821 964
   107   ABDIN ZH              J EGYPT MED ASSOC               55   622 972
   108   ARIAS-STELLA J        AM J PATHOL                     41    55 962
   109   PENALOZA D            PEDIATRICS                      34   568 964
   110   VOGEL JHK             J PEDIATR                       64   315 964
   111   CUDKOWICZ L           BULL AM COLL CHEST PHYSICIANS    9    16 970
   112   COX MA                J PEDIATR                       67   192 965
   113   NOONAN JA             CIRCULATION SUPPL 2             32   164 965
   114   MENASHE VD            J PEDIATR                       67   198 965
   115   LUKE MJ               PEDIATRICS                      37   762 966
   116   LEVY AM               N ENGL J MED                   277   506 967
   117   JOHNSON EA            J MED SOC NJ                    64   220 967
   118   PILAPIL VR            SURG FORUM                      18   493 967
   119   AINGER LE             BR HEART J                      30   356 968
   120   GERALD B              RADIOLOGY                       90   679 968
   121   SETLIFF RC            LARYNGOSCOPE                    78   845 968
   122   BLAND JW JR           AM J CARDIOL                    23   830 969
   123   CAYLER GG             AM J DIS CHILD                 118   708 969
   124   JERESATY RM           AM J DIS CHILD                 117   710 969
   125   MACARTNEY FJ          ARCH DIS CHILD                  44   585 969
   126   MASSUMI RA            DIS CHEST                       55   110 969
   127   GRESHAM EL            CLIN PEDIATR                    10   236 971
   128   EDISON BD             ARCH OTOLARYNGOL                98   205 973
   129   CHAPMAN EM            MEDICINE                        18   167 939
   130   STEINBORN KE          ARCH INTERN MED                110   249 962
   131   DOUGLAS FG            J APPL PHYSIOL                  33   559 972
   132   JENAB M               PEDIATRICS                      24    23 959
   133   CAYLER GG             PEDIATRICS                      27   237 961
   134   MACGREGOR MI          JOHNS HOPKINS MED J            126   279 970
   135   DOLL E                BEITR KLIN ERFORSCH TUBERK     141    88 969
   136   SCHWARTZ BA           REV NEUROL                     116   677 967
   137   SCHWARTZ BA           REV EEG NEUROPHYSIOL             4    79 974
   138   FISHMAN LS            AM J DIS CHILD                 110   155 965
   139   FRUHMANN G            BULL PHYSIOPATH RESPIR NANCY     8  1173 972
   140   ROYCE SW              PEDIATRICS                       8   255 951
   141   GOLDRING RM           J PEDIATR                       65   501 964
   142   BOWDEN DH             AM J MED                        38   226 965
   143   MOSS AJ               J PEDIATR                       67   797 965
   144   KELMINSON LL          PEDIATRICS                      39    24 967
   145   SIASSI B              J PEDIATR                       78   794 971
   146   OPPENHEIMER EH        JOHNS HOPKINS MED J            131   351 972
   147   ANON                  GUIDE TO DIAGNOSIS AND MANAGE            971
   148   GERBEAUX J            ANN PEDIATR (PARIS)             19   557 972
   149   BAAR HS               ARCH DIS CHILD                  32   199 957
   150   SWAYE P               DIS CHEST                       55     7 969
   151   PERMUTT S             CHEST SUPPL                     63   25S 973
   152   GRIFFIN JT            PEDIATRICS                      24    54 959
   153   RICHARDS W            AM J DIS CHILD                 110     4 965
   154   MIYAMOTO T            CIRCULATION                     22    90 960
   155   QUIVERS WW            AM J CARDIOL                    14   616 964
   156   OLIVA PB              CHEST                           58   167 970
   157   LIEBERMAN J           MED CLIN NORTH AM               57   691 973
   158   SCOTT-DUNBAR J        AM J ROENTG RAD THER NUCL MED  109   227 970
   159   LAFOURCADE J          REV PRAT                        17  3479 967
   160   OSHEA PA              JOHNS HOPKINS MED J            126   320 970
   161   GERBEAUX J            ANN PEDIATR (PARIS)             19   565 972
   162   CHASE HV              MD STATE MED J                  19    65 970
   163   CHIN TDY              MYCOPATHOL MYCOL APPL           41    35 970
   164   MACKINNON JE          MYCOPATHOL MYCOL APPL           41   187 970
   165   KEPRON MW             CAN MED ASSOC J                106   243 972
   166   HODGMAN JE            PEDIATRICS                      44   179 969
   167   KRAUSS AN             J PEDIATR                       77    27 970
   168   GROSSMAN H            AM J ROENTG RAD THER NUCL MED  114   293 972
   169   BOMSEL F              ANN RADIOL (PARIS)              17   305 974
   170   NORTHWAY WH JR        N ENGL J MED                   276   357 967
   171   SHEPARD FM            N ENGL J MED                   279  1063 968
   172   DE VAN HEESE H        J PEDIATR                       76   183 970
   173   BOMSEL F              ANN RADIOL (PARIS)              16    70 973
   175   NAEYE RL              DIS CHEST                       44   374 963
   176   NORTON WL             ANN INTERN MED                  73   317 970
   177   JORDAN JD             AM J DIS CHILD                 108   174 964
   178   GROSS M               AM REV RESPIR DIS              105   572 972
   179   HEJTMANCIK MR         AM HEART J                      68   119 964
   180   MEISLIN AG            PEDIATRICS                      42    37 968
   181   KOERNER SK            AM HEART J                      88   115 974
   183   PERLOFF JK            PROG CARDIOVASC DIS              9   303 967
   184   LIEBMAN J             CIRCULATION                     35   552 967
   185   BURGESS JH            CIRCULATION                     49   541 974
   186   KNUDSON RJ            MED CLIN NORTH AM               47   681 973
   187   BAUM GL               MED CLIN NORTH AM               57   623 973
   188   DOWNES JJ             PEDIATR CLIN NORTH AM           19   423 972
   189   MORGAN AD             AM HEART J                      73   700 967
   190   RUTKOWSKI MM          AM HEART J                      86   270 973
   191   HAYES CJ              PEDIATRICS                      52   561 973
   192   NADAS AS              PEDIATRIC CARDIOLOGY                 286 972
   193   MOSS AJ               MOD PROBL PEDIATR               10   187 967
   194   CROWELL JW            AM J PHYSIOL                   206   313 964
   195   WILLIAMS JF JR        AM J CARDIOL                    16   534 965
   196   HERNANDEZ A           AM J DIS CHILD                 115   576 968

PN 75076
RN 00242
AN 76021663
AU Lykkegaard-E.  Pedersen-J-T.
TI Classes of skin fibroblast metachromasia in cystic fibrosis
   correlated with lung function tests.
SO Dan-Med-Bull. 1975 Jul. 22(5). P 175-7.
MJ CYSTIC-FIBROSIS: pp.  LUNG: pp.
MN ADOLESCENCE.  ADULT.  BIOPSY.  CELLS-CULTURED.  CHILD.
   CYSTIC-FIBROSIS: pa.  FEMALE.  FIBROBLASTS.  HUMAN.  MALE.
   RESPIRATORY-FUNCTION-TESTS.  SKIN: pa.  STAINS-AND-STAINING.
EX Lung function tests were conducted in 35 patients with cystic
   fibrosis and correlated to class of skin fibroblast metachromasia.
   Seven patients belonged to class I (vesticular metachromasia), 16 to
   class II (generalized metachromasia), and 12 to class III (no
   metachromasia).  Class I patients had significantly lower vital
   capacity (VC) than class II patients.  As regards the other lung
   function tests, no general trends were found in class I patients
   compared with the other two classes.  For class III patients the lung
   function tests reflected more serious lung changes than those of
   class II patients; statistically significant differences were found
   as regards residual volume/total lung capacity, one-second forced
   expiratory volume (FEV1), and FEV1/VC.  The differences were not due
   to varying intensity of treatment.  The results are in accordance
   with the findings in a previous study of the clinical and
   radiological lung symptoms and serum protein values in CF when
   correlated to metachromatic classes.
RF 001   DANES BS              IN: LAWSON D PROC 5TH INT CF          67 969
   002   DANES BS              LANCET                           1  1061 968
   003   DANES BS              J EXP MED                      129   775 969
   004   DANES BS              AM J HUM GENET                  23   297 971
   005   HOYBYE G              UGESKR LAEGER                  132  2007 970
   006   LYKKEGAARD E          DAN MED BULL                    22   169 975
   007   THUESEN-PEDERSEN J    DAN MED BULL                    21    12 974
   008   POGUE RE              MINN MED                        52  1551 969
   009   POLGAR G              PULMONARY FUNCTION TESTING IN            971
CT   1   LYKKEGAARD E          DAN MED BULL                    22   177 975
     2   LYKKEGAARD E          DAN MED BULL                    22   169 975
     3   WEEKE B               DAN MED BULL                    23   155 976
     4   DANES BS              CLIN GENET                      11    83 977
     5   DANES BS              CLIN GENET                      13   327 978
     6   JAKEL HP              BIOL ZENTRALBL                  98    55 979
     7   WINGE P               DAN MED BULL                    29   358 982
     8   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982

PN 75077
RN 00243
AN 76021664
AU Lykkegaard-E.
TI Classes of skin fibroblast metachromasia in cystic fibrosis
   correlated with growth parameters.
SO Dan-Med-Bull. 1975 Jul. 22(5). P 177-80.
MJ CYSTIC-FIBROSIS: pp.  GROWTH.
MN ADOLESCENCE.  BIOPSY.  BODY-HEIGHT.  BODY-WEIGHT.  CHILD.
   CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: pa.  FEMALE.  FIBROBLASTS.  HUMAN.
   MALE.  RETROSPECTIVE-STUDIES.  SKIN: pa.  STAINS-AND-STAINING.
AB Metachromasia of cultured skin fibroblasts from patients with cystic
   fibrosis (CF), and the assignment of the fibroblasts to one of
   three classes after the morphological distribution of the
   metachromatic staining, have been described by Danes and Bearn
   (1968, 1969) and Danes (1969).  In two previous studies from this
   hospital (Lykkegaard & Jacobsen 1975, Lykkegaard & Thuesen Pedersen
   1975) the clinical, radiological, and functional severity of the
   lung disease and the serum protein pattern in CF patients were
   studied in relation to classes of skin fibroblast metachromasia.  It
   was found that class III patients tended to be more severely
   affected than class II patients, and more than class I + II
   patients, and, possibly, class I patients were also more severely
   affected than class II patients.  Sproul and Huang (1964), in a
   study of growth patterns in cystic fibrosis, found a significant
   correlation between severity of the respiratory disease and height
   and weight retardation.  In the present study, height and weight
   development in 98 CF patients are correlated with class of skin
   fibroblast metachromasia.
RF 001   DANES BS              IN: LAWSON D PROC 5TH INT CF          67 969
   002   DANES BS              LANCET                           1  1061 968
   003   DANES BS              J EXP MED                      129   775 969
   004   LYKKEGAARD E          DAN MED BULL                    22   169 975
   005   LYKKEGAARD E          DAN MED BULL                    22   175 975
   006   SPROUL A              J PEDIATR                       65   664 964
   007   TANNER JM             ARCH DIS CHILD                  41   613 966
CT   1   LYKKEGAARD E          DAN MED BULL                    22   169 975
     2   WEEKE B               DAN MED BULL                    23   155 976
     3   DANES BS              CLIN GENET                      11    83 977
     4   DANES BS              CLIN GENET                      13   327 978
     5   JAKEL HP              BIOL ZENTRALBL                  98    55 979
     6   WINGE P               DAN MED BULL                    29   358 982
     7   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982

PN 75078
RN 00244
AN 76021662
AU Lykkegaard-E.  Jacobsen-L.
TI Classes of skin fibroblast metachromasia in cystic fibrosis
   correlated with clinical parameters.
SO Dan-Med-Bull. 1975 Jul. 22(5). P 169-74.
MJ CYSTIC-FIBROSIS: pa.
MN ADOLESCENCE.  ADULT.  AGE-FACTORS.  BIOPSY.  BLOOD-PROTEINS: an.
   CELLS-CULTURED.  CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: ra, bl.
   FEMALE.  FIBROBLASTS.  HUMAN.  MALE.  RETROSPECTIVE-STUDIES.
   SEX-FACTORS.  SKIN: pa.  STAINS-AND-STAINING.
EX A retrospective study of clinical and radiological lung symptoms and
   intensity of treatment of 98 patients with cystic fibrosis was
   conducted.  The results were correlated to class of skin fibroblast
   metachromasia.  Fourteen patients belonged to class I (vesicular
   metachromasia), 52 to class II (generalized metachromasia), and 32 to
   class III (no metachromasia).  All patients above 16 years of age
   (six patients) were class II.  Simple scoring systems for clinical
   lung symptoms and for treatment of lung disease were developed.  When
   compared at the same ages, class I and III patients were more
   severely affected (judged by the clinical lung symptoms) than class
   II patients, and they had been more intensively treated.  Comparing
   class I + II patients (metachromatic fibroblasts) with class III
   patients (ametachromatic fibroblasts), it was found that class III
   patients were more severely affected and had been more intensively
   treated than class I + II patients.  As regards chest radiographs
   (judged by Norman's system) a similar pattern was seen, but no
   statistically significant differences were found.  In 68 patients (9
   of class I, 35 of class II, and 24 of class III) the serum protein
   electrophoretic fractions were studied.  It was found that class III
   patients had more severe alterations than class II patients, and more
   than class I + II patients.  The proportion of female patients in
   class III was greater than in the other two classes, but this could
   not explain the differences.  Because of the small number of patients
   in class I, the differences between class I and class II patients are
   more doubtful than the differences between class III and class II
   patients, or between class III and class I + II patients.
RF 001   BEARN AG              TRANS ASSOC AM PHYSICIANS       82   248 969
   002   BOWMAN BH             SCIENCE                        164   325 969
   003   CONOVER JH            LANCET                           1  1122 973
   004   DANES BS              IN: LAWSON D PROC 5TH INT CF          67 969
   005   DANES BS              LANCET                           1  1061 968
   006   DANES BS              J EXP MED                      129   775 969
   007   DANES BS              LANCET                           2   437 969
   008   DANES BS              J EXP MED                      136  1313 972
   009   DANES BS              AM J HUM GENET                  23   297 971
   010   DANES BS              NATURE                         222   685 969
   011   FLENSBORG EW          ACTA PAEDIATR SCAND             61   383 972
   012   LAURELL CB            CLIN CHEM                        2    99 956
   013   LYKKEGAARD E          PROC EWGCF 4TH ANNU MTG                  973
   014   LYKKEGAARD E          DAN MED BULL                    22   177 975
   015   LYKKEGAARD E          DAN MED BULL                    22   175 975
   016   LYKKEGAARD E          DAN MED BULL                    21   232 974
   017   NORMAN AP             PROC EWGCF 2ND ANNU MTG                  971
   018   POGUE RE              MINN MED                        52  1551 969
   019   RASK MADSEN J         PROC EWGCF 4TH ANNU MTG                  973
CT   1   LYKKEGAARD E          DAN MED BULL                    22   177 975
     2   LYKKEGAARD E          DAN MED BULL                    22   175 975
     3   WEEKE B               DAN MED BULL                    23   155 976
     4   DANES BS              CLIN GENET                      11    83 977
     5   DANES BS              CLIN GENET                      13   327 978
     6   JAKEL HP              BIOL ZENTRALBL                  98    55 979
     7   WINGE P               DAN MED BULL                    29   358 982
     8   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982

PN 75079
RN 00245
AN 75131670
AU Sorenson-R-L.  Shank-R-D.  Elde-R-P.
TI Immunoperoxidase demonstration of human serum globulin binding to
   islet tissue.
SO Diabetes. 1975 Feb. 24(2). P 230-7.
MJ DIABETES-MELLITUS-INSULIN-DEPENDENT: me.  IMMUNOGLOBULINS: me.
   ISLANDS-OF-LANGERHANS: me.  PEROXIDASES.
MN ADOLESCENCE.  ADULT.  ANIMAL.  CHILD.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: me.  DIABETES-MELLITUS: ci.  GOATS: im.  HUMAN.
   IGG.  INFANT.  ISLANDS-OF-LANGERHANS: pa.  PROTEIN-BINDING.  RATS.
   STREPTOZOTOCIN.
AB Sera from juvenile diabetic and nondiabetic controls were tested,
   using the immunoperoxidase method, for the presence of islet-binding
   immunoglobulins. All diabetic sera tested contained an islet-binding
   protein and on the average the sera were more positive than age-
   matched controls. Normal adult sera are undifferentiated from
   juvenile diabetic sera. Most sera from children less than two years
   of age did not bind to islet tissue and sera from cystic fibrosis
   patients had a markedly diminished ability to bind to islet tissue.
   The binding protein appears to be an immunoglobulin which selectively
   reacts with elements of the islet beta cell.
RF 001   GEPTS W               DIABETES                        14   519 965
   002   LECOMPTE PM           ARCH PATHOL                     66   450 958
   003   MEYENBURG HV          SCHWEIZ MED WOCHENSCHR          21   554 940
   004   RENOLD AE             CIBA FOUND COLLOQUIA ENDOCRIN   15   122 964
   005   LECOMPTE PM           DIABETES                        15   586 966
   006   GRODSKY GM            DIABETES                        14   396 965
   007   KOREAKOVA L           Z MIKROSK ANAT FORSCH           85    85 972
   008   NERUP J               DIABETES                        20   424 971
   009   UNGAR B               LANCET                           2   415 968
   010   IRVINE WJ             LANCET                           2   163 970
   011   PETTIT MD             J CLIN ENDOCRINOL METAB         21   209 960
   012   BLIZZARD RM           CLIN EXP IMMUNOL                 2    19 967
   013   ANON                  LANCET                           2   193 970
   014   HUNG W                MED ANN DC                      39   487 970
   015   KOGUT MD              J PEDIATR                       81   307 972
   016   LANDING BH            J CLIN ENDOCRINOL METAB         23   119 962
   017$  DECKERT T             ACTA MED SCAND                 474    30 967
   018   NERUP J               ACTA ENDOCRINOL                 72   279 973
   019   PAV J                 LANCET                           2   221 963
   020   MANCINI AM            LANCET                           1  1189 965
   021   CHETTY MP             LANCET                           1    67 965
   022   NAKANE PK             J HISTOCHEM CYTOCHEM            14   929 966
   023   ELDE RP               THESIS                                   974
   024   SNEDECOR GW           STATISTICAL METHODS                      967
   025   KABAT EA              EXPERIMENTAL IMMUNOCHEMISTRY             961
   026   DESBUQUOIS B          J CLIN ENDOCRINOL METAB         33   732 971
   028   GOMORI G              AM J CLIN PATHOL                20   665 950
   029   GRIMELIUS L           IN: BROLIN SE                            964
   030   HELLERSTROM C         IN: BROLIN SE                            964
CT   1   CHRISTY M             CLIN ENDOCRINOL METAB            6   305 977
     2   MONIER JC             LYON MED                       237    11 977
     3   APPEL MC              DIABETOLOGIA                    15   327 978
     4   LERNMARK A            N ENGL J MED                   299   375 978
     5   KALDANY A             DIABETES                        28   102 979
     6   BUSCHARD K            DAN MED BULL                    32   139 985

PN 75080
RN 00246
AN 75209073
AU Schoni-M.  Kaiser-D.  Drack-E.  Axmacher-U.
TI Excretion of trypsin-like activity, electrolytes and protein in
   mixed and parotid saliva of patients with cystic fibrosis of the
   pancreas.
SO Eur-J-Clin-Invest. 1975 Apr. 5(2). P 153-8.
MJ CYSTIC-FIBROSIS: me.  SALIVA: me.  TRYPSIN: me.
MN CALCIUM: an.  CHILD.  CHILD-PRESCHOOL.  HUMAN.
   HYDROGEN-ION-CONCENTRATION.  PAROTID-GLAND: se.  PROTEINS: an.
   SALIVA: an.
AB The esterolytic activity of mixed and parotid saliva in cystic
   fibrosis (CF) patients and normal subjects was determined using BAEE
   (alpha-Benzoyl-1-arginine-ethylester) as the substrate. Using soybean-
   trypsin-inhibitor the trypsin-like activity (TLA) was measured and
   plotted as a function of parotid flow rate. In addition calcium,
   protein and pH were determined. Trypsin-like activity in mixed and
   parotid saliva showed large individual variations in CF and normal
   children. In parotid saliva we could not find any significant
   difference, whereas a reduction of TLA in mixed saliva of CF patients
   was observed. The fact that our normal values fell within the range
   of heterozygotes reported by Rao et al. (19), makes their hypothesis
   of a close relationship between reduced TLA and the genetic defect
   very doubtful. Protein, calcium and pH increased with augmented
   salivation and no difference between CF patients and normal age
   matched children could be found except for the pH at a flow rate
   above 0.75 ml/min per m2 body surface where significantly lower pH
   values resulted. The relevance of reduced TLA to the pathogenesis of
   cystic fibrosis is discussed.
RF 001   BOWMAN BH             SCIENCE                        167   871 970
   002   CONOVER JH            PEDIATR RES                      7   220 973
   003   FREY EK               KALLIKREIN KININ SYSTEM INH              968
   004   GIBSON LE             PEDIATRICS                      48   695 971
   005   GUGLER EC             J PEDIATR                       71   585 967
   007   HEIDLAND A            KLIN WOCHENSCHR                 50   959 972
   008   KAISER D              PEDIATR RES                      5   167 971
   009   KAISER D              IN: MANGOS JA                        247 973
   010   KAISER D              PFLUEGERS ARCH                 349    63 974
   011   KASSELL B             IN: PERTINAUM GE                19   853 970
   012   KREUSSER W            EUR J CLIN INVEST                2   398 972
   013   LOCKHART LH           SOUTH MED J                     61  1356 968
   014   LOURIE RS             AM J DIS CHILD                  65   455 943
   015   LOWRY OH              J BIOL CHEM                    193   265 951
   016   MANDEL ID             AM J DIS CHILD                 110   646 965
   017   MANGOS JA             PEDIATR RES                      2   378 968
   018   OUCHTERLONY O         ACTA PATH MICROBIOL SCAND       26   507 949
   019   RAO GJS               J PEDIATR                       80   573 972
   020   RECTOR FC             J CLIN INVEST                   44   278 965
   021   RICK W                METHODS IN ENZYMATIC ANALYSIS        807 965
   022   SCHNEYER LH           PHYSIOL REV                     52     3 972
   023   SPOCK A               PEDIATR RES                      1   173 967
   024   TRAUTSCHOLD I         HOPPE SEYLERS Z PHYSIOL CHEM   325    48 961
   025   WALLACH D             EUR J BIOCHEM                   21   433 971
   026   WERLE E               BIOCHEM Z                      323   279 952
   027   WERLE E               ARZNEIMITTEL FORSCH             18   281 964
   028   WERLE E               ARCH INT PHARMACODYN THER      131   257 961
   029   WERLE E               BIOCHEM Z                      290   129 937
   030   WERLE E               BIOCHEM Z                      301   329 939
   031   YOUNG JA              PFLUEGERS ARCH                 319   185 970
CT   1   GRIMMEL K             ACTA HEPATOGASTROENTEROL        23   334 976
     2   HAUBRICH J            ARCH OTO RHINO LARYNGOL        213     1 976
     3   MUNZEL M              ARCH OTO RHINO LARYNGOL        213   209 976
     4   CHILLA R              ARCH OTO RHINO LARYNGOL        214   367 977
     5   RAO GJS               ENZYME                          23   314 978
     6   SLAVOTINEK AH         AUST NZ J MED                   11    91 981
     7   KATZ S                CELL CALC                        5   421 984
     8   KONARSKA L            J CLIN CHEM CLIN BIOCHEM        23   337 985

PN 75081
RN 00247
AN 76043991
AU Berry-H-K.
TI Screening for genetic disorders.
SO Fed-Proc. 1975 Nov. 34(12). P 2134-9. (REVIEW).
MJ MASS-SCREENING.  METABOLISM-INBORN-ERRORS: di.
MN LIPOIDOSIS: di.  AMINO-ACID-METABOLISM-INBORN-ERRORS: di.
   BIOLOGICAL-ASSAY.  CHILD.  CHROMATOGRAPHY-THIN-LAYER.
   CYSTIC-FIBROSIS: di.  DIAGNOSIS-LABORATORY.  GALACTOSEMIA: di.
   HUMAN.  HYPOTHYROIDISM: di.  INFANT.  INFANT-NEWBORN.  JEWS.
   MAPLE-SYRUP-URINE-DISEASE: di.  METABOLISM-INBORN-ERRORS: fg, me.
   MUSCULAR-DYSTROPHY: di.  REVIEW.  SUPPORT-U-S-GOVT-P-H-S.
   SUPPORT-U-S-GOVT-NON-P-H-S.
EX The past 50 years in developed countries have seen a steady decline
   in infant mortality from diseases associated with infections and
   malnutrition.  During the period the contribution from genetic
   diseases and congenital malformations has risen significantly.
   Genetically oriented screening programs have a high potential to
   contribute to the overall improvement of health in both developed
   and underdeveloped countries.  In this review only procedures for
   screening for hereditary biochemical disorders will be considered.
   Criteria for selection of genetic traits to be screened, the schedule
   for screening, specimens for screening, the screening of newborn
   infants, the testing of older infants, the testing of high-risk
   infants and children, the screening of families with genetic
   diseases, and screening for carriers in selected populations are
   discussed.
RF 001   ALLAN JD              AM J DIS CHILD                 126    22 973
   002   AMBROSE JA            CLIN CHEM                       15    15 969
   003   AMBROSE JA            APPLIC BASIC PRIN FLUOROMETRY            972
   004   BERRY HK              CLIN CHEM                        5   603 959
   006   BERRY HK              AM J DIS CHILD                 129   165 975
   007   BERRY HK              CLIN CHEM                       14  1033 968
   008   BEUTLER E             J LAB CLIN MED                  68   137 966
   009   BREMER HJ             MONATSSCHR KINDERHEILKD        117    32 969
   010   CHILDS B              IN: SUTTON HE                          3 972
   011   DUSSAULT JH           UNION MED CAN                  102  2062 973
   012   MITTMAN C             ISR J MED SCI                    9  1311 973
   013   ANON                  GENETIC SCREENING PROG PRIN A            975
   014   GHADIMI H             IN: NYHAN WL                         265 975
   015   GREEN MN              PEDIATRICS                      41   989 968
   016   GUTHRIE R             PEDIATRICS                      32   338 963
   017   GUTHRIE R             BIRTH DEF ORIG ART SER           4    92 968
   018   HILL JB               CLIN CHEM                       11   451 965
   019   IRELAND JT            ANN CLIN BIOCHEM                 9   129 972
   020   JELLUM E              CLIN CHEM                       18   800 972
   021   LABERGE C             AM J HUM GENET                  21    36 969
   022   LEVY HL               N ENGL J MED                   288  1299 973
   023   LEVY HL               PEDIATRICS                      49   825 972
   024   LEVY HL               N ENGL J MED                   291  1214 974
   025   LIGHT IJ              AM J DIS CHILD                 112   229 966
   026   LIGHT IJ              AM J DIS CHILD                 125   243 973
   027   LOWDEN JA             CLIN CHEM                       19  1345 973
   028   MCKUSICK VA           IN: CARSON NAJ                       179 971
   029   MENKES JH             PEDIATRICS                      49   218 972
   030   MILUNSKY A            PRENATAL DIAGNOSIS OF HEREDIT            973
   031   MOTULSKY AG           SCIENCE                        185   653 974
   032   NITOWSKY HM           AM J MENT DEFIC                 77   538 973
   033   PARTINGTON MW         BIOL NEONATE                    18   121 971
   034   PASIEKA AE            CLIN BIOCHEM                     2    41 968
   035   POPKIN JS             LANCET                           1   721 974
   036   PROSSER R             ARCH DIS CHILD                  49   597 974
   037   OBRIEN JS             N ENGL J MED                   283    15 970
   038   RAINE DN              LANCET                           2   996 974
   039   SCHMIDT L             IN: NYHAN WL                         675 975
   040   SCRIVER CR            PEDIATRICS                      54   616 974
   041   SCRIVER CR            CLIN BIOCHEM                     6   142 973
   042   SCRIVER CR            AMINO ACID METABOL DISORDERS             973
   043   SCRIVER CR            CAN MED ASSOC J                108  1111 973
   044   SHIH VE               LAB TECH FOR DETECTION HEREDI            973
   045   STEPHAN U             PEDIATRICS                      55    35 975
   046   THALHAMMER O          ACTA UNIV CAROL MED MONOGR      56    79 973
   047   THOMAS GH             PEDIATR CLIN NORTH AM           20   105 973
   048   TOCCI PM              IN: NYHAN WL                         461 967
   049   ANON                  WHAT ARE FACTS GENET DISEASE           9 975
   050   WILLIAMS KM           AUST J BIOL SCI                 26   831 973
   051   ZELLWEGER H           PEDIATRICS                      55    30 975
CT   1   MEE JML               BIOMED MASS SPECTROMET           4   178 977
     2   NARAYANAN KR          ARCH TOXICOL                    38    61 977
     3   PONGOR S              ACTA BIOCHIM BIOPHYS            13   117 978
     4   MACHILL G             BIOL ZENTRALBL                 100   449 981

PN 75082
RN 00248
AN 76189166
AU Hook-E-B.  Bonenfant-R.
TI Parathenar palmar pattern: a dermatoglyphic sign of possible
   clinical significance.
SO Hum-Hered. 1975. 25(6). P 509-12.
MJ CYSTIC-FIBROSIS: fg.  DERMATOGLYPHICS.  HEART-DEFECTS-CONGENITAL:  fg.
MN FEMALE.  HUMAN.  MALE.
AB The frequency of a 'double proximal axial triradius' (DPAT), which
   results in a palmar parathenar pattern, has been reported to be
   increased in those with ventricular septal defect (BSD). We scored
   the presence of this pattern in 313 patients with congenital heart
   defects (including 86 with isolated VSD), 176 with cystic fibrosis
   (CF) or relatives of those with CF, and 333 with no known clinical
   disease who were unrelated to individuals with CF. The frequencies in
   these three groups were 1.6, 2.3, and 0.6%, respectively. None of
   those with isolated VSD defect had a DPAT. All five individuals in
   the heart defect group with a DPAT had pulmonic stenosis. Of the
   total of eleven individuals in our series with DPAT patterns, eight
   were affected only on the right hand. The frequency of DPAT in
   individuals with no known disease in this series was 4/406=1.0%, more
   than double the frequency in a control series, published previously
   by DAVID, 5/1,129=0.4%. If the 73 relatives of those with CF are
   excluded from our own 'control' group, the frequency of DPAT in this
   group is then 0.6%, closer to the results in DAVID's control series.
RF 001   DAVID TJ              J PEDIATR                       79   343 971
   002   CUMMINS H             FINGER PRINTS PALMS AND SOLES        103 961
   003   HOOK EB               TERATOLOGY                       9   233 974
CT   1   DENNIS RLH            ANN HUM BIOL                     5   269 978
     2   DAVID TJ              J MED GENET                     18   344 981

PN 75083
RN 00249
AN 75210370
AU Altland-K.  Schmidt-S-R.  Kaiser-G.  Knoche-W.
TI Demonstration of a factor in the serum of homozygotes and
   heterozygotes for cystic fibrosis by a non-biological technique.
SO Humangenetik. 1975 Jul 23. 28(3). P 207-16.
MJ BLOOD-PROTEINS: an.  CYSTIC-FIBROSIS: bl.
MN BLOOD-PROTEIN-ELECTROPHORESIS: mt.  COMPLEMENT-3.
   CYSTIC-FIBROSIS:  fg.  HETEROZYGOTE.  HOMOZYGOTE.  HUMAN.  IGG.   
   ISOELECTRIC-POINT.  MOLECULAR-WEIGHT.
AB A factor has been isolated from serum of homozygotes and obligate
   heterozygotes for cystic fibrosis using isoelectric focusing and
   disc electrophoresis as analytical methods.  The factor is focused
   within an IgG-fraction with an isoelectric point of pH 8 to 9 but
   differs from IgG in its lower molecular weight.  It is thus similar
   to, if not identical with, the ciliary dyskinesia factor.
RF 001   AWDEH ZL              NATURE                         219    66 968
   002   BESLEY GTN            J MED GENET                      6   278 969
   003   BOKISCH VA            J CLIN INVEST                   49  2427 970
   004   BOWMAN BH             LANCET                           1   404 974
   005   BOWMAN BH             SCIENCE                        164   325 969
   006   BOWMAN BH             SCIENCE                        167   871 970
   007   CONOVER JH            PEDIATR RES                      7   224 973
   008   CONOVER JH            PEDIATR RES                      7   220 973
   009   CONOVER JH            LIFE SCI                        14   253 974
   010   CRAWFURD MDA          IN: LAWSON D PROC 5TH INT CF          42 969
   011   DANES BS              J EXP MED                      137  1538 973
   012$  HJERTEN S             ARCH BIOCHEM BIOPHYS SUPPL       1   147 962
   013   LIEBERMAN J           AM REV RESPIR DIS              109   399 974
   014   LIEBERMAN J           AM REV RESPIR DIS              111   100 975
   015   MARCHI AG             HELV PAEDIATR ACTA              28   427 973
   016   REISFELD RA           NATURE                         195   281 962
   017   RAO GJS               PEDIATR RES                      8   684 974
   018   RAO GJS               SCIENCE                        177   610 972
   019   SCHMOYER IR           BIOCHEM BIOPHYS RES COMMUN      46  1923 972
   020   SPOCK A               PEDIATR RES                      1   173 967
   021   VALLOTA EH            J EXP MED                      137  1109 973
   022   VESTERBERG O          SCIENCE TOOLS                   20    22 973
   023   WILSON GB             CLIN CHIM ACTA                  49    79 973
CT   1   WILSON GB             PEDIATR RES                     10  1001 976
     2   FORSTNER G            CLIN CHIM ACTA                  70   459 976
     3   WOOD RE               AM REV RESPIR DIS              113   833 976
     4   THOMAS JM             PEDIATR RES                     11  1148 977
     5   THOMAS JM             PEDIATR RES                     11   138 977
     6   WILSON GB             PEDIATR RES                     11   986 977
     7   TULLY GW              PEDIATR RES                     13  1078 979
     8   JAKEL HP              BIOL ZENTRALBL                  98    55 979
     9   ALTLAND K             ELECTROPHORESIS                  2    49 981
    10   NEVIN GB              HUM GENET                       56   387 981
    11   HALLINAN FM           CLIN CHIM ACTA                 117   103 981
    12   MCNEELY MC            PEDIATR RES                     16    21 982
    13   ALTLAND K             CLIN CHEM                       28  1000 982
    14   SHIBATA K             HUM GENET                       61   210 982
    15   JAMIESON A            HUM GENET                       70   168 985

PN 75084
RN 00250
AN 76045098
AU Cunningham-D-G.  Gatti-W-M.  Eitenmiller-A-M.  Van-Gorder-P-N.
TI Cystic fibrosis: involvement of the ear, nose, and paranasal sinuses.
SO Ill-Med-J. 1975 Oct. 148(4). P 470-1, 474.
MJ CYSTIC-FIBROSIS: co.  DEAFNESS: et.  NASAL-POLYPS: et.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.  FRONTAL-SINUS: ab.
   HUMAN.  INFANT.  PSEUDOMONAS-AERUGINOSA: ip.  SINUSITIS: mi.
EX Twenty-six patients with cystic fibrosis all exhibited disease of the
   paranasal sinuses, consisting of opacification of the maxillary
   sinuses either alone or as part of a parasinusitis.  Symptoms of
   sinusitis seldom occurred and treatment was not generally required.
   Agenesis or delayed development of frontal sinuses was also seen in
   the majority of patients.  Nasal polyps occurred in 27% of the
   patients, all of whom were over five years of age.  Excluding those
   patients under five years of age, none of whom had polyps, the
   incidence was 36%.  In general, polyps were not observed in those
   patients with severe disease.  Mild degrees of conductive hearing
   loss were noted in the younger age groups especially, but no
   instance of severe hearing loss or nerve conduction disturbance was
   encountered.  Such mild degrees of hearing loss may merely reflect
   the application of standards too stringent for this age group.
   Throat and nose cultures on 26 patients revealed pseudomonas
   aeruginosa in eighteen cases, reflecting the flora of the
   tracheobronchial tree.  Other organisms were encountered on an
   unpredictable basis with findings consistent with those anticipated
   in this age group of patients.
RF 001   DI SANTAGNESE PA      AM FAM PHYSICIAN                 7   102 973
   002   SHWACHMAN H           PEDIATRICS                      46   335 970
   003   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   004   GIBSON LE             PEDIATRICS                      23   545 959
   005   DOGGETT RG            INFECT IMMUN                     6   628 972
   006   WILLIAMS RJ           J MED MICROBIOL                  6   409 972
   007   CUNNINGHAM DG         ILL MED J                      145   493 974
   008   JERGER J              ARCH OTOLARYNGOL                93   111 971
   009   NEELY JG              TRANS AM ACAD OPHTHALMOL OTOL   76   313 972
   010   PENNINGTON CL         ARCH OTOLARYNGOL                63   576 956
   011   SHWACHMAN H           PEDIATRICS                      30   389 962
   012   KULCZYCKI LL          ARCH OTOLARYNGOL                92    54 970
CT   1   FRIED MP              LARYNGOSCOPE                    94   192 984
     2   DAVID TJ              J ROY SOC MED                   79    23 986

PN 75085
RN 00251
AN 76215175
AU Heinrich-H-C.
TI Clinical aspects of iron absorption and turnover.  pp.  34-61.
SO In: Kief H, et.al., ed. Iron metabolism and its disorders.
   Amsterdam, Excerpta Medica, 1975. W3 EX89 no.366 1975.
MJ INTESTINAL-ABSORPTION.  IRON: me.
MN ADMINISTRATION-ORAL.  CYSTIC-FIBROSIS: me.  DIGESTION.  FECES: an.
   GASTRECTOMY.  GASTRIC-MUCOSA: me.  HETEROZYGOTE.  HOMOZYGOTE.  HUMAN.
   INTESTINAL-MUCOSA: me.  IRON: ad, df.  MALABSORPTION-SYNDROMES: me.
   MONOGRAPH.  THALASSEMIA: fg, me.
AB The diagnostic 10 micro-mole (0.56 mg) 59Fe2 absorption whole body
   retention test (Fig. 1) has now been in use for 10 years for the
   detection of depleted iron stores in subjects with iron deficiency
   (Heinrich et al., 1966; Heinrich and Bartels, 1967).  Further
   studies were necessary to investigate the clinical reliability of
   increased 59Fe2 absorption in patients with erythroblastic
   hyperplasia, which may control the regulation of iron absorption by
   iron stores.  The relationship between iron absorption and iron
   stores was studied in pancreatic insufficiency to reinvestigate the
   effect of pancreatic secretion on iron absorption.  Iron absorption
   in patients with gluten-sensitive enteropathy was investigated in
   order to correlate the impairment of iron absorption with the degree
   of villous atrophy and to study its recovery on a gluten-free diet.
   Dietary iron absorption was measured in patients with gastric
   mucosal atrophy and partial gastrectomy to investigate the extent to
   which iron malabsorption is responsible for the high incidence of
   iron deficiency in such patients.  The combination of the diagnostic
   59Fe2 absorption test and measurement of the whole body 59Fe2
   elimination rate is a useful routine procedure for the detection and
   quantification of gastrointestinal or urogenital blood loss as a
   cause of iron deficiency.
RF 001   BENDER-GOETZE C       Z KINDERHEILK                  118   283 975
   002   CONRAD ME             IN: HALLBERG L                        87 970
   003   HEINRICH HC           IN: HALLBERG L                       213 970
   004   HEINRICH HC           LANCET                           2  1256 970
   005   HEINRICH HC           KLIN WOCHENSCHR                 45   553 967
   006   HEINRICH HC           BIOCHEM MED                      5   472 971
   007   HEINRICH HC           KLIN WOCHENSCHR                 49   819 971
   008   HEINRICH HC           KLIN WOCHENSCHR                 49   819 971
   009   HEINRICH HC           KLIN WOCHENSCHR                 44   827 966
   010   HEINRICH HC           Z KINDERHEILK                  115     1 973
   011   KRAUSE U              IN: HALLBERG L                       505 970
   012   BAIRD IM              Q J MED                         28    21 959
   013   BAIRD IM              Q J MED                         28    21 959
   014   NADLER SB             SURGERY                         51   224 962
   015   SMITH MD              CLIN SCI                        16    23 957
   016   TURNBULL A            IN: JACOBS A                         369 974
   017   WEINFELD A            IN: HALLBERG L                       329 970
CT   1   COOK JD               CLIN HAEMATOL                    6   567 977
     2   WORWOOD M             SEM HEMATOL                     14     3 977
     3   HEINRICH HC           KLIN WSCHR                      55  1043 977
     4   HEINRICH HC           KLIN WSCHR                      55   587 977
     5   HEINRICH HC           KLIN WSCHR                      55   595 977
     6   BARTELS U             SCAND J GASTROENTEROL           13   649 978
     7   HEINRICH HC           KLIN WSCHR                      56  1057 978
     8   HEINRICH HC           MED KLIN                        73  1335 978
     9   HEINRICH HC           MED KLIN                        73  1163 978
    10   HEINRICH HC           DTSCH MED WSCHR                103   753 978
    11   GOLTNER E             GYNAKOLOGE                      12    52 979
    12   HEINRICH HC           MED WELT                        30    89 979
    13   HEINRICH HC           KLIN WSCHR                      57   187 979
    14   HEINRICH HC           ACTA HAEMATOL                   62    56 979
    15   HEINRICH HC           MED KLIN                        74  1225 979
    16   HEILMANN E            DTSCH MED WSCHR                104  1325 979
    17   HEINRICH HC           DTSCH MED WSCHR                104  1496 979
    18   GOLTNER E             MED KLIN                        75    44 980
    19   MCLAREN GD            CRC CRIT REV CLIN LAB SCI       19   205 983
    20   MANDELBAUM AY         KLIN MED                        61   121 983
    21   DOMMISSE J            S AFR MED J                     64  1047 983
    22   HUEBERS HA            BLOOD                           64   763 984
    23   FINCH CA              CLIN PHYSIOL BIOCHEM             4     5 986
    24   HUEBERS HA            PHYSIOL REV                     67   520 987

PN 75086
RN 00252
AN 76045374
AU Chandra-R-K.
TI Alpha-fetoprotein in serum and amniotic fluid in the diagnosis of
   neonatal hepatitis syndrome, Indian childhood cirrhosis, cystic
   fibrosis, ataxia telangiectasia and spina bifida.
SO Indian-Pediatr. 1975 Jul. 12(7). P 545-8.
MJ ALPHA-FETOPROTEINS: an.  AMNIOTIC-FLUID: an.  FETAL-PROTEINS: an.
MN ATAXIA-TELANGIECTASIA: di.  CHILD.  CYSTIC-FIBROSIS: di.  FEMALE.
   HEPATITIS: di.  HUMAN.  INFANT-NEWBORN.  INFANT-NEWBORN-DISEASES: di.
   LIVER-CIRRHOSIS: di.  PREGNANCY.  PRENATAL-DIAGNOSIS.
   SPINA-BIFIDA:  di.
AB Alpha-fetoprotein (A.F.P.) was detected and quantitated by the methods
   of immunodiffusion in agarose, counterimmunoelectrophoresis and
   radioimmunoassay.  Serum A.F.P. level was raised in patients and
   siblings of Indian childhood cirrhosis, cystic fibrosis homozygotes
   heterozygotes, neonatal hepatitis and ataxia telangiectasia.  It was
   mildly elevated in biliary atresia.  In women with previous history
   of a child with severe neural tube defect, raised amniotic fluid
   levels of A.F.P. were associated with anencephaly or spina bifida.
   The diagnostic utility of A.F.P. in pediatrics, especially in
   genetic counselling, is discussed.
RF 001   GITLIN D              J CLIN INVEST                   45  1826 966
   002   CHANDRA RK            MED CHIR DIG                     3    63 974
   003   CHANDRA RK            ARCH DIS CHILD                  48   157 973
   004   NAYAK NC              LANCET                           1    86 972
   008   RAMALINGASWAMI V      IN: POPPER H                     3   222 970
   009   ABELEV GI             TRANSPLANTATION                  1   174 963
   010   TATARINOV YS          VOPR MED KHIM                   11    20 965
   011   CHANDRA RK            TECH REP SERIES NO 24 INDIAN             973
   012   CHANDRA RK            INDIAN J MED RES                61   466 973
   014   BROCK DJH             LANCET                           2   197 972
   015   ALLAN LD              LANCET                           2   522 973
CT   1   CHANDRA RK            INT ARCH ALLERGY APPL IMMUNOL   53   180 977
     2   ZELTZER PM            J PEDIATR SURG                  13   381 978
     3   MIZEJEWSKI GJ         CLIN CHEM                       28  1207 982
     4   MIZEJEWSKI GJ         PEDIATR RES                     17    47 983

PN 75087
RN 00253
AN 76024261
AU Baran-D.  Dachy-A.  Klastersky-J.
TI Concentration of gentamicin in bronchial secretions of children with
   cystic fibrosis of tracheostomy.  (Comparison between the
   intramuscular route, the endotracheal instillation and
   aerosolization).
SO Int-J-Clin-Pharmacol-Biopharm. 1975 Oct. 12(3). P 336-41.
MJ CYSTIC-FIBROSIS: me.  GENTAMICINS: me.
   RESPIRATORY-TRACT-INFECTIONS:  dt.  SPUTUM: an.  TRACHEOTOMY.
MN ADOLESCENCE.  AEROSOLS.  CHILD.  CHILD-PRESCHOOL.  COMPARATIVE-STUDY.
   CYSTIC-FIBROSIS: mi, co.  GENTAMICINS: ad, an, bl.  HUMAN.  INFANT.
   INJECTIONS-INTRAMUSCULAR.  INTUBATION-INTRATRACHEAL.
   PSEUDOMONAS-AERUGINOSA.  PSEUDOMONAS-INFECTIONS: dt.
AB The levels of gentamicin in blood and in secretions of the
   tracheobronchial tree were measured in 14 children (8 with cystic
   fibrosis and 6 with tracheostomy) in a cross over fashion after the
   administration of 40 mg of gentamicin by aerosol or by endotracheal
   injection. High levels of gentamicin (greater than 20 mug/ml) within
   the bronchial secretions were observed in 7 children after
   aerosolization and in 11 children after endotracheal instillation.
   Corresponding blood levels were low (less than 3 mug/ml) in all
   patients and no detectable levels were found in 10 children after
   aerosolization and in 6 children after endotracheal instillation. No
   significant differences were observed between children with cystic
   fibrosis and those with tracheostomy. Since intramuscular injection
   of gentamicin (a single dose of 1.5 mg/kg) resulted in low levels of
   gentamicin within the bronchial secretions (less than 2 mug/ml in 10
   patients, among whom 4 had undetectable levels); it is concluded that
   the administration of an antibiotic such as gentamicin, directly to
   the trachea by endotracheal injection or by aerosolization might
   prove to be helpful when the infection is confined mainly to the
   tracheo-bronchial tree.
RF 001   DAVIS WW              APPL MICROBIOL                  22   659 971
   002   GATMAITAN BG          AM J MED SCI                   260    90 970
   003   KLASTERSKY J          J INFECT DIS                   129   187 974
   004   KLASTERSKY J          CHEST                           61   117 972
   005   KLASTERSKY J          CHEST                           65   650 974
   006   LOWBURY EJL           J MED MICROBIOL                  3    39 970
   007   MARKS MI              J PEDIATR                       79   822 971
   008   MEARNS MB             ARCH DIS CHILD                  47   902 972
   009   PENNINGTON JE         AM J MED                        55   155 973
   010   PENNINGTON JE         J INFECT DIS                   128    63 973
   011   PINES A               BR MED J                         1   663 970
   012   RAMIREZ JR            CHEST                           58   352 970
   013   ROSE HD               J CLIN PHARMACOL                10   274 970
   014   SWIFT DL              IN: LAWSON D PROC 5TH INT CF             969
CT   1   LI PK                 CLIN CHEM                       26  1631 980
     2   TABACHNIK E           AM REV RESPIR DIS              122    97 980
     3   LOURENCO RV           ARCH INTERN MED                142  2299 982
     4   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    75 982
     5   MAXWELL D             J ANTIMICROB CHEMOTHER          11   203 983
     6   COURCOL RJ            INT J CLIN PHARMACOL RES         5    87 985
     7   MENDELMAN PM          AM REV RESPIR DIS              132   761 985
     8   AGUILERA D            PATHOL BIOL (PARIS)             34   657 986
     9   STOUT SA              DRUG INTEL CLIN PHARM           21   322 987

PN 75088
RN 00254
AN 75114429
AU Arad-I.  Lafair-J-S.  Shapira-E.
TI Application of the cilia dyskinesis test in the diagnosis of cystic
   fibrosis in an adolescent.
SO Isr-J-Med-Sci. 1975 Jan. 11(1). P 10-4.
MJ CILIA: ph.  CYSTIC-FIBROSIS: di.
MN ACID-BASE-EQUILIBRIUM.  ADOLESCENCE.  ADULT.  CHILD.
   CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: fg, mi, bl.  ELECTROLYTES: an.
   FEMALE.  HETEROZYGOTE.  HOMOZYGOTE.  HUMAN.  IGA: an.  IGG: an.
   IGM:  an.  MALE.  PEDIGREE.  RABBITS.  RESPIRATORY-FUNCTION-TESTS.
   SERUM-GLOBULINS: du.  SPUTUM: mi.  SWEATING.  TRACHEA: ph.
AB In certain cases of obscure chronic lung disease, the possibility of
   a genetic disorder, such as cystic fibrosis of the pancreas, should
   be considered. When the genetic defect fails to cause pancreatic
   involvement, the partial expression of cystic fibrosis is
   encountered. Elevation of sweat electrolyte levels is not sufficient
   to confirm the diagnosis of cystic fibrosis in adults since normal
   levels vary widely in both adolescents and adults. Other tests
   should, therefore, be utilized. The cilia dyskinesis test is positive
   in both homozygous and heterozygous patients with cystic fibrosis.
   Utilization of this technique in a family study confirmed the
   diagnosis of partial expression of cystic fibrosis in an adolescent
   female.
RF 001   DI SANTAGNESE PA      MOD PROBL PEDIATR               10    10 967
   002   DI SANTAGNESE PA      IN: NELSON WE                        771 964
   003   ANDERSON CM           MOD PROBL PEDIATR               10   344 967
   004   DI SANTAGNESE PA      MOD PROBL PEDIATR               10   135 967
   005   SHWACHMAN H           PEDIATRICS                      36   689 965
   006   SHWACHMAN H           CF CLUB ABST                     7       966
   007   SPOCK A               PEDIATR RES                      1   173 967
   008   SHAPIRA E             J LAB CLIN MED                  77   877 971
   009   SHWACHMAN H           MOD PROBL PEDIATR               10   158 967
   010   GRAND RJ              J PEDIATR                       70   346 967
   011   GRAND RJ              J PEDIATR                       70   357 967
   012   PEREIRA C             J PEDIATR                       78  1036 971
   013   LOBECK CC             J PEDIATR                       62   393 963
   014   TAUSSIG LM            J PEDIATR                       79  1034 971
   015   MAY CD                AM J DIS CHILD                 109     2 965
   016   CABANEL G             MOD PROBL PEDIATR               10   284 967
   017   CRAWFURD MDA          IN: LAWSON D PROC 5TH INT CF          42 969
   018   BESLEY GTN            J MED GENET                      6   278 969
   019   IACOCCA VF            J PEDIATR                       79   508 971
   020   BOWMAN BH             SCIENCE                        164   325 969
   021   CHERRY JD             J PEDIATR                       79   937 971
   022   LEVIN S               ISR J MED SCI                    2   333 966
   023   MANCINI G             IMMUNOCHEMISTRY                  2   235 965
CT   1   WIEDERHOLD ML         ANNU REV BIOPHYS BIOENG          5    39 976
     2   GABRIDGE MG           PEDIATR RES                     13    31 979

PN 75089
RN 00255
AN 76068923
AU Parsons-R-L.  Paddock-G-M.
TI Absorption of two antibacterial drugs, cephalexin and
   co-trimoxazole, in malabsorption syndromes.
SO J-Antimicrob-Chemother. 1975. 1(3 Suppl). P 59-67.
MJ CEPHALEXIN: me.  MALABSORPTION-SYNDROMES: me.  SULFAMETHOXAZOLE: me.
   TRIMETHOPRIM: me.
MN CELIAC-DISEASE: me.  CHOLESTYRAMINE: ae.  CYSTIC-FIBROSIS: me.
   DIVERTICULOSIS: me.  DRUG-COMBINATIONS.  CROHN-DISEASE: me.  HUMAN.
   INTESTINAL-ABSORPTION.  MALABSORPTION-SYNDROMES: ci.  TIME-FACTORS.
AB Plasma concentrations and urinary excretion of cephalexin,
   trimethoprim and sulphamethoxazole (co-trimoxazole) were measured in
   normal subjects and in patients with coeliac disease, small bowel
   diverticulosis, Crohn's disease, cystic fibrosis (cephalexin only)
   and after administration of cholestyramine.  The absorption of
   cephalexin was improved in coeliac disease diverticulosis and cystic
   fibrosis.  In Crohn's disease the peak plasma level was reduced and
   delayed.  The absorption of both trimethoprim and sulphamethoxazole
   was increased in all three conditions.  However there was a
   disproportionate increase in the plasma level of trimethoprim in
   coeliac disease and diverticulosis when compared with that of
   sulphamethoxazole.  In Crohn's disease there was a threefold
   increase in the peak plasma level of sulphamethoxazole.  After
   cholestyramine administration there was malabsorption of all three
   drugs.
RF 001   BRODIE BB             ABSORPTION DISTRIBUTION DRUGS         16 964
   002   CHANARIN I            BR MED J                         1   651 972
   003   DAVIES JA             POSTGRAD MED J                  46    16 970
   004   DAVIS AE              AUSTRALAS ANN MED               17    63 968
   005   GROVE DC              ASSAY METH OF ANTIBIOTICS                955
   006   HASHIM SA             PROC SOC EXP BIOL MED          106   173 961
   007   MARGET W              POSTGRAD MED J                  47    54 971
   008   MATILLA MJ            ARZNEIMITTEL FORSCH             23   583 973
   009   PARSONS RL            PROC INT CONG CHEMOTHER 8TH      1   499 974
   010   PARSONS RL            PROC INT CONG CHEMOTHER 8TH      1   534 974
   011   PARSONS RL            BR J CLIN PHARMACOL              1   348 974
   012   PARSONS RL            J ANTIMICROB CHEMOTHER           1    39 975
   013   RIEDER J              CHEMOTHERAPY                    17     1 972
   014   SCHWARTZ DE           CHEMOTHERAPY (SUPPL)            14    22 969
   015   PARSONS RL            BR J CLIN PHARMACOL              1   348 974
CT   1   SCHNEIDER RE          BR MED J                         2   794 976
     2   PARSONS RL            BR MED J                         1   103 977
     3   PARSONS RL            CLIN PHARMACOKINET               2    45 977
     4   AMOLO JGC             E AFR MED J                     54   565 977
     5   KASANEN A             ANN CLIN RES                    10     5 978
     6   COOKE DM              CHEMOTHERAPY                    25   356 979
     7   WILSON K              METH FIND EXP CLIN PHARMACOL     3   189 981
     8   GIDUMAL R             MT SINAI J MED                  48     7 981
     9   EVARD D               GASTROENTEROL CLIN BIOL          7   398 983
    10   GRIFFITH RS           POSTGRAD MED J                  59    16 983
    11   WELLING PG            CLIN PHARMACOKINET               9   404 984
    12   WELLING PG            J CLIN HOSP PHARM                9   163 984

PN 75090
RN 00256
AN 75114793
AU Roussel-P.  Lamblin-G.  Degand-P.
TI Heterogeneity of the carbohydrate chains of sulfated bronchial
   glycoproteins isolated from a patient suffering from cystic fibrosis.
SO J-Biol-Chem. 1975 Mar 25. 250(6). P 2114-22.
MJ CARBOHYDRATES: an.  CYSTIC-FIBROSIS: me.  GLYCOPROTEINS: an.
   SPUTUM:  an.  SULFATES: an.
MN ACETAMIDES: an.  AMINO-ACIDS: an.  BLOOD-GROUPS.  BOROHYDRIDES.
   GALACTOSE: an.  GLYCOPROTEINS: ip.  HUMAN.  NEURAMINIC-ACIDS: an.
   OLIGOSACCHARIDES: an.  SUPPORT-U-S-GOVT-P-H-S.
AB Sulfated glycoproteins having blood group H activity were isolated
   from the sputum of a child suffering from cystic fibrosis, by
   reduction of the fibrillar mucus, chromatography on ECTEOLA-
   cellulose, and gel filtration on Sepharose 4B. The sulfated
   glycoproteins were degraded with alkaline borohydride, and the
   degradation products were fractionated by chromatography on ion
   exchange resins and by gel filtration. The carbohydrate chains thus
   obtained have a wide heterogeneity with regard to acidity and
   molecular size. The neutral chains contain blood group H active
   oligosaccharides and incomplete chains as short as 1 residue of 2-
   acetamido-2-deoxy-D-galactose. The minimal size of the neuraminic
   acid-containing chains is less than that of the sulfated chains,
   which increases with the degree of sulfation. The sulfate groups are
   linked at C-6 at the D-galactose residues.
RF 001   BISERTE G             EXP ANNU BIOCHIM MED            24    85 963
   002   HAVEZ R               CLIN CHIM ACTA                  17   281 967
   003   HAVEZ R               EXP ANNU BIOCHIM MED            32   121 973
   004   HAVEZ R               CLIN CHIM ACTA                  17   463 967
   005   LAMB D                J PATHOL                        98   213 969
   006   DEGAND P              BIOCHIM BIOPHYS ACTA           320   318 973
   007   DEGAND P              CLIN CHIM ACTA                  50   223 974
   008   LAMBLIN G             BIOCHIM BIOPHYS ACTA           322   372 973
   009   ASSELAIN R            COLLOQ INT PATHOL THORAC LILL        101 968
   010   ROUSSEL P             COLLOQ INT PATHOL THORAC LILL        155 968
   011   LAMBLIN G             CLIN CHIM ACTA                  36   329 972
   012   ROUSSEL P             CLIN CHIM ACTA                  36   315 972
   013   REID L                MOD PROBL PEDIATR               10   195 967
   014   LEV R                 AM J PATHOL                     46    23 965
   015   LAMB D                COLLOQ INT PATHOL THORAC LILL        143 968
   016$  CRIMMIN WRC           J CHEM SOC                          2838 957
   017   LLOYD AG              BIOCHEM J                       83   455 962
   018   WALKER E              CARBOHYD RES                    35   270 974
   019   HAVEZ R               BULL SOC CHIM BIOL              51   245 969
   020   DEMAILLE J            BULL SOC CHIM FRANCE          1965  3506 965
   021   DUBOIS M              ANAL CHEM                       28   350 956
   022   AMINOFF D             BIOCHEM J                       81   384 961
   023   LAGUNOFF D            ARCH BIOCHEM BIOPHYS            99   396 962
   024   YAPHE W               ANAL CHEM                       32  1327 960
   025   SPENCER B             BIOCHEM J                       75   435 960
   026   SAMPSON P             PROC NAT ACAD SCI USA           68  2329 971
   027   HORTON D              IN: JEANLOZ RW                  1A    92 969
   028   REINHOLD VN           METHODS ENZYMOL                 25   244 972
   029   WOODS KR              BIOCHIM BIOPHYS ACTA           133   369 967
   030   CROS C                EUR J BIOCHEM                    7   463 969
   031   BOURRILLON R          BULL SOC CHIM BIOL              41   267 959
   032   MENZIES IS            IN: SMITH I                      1   310 969
   033   PARTRIDGE SM          BIOCHEM SOC SYMP                 3    52 949
   034   TREVELYAN WE          NATURE                         166   444 950
   035   PARTRIDGE SM          BIOCHEM J                       42   238 948
   036   POTTER JL             ANN NY ACAD SCI                106   692 963
   037   WATKINS WM            IN: GOTTSCHALK A                     830 972
   038   CARLSON DM            J BIOL CHEM                    241  2984 966
   039   BRAY BA               J BIOL CHEM                    242  3373 967
   040   KABAT EA              BIOCHEMISTRY                     4  1632 965
   041   ROVIS L               BIOCHEMISTRY                    12  1955 973
   042   CARLSON DM            J BIOL CHEM                    243   616 968
   043   BAIG MM               J BIOL CHEM                    247  6111 972
   044   ROVIS L               BIOCHEMISTRY                    12  5340 973
CT   1   LAFITTE JJ            LILLE MED                       20   798 975
     2   HOUDRET N             BIOCHIMIE                       57   603 975
     3   BOERSMA A             C R ACAD SCI (D)(PARIS)        281  1269 975
     4   LAFITTE JJ            C R ACAD SCI (D)(PARIS)        281  1901 975
     5   WILSON GB             SCAND J IMMUNOL                  5   828 976
     6   FORSTNER JF           PEDIATR RES                     10   609 976
     7   WU JT                 PEDIATR RES                     10   235 976
     8   SIMPSON DL            BIOCHEMISTRY                    15  5449 976
     9   LHERMITTE M           BIOCHIMIE                       58   367 976
    10   WOOD RE               AM REV RESPIR DIS              113   833 976
    11   NEWMAN W              ARCH BIOCHEM BIOPHYS           172   524 976
    12   MAISONROUGEMCAULIFFE  ARCH BIOCHEM BIOPHYS           175    81 976
    13   BOAT TF               ARCH BIOCHEM BIOPHYS           177    95 976
    14   SANTAGNESE PAD        N ENGL J MED                   295   481 976
    15   LAMBLIN G             BULL EUR PHYSIOPATH RESP        13   175 977
    16   LAFITTE JJ            CARBOHYD RES                    56   383 977
    17   LHERMITTE M           BIOCHIMIE                       59   611 977
    18   LAMBLIN G             CLIN CHIM ACTA                  79   425 977
    19   BARTON AD             PROC SOC EXP BIOL MED          156     8 977
    20   GALLAGHER JT          TRENDS BIOCHEM SCI               3    38 978
    21   FORSTNER JF           DIGESTION                       17   234 978
    22   CLAMP JR              BR MED BULL                     34    25 978
    23   PARTHASARATHY N       J SCI INDUSTR RES               37   305 978
    24   SUZUKI M              CLIN CHIM ACTA                  87   229 978
    25   ROUSSEL P             LUNG                           154   241 978
    26   SACHDEV GP            BIOCHIM BIOPHYS ACTA           536   184 978
    27   BOAT TF               ACS SYMPOSIUM SERIES          1978   108 978
    28   LAFITTE JJ            BULL EUR PHYSIOPATH RESP        15   667 979
    29   FELDHOFF PA           BIOCHEMISTRY                    18  2430 979
    30   ROSE MC               BIOCHEMISTRY                    18  4030 979
    31   LAMBLIN G             BIOCHIMIE                       61    23 979
    32   KAIZU T               COMP BIOCHEM PHYSIOL (B)        62   195 979
    33   LIAO TH               BIOCHIM BIOPHYS ACTA           577   442 979
    34   SACHDEV GP            BIOCHEM MED                     24    82 980
    35   ROUSSEL P             LILLE MED                       25   594 980
    36   BOAT TF               FED PROC                        39  3067 980
    37   LOPEZVIDRIERO MT      J COMP PATHOL                   90   415 980
    38   LAMBLIN G             J BIOL CHEM                    255  4595 980
    39   GALABERT C            CLIN RESP PHYSIOL               17   197 981
    40   LETREUT A             BIOCHIMIE                       63   425 981
    41   LHERMITTE M           CARBOHYD RES                    92   333 981
    42   BOERSMA A             CARBOHYD RES                    95   227 981
    43   SHERMAN JM            AM REV RESPIR DIS              124   476 981
    44   BHASKAR KR            J BIOL CHEM                    256  7583 981
    45   TABACHNIK NF          J BIOL CHEM                    256  7161 981
    46   HOUDRET N             BIOCHIM BIOPHYS ACTA           668   413 981
    47   LAINE A               BIOCHIM BIOPHYS ACTA           668   429 981
    48   HEIFETZ A             BIOCHEMISTRY                    21   171 982
    49   WOODWARD H            BIOCHEMISTRY                    21   694 982
    50   MAZZUCA M             J HISTOCHEM CYTOCHEM            30   956 982
    51   TURCK D               ARCH FR PEDIATR                 39   405 982
    52   BALDUYCK M            BIOCHEM BIOPHYS RES COMMUN     109  1247 982
    53   VANHALBEEK H          EUR J BIOCHEM                  127     7 982
    54   GALLAGHER JT          ADV EXP MED BIOL               144   335 982
    55   REID L                ADV EXP MED BIOL               144   369 982
    56   SLOMIANY A            BIOCHIM BIOPHYS ACTA           710   106 982
    57   REID L                EXP LUNG RES                     4   157 983
    58   SPICER SS             EXP LUNG RES                     4   137 983
    59   WARREN L              BIOMEMBRANES                    11    53 983
    60   FRATES RC             PEDIATR RES                     17    30 983
    61   BLOOMFIELD VA         BIOPOLYMERS                     22  2141 983
    62   BOERSMA A             CARBOHYD RES                   115   175 983
    63   CHACE KV              CLIN CHIM ACTA                 132   143 983
    64   LAMBLIN G             BIOCHEM SOC TRANS               12   599 984
    65   LLOYD C               IN VITRO                        20   416 984
    66   STELANDER M           EUR J RESPIR DIS                65     5 984
    67   SLAYTER HS            EUR J BIOCHEM                  142   209 984
    68   GUEANT JL             CLIN CHIM ACTA                 143   217 984
    69   LAMBLIN G             EUR J BIOCHEM                  143   227 984
    70   HARDING SE            BIOCHEM J                      219  1061 984
    71   LAMBLIN G             J BIOL CHEM                    259  9051 984
    72   BHASKAR KR            EXP LUNG RES                     9   289 985
    73   CHACE KV              BIOCHEMISTRY                    24  7334 985
    74   STOWELL CP            CARBOHYD RES                   151   279 986
    75   HOUDRET N             BIOCHIM BIOPHYS ACTA           880    54 986
    76   MAWHINNEY TP          J BIOL CHEM                    262  2994 987

PN 75091
RN 00257
AN 75170286
AU Lazarides-E.
TI Tropomyosin antibody: the specific localization of tropomyosin in
   nonmuscle cells.
SO J-Cell-Biol. 1975 Jun. 65(3). P 549-61.
MJ FIBROBLASTS: ul.  TROPOMYOSIN: ip.
MN ACTINS: im, ip.  ANTIBODY-FORMATION.  ANTIBODY-SPECIFICITY.
   CELL-LINE.  CHICKENS: im.  CHROMATOGRAPHY-DEAE-CELLULOSE.
   CYSTIC-FIBROSIS.  ELECTROPHORESIS-POLYACRYLAMIDE-GEL.
   FLUORESCENT-ANTIBODY-TECHNIC.  HUMAN.  MICE-INBRED-STRAINS: em.
   MICROSCOPY-FLUORESCENCE.  PERIODICITY.  RABBITS: im.  SKIN.
   TROPOMYOSIN: im.  SUPPORT-U-S-GOVT-P-H-S.  MICE.
AB An antibody against purified chicken skeletal muscle tropomyosin is
   used in indirect immunofluorescence to visualize the localization of
   tropomyosin in a variety of nonmuscle cells. The antibody produces a
   fluorescent pattern which is very similar to that obtained with an
   actin-specific antibody. This pattern is composed of fluorescent
   fibers which are shown to be coincident with the fibers seen with
   phase-contrast optics. High resolution epifluorescent microscopy
   reveals that fibers stained with the actin antibody show a continuous
   fluorescence, while fibers reacted with the tropomyosin antibody show
   a periodic fluorescence. Measurements indicate that the lengths of
   the fluorescent segments are variable with an average of 1.2 mum
   while the spacing between segments is approximately 0.4 mum.
RF 001   ALLERA A              CYTOBIOLOGIE                     6   261 972
   002   ANDERSEN CW           J VIROL                         12   241 973
   003   BEHNKE O              J ULTRASTRUCT RES               37   351 971
   004   BUCKLEY IK            PROTOPLASMA                     64   349 967
   005   COHEN I               J MOL BIOL                      68   383 972
   006   CUMMINS P             BIOCHEM J                      133   765 973
   007   CUMMINS P             BIOCHEM J                      141    43 974
   008   EBASHI S              PROG BIOPHYS MOL BIOL           18   123 968
   009   ENDO M                J BIOCHEM (TOKYO)               60   605 966
   010   FINE RE               NATURE NEW BIOL                245   182 973
   011   GOLDMAN RD            J CELL BIOL                     52   246 972
   012   GOLDMAN RD            COLD SPRING HARBOR SYMP QUANT   37   523 972
   013   GOLDMAN RD            EXP CELL RES                    90   333 975
   014   HUXLEY HE             J MOL BIOL                       7   281 963
   015   HUXLEY HE             HARVEY LECTURES                 60    85 966
   016   ISHIKAWA H            J CELL BIOL                     43   312 969
   017   LAEMMLI UK            NATURE                         227   680 970
   018   LAZARIDES E           PROC NAT ACAD SCI USA           71  4742 974
   019   LAZARIDES E           PROC NAT ACAD SCI USA           71  2268 974
   020   OHTSUKI I             J BIOCHEM (TOKYO)               61   817 967
   021   ORR TS                NATURE                         236   350 972
   022   PAGE SG               J CELL BIOL                     19   369 963
   023   PEPE FA               J CELL BIOL                     28   505 966
   024   POLLARD TD            IN: FASMAN GD                    2     1 974
   025   RASH JE               NATURE NEW BIOL                237   160 972
   026   SCHROEDER TE          Z ZELLFORSCH MIKROSK ANAT      109   431 970
   027   SPOONER BS            J CELL BIOL                     49   595 971
   028   SPUDICH JA            J BIOL CHEM                    246  4866 971
   029   SPUDICH JA            COLD SPRING HARBOR SYMP QUANT   37   585 972
   030   SPUDICH JA            J MOL BIOL                      72   619 972
   031   WEBER K               PROC NAT ACAD SCI USA           71  4561 974
   032   WESSELLS NK           SCIENCE                        171   135 971
   033   WOOLEY DE             ARCH BIOCHEM BIOPHYS           150   519 972
   034   YANG Y                J BIOL CHEM                    247  4503 972
CT   1   LAZARIDES E           CELL                             6   289 975
     2   HOLTZER H             Q REV BIOPHYS                    8   523 975
     3   AGOSTINI B            Z NATURFORSCH (C)               30   793 975
     4   WEBER K               EXP CELL RES                    95   111 975
     5   GROSCHELSTEWART U     CELL TISSUE RES                165    13 975
     6   BRETSCHER MS          NATURE                         258    43 975
     7   KORN ED               TRENDS BIOCHEM SCI               1    55 976
     8   GOLDMAN RD            J SUPRAMOL STRUCT                5   155 976
     9   LAZARIDES E           J SUPRAMOL STRUCT                5   531 976
    10   MILLER F              CLIN IMMUNOL IMMUNOPATHOL        5   416 976
    11   POLLARD TD            J SUPRAMOL STRUCT                5   317 976
    12   GASSNER G             DIFFERENTIATION                  7    39 976
    13   BOOTH AG              J CELL SCI                      21   449 976
    14   IZZARD CS             J CELL SCI                      21   129 976
    15   SCHEINMAN JI          LAB INVEST                      34   150 976
    16   GARANT PR             J PERIODONTOL                   47   380 976
    17   LAZARIDES E           J CELL BIOL                     68   202 976
    18   FUJIWARA K            J CELL BIOL                     71   848 976
    19   WEBER K               EXP CELL RES                   102   285 976
    20   BUCKLEY IK            J MICROSC                      107   129 976
    21   LAGENAUR C            J BACTERIOL                    128   435 976
    22   WOHLFARTHBOTTERMANN K CELL TISSUE RES                165   327 976
    23   ISENBERG G            CELL TISSUE RES                166   427 976
    24   EATON BL              SCIENCE                        192  1337 976
    25   NICOLSON GL           N ENGL J MED                   295   197 976
    26   HYNES RO              BIOCHIM BIOPHYS ACTA           458    73 976
    27   WILLINGHAM MC         CELL                            10   375 977
    28   STRAULI P             EUR J CANCER                    13     1 977
    29   KEENAN TW             CYTOBIOLOGIE                    14   259 977
    30   LOOR F                PROG ALLERGY                    23     1 977
    31   MUSSINI JM            PATHOL BIOL (PARIS)             25   477 977
    32   RUTTER G              J GEN VIROL                     37   233 977
    33   SILVERSTEIN SC        ANNU REV BIOCHEM                46   669 977
    34   VASILIEV JM           INT REV CYTOL                   50   159 977
    35   BRAY D                BIOCHIMIE                       59     1 977
    36   RUBENSTEIN PA         PROC NAT ACAD SCI USA           74   120 977
    37   ISHIURA M             J BIOCHEM                       82   105 977
    38   CHAMLEY JH            CELL TISSUE RES                177   445 977
    39   CHAMLEYCAMPBELL J     CELL TISSUE RES                183   153 977
    40   YANG YZ               J BIOL CHEM                    252  3374 977
    41   SANCHEZ G             MORFOL NORMAL PATOL (A)          2   119 978
    42   VARELA H              MORFOL NORMAL PATOL (A)          2   215 978
    43   TRIFARO JM            NEUROSCIENCE                     3     1 978
    44   GORDON WE             CELL                            13   249 978
    45   CARMON Y              CELL                            14   393 978
    46   OSBORN M              CELL                            14   477 978
    47   GRANGER BL            CELL                            15  1253 978
    48   WANG E                J HISTOCHEM CYTOCHEM            26   745 978
    49   HEATH JP              J CELL SCI                      29   197 978
    50   STOSSEL TP            ANNU REV MED                    29   427 978
    51   JOCKUSCH BM           HISTOCHEMISTRY                  55   177 978
    52   BAGBY RM              HISTOCHEMISTRY                  58   219 978
    53   LLEWELLYNSMITH IJ     DEVELOP BIOL                    67    40 978
    54   FUJIWARA K            J CELL BIOL                     77   182 978
    55   KREIBICH G            J CELL BIOL                     77   464 978
    56   BRETSCHER A           J CELL BIOL                     79   839 978
    57   GERACE L              J CELL BIOL                     79   546 978
    58   WANG E                J CELL BIOL                     79   708 978
    59   CORCES VG             EUR J BIOCHEM                   83   529 978
    60   ISHIMODATAKAGI T      J BIOCHEM                       83  1757 978
    61   BRETSCHER A           EXP CELL RES                   116   397 978
    62   GORDON WE             EXP CELL RES                   117   253 978
    63   WEBSTER RE            EXP CELL RES                   117    47 978
    64   WILLIAMSON DL         CURRENT MICROBIOL                2   143 979
    65   DIAZFLORES L          MORFOL NORMAL PATOL (A)          3    63 979
    66   AUNIS D               NEUROSCI LETT                   13    35 979
    67   MCMILLAN SA           CLIN IMMUNOL IMMUNOPATHOL       14   256 979
    68   OTTO JJ               CELL                            17   285 979
    69   DRIESSCHE TV          ANNEE BIOL                      18   417 979
    70   RATHKE PC             EUR J CELL BIOL                 19    40 979
    71   OSBORN M              EUR J CELL BIOL                 20    28 979
    72   ELFVIN MJ             J HISTOCHEM CYTOCHEM            27  1478 979
    73   CAMPBELL GR           J CELL SCI                      37   303 979
    74   WEHLAND J             J CELL SCI                      37   257 979
    75   YOUNG RB              J ANIMAL SCI                    48   837 979
    76   CHAMLEYCAMPBELL J     PHYSIOL REV                     59     1 979
    77   GARRELS JI            DEVELOP BIOL                    73   134 979
    78   FERAMISCO JR          PROC NAT ACAD SCI USA           76  3967 979
    79   GOLDMAN RD            J CELL BIOL                     80   759 979
    80   WILLARD M             J CELL BIOL                     81   581 979
    81   YOUNG RB              J CELL BIOL                     81   115 979
    82   LESSARD JL            ANAL BIOCHEM                    94   140 979
    83   HILLER G              VIROLOGY                        98   142 979
    84   ISHIMODATAKAGI T      EXP CELL RES                   119   423 979
    85   ZIGMOND SH            EXP CELL RES                   119   205 979
    86   GORDON WE             EXP CELL RES                   120   335 979
    87   WYLIE CC              EXP CELL RES                   121   315 979
    88   KLEVE MG              J EXP ZOOL                     209    21 979
    89   YAMAUCHI T            J BIOL CHEM                    254  6408 979
    90   FEUCHTER FA           UROL RES                         8   139 980
    91   KELLEY RO             MECH AGEING DEV                 13   127 980
    92   GROSCHELSTEWART U     EUR J CANCER                    16     2 980
    93   UMEDA PK              BIOCHEMISTRY                    19  1955 980
    94   ALLEN RE              EUR J CELL BIOL                 21   247 980
    95   WEHLAND J             EUR J CELL BIOL                 21   188 980
    96   GODMAN G              EUR J CELL BIOL                 22   745 980
    97   GODMAN G              EUR J CELL BIOL                 22   733 980
    98   KREIS TE              CELL                            22   555 980
    99   WYLIE CC              BIOSCIENCE                      30    27 980
   100   LUTZ H                CANCER RES                      40  3642 980
   101   LEMANSKI LF           J EMBRYOL EXP MORPHOL           55     1 980
   102   SMALL JV              INT REV CYTOL                   64   241 980
   103   BAGBY RM              HISTOCHEMISTRY                  69   113 980
   104   HODGE AJ              J ULTRASTRUCT RES               70   220 980
   105   BYERS HR              PROC NAT ACAD SCI USA           77  6657 980
   106   RACHUBINSKI RA        J CELL BIOL                     84   705 980
   107   BRETSCHER A           J CELL BIOL                     86   335 980
   108   SANGER JM             J CELL BIOL                     86   568 980
   109   SCHLOSS JA            J CELL BIOL                     87   633 980
   110   BRITCH M              EXP CELL RES                   125   221 980
   111   RAMAEKERS FCS         EXP CELL RES                   127   309 980
   112   WEHLAND J             EXP CELL RES                   127   397 980
   113   OSBORN M              EXP CELL RES                   129   103 980
   114   PAULIN D              J MOL BIOL                     144    95 980
   115   MANJULA BN            J EXP MED                      151   695 980
   116   ABERCROMBIE M         PROC R SOC LOND (B)            207   129 980
   117   FRANKO MC             J NEUROIMMUNOL                   1   391 981
   118   MOSS M                MOL CELL BIOL                    1   289 981
   119   GOMER RH              CELL                            23   524 981
   120   DEBUS E               EUR J CELL BIOL                 24    45 981
   121   KALNINS VI            EUR J CELL BIOL                 24    36 981
   122   WEHLAND J             EUR J CELL BIOL                 24   176 981
   123   BIRCHMEIER W          COLD SPRING HARBOR SYMP Q BIO   46   755 981
   124   BLOSE SH              COLD SPRING HARBOR SYMP Q BIO   46   455 981
   125   FRANK ED              PROC NAT ACAD SCI USA           78  3020 981
   126   HENDRICKS M           PROC NAT ACAD SCI USA           78  5633 981
   127   DHANARAJAN ZC         DEVELOP BIOL                    82   317 981
   128   PENG HB               DEVELOP BIOL                    88   121 981
   129   ALLEN RD              J CELL BIOL                     91  S148 981
   130   MELYGOUBERT B         J IMMUNOL                      127   399 981
   131   BRITCH M              EXP CELL RES                   131   161 981
   132   KOENIG CS             EXP CELL RES                   131   319 981
   133   NELSON GA             EXP CELL RES                   131   149 981
   134   HILLER G              EXP CELL RES                   132    81 981
   135   BRETSCHER A           EXP CELL RES                   135   213 981
   136   COTE GP               J BIOL CHEM                    256  7257 981
   137   GIOMETTI CS           J BIOL CHEM                    256  1840 981
   138   KEEN JH               J BIOL CHEM                    256  2538 981
   139   LETOURNEAU PC         J NEUROSCI                       2   806 982
   140   DOMINGUEZ C           MORFOL NORMAL PATOL (B)          6   157 982
   141   LAZARIDES E           METH CELL BIOL                  24   313 982
   142   OSBORN M              METH CELL BIOL                  24    97 982
   143   HILLER G              J VIROL                         44   647 982
   144   ALLORE RJ             CAN J BIOCHEM                   60    57 982
   145   YAHARA I              J CELL BIOL                     92    69 982
   146   BYERS HR              J CELL BIOL                     93   804 982
   147   OHASHI K              J CELL BIOL                     95    85 982
   148   WEBER K               PATHOL RES PRACT               175   128 982
   149   RABINOWITZ SS         J BIOL CHEM                    257  3291 982
   150   GENY B                BIOCHIM BIOPHYS ACTA           692   345 982
   151   LEVINE AM             CLIN ORTHOP                   1982   240 982
   152   DABROWSKA R           J MUSCLE RES CELL MOTIL          4    83 983
   153   FATTOUM A             BIOCHEMISTRY                    22  1187 983
   154   OSBORN M              EUR J CELL BIOL                 29   179 983
   155   SANGER JW             EUR J CELL BIOL                 31   197 983
   156   ITO Y                 J VIROL                         48   709 983
   157   COTE GP               MOL CELL BIOCHEM                57   127 983
   158   GABBIANI G            PROC NAT ACAD SCI USA           80  2361 983
   159   KOBAYASHI R           J BIOCHEM                       94   171 983
   160   SANGER JW             J CELL BIOL                     96   961 983
   161   LEMANSKI LF           DEVELOP BIOL                    97   338 983
   162   NAGELE RG             EXP CELL RES                   143   153 983
   163   TALBOT K              J MOL BIOL                     164   159 983
   164   MACLEOD AR            J MOL BIOL                     167   523 983
   165   MATSUMURA F           J BIOL CHEM                    258  6636 983
   166   LAZARIDES E           CURR CONTENTS LIFE SCIENCES   1983    19 983
   167   HENDRICKS M           MOL CELL BIOL                    4  1823 984
   168   MASUDA H              CELL MOTIL                       4   315 984
   169   KNOX P                MOL ASP MED                      7   177 984
   170   PAYNE MR              TRENDS BIOCHEM SCI               9   361 984
   171   LANGANGER G           J SUBMICROSC CYTOL              16    43 984
   172   SHARPE AH             COMPR VIROL                     19   431 984
   173   SCEBAT L              ATHEROSCLEROSIS                 51   269 984
   174   OWADA MK              PROC NAT ACAD SCI USA           81  3133 984
   175   LIN JJC               J CELL BIOL                     98   116 984
   176   LANGANGER G           J CELL BIOL                     99  1324 984
   177   SANGER JW             J CELL BIOL                     99   918 984
   178   GOLDMAN JE            BRAIN RES                      106    85 984
   179   FOWLER VM             J BIOL CHEM                    259  5978 984
   180   BENZEEV A             BIOCHIM BIOPHYS ACTA           780   197 984
   181   WAHRMAN MZ            TUMOUR BIOL                      6    41 985
   182   WARREN RH             EUR J CELL BIOL                 38   245 985
   183   LIM SS                CAN J BIOCHEM CELL BIOL         63   470 985
   184   BRETSCHER A           J CELL BIOL                    100  1656 985
   185   MURAMATSU H           DEVELOP BIOL                   110   284 985
   186   BURGOYNE RD           FEBS LETTERS                   179    25 985
   187   KREISBERG JI          AM J PHYSIOL                   249  F227 985
   188   YAMASHIROMATSUMURA S  J BIOL CHEM                    260  5087 985
   189   BURGOYNE RD           BRAIN RES                      361   178 985
   190   CANDE WZ              CELL MOTIL CYTOSKELETON          6   640 986
   191   KARLIK CC             MOL CELL BIOL                    6  1965 986
   192   GUEST JF              ELECTROPHORESIS                  7   512 986
   193   BRETT JG              TISSUE CELL                     18   175 986
   194   DOBROWOLSKI Z         EUR J CELL BIOL                 41    65 986
   195   JOST E                BIOL CELL                       57   111 986
   196   SHIRAKATA M           COMP BIOCHEM PHYSIOL (B)        85    71 986
   197   AMATO PA              J CELL BIOL                    102  1074 986
   198   ANTIN PB              J CELL BIOL                    102  1464 986
   199   LANGANGER G           J CELL BIOL                    102   200 986
   200   GRAIN J               INT REV CYTOL                  104   153 986
   201   IIDA K                EXP CELL RES                   164   492 986
   202   BROSCHAT KO           J BIOL CHEM                    261  3350 986
   203   TAMM SL               CELL MOTIL CYTOSKELETON          7   116 987
   204   MIZUSHIMA Y           BIOMED RES                       8    73 987
   205   GALLOWAY PG           J NEUROPATHOL EXP NEUROL        46   185 987
   206   MACLEOD AR            J MOL BIOL                     194     1 987
   207   HALLAUER PL           J BIOL CHEM                    262  3590 987

PN 75092
RN 00258
AN 76095429
AU Warwick-W-J.  Pogue-R-E.  Gerber-H-U.  Nesbitt-C-J.
TI Survival patterns in cyctic fibrosis.
SO J-Chronic-Dis. 1975 Dec. 28(11-12). P 609-22.
MJ CYSTIC-FIBROSIS: mo.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: co, oc.  DISEASES-IN-TWINS.  FEMALE.  HUMAN.  INFANT.
   INFANT-NEWBORN.  INTESTINAL-OBSTRUCTION: co.  LIFE-EXPECTANCY.
   LONGITUDINAL-STUDIES.  MALE.  MECONIUM: me.  RACIAL-STOCKS.
   REGISTRIES.  SEX-FACTORS.  TWINS-DIZYGOTIC.  TWINS-MONOZYGOTIC.
   UNITED-STATES.
AB This paper describes the Data Registry System of the Cystic Fibrosis
   Foundation.  Through this system an annual up-dated and corrected
   data base has been prepared for cystic fibrosis patients seen at
   U.S.A. Centers from 1966 through 1972.  From the data base, a large
   number of life table studies are calculated.  A study is specified
   by its data base, the observation period, analysis age (age year or
   year since diagnosis), the Centers included, and the condition of
   patients at birth, and possible additional factors such as sex, age
   at diagnosis, or race.  The annual rates of mortality are measured
   by a force of mortality technique.  Two techniques have been used to
   appraise the mortality of particular groups, graphing the cumulative
   survival function for the group together with the cumulative
   survival function for a comparative group, and calculation of
   mortality ratios of actual to expected deaths (by an applicable
   standard mortality table).  This latter approach lends itself
   readily to tests of significance.  For the purpose of calculating
   mortality ratios, two standard tables have been prepared on the
   basis of the 1972 Data Base and the 1966-1972 observations.  The
   first of these standard tables is for use with age year studies, and
   the second is for years since diagnosis studies.  The paper comments
   on the number of mortality studies by calendar year, by sex, by
   condition at birth, by age at diagnosis, and of survival from
   diagnosis of patients diagnosed in 1966-1972.  The calendar year
   studies indicate an improvement trend in the survival experience
   from 1966 to 1972 but a change may be occurring.  The study by sex
   exhibits a higher female mortality.  The 7% of patients who have
   meconium ileus at birth show a significantly higher first-year
   mortality, and a somewhat lower survival rate thereafter even if the
   first year of life experience is excluded.  Mortality data for
   groups specified by age at diagnosis are given.  For patients
   diagnosed during 1966-1972, there is some indication of better
   survival than for patients diagnosed prior to 1966.  The
   continuation of these mortality studies on an annual basis should
   further our understanding of survival patterns for cystic fibrosis
   patients.
RF 001   WARWICK WJ            J ASTHMA RES                     5   277 968
   002   WARWICK WJ            IN: LAWSON D PROC 5TH INT CF         320 969
   003   SHWACHMAN H           PEDIATRICS                      46   335 970
   004   WECK FA               REC AM INST ACTUARIES           36    23 947
CT   1   HOIBY N               ACTA PATH MICROBIOL SCAND (C) S262     3 977
     2   BURDICK AB            HUM HERED                       27   366 977
     3   KRAEMER R             HELV PAEDIATR ACTA              32   107 977
     4   KRAEMER R             SCHWEIZ MED WOCHENSCHR         107   271 977
     5   KRAEMER R             SCHWEIZ MED WOCHENSCHR         107  1105 977
     6   LHEUREUX PR           AM J ROENTGENOL                128   953 977
     7   WARWICK WJ            JAMA                           238  2159 977
     8   KRAEMER R             ACTA PAEDIATR SCAND             67    33 978
     9   GURWITZ D             PEDIATR CLIN NORTH AM           26   603 979
    10   SANTAGNESE PAD        AM J MED                        66   121 979
    11   ANON                  CAN MED ASSOC J                121  1193 979
    12   COHEN LF              LANCET                           2   842 980
    13   JONES MB              J CHRON DIS                     33   697 980
    14   HUBBARD VS            AM J DIS CHILD                 134   317 980
    15   STERN RC              AM J DIS CHILD                 134   267 980
    16   ELEJALDE BR           REV BRASIL GENET                 5   409 982
    17   STAFFORD RJ           CLIN GASTROENTEROL              11   141 982
    18   KANG SB               ANESTH ANALG CLEVE              61   793 982
    19   LIMACHER F            SCHWEIZ MED WOCHENSCHR         112   264 982
    20   TUMMLER B             MONATSSCHR KINDERHEILKD        130   157 982
    21   SINNEMA G             ACTA PAEDIATR SCAND             72   427 983

PN 75093
RN 00259
AN 75151860
AU Murad-F.  Moss-W-W.  Johanson-J.  Selden-R-F.
TI Urinary excretion of adenosine 3',5'-monophosphate and guanosine
   3',5'-monophosphate in normal children and those with cystic
   fibrosis.
SO J-Clin-Endocrinol-Metab. 1975 Apr. 40(4). P 552-9.
MJ ADENOSINE-CYCLIC-MONOPHOSPHATE: ur.  CYSTIC-FIBROSIS: ur.
   GUANOSINE-CYCLIC-MONOPHOSPHATE: ur.
MN ADOLESCENCE.  AGE-FACTORS.  BODY-SURFACE-AREA.  BODY-WEIGHT.  CHILD.
   CHILD-PRESCHOOL.  COMPARATIVE-STUDY.  CREATININE: ur.
   DIURNAL-RHYTHM.  FEMALE.  HUMAN.  MALE.  SUPPORT-U-S-GOVT-P-H-S.
AB The urinary excretion of adenosine 3',5'-monophosphate (cyclic AMP)
   and guanosine 3',5'-monophosphate (cyclic GMP) was examined in 98
   normal children and 46 children with cystic fibrosis between the ages
   of 9 months and 18 yr. Diurnal variations in cyclic AMP and cyclic
   GMP excretion were observed in subjects from either group, and peak
   levels of cyclic nucleotide excretion were generally observed during
   the period of 0700 to 2100 h. Excretion rates (mumol/day) of cyclic
   AMP and cyclic GMP increased significantly with age. When cyclic AMP
   and cyclic GMP excretion rates were normalized for urinary creatine,
   or body weight, the values declined significantly with age in both
   groups of patients. Cyclic GMP excretion normalized for body surface
   area also decreased with age, while the value for cyclic AMP (2.86
   plus or minus 0.08 mumol/day/m2, mean plus or minus SE) was constant
   with age in both normals and cystic fibrosis children. With some
   comparisons of age groups there were significant differences in
   cyclic nucleotide excretion between normal subjects and children with
   cystic fibrosis. The differences noted were dependent upon the
   methods used to normalize excretion rates (urinary creatine, body
   weight, surface area, and the ratio of cyclic AMP to cyclic GMP
   excreted). In general patients with cystic fibrosis excreted greater
   amounts of cyclic GMP than did normals. The most striking comparison
   was the ratio of cyclic AMP to cyclic GMP excreted which was 9.09
   plus or minus 0.50 in all normal children and 4.41 plus or minus 0.32
   in children with cystic fibrosis (P smaller than 0.001).
RF 001   MURAD F               ADV CYCLIC NUCLEO RES            3   355 973
   002   CHASE LR              J CLIN INVEST                   48  1832 969
   003   KAMINSKY NI           J CLIN INVEST                   49  2387 970
   004   MURAD F               N ENGL J MED                   286  1382 972
   005   AUGUST GP             J CLIN ENDOCRINOL METAB         37   476 973
   006   BERNSTEIN RA          J LAB CLIN MED                  80   772 972
   007   LINARELLI LG          PEDIATRICS                      50    14 972
   008   TSANG CP              J CLIN ENDOCRINOL METAB         35   809 972
   009   SIMOPOULOS AP         PROC AM PEDIATR SOC ANNU MTG         201 971
   010   GOLDBERG ND           ADV CYCLIC NUCLEO RES            3   155 973
   011   MOSS WW               CLIN RES                             45A 973
   012   GILMAN AG             PROC NAT ACAD SCI USA           67   305 970
   013   MURAD F               PROC NAT ACAD SCI USA           68   736 971
   014   STEINER AL            J BIOL CHEM                    247  1114 972
   015   BONSNES RW            J BIOL CHEM                    158   581 945
   016   SAGEL J               J CLIN ENDOCRINOL METAB         37   570 973
   017   BROADUS AE            J CLIN INVEST                   49  2222 970
   018   BALL JH               J CLIN INVEST                   51  2124 972
   019   HARDMAN JG            J BIOL CHEM                    244  6354 969
CT   1   ROOF BS               MECH AGEING DEV                  5   289 976
     2   CRISS WE              CANCER RES                      36  1714 976
     3   VITEK V               J CLIN ENDOCRINOL METAB         42   781 976
     4   VITEK V               CLIN CHIM ACTA                  70   227 976
     5   DISANTAGNESE PA       N ENGL J MED                   295   597 976
     6   BROADUS AE            ADV CYCLIC NUCLEO RES            8   509 977
     7   GOLDBERG ND           ANNU REV BIOCHEM                46   823 977
     8   PERLOW MJ             BRAIN RES                      126   391 977
     9   DAVIS PB              CLIN CHIM ACTA                  87   285 978
    10   WAALER PE             HORM RES                        11   318 979
    11   SACK J                ISR J MED SCI                   15   937 979
    12   BUCHWALD M            ADV CYCLIC NUCLEO RES           12   243 980
    13   REINHARDT D           INT J CLIN PHARMACOL THER TOX   18   399 980
    14   MARKOVAC J            BIOCHEM MED                     26   299 981
    15   KRUSE K               J CLIN ENDOCRINOL METAB         53  1251 981
    16   SATO T                CLIN CHIM ACTA                 110   215 981
    17   MOUGIN C              C R SOC BIOL (PARIS)           176   319 982
    18   THODE J               SCAND J CLIN LAB INVEST         45   185 985

PN 75094
RN 00260
AN 76025431
AU Zierdt-C-H.  Williams-R-L.
TI Serotyping of Pseudomonas aeruginosa isolates from patients with
   cystic fibrosis of the pancreas.
SO J-Clin-Microbiol. 1975 Jun. 1(6). P 521-6.
MJ CROSS-INFECTION: mi.  CYSTIC-FIBROSIS: mi.  CROSS-INFECTION: mi.
   PSEUDOMONAS-AERUGINOSA: cl.  SEROTYPING: mt.
MN AGGLUTINATION-TESTS.  BIOLOGICAL-PRODUCTS: bi.
   PSEUDOMONAS-AERUGINOSA: me.  SPECIES-SPECIFICITY.
AB Pseudomonas aeruginosa isolates (173) from 144 patients with cystic
   fibrosis (CF) of the pancreas in seven hospitals were serotyped with
   the agglutination systems of Homma (1974) and Fisher et al. (1969).
   The two systems were complementary. Strains from CF patients were
   much less likely to furnish a stable type on repetitive typing tests
   than strains from other patients. This was related to the frequent
   occurrence of mucoid P. aeruginosa strains. The 173 strains were
   divided among 11 Homma serotypes. A single Homma type (type 8)
   capable of mucoid growth comprised 104 (60%) CF strains. Eight
   serotypes were detected in 77 strains from 48 CF patients in one
   hospital; three strains were detected in one hospital CF unit; and
   two strains were detected in each of five hospital CF units. The CF
   serotype comprised from 50 to 93% of CF strains in the seven
   hospitals. These P. aeruginosa strains dissociated in vivo as judged
   by mucoid and nonmucoid colonies on primary culture plates and
   continued to dissociate during subcultures. Both colony type were the
   same serotype. The tendency to regard colonial phenotypes (mucoid,
   nonmucoid, rough) as separate strains was erroneous. Repetitive
   typing with the two systems gave better results than a single system.
   The mucoid P. aeruginosa strain is probably spread from patient to
   patient, rather than acquiring its mucoid characteristic de novo in
   the CF patient. It is not known why the mucoid CF strain has a
   peculiar predilection for CF patients, nor why it generally loses the
   quality in culture but retains it indefinitely in the patient.
RF 001   CETIN ET              J BACTERIOL                     89  1432 965
   002   CHADWICK P            CAN J MICROBIOL                 18  1153 972
   003   DOGGETT RG            APPL MICROBIOL                  18   936 969
   004   ELSTON HR             AM J CLIN PATHOL                48   519 967
   005   FISHER MW             J BACTERIOL                     98   835 969
   006   GOTO S                JAPAN J MICROBIOL               15   317 971
   007   HOMMA JY              JAPAN J EXP MED                 44     1 974
   008   HOMMA JY              JAPAN J EXP MED                 42   171 972
   009   HOMMA JY              JAPAN J EXP MED                 41    89 971
   010   JONES LF              APPL MICROBIOL                  27   400 974
   011   KAWAHARAJO K          JAPAN J EXP MED                 43   225 973
   012   SHIONOYA H            JAPAN J EXP MED                 38    81 968
   013   ZIERDT CH             J BACTERIOL                     87  1003 964
CT   1   WALLACE R             REV CAN BIOL                    35    87 976
     2   VERON M               BULL INSTITUT PASTEUR           74   295 976
     3   REYNOLDS HY           JAMA                           236  2190 976
     4   DISANTAGNESE PA       N ENGL J MED                   295   597 976
     5   HOIBY N               ACTA PATH MICROBIOL SCAND (C) S262     3 977
     6   HIRAO Y               JAP J EXP MED                   47   249 977
     7   HOIBY N               SCAND J RESPIR DIS              58    65 977
     8   MARKOWITZ SM          INFECT IMMUN                    22   530 978
     9   KULCZYCKI LL          JAMA                           240    30 978
    10   SEALE TW              J CLIN MICROBIOL                 9    72 979
    11   THOMASSEN MJ          J INFECT DIS                   140   873 979
    12   WOODS DE              INFECT IMMUN                    30   694 980
    13   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   88   125 980
    14   BALTIMORE RS          J INFECT DIS                   141   238 980
    15   REYNOLDS HY           CLIN CHEST MED                   2   103 981
    16   FICK RB               J CLIN INVEST                   68   899 981
    17   PENNINGTON JE         J CLIN INVEST                   68  1140 981
    18   MACONE AB             N ENGL J MED                   304  1445 981
    19   KELLY NM              LANCET                           2   688 982
    20   PUGASHETTI BK         J CLIN MICROBIOL                16   686 982
    21   SPEERT DP             J PEDIATR                      101   227 982
    22   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    33 982
    23   ANON                  LANCET                           2   257 983
    24   FICK RB               BULL EUR PHYSIOPATH RESP        19   151 983
    25   BOYD RL               INFECT IMMUN                    39  1403 983
    26   HANCOCK REW           INFECT IMMUN                    42   170 983
    27   JOHNSON SR            OBSTET GYNECOL                  61  S  2 983
    28   BUCKMIRE FLA          MICROBIOS                       41    49 984
    29   FICK RB               J CLIN INVEST                   74   236 984
    30   FICK RB               AM REV RESPIR DIS              129    76 984
    31   HANCOCK REW           J INFECT DIS                   149   220 984
    32   PEDERSEN SS           ACTA PAEDIATR SCAND             75   840 986
    33   SPEERT DP             J HOSP INFECT                    9    11 987
    34   ANASTASSIOU ED        J CLIN MICROBIOL                25   656 987
    35   KOMIYAMA K            CAN J MICROBIOL                 33   221 987
    36   OGLE JW               J INFECT DIS                   155   119 987

PN 75095
RN 00261
AN 75212529
AU Green-M.  Mascia-A-V.  Behrendt-H.
TI The source of Na+ and Cl- activities on the skin surface.
   Experiences with electrode measurements in children.
SO J-Lab-Clin-Med. 1975 Sep. 86(3). P 494-8.
MJ CHLORIDES: an.  SKIN: an.  SODIUM: an.  SWEAT: an.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS.
   ELECTRODES.  HUMAN.  INFANT.  INFANT-NEWBORN.  MALE.
AB We have used ion-specific electrodes in an attempt to map the sodium
   and chloride activities on the skin under differing surface
   conditions. The range of values and the standard deviations are so
   wide that a baseline for the untreated dry skin is precluded. In
   patients with cystic fibrosis, a wide range of values is also found.
   For this group, measurements on dry skin taken immediately after
   washing were in the same low range as for healthy subjects. The range
   of measurements on the dry skin of newborn infants was similar for
   full-term infants with reactive sweat glands and for premature
   infants who failed to show sweating responsiveness to natural reflex
   stimulation as well as local glandular stimulation with sudorific
   drugs. For only two conditions have measurements of sodium and
   chloride activities on the surface of the skin been of value: (1) on
   the sweat-covered skin for the detection of the high values
   encountered in cystic fibrosis, and (2) on the dry skin surface,
   deprived of autonomic innervation (spinal paraplegia), extremely low
   sodium and chloride activities reflect absent gland activity.
RF 001   GOLDBLOOM RB          N ENGL J MED                   269  1349 963
   002   SEKELJ P              IN: EINSENMAN G                      540 967
   003   WARWICK WJ            PEDIATRICS                      36   261 965
   004   HANSEN L              AM J CLIN PATHOL                49   834 968
   005   GREEN M               CLIN CHEM                       18   427 972
   006   DAHMS H               CLIN CHEM                       14   859 968
   007   SULZBERGER MB         ARCH DERMATOL                   81   235 960
   008   KOPITO L              PEDIATRICS                      43   794 969
   009   JONES JD              MAYO CLIN PROC                  45   768 970
   010   KENNEY JF             MATH OF STAT PART ONE                256 954
   011   SECKENDORF R          J APPL PHYSIOL                  16   796 961
   012   BEHRENDT H            AM J DIS CHILD                 117   299 969
   013   BEHRENDT H            N ENGL J MED                   286  1376 972
CT   1   ANJO DM               BR J DERMATOL                  105    39 981

PN 75096
RN 00262
AN 75152611
AU Pacharee-P.
TI Fibrocystic disease of the pancreas: a case report.
SO J-Med-Assoc-Thai. 1975 Feb. 58(2). P 110-2.
MJ CYSTIC-FIBROSIS: pa.
MN HUMAN.  INFANT.  MALE.
EX An autopsy case of cystic fibrosis of the pancreas in a 2-month-old
   Thai male infant is reported.  The patient suffered from chronic
   repeated lung infection and died of lung disease.  This case seems to
   be the first reported case in Thailand.
RF 001   DI SANTAGNESE PA      IN: NELSON WE                        856 969
   002   ANDERSEN DH           AM J DIS CHILD                  56   344 938

PN 75097
RN 00263
AN 75191915
AU Adinolfi-A.  Adinolfi-M.  Lessof.
TI Alpha-feto-protein during development and in disease.
SO J-Med-Genet. 1975 Jun. 12(2). P 138-51.
MJ ALPHA-FETOPROTEINS.  FETAL-PROTEINS.
MN ALPHA-FETOPROTEINS: an, me, ph.  AMNIOTIC-FLUID: an.
   ANENCEPHALY: me.  ANIMAL.  ANTIGEN-ANTIBODY-REACTIONS.
   CONCANAVALIN-A: pd.  CYSTIC-FIBROSIS: me.  DOWNS-SYNDROME: me.
   FEMALE.  GASTROINTESTINAL-NEOPLASMS: me.  GESTATIONAL-AGE.
   HEPATITIS: me.  HEPATOMA: me.  HUMAN.  IMMUNOLOGIC-TECHNICS.
   INFANT-NEWBORN.  LIVER: cy.  METABOLISM-INBORN-ERRORS: me.   
   NEOPLASM-METASTASIS.  NEOPLASMS-EXPERIMENTAL: me.  PREGNANCY.
   SPINA-BIFIDA: me.  TERATOMA: me.
AB An alpha-feto-protein (AFP) is present in many mammals, in birds, and
   in sharks during development. The AFP present in different species
   have similar physicochemical properties and often have common
   antigenic determinants. Their study, both in health and disease, has
   provided a useful model for the understanding of other phase-specific
   antigens and the activation of the genes which control their
   synthesis. In the human fetus, the level of AFP falls with increasing
   maturity. The more sensitive methods of detection have disclosed that
   this fetal protein persists in trace amounts throughout life and its
   level increases in maternal blood during pregnancy. The principal
   sites of synthesis are the fetal liver and in some mammals, the yolk
   sac splanchnopleur. In humans as well as in mice and cows, it is
   notable that the synthesis of AFP is increased in liver cancer cells
   and that high levels of this protein are present in serum. Elevated
   values of AFP have also been detected in human subjects with
   undifferentiated tumours of the testis and ovary. A fall to normal
   levels has been noted in cases of complete remission after surgery
   and a return to high levels in patients who develop metastases. In
   some patients with hepatitis a temporary rise in the level of AFP has
   also been observed. In recent years, the detection of high levels of
   AFP in amniotic fluid has proved to be of great value for the
   prenatal diagnosis of neural-tube defects. Abnormal levels have also
   been found in the amniotic fluid or in maternal serum in cases of
   spontaneous abortion. Such measurements are now being assessed as a
   method of monitoring abnormal pregnancy.
RF 001   ABELEV GI             PROG EXP TUMOR RES               7   104 965
   002   ABELEV GI             CANCER RES                      28  1344 968
   003   ABELEV GI             ADV CANCER RES                  14   295 971
   004   ABELEV GI             NEOPLASMA                       20   563 973
   005   ABELEV GI             INT J CANCER                     2   551 967
   006   ABELEV GI             IN: MASSEYEFF R                      141 974
   007   ABELEV GI             TRANSPLANTATION                  1   174 963
   008   ADAMSON RH            IN: ANDERSON NG                  2   331 972
   009   ADINOLFI A            RICERCA                          1   316 971
   010   ADINOLFI A            BIOCHIM BIOPHYS ACTA           251   197 971
   011   ADINOLFI M            IN: BENSON PF                        224 971
   013   ADINOLFI M            DEVELOP MED CHILD NEUROL         9   609 967
   014   ADINOLFI M            ATTI ASSOC GENETICA ITALIANA    12   133 967
   015   ADINOLFI M            PROC INT SYMP IMMUN REPRO 2ND        558 973
   016   AKEYAMA T             N ENGL J MED                   287   989 972
   017   ALEXANDER P           NATURE                         235   137 972
   018   ALLAN LD              LANCET                           2   522 973
   019   ALPERT E              LANCET                           1   626 974
   020   ALPERT E              ANN NY ACAD SCI                209   387 973
   021   ALPERT E              GASTROENTEROLOGY                61   137 971
   022   ALPERT E              N ENGL J MED                   278   984 968
   023   ALPERT E              LANCET                           2   465 970
   024   ALPERT ME             CLIN RES                        17   461 969
   025   ALPERT ME             AM J MED                        46   794 969
   026   ANDERSON NG           IN: ANDERSON NG                  1     7 971
   027   ANDERSON NG           IN: ANDERSON NG                  2   361 972
   028   ANDREOLI M            J CLIN INVEST                   41  1070 962
   029   ANDRIEU J             PRESSE MED                      79  1595 971
   030   ANSSEL C              IN: MASSEYEFF R                       17 974
   031   BAGSHAWE A            LANCET                           2   268 970
   032   BAKIROV RD            BULL EXP BIOL MED               65    45 968
   033   BALLAS M              AM J CLIN PATHOL                57   511 972
   034   BELANGER L            PATHOL BIOL (PARIS)             21   457 973
   035   BELANGER L            PATHOL BIOL (PARIS)             21   449 973
   036   BELANGER L            IN: MASSEYEFF R                          974
   037   BELANGER L            CLIN CHIM ACTA                  48    15 973
   038   BERGSTRAND CG         SCAND J CLIN LAB INVEST          8   174 956
   039   BERGSTRAND CG         SCAND J CLIN LAB INVEST          9   277 957
   040   BERGSTRAND CG         ACTA PAEDIATR SCAND             61   128 972
   041   BERNADES P            PRESSE MED                      79  1585 971
   042   BODMAN J              CLIN CHIM ACTA                   4   103 959
   043   BOURREILLE J          PRESSE MED                      78  1277 970
   044   BRANCH WR             INT J CANCER                    10   451 972
   045   BRANCH WR             Z ZELLFORSCH                   135   501 972
   046   BROCK DJH             LANCET                           2   923 973
   047   BROCK DJH             LANCET                           2  1252 972
   048   BROCK DJH             LANCET                           1   569 974
   049   BROCK DJH             LANCET                           2   197 972
   050   BUFFE D               GANN MOGR CANCER RES            14   117 973
   051   BUFFE D               BIOMEDICINE                     19   172 973
   052   BURTIN P              BULL SOC CHIM BIOL              49  1389 967
   053   CHANDRA RK            ARCH DIS CHILD                  48   157 973
   054   CHANDRA RK            BR MED J                         1   714 975
   055   ECONOMOPOULOS P       LANCET                           1  1337 970
   056   ENDO Y                KANZO                           10   143 969
   057   ENGELHARDT NV         INT J CANCER                     7   198 971
   058   ENGELHARDT NV         BULL EXP BIOL MED               65    62 969
   059   FLORIN-CHRISTENSEN A  CLIN EXP IMMUNOL                16   599 974
   060   FOLI AK               LANCET                           2  1267 969
   061   FOY H                 LANCET                           2   663 970
   062   FOY H                 LANCET                           1   411 970
   063   FOY H                 NATURE                         225   952 970
   064   FOY H                 LANCET                           1  1336 970
   065   VAN FURTH R           NATURE                         222  1296 969
   066   GALDO A               ARCH FR PEDIATR                 16   954 959
   067   GAROFF L              J OBSTET GYNAECOL BR COMMONW    80   695 973
   068   GEFFROY Y             SEM HOP PARIS                   47  1281 971
   069   GEFFROY Y             PRESSE MED                      78  1107 970
   070   GITLIN D              IN: MASSEYEFF R                       55 974
   071   GITLIN D              J CLIN INVEST                   45  1826 966
   072   GITLIN D              J CLIN INVEST                   46  1010 967
   073   GITLIN D              COMPAR BIOCHEM BIOL             21   327 967
   074   GITLIN D              BIOCHIM BIOPHYS ACTA           147   334 967
   075   GITLIN D              NATURE                         228   995 970
   076   GITLIN D              CANCER RES                      32   979 972
   077   GOUSSEV AI            INT J CANCER                     7   207 970
   078   HALBRECHT I           NATURE                         178   794 956
   079   HARRIS R              LANCET                           1   429 974
   080   HIRAI H               GANN MOGR CANCER RES            14    19 973
   081   HIRSZFELD L           Z IMMUNITATS EXP THER           75   209 932
   082   HULL EW               J NATL CANCER INST              42  1035 969
   083   HULL EW               LANCET                           1   779 970
   084   HULL EW               CLIN RES                        17   403 969
   085   HULL EW               IN: ANDERSON NG                  2   317 972
   086   HYVARINEN M           J PEDIATR                       82   430 973
   087   KARLSSON BW           ACTA PAEDIATR SCAND             61   133 972
   088   KARVOUNTZIS GG        ANN INTERN MED                  80   156 974
   089   KEKOMAKI M            INT J CANCER                     8   250 971
   090   KITHIER K             IN: ANDERSON NG                  2   351 972
   091   KITHIER K             NATURE                         212   414 966
   092   KITHIER K             BIOCHIM BIOPHYS ACTA           160   135 968
   093   KOHN J                J CLIN PATHOL                   23   733 970
   094   KRESNO SB             LANCET                           1  1178 970
   095   KRESNO SB             PROTIDES BIOL FLUIDS            18   243 971
   096   KROES R               CANCER RES                      32  1526 972
   097   LARDINOIS R           CLIN CHIM ACTA                  37    81 972
   098   LAURELL CB            ANAL BIOCHEM                    15    45 966
   099   LIN TY                SCAND J GASTROENTEROL SUPPL      6   223 970
   100   MARKLEIN G            Z KINDERHEILK                  113   327 972
   101   MARX JL               SCIENCE                        183  1279 974
   102   MASOPUST J            INT J CANCER                     3   364 968
   103   MASOPUST J            ANN PAEDIATR                   204   138 965
   104   MASOPUST J            PROTIDES BIOL FLUIDS            18   239 971
   105   MASOPUST J            PROTIDES BIOL FLUIDS            18    37 971
   106   MASOPUST J            PROTIDES BIOL FLUIDS            18    63 971
   107   MASSEYEFF R           PATHOL BIOL (PARIS)             20   703 972
   108   MASSEYEFF R           RICERCA                          3    27 973
   109   MASSEYEFF R           IN: MASSEYEFF R                      313 974
   110   MASSEYEFF R           BULL SOC MED AFRIQUE NOIRE      13   537 968
   111   MAWAS C               LANCET                           1  1292 970
   112   MAWAS C               REV EUR ETUD CLIN BIOL          16   430 971
   113   MAWAS C               INT J CANCER                     4    76 969
   114   MURALT G DE           HELV PAEDIATR ACTA              16   517 961
   115   MURGITA RA            J EXP MED                      141   269 975
   116   MURGITA RA            J EXP MED                      141   440 975
   117   NECHAUD B DE          INT J CANCER                     8    71 971
   118   NECHAUD B DE          INT J CANCER                    11   104 973
   119   NECHAUD B DE          PRESSE MED                      77  1945 969
   120   NEVIN NC              LANCET                           1  1383 973
   121   NISHI S               CANCER RES                      30  2507 970
   122   NISHI S               PROTIDES BIOL FLUIDS            18    43 971
   123   NISHI S               GANN MOGR CANCER RES            14    79 973
   124   NISHI S               J IMMUNOL                      109   957 972
   125   NORGAARD-PEDERSEN B   CLIN CHIM ACTA                  48   345 973
   126   OCONOR GT             CANCER                          25  1091 970
   127   OKON E                BR J CANCER                     27   362 973
   128   OLOVNIKOV AM          BULL EXP BIOL MED               68   102 969
   129   PEDERSEN K            NATURE                         154   575 944
   130   PEROVA SD             BULL EKSPRE BIOL MEDIT          71    45 971
   131   PORTUGAL ML           INT J CANCER                     6   383 970
   132   PREHN RT              IN: TRENTIN JJ                       105 967
   133   PREHN RT              IN: MIHICH E                         265 967
   134   PURVES LR             CANCER                          25  1261 970
   135   PURVES LR             S AFR MED J                     44   590 970
   136   PURVES LR             LANCET                           1  1007 973
   137   PURVES LR             CANCER                          31   578 973
   138   PURVES LR             S AFR MED J                     42  1138 968
   139   ROBERTS JAF           INTRO MEDICAL GENETICS                   970
   140   RUOSLAHTI E           INT J CANCER                     7   218 971
   141   RUOSLAHTI E           IN: ANDERSON NG                  2   345 972
   143   SELLER MJ             LANCET                           2    73 973
   144   SELLER MJ             LANCET                           1   428 974
   145   SEPPALA M             INT J FERTIL                    18   206 973
   146   SEPPALA M             OBSTET GYNECOL                  42   613 973
   148   SEPPALA M             AM J OBSTET GYNECOL            112   208 972
   149   SEPPALA M             J PERINATAL MED                  1   104 973
   150   SEPPALA M             AM J OBSTET GYNECOL            115    48 973
   151   SEPPALA M             ANN MED EXP BIOL FENNIAE        45    16 967
   152   SIMONS MJ             LANCET                           1  1234 974
   153   SMITH CJ              BIOCHIM BIOPHYS ACTA           317   231 973
   154   SMITH JB              INT J CANCER                     8   421 971
   155   SWARTZ SK             IN: MASSEYEFF R                       97 974
   156   TATARINOV YS          VOPR MED KHIM                   10    90 964
   157   TATARINOV YS          VOPR MED KHIM                   10   584 964
   158   URIEL J               NATURE NEW BIOL                244   190 973
   159   URIEL J               BIOCHEM BIOPHYS RES COMMUN      46  1175 972
   160   URIEL J               C R ACAD SCI (D)(PARIS)        265    75 967
   161   URIEL J               PRESSE MED                      76  1415 968
   162   WALD NJ               BR MED J                         1   651 975
   163   WALD NJ               LANCET                           1   765 974
   164   WALDMANN TA           LANCET                           2  1112 972
   165   WARD AM               LANCET                           2   345 974
   166   WARNOCK ML            CLIN CHIM ACTA                  24     5 969
   167   WATABE H              CANCER RES                      31  1192 971
   168   ZELTZER PM            LANCET                           1   373 974
   169   ZIMMERMAN EF          BIOCHEM J                      134   807 973
   170   ZIZKOVSKY V           IN: MASSEYEFF R                      125 974
CT   1   SELL S                J NATL CANCER INST              60    19 978
     2   CZOKALO M             EXP PATHOL (JENA)               17   176 979
     3   SCHLAGER SI           J NATL CANCER INST              70   753 983
     4   ROSENTHAL SR          BULL INSTITUT PASTEUR           81    55 983
     5   SELL S                DEVELOP BRAIN RES               22    49 985
     6   FUHRMANN W            HUM GENET                       69    47 985
     7   BARFORD DA            AM J OBSTET GYNECOL            151  1038 985
     8   WONG LT               J CHROMATOGR                   341   452 985
     9   STAPLES J             LANCET                           2  1277 986

PN 75098
RN 00264
AN 76146441
AU Danes-B-S.
TI The search for relevant cell culture research in cystic fibrosis:
   one researcher's opinion.
SO J-Med-Genet. 1975 Dec. 12(4). P 405-7.
MJ CELLS-CULTURED.  CYSTIC-FIBROSIS: pa.  RESEARCH.
MN CELL-LINE.  CYSTIC-FIBROSIS: fg.  HUMAN.
EX Recently there has been a plethora of research approaches using cell
   culture to study cystic fibrosis.  Although these efforts can be
   lauded as attempts to understand one of the most common genetic
   disorders affecting the Caucasian population, such research should be
   relevant to the clinical entity known as cystic fibrosis.  The
   ultimate objectives of this research should be to determine the, as
   yet unknown, basic defect and to develop an assay for heterozygote
   detection.
RF 001   BARTMAN J             J PEDIATR                       76   430 970
   002   BOWMAN BH             PROC NAT ACAD SCI USA           70   548 973
   003   BOWMAN BH             SCIENCE                        164   325 969
   004   CAUDILL M             LANCET                           1    32 974
   005   CONOVER JH            PEDIATR RES                      7   224 973
   006   CONOVER JH            PEDIATR RES                      7   220 973
   007   CONOVER JH            LANCET                           1  1122 973
   008   CONOVER JH            LANCET                           2  1501 973
   009   DANES BS              BIRTH DEF ORIG ART SER           8   114 972
   010   DANES BS              LANCET                           2   765 973
   011   DANES BS              BIOCHEM GENET                   12   359 974
   012   DANES BS              LANCET                           2   437 969
   013   DANES BS              J EXP MED                      129   775 969
   014   DANES BS              BIOCHEM BIOPHYS RES COMMUN      36   919 969
   015   DANES BS              J EXP MED                      136  1313 972
   016   FARBER S              J MICH MED SOC                  44   587 945
   017   GIBSON LE             LANCET                           2   189 970
   018   HOUCK JC              PROC SOC EXP BIOL MED          135   369 970
   019   JOHANSEN PG           LANCET                           1   455 968
   020   MATALON R             BIOCHEM BIOPHYS RES COMMUN      33   954 968
   021   NADLER HL             LANCET                           2    84 969
   022   PALLAVICINI JC        J PEDIATR                       77   280 970
   023   RENNERT OM            IN: MANGOS JA                         41 973
   024   ROBERTSON JA          LANCET                           1  1256 974
   025   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   026   SPOCK A               PEDIATR RES                      1   173 967
   027   WOOD RE               LANCET                           2  1452 973
CT   1   JAKEL HP              BIOL ZENTRALBL                  98    55 979

PN 75099
RN 00265
AN 76097649
AU Govan-J-R.
TI Mucoid strains of Pseudomonas aeruginosa: the influence of culture
   medium on the stability of mucus production.
SO J-Med-Microbiol. 1975 Nov. 8(4). P 513-22.
MJ CULTURE-MEDIA.  MUCUS: se.  PSEUDOMONAS-AERUGINOSA: me.
MN ACETYLCYSTEINE: pd.  CETRIMONIUM-COMPOUNDS: pd.  CITRATES: pd.
   CYSTIC-FIBROSIS: mi.  DEOXYCHOLIC-ACID: pd.  FERRIC-COMPOUNDS: pd.
   HUMAN.  LACTOSE: pd.  PHOSPHATIDYLCHOLINES: pd.  NEUTRAL-RED: pd.
   POLYSORBATES: pd.  PSEUDOMONAS-AERUGINOSA: gd, ip.
   SODIUM-DODECYL-SULFATE: pd.  SPECIES-SPECIFICITY.
   SURFACE-ACTIVE-AGENTS: pd.  THIOSULFATES: pd.
AB Mucoid strains of Pseudomonas aeruginosa isolated from the
   respiratory tract of patients with cystic fibrosis (CF), those
   obtained from non-CF patients, and those obtained in vitro by the
   action of phage, were found to be stable in their mucoid colonial
   form when serially subcultured on deoxycholate-citrate agar. The
   ability of anionic, cationic and neutral surfactants to stabilise
   mucus production is described. The possible importance of dipalmitoyl
   lecithin as a stabilising agent for mucus production in vivo is
   considered, with particular reference to the role of mucoid P.
   aeruginosa in CF disease.
RF 001   BROWN ES              AM J PHYSIOL                   207   402 964
   002   BURNS MW              LANCET                           1   270 968
   003   DIAZ F                J INFECT DIS                   121   269 970
   004   DOGGETT RG            APPL MICROBIOL                  18   936 969
   005   DOGGETT RG            IN: LAWSON D PROC 5TH INT CF         175 969
   006   DOGGETT RG            J PEDIATR                       68   215 966
   007   DOGGETT RG            J BACTERIOL                     87   427 964
   008   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   81   298 973
   009   IACOCCA VF            AM J DIS CHILD                 106   315 963
   010   KELLY M               J GEN MICROBIOL                 27   305 962
   011   KUENZIG MC            J APPL PHYSIOL                  20   779 965
   012   MARTIN DR             J MED MICROBIOL                  6   111 973
   013   SCHWARZMANN S         INFECT IMMUN                     3   762 971
   014   STANISICH V           GENETICS                        61   327 969
   015   STANISICH V           GENET RES CAMB                  13    57 969
   016   SUTHERLAND IW         J GEN MICROBIOL                 39   373 965
   017   THANNHAUSER SJ        J BIOL CHEM                    166   669 946
   018   WILLIAMS RJ           J MED MICROBIOL                  6   409 973
   019   ZIERDT CH             J BACTERIOL                     87  1003 964
CT   1   VERON M               BULL INSTITUT PASTEUR           74   295 976
     2   HOIBY N               ACTA PATH MICROBIOL SCAND (C) S262     3 977
     3   BROWN MRW             J ANTIMICROB CHEMOTHER           3   198 977
     4   JONES SE              J PHARMACY PHARMACOL            29  P 69 977
     5   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   85   107 977
     6   GOVAN JRW             J ANTIMICROB CHEMOTHER           4   233 978
     7   MARKOWITZ SM          INFECT IMMUN                    22   530 978
     8   MIAN FA               J BACTERIOL                    134   418 978
     9   MARESZBABCZYSZYN J    ARCH IMMUNOL THER EXP           27   585 979
    10   HOLLOWAY BW           MICROBIOL REV                   43    73 979
    11   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   87   229 979
    12   GOVAN JRW             J GEN MICROBIOL                110   229 979
    13   MARRIE TJ             J INFECT DIS                   139   357 979
    14   THOMASSEN MJ          J INFECT DIS                   140   873 979
    15   BOYCE JR              LANCET                           2   268 980
    16   CHENG KJ              CAN J MICROBIOL                 26  1104 980
    17   LAM J                 INFECT IMMUN                    28   546 980
    18   RUHEN RW              J CLIN PATHOL                   33  1221 980
    19   FYFE JAM              J GEN MICROBIOL                119   443 980
    20   COSTERTON JW          CRC CRIT REV MICROBIOL           8   303 981
    21   IRVIN RT              ANTIMICROB AGENTS CHEMOTHER     19  1056 981
    22   CHENG KJ              CAN J MICROBIOL                 27   461 981
    23   OHMAN DE              INFECT IMMUN                    33   142 981
    24   COSTERTON JW          ANNU REV MICROBIOL              35   299 981
    25   GOVAN JRW             J GEN MICROBIOL                125   217 981
    26   MACONE AB             N ENGL J MED                   304  1445 981
    27   BAKER NR              CURRENT MICROBIOL                7    35 982
    28   PUGASHETTI BK         J CLIN MICROBIOL                16   686 982
    29   BOYCE JR              INFECT IMMUN                    37   840 982
    30   BOYCE JR              INFECT IMMUN                    37   695 982
    31   CHAN R                INFECT IMMUN                    37  1170 982
    32   OHMAN DE              INFECT IMMUN                    37   662 982
    33   JARRELL KF            J INVERTEBRATE PATHOL           39   395 982
    34   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    33 982
    35   COSTERTON JW          REV INFECT DIS                   5  S867 983
    36   OMBAKA EA             REV INFECT DIS                   5  S880 983
    37   COSTERTON JW          PROG FOOD NUTR SCI               7    91 983
    38   OLIVER AM             J CLIN LAB IMMUNOL              10   221 983
    39   HACKING AJ            J GEN MICROBIOL                129  3473 983
    40   COSTERTON JW          REV INFECT DIS                   6  S608 984
    41   MORRISON AJ           REV INFECT DIS                   6  S627 984
    42   KEREN G               J INFECT                         9    22 984
    43   GRISTINA AG           ORTHOP CLIN NORTH AM            15   517 984
    44   CHAN R                J CLIN MICROBIOL                19     8 984
    45   MILLER RV             J CLIN MICROBIOL                19   717 984
    46   COSTERTON JW          DEVELOP IND MICROBIOL           25   363 984
    47   CHAN R                CAN J MICROBIOL                 30   451 984
    48   LAMBE DW              CAN J MICROBIOL                 30   809 984
    49   MESHULAM T            CLIN IMMUNOL IMMUNOPATHOL       32   151 984
    50   MAYBERRYCARSON KJ     INFECT IMMUN                    43   825 984
    51   MILLS J               INFECT IMMUN                    43   359 984
    52   HANSEN JB             APPL ENVIRON MICROBIOL          47   704 984
    53   CUTRI SS              J APPL BACT                     57   291 984
    54   DARZINS A             J BACTERIOL                    159     9 984
    55   LINKER A              J BACTERIOL                    159   958 984
    56   MARRIE TJ             J CLIN MICROBIOL                22   924 985
    57   COSTERTON JW          DEVELOP IND MICROBIOL           26   249 985
    58   FERRIS FG             BIOSCIENCE                      35   172 985
    59   MARCUS H              INFECT IMMUN                    47   723 985
    60   TAJIMA M              JAP J VET SCI                   47   217 985
    61   SHABTAI Y             APPL ENVIRON MICROBIOL          49   192 985
    62   LUZAR MA              INFECT IMMUN                    50   577 985
    63   GRISTINA AG           J BONE JOINT SURG              67A   264 985
    64   DARZINS A             J BACTERIOL                    161   249 985
    65   OHMAN DE              J BACTERIOL                    162  1068 985
    66   GRISTINA AG           SCIENCE                        228   990 985
    67   MACGEORGE J           J MED MICROBIOL                 21   331 986
    68   KRIEG DP              J CLIN MICROBIOL                24   986 986
    69   MAYBERRYCARSON KJ     MICROBIOS                       48   189 986
    70   SHABTAI Y             APPL ENVIRON MICROBIOL          52   146 986
    71   REED WP               SURGERY                         99   308 986
    72   BANERJEE PC           ARCH MICROBIOL                 145   408 986
    73   DERETIC V             J BACTERIOL                    165   510 986
    74   DERETIC V             BIO TECHNOL                      5   469 987
    75   ANASTASSIOU ED        J CLIN MICROBIOL                25   656 987
    76   DERETIC V             J BACTERIOL                    169   351 987

PN 75100
RN 00266
AN 75171532
AU Oppenheimer-E-H.  Esterly-J-R.
TI Hepatic changes in young infants with cystic fibrosis: possible
   relation to focal biliary cirrhosis.
SO J-Pediatr. 1975 May. 86(5). P 683-9.
MJ CYSTIC-FIBROSIS: pa.  LIVER-CIRRHOSIS-BILIARY: et.  LIVER: pa.
MN AGE-FACTORS.  AUTOPSY.  BILE-DUCTS-INTRAHEPATIC: pa.
   CHOLESTASIS:  et, pa.  CYSTIC-FIBROSIS: co.  HUMAN.  INFANT.
   INFANT-NEWBORN.  LIVER-CIRRHOSIS-BILIARY: pa.  MALE.  MUCUS.
AB Focal biliary cirrhosis is an uncommon finding in infants with cystic
   fibrosis, but it is present in more than a fifth of surviving
   children and adolescents. It was found at postmortem examination in
   only five of 47 infants with CF younger than 3 months, in five of 32
   infants from 3 to 12 months, and in 18 of 67 children older than 1
   year. In infants under 3 months, excessive mucus in intrahepatic bile
   ducts was seen in 11 necropsies; in 15 others there were only
   nonspecific periportal changes. Cholestasis was found in the livers
   of 18 of the 26 infants. Excessive mucus in the biliary tree was
   occasionally associated with periportal changes and cholestasis in
   older infants. The periportal changes, which are regarded as
   nonspecific, were never found in infants more than 1 year of age.
RF 001   BODIAN M              FIBROCYSTIC DIS OF THE PANCRE            952
   002   DI SANTAGNESE PA      PEDIATRICS                      18   387 956
   003   CRAIG JM              AM J DIS CHILD                  93   357 957
   004   GRAND RJ              CLIN PEDIATR                     9   588 970
   005   KOPEL FB              GASTROENTEROLOGY                62   483 972
   006   BERNSTEIN JG          AM J DIS CHILD                  99   804 960
   007   HOLSCLAW DS           AM J DIS CHILD                 109   101 965
   008   GATZIMOS CD           AM J DIS CHILD                  89   182 955
   009   TALAMO RC             AM J DIS CHILD                 115    74 968
   010   VALMAN HB             ARCH DIS CHILD                  46   805 971
   011   JEAN R                ARCH FR PEDIATR                 27   849 970
   012   TAYLOR WF             AM J DIS CHILD                 123   161 972
   013   TOULOUKIAN RJ         ARCH SURG                      106    58 973
   014   RAGER R               AM J PATHOL                     74    6A 974
   015   SHIER KJ              CAN MED ASSOC J                 89   645 963
   016   MUECKE D              DTSCH GESUNDHEITSW              27  1723 972
   017   ROSCHLAU G            DTSCH GESUNDHEITSW              27  1722 972
CT   1   SHWACHMAN H           PEDIATR CLIN NORTH AM           22   787 975
     2   WALKER WA             PEDIATR CLIN NORTH AM           22   929 975
     3   ISENBERG JN           AM J GASTROENTEROL              65   134 976
     4   JAVITT NB             GASTROENTEROLOGY                70  1172 976
     5   STERN RC              GASTROENTEROLOGY                70   645 976
     6   SCHUSTER SR           J PEDIATR SURG                  12   201 977
     7   MATHIS RK             J PEDIATR                       90   864 977
     8   ROSENSTEIN BJ         J PEDIATR                       91  1022 977
     9   ROY CC                N ENGL J MED                   297  1301 977
    10   SCHWARZ HP            HELV PAEDIATR ACTA              33   351 978
    11   BUTS JP               J PEDIATR                       92   729 978
    12   VITULLO BB            J PEDIATR                       93  1060 978
    13   STARKEY BJ            MONOGR PAEDIATR                 10    12 979
    14   FINBERG L             N ENGL J MED                   300   420 979
    15   CUNNINGHAM DG         J COMPUT ASSIST TOMOGR           4   151 980
    16   ARBORGH B             SCAND J GASTROENTEROL           15    73 980
    17   DAVIDSON GP           J CLIN PATHOL                   33   390 980
    18   GORIUP U              HELV PAEDIATR ACTA              35   177 980
    19   MIELIVERGANI G        ARCH DIS CHILD                  55   696 980
    20   BALISTRERI WF         J PEDIATR                       97   689 980
    21   WILLI UV              AM J ROENTGENOL                134  1005 980
    22   PARK RW               GASTROENTEROLOGY                81  1143 981
    23   LLOYDSTILL JD         J PEDIATR                       99   580 981
    24   ROY CC                J PEDIATR GASTROENTEROL NUTR     1   469 982
    25   MOWAT AP              CLIN GASTROENTEROL              11   171 982
    26   STAFFORD RJ           CLIN GASTROENTEROL              11   141 982
    27   GASKIN KJ             PEDIATR RES                     16   554 982
    28   CHOW CW               EUR J PEDIATR                  139   240 982
    29   ROSENSTEIN BJ         JOHNS HOPKINS MED J            150   113 982
    30   SPIVAK W              J PEDIATR GASTROENTEROL NUTR     2   381 983
    31   SCHWARTZ AM           J COMPUT ASSIST TOMOGR           7   530 983
    32   WATSON S              CLIN PEDIATR                    22    30 983
    33   DOHERTY DE            SOUTH MED J                     76  1580 983
    34   PERKINS WG            CLIN PEDIATR                    24   107 985
    35   ROBB TA               GUT                             26  1246 985
    36   FEIGELSON J           ANN PEDIATR (PARIS)             32   218 985
    37   HULTCRANTZ R          HEPATOLOGY                       6   881 986
    38   KING A                PEDIATR RES                     20   536 986
    39   TANNER MS             J ROY SOC MED                   79    38 986
    40   MCHUGO JM             BR J RADIOL                     60   137 987

PN 75101
RN 00267
AN 75153056
AU Scanlin-T-F.  Shapiro-R-S.  Rosenlund-M-L.
TI Letter: Vocal cord paralysis in cystic fibrosis.
SO J-Pediatr. 1975 Jun. 86(6). P 984-5.
MJ CYSTIC-FIBROSIS: co.  VOCAL-CORD-PARALYSIS: et.
MN ADOLESCENCE.  COUGH: pp.  CYSTIC-FIBROSIS: rh.  HUMAN.
   HYPERTROPHY:  ra.  MALE.  POLYTETRAFLUOROETHYLENE: tu.
   TOMOGRAPHY-X-RAY.  SUPPORT-U-S-GOVT-NON-P-H-S.
   VOCAL-CORD-PARALYSIS: ra.  VOCAL-CORDS:  ra.
EX Many conditions have been reported to cause vocal cord paralysis.
   To our knowledge cystic fibrosis has not been described as one of
   these conditions.  A 15-year-old white male with cystic fibrosis,
   who has been treated at our hospital, reported hoarseness of two
   week's duration on a routine clinic visit in March, 1973.  In March,
   1974, mirror laryngoscopy revealed a paralysis of the left vocal
   cord in the paramedian position, consistent with paralysis of the
   left recurrent laryngeal nerve.  It is felt that the vocal cord
   paralysis in this patient with cystic fibrosis is due to compression
   of the left recurrent laryngeal nerve by an enlarged pulmonary artery.
RF 001   DEDO HH               LARYNGOSCOPE                    80  1455 970
   002   DEDO HH               ANN OTOL RHINOL LARYNGOL        82   661 973

PN 75102
RN 00268
AN 75213258
AU Desor-J-A.  Maller-O.
TI Taste correlates of disease states: cystic fibrosis.
SO J-Pediatr. 1975 Jul. 87(1). P 93-6.
MJ CYSTIC-FIBROSIS: co.  TASTE-DISORDERS: et.
MN ADOLESCENCE.  CHILD.  CHILD-PRESCHOOL.  COMPARATIVE-STUDY.  FEMALE.
   HUMAN.  MALE.  PANCREAS: pa.  SODIUM-CHLORIDE: du.  TASTE-BUDS: pp.
   TASTE-DISORDERS: di.  SUPPORT-U-S-GOVT-P-H-S.
EX The purpose here was to test for a generalized abnormal sensitivity
   of the external chemoreceptive systems using a standardized method
   that separates sensory activity from biasing factors known to affect
   measurement of sensitivity.  The frequency distributions of salt
   taste sensitivity for patients with cystic fibrosis are given.
   Normal siblings and control patients did not differ statistically,
   and they were combined into a single control group for analyses.  The
   patients with cystic fibrosis did not differ as a group from the
   normal subjects in salt sensitivity.  There were, however, two
   children with cystic fibrosis with taste sensitivities well below
   those observed among the normal children.  No age or sex differences
   in sensitivity were observed.  The taste sensitivity of the children
   with cystic fibrosis did not correlate with the Shwachman and
   Kulczycki rating of the severity of their disease.  Of the seven
   children who had determinations of sweat electrolytes at the time of
   taste testing, three failed to excrete sufficient amounts for
   measurements.  Patients with cystic fibrosis, as a group, were not
   found to have more sensitive taste acuity than normal.  This
   corroborates the findings of Wotman and associates and strongly
   suggests that a general abnormality of the taste system is not
   routinely symptomatic of cystic fibrosis.  Henkin and Powell
   hypothesized that extremely acute taste is related to elevations in
   the concentration of electrolytes in sweat.  This seems unlikely
   since the patients given sweat tests in the present study all had the
   high levels of sodium and chloride characteristic of cystic fibrosis,
   yet all had taste sensitivities in the normal range.  Wotman and
   associates suggested that perhaps the severity of the disease
   accounts for the appearance of hypersensitivity in the chemoreceptive
   systems.  The clinical ratings of the severity of the disease did not
   correlate with taste sensitivity.
RF 001   HENKIN RI             SCIENCE                        138  1107 962
   002   WOTMAN S              AM J DIS CHILD                 108   372 964
   003   MANLAPAS FC           J PEDIATR                       66     8 965
   004   BLAKESLEE AF          PROC NAT ACAD SCI USA           18   120 932
   005   BARNICOT NA           ANN EUGEN                       16   119 951
   006   COOMBS CH             MATH PSYCHOL                         165 970
   007   SHWACHMAN H           AM J DIS CHILD                  96     6 958
CT   1   BARTOSHUK LM          AM J CLIN NUTR                  31  1068 978
     2   BURGE JC              KIDNEY INT                      15    49 979
     3   RUSSELL RM            ANN INTERN MED                  99   227 983
     4   SCHIFFMAN SS          N ENGL J MED                   308  1275 983
     5   WEIFFENBACH JM        CHEM SENSES                      9   193 984

PN 75103
RN 00269
AN 75078947
AU Baig-M-M.  Cetorelli-J-J.  Roberts-R-M.
TI Plasma membrane components of skin fibroblasts from normal
   individuals and patients with cystic fibrosis.
SO J-Pediatr. 1975 Jan. 86(1). P 72-6.
MJ CELL-MEMBRANE: an.  CYSTIC-FIBROSIS: pa.  FIBROBLASTS: ul.
   GLYCOPROTEINS: an.  PROTEINS: an.  SKIN: cy.
MN BIOPSY.  CARBON-RADIOISOTOPES.  CATTLE.  CELL-LINE.
   CELL-MEMBRANE: ul, ip.  CENTRIFUGATION.  CHILD.  CHILD-PRESCHOOL.   
   CYSTIC-FIBROSIS: me.  ELECTROPHORESIS-POLYACRYLAMIDE-GEL.
   FIBROBLASTS: gd.  FUCOSE: me.  GLUCOSAMINE: me.  HETEROZYGOTE.
   HUMAN.  LEUCINE: me.  SKIN: pa.  TRITIUM.  SUPPORT-U-S-GOVT-P-H-S.
AB Plasma membranes have been isolated without proteolytic modification
   from fibroblast lines derived from patients with CF, from
   heterozygous parents, and from normal children. The cells had been
   grown in the presence of 3H- OR 14C- labeled L-leucine, D-
   glucosamine, and L-fucose. Membranes were mixed in suitable
   combinations to allow comparisons to be made between the different
   cell types. No differences in the plasma membrane composition, as
   revealed by divergence in 3H- or 14C-profiles, could be detected
   after gel electrophoresis. Identical protein and glycoprotein
   components were present in approximately similar amounts in all
   groups of cells;
RF 001   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   002   LOBECK CC             IN: STANBURY JB                     1605 972
   003   GUGLER EC             J PEDIATR                       71   585 967
   004   GIBSON LE             PEDIATRICS                      48   695 971
   005   BARTMAN J             J PEDIATR                       76   430 970
   006   DANES BS              BIOCHEM BIOPHYS RES COMMUN      36   919 969
   007   DANES BS              J EXP MED                      129   775 969
   008   DANES BS              NATURE                         222   685 969
   009   FITZPATRICK DF        NATURE NEW BIOL                235   173 972
   010   MATALON R             BIOCHEM BIOPHYS RES COMMUN      33   954 968
   011   NADLER HL             LANCET                           2    84 969
   012   PALLAVICINI JC        J PEDIATR                       77   280 970
   013   RENNERT OM            IN: MANGOS JA                         41 973
   014   RENNERT OM            CLIN PEDIATR                    11   351 972
   015   PITOT HC              PROC SYMP MOLE BASIS HUM              14 972
   016   BARLAND P             J CELL BIOL                     45   662 970
   017   WEBER K               J BIOL CHEM                    244  4406 969
   018   TURNER JC             INT J APPL RADIAT ISOTOP        19   557 968
CT   1   CHANGUS JE            AM J PATHOL                     80   317 975
     2   CHOU L                PEDIATR RES                     10   176 976
     3   DANES BS              TEX REP BIOL MED                34   135 976
     4   WARD JB               TEX REP BIOL MED                34    11 976
     5   CHANGUS JE            ARCH PATHOL LAB MED            100     7 976
     6   WOOD RE               AM REV RESPIR DIS              113   833 976
     7   SANTAGNESE PAD        N ENGL J MED                   295   481 976
     8   YOKOYAMA M            PEDIATR RES                     11   765 977
     9   QUISSELL DO           ANAL BIOCHEM                    79   240 977
    10   OWEN E                J MOL MED                        3   203 978
    11   PENA SDJ              PEDIATR RES                     12   887 978
    12   PEARSON RD            PEDIATR RES                     13   834 979
    13   JAKEL HP              BIOL ZENTRALBL                  98    55 979
    14   BAIG MM               CIRC RES                        46   651 980
    15   MALER T               BIOCHIM BIOPHYS ACTA           598     1 980
    16   HARRIS A              CLIN CHIM ACTA                 128    41 983
    17   KARLSSON S            J MED GENET                     21   441 984

PN 75104
RN 00270
AN 76047850
AU Bang-F-B.
TI Comparative pathology of marine invertebrates and the study of human
   disease.
SO J-Pediatr. 1975 Dec. 87(6 PT 2). P 1062-6.
MJ MARINE-BIOLOGY.  MODELS-BIOLOGICAL.
MN ANIMAL.  ARACHNIDA: mi.  CLAMS: me.  CRABS: im.  CYSTIC-FIBROSIS: me.
   HUMAN.  MUCUS: se.  OYSTERS: me.  STARFISH: im.
EX Studies on an infection with gram-negative bacteria in Limulus led to
   the discovery of the extreme sensitivity of the amebocytes to a
   gram-negative endotoxin.  This led to the development of a method for
   measuring very small amounts of endotoxin in biologic fluids and in
   human blood.  Yet, had the original observation of Cantacuzene on the
   large common edible spider crab been followed, this remarkable
   sensitivity of marine arthropod blood to endotoxin would have been
   recognized much earlier.  The original work of Metchnikoff on sea
   star larvae stimulated him to develop the major theory of
   phagocytosis but, until the adult animal of the same genus was
   re-examined half a century later, the presence of a powerful
   substance which selectively inhibits growth of lymphocytes following
   primary immunization remained unknown.  Though mucus secretion is a
   fundamental characteristic of most invertebrate phyla and all
   vertebrates, little is known about the regulatory mechanism of the
   secretory process; studies of the responses of specialized
   invertebrate secretory cells to infection have now led to a new means
   of studying macromolecular control of mucus secretion in man.  These
   three stories emphasize the continuing need to study disease as a
   biologic phenomenon.
RF 001   ZEPP HD               NATURE NEW BIOL                229   119 971
   002   CONOVER JH            CURR TOP MICROBIOL IMMUNOL      55    85 971
   003   POCOCK RI             ANN MAG NAT HIST                 9   256 902
   004   LOEB L                J MED RES                        7   145 902
   005   LOEB L                UNIV PENNSYLVANIA MED BULL      18    91 905
   006   LEVIN J               BULL JOHNS HOPKINS HOSP        115   337 964
   007   HARTLINE HK           HARVEY LECTURES                 37    39 941
   008   BANG FB               BULL JOHNS HOPKINS HOSP         98   325 956
   009   LEVIN J               THROMB HAEMOST                  19   186 968
   010   YOUNG NS              J CLIN INVEST                   51  1790 972
   011   SULLIVAN JD JR        APPL MICROBIOL                  28  1023 974
   012   LEVIN J               N ENGL J MED                   283  1313 970
   013   LEVIN J               ANN INTERN MED                  76     1 972
   014   NACHUM R              N ENGL J MED                   289   931 973
   016   COOPER JF             J LAB CLIN MED                  78   138 971
   019   KLEIN KB              LANCET                           2    50 974
   020   LOEB L                J MED RES                       10   407 903
   021   PEARSON AD            LANCET                           1  1194 973
   022   CANTACUZENE J         C R SOC BIOL (PARIS)            84  1007 921
   023   METCHNIKOFF E         LECONS PATHOLOGIE COMPAREE DE            892
   024   METCHNIKOFF O         LIFE OF ELIE METCHNIKOFF 1845            921
   025   BANG FB               J INSECT PATHOL                  4   401 962
   026   REINISCH CL           CELL IMMUNOL                     2   496 971
   027   REINISCH CL           NATURE                         250   349 974
   029   PRENDERGAST RA        NATURE                         227   277 970
   030   PRENDERGAST RA        ANN NY ACAD SCI                234     7 974
   031   WILLENBORG DO         J EXP MED                      139   820 974
   033   ANON                  ANN INST PASTEUR                42   137 934
   034   CANTACUZENE J         C R SOC BIOL (PARIS)            92  1133 925
   035   CANTACUZENE J         ARCH ROUM PATHOL EXP             1     7 928
   036   BANG FB               CAHIERS BIOL MAR                 3   363 962
   037   BANG BG               AM J PATHOL                     68   407 972
   039   BOWMAN BH             SCIENCE                        164   325 969
   040   BANG BG               LANCET                           2  1292 974

PN 75105
RN 00271
AN 76007103
AU Seidmon-E-J.  Mosovich-L-L.  Neter-E.
TI Colonization by Enterobacteriaceae of the respiratory tract of
   children with cystic fibrosis of the pancreas and their antibody
   response.
SO J-Pediatr. 1975 Oct. 87(4). P 528-33.
MJ ANTIBODY-FORMATION.  CYSTIC-FIBROSIS: co.
   ENTEROBACTERIACEAE-INFECTIONS: co.  RESPIRATORY-TRACT-INFECTIONS: co.
MN ADOLESCENCE.  ADULT.  ANTIBODIES-BACTERIAL.  CHILD.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: im.  ENTEROBACTERIACEAE-INFECTIONS: im.
   ENTEROBACTERIACEAE: im.  FEMALE.  HUMAN.  INFANT.  MALE.
   RESPIRATORY-TRACT-INFECTIONS: im.  SUPPORT-U-S-GOVT-P-H-S.
AB Of 72 patients with fibrosis, 49 harbored Enterobacteriaceae in the
   respiratory tract, including Escherichia coli, Klebsiella, and
   Enterobacter. Colonization by two to four genera was documented in 29
   subjects. Staphylococcus aureus was recovered from 44 of these 49
   patients. The distribution of serogroups of E. coli was similar to
   that seen in patients with urinary tract infection. Antibody response
   against the O antigens of the patients' own Enterobacteriaceae was
   documented in 29 of these 49 children and encountered more often in
   patients with severe disease. Colonization by Enterobacteriaceae in
   the absence of Pseudomonas aeruginosa was seen more frequently in
   children with the mild form of the illness.
RF 001   HUANG NN              J PEDIATR                       59   512 961
   002   DOGGETT RG            J BACTERIOL                     87   427 964
   003   DOGGETT RG            J PEDIATR                       68   215 966
   004   IACOCCA VF            AM J DIS CHILD                 106   315 963
   005   FEIGELSON J           ARCH FR PEDIATR                 24  1135 967
   006   MEARNS MB             ARCH DIS CHILD                  47   902 972
   007   MAY JR                ARCH DIS CHILD                  47   908 972
   008   EDWARDS PR            IDENTIFICATION OF ENTEROBACTE            972
   009   NETER E               ANN NY ACAD SCI                 66   141 956
   010   DIAZ F                J INFECT DIS                   121   269 970
   011   HUANG NN              J PEDIATR                       78   338 971
   012   NETER E               N ENGL J MED                   261  1162 959
   013   ELSEA WR              PUBLIC HEALTH REP               82   347 967
   014   NETER E               AM J PUBLIC HEALTH              52    61 962
   015   NETER E               IN: PRIER JE                          37 974
   016   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   81   298 973
   017   DOGGETT RG            INFECT IMMUN                     6   628 972
   018   MARTINEZ-TELLO FJ     J IMMUNOL                      101   989 968
CT   1   NETER E               ZENTRALBL BAKT MIKROB HYG (A)  235     3 976
     2   HOIBY N               ACTA PATH MICROBIOL SCAND (C) S262     3 977
     3   DOLBY JM              J HYG LOND                      78   235 977
     4   OLLING S              SCAND J INFECT DIS            1977     7 977
     5   KLINGER JD            J INFECT DIS                   138    49 978
     6   NETER E               ZENTRALBL BAKT PARA INFEK HYG  243   349 979
     7   BURDON MG             CLIN GENET                      17   249 980
     8   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    33 982
     9   FRIEND PA             J INFECT                        13    55 986

PN 75106
RN 00272
AN 76007111
AU Ellis-C-E.  Hill-D-E.
TI Growth, intelligence, and school performance in children with cystic
   fibrosis who have had an episode of malnutrition during infancy.
SO J-Pediatr. 1975 Oct. 87(4). P 565-8.
MJ CYSTIC-FIBROSIS: pp.  GROWTH.  INFANT-NUTRITION-DISORDERS: pp.
   INTELLIGENCE.
MN ACHIEVEMENT.  CHILD.  CYSTIC-FIBROSIS: co.  FEMALE.
   FOLLOW-UP-STUDIES.  HUMAN.  INFANT-NUTRITION-DISORDERS: et.  MALE.
   SOCIAL-ADJUSTMENT.
EX In this study, we have compared two groups of children with cystic
   fibrosis.  One group of CF children had severe malnutrition in the
   first year of life, whereas the second group of CF children had not
   been malnourished.  The catch-up growth experienced by both the
   control and malnourished groups was impressive and was generally
   complete in terms of height and weight for age.  This finding is
   consistent with other reports regarding catch-up growth following
   malnutrition associated with celiac disease, anorexia nervosa, renal
   acidosis, Cushing syndrome, and hypothyroidism.  Though the
   malnourished group tended to have lower IQ and school performance
   scores, the differences were not statistically significant except for
   backward digit span.  That difference may indicate an organic
   impairment due to malnutrition or to any of several other factors.
   Our data fail to demonstrate any permanent or devastating effect of
   early malnutrition during a very rapid growth phase on the subsequent
   growth, IQ, and school performance in children with cystic fibrosis
   studied at age 7 to 10 years.
RF 001   SCRIMSHAW NS          MALNUTRITION LEARNING AND BEH            968
   002   CRAVIOTO J            PEDIATRICS PART 2 SUPPL         38   319 966
   003   LATHAM MC             PHYSIOL REV                     54   541 974
   004   KAPLAN BJ             PSYCHOL BULL                    78   321 972
   005   DOBBING J             PEDIATRICS                      53     2 974
   006   GRAHAM GG             AM J CLIN NUTR                  25  1184 972
   007   GOMEZ F               J TROP PEDIATR                   2    77 956
   008   SPROUL A              J PEDIATR                       65   664 964
   009   KULCZYCKI LL          CLIN PROC CHILD HOSP DC         25   320 969
   010   LLOYD-STILL JD        PEDIATRICS                      54   306 974
CT   1   CHEEK DB              AM J CLIN NUTR                  29  1149 976
     2   HILL DE               POSTGRAD MED                    62   103 977
     3   EISENBERG L           BR J PSYCHIATRY                131   225 977
     4   BROZEK J              ANNU REV PSYCHOL                29   157 978
     5   CELEDON JM            EARLY HUM DEV                    3   267 979
     6   CELEDON JM            J MENT DEFIC RES                24    27 980
     7   MACLEAN WC            J PEDIATR                       97   316 980
     8   RICCIUTI HN           J AM DIET ASSOC                 79   115 981
     9   GRAHAM GG             AM J DIS CHILD                 136   348 982
    10   ANDRASSY RJ           J PEDIATR SURG                  18   431 983
    11   ASHWORTH A            NUTR REV                        44   157 986

PN 75107
RN 00273
AN 75091389
AU Moss-A-J.  Finkelstein-S.  Crudup-C.  Young-G-A.  Dooley-R-R.
   Osher-A-B.
TI Absorption of digoxin in children with cystic fibrosis.
SO J-Pediatr. 1975 Feb. 86(2). P 295-7.
MJ CYSTIC-FIBROSIS: me.  DIGOXIN: me.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: co.
   DIGOXIN: ad, tu.  HUMAN.  PULMONARY-HEART-DISEASE: dt, et.
AB The absorption of digoxin in cystic fibrosis was evaluated in 16
   subjects by assessing the relationship between dosage expressed in
   mug/kg/day and serum digoxin concentration. The results indicate that
   the same relationship exists between maintenance dosage and serum
   levels in these patients and in patients without cystic fibrosis.
   Thus, no evidence of impaired absorption was found.
RF 001   ROYCE SW              PEDIATRICS                       8   255 951
   002   WHITE WF              J AM PHARMACOL ASSOC            41    42 952
   003   GELLIS SS             CURRENT PEDIATRIC THERAPY            137 973
   004   MARCUS FI             CIRCULATION                     34   865 966
   005   SMITH TW              N ENGL J MED                   281  1212 969
   006   FOGELMAN AM           LANCET                           2   727 971
   007   BROWN DD              J LAB CLIN MED                  82   201 973
   008   HUFFMAN DH            JAMA                           222   957 972
   009   ROGERS MC             N ENGL J MED                   287  1010 972
   010   OMALLEY K             ARCH DIS CHILD                  48    55 973
   011   HAYES CJ              PEDIATRICS                      52   561 973
   012   HERNANDEZ A           PEDIATRICS                      44   418 969
   013   BELLER GA             N ENGL J MED                   284   989 971
CT   1   WOOD RE               AM REV RESPIR DIS              113   833 976
     2   WETTRELL G            CLIN PHARMACOKINET               2    17 977
     3   KOUP JR               DRUG INTEL CLIN PHARM           12   244 978
     4   SCHNEIWEISS F         DRUG INTEL CLIN PHARM           16   132 982
     5   MOSS AJ               PEDIATRICS                      70   728 982
     6   COATES AL             CHEST                           82   543 982
     7   LESTER LA             SEM RESPIR MED                   6   285 985
     8   WETTRELL G            THER DRUG MONITOR                8   129 986

PN 75108
RN 00274
AN 76047933
AU Lukash-F.  Zwiren-G-T.  Andrews-H-G.
TI Significance of absent vas deferens at hernia repair in infants and
   children.
SO J-Pediatr-Surg. 1975 Oct. 10(5). P 765-9.
MJ HERNIA-INGUINAL: su.  VAS-DEFERENS: ab.
MN CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: co.  HUMAN.  INFANT.
   KIDNEY: ab.  MALE.  VAS-DEFERENS: em.
AB An absent vas deferens may be associated with unilateral renal
   agenesis or undiagnosed cystic fibrosis. Such patients should be
   further evaluated with a sweat chloride and intravenous pyelogram.
   The finding of absent vas deferens during exploration for an
   undescended testis does not provide absolute evidence for absence of
   the testis, since these structures have independent embryologic
   origins.
RF 001   EMANUEL B             AM J DIS CHILD                 127    17 974
   002   GRACEY M              N ENGL J MED                   280   276 969
   003   HOLSCLAW DS           J UROL                         106   568 971
   004   HOLSCLAW DS           BR MED J                         3   356 969
   005   HOLSCLAW DS           PEDIATRICS                      48   442 971
   006   KAPLAN E              N ENGL J MED                   279    65 968
   007   LANDING BH            ARCH PATHOL                     88   569 969
   008   OLSON JR              J CLIN PATHOL                   22   725 969
   009   OPPENHEIMER EH        J PEDIATR                       75   806 969
   010   SOLOWAY HM            ANN SURG                       109   267 939
   011   WANG CI               AM J DIS CHILD                 119   236 970
   012   AMELAR RD             JAMA                           213    12 970
   013   CHARNY CW             J UROL                          93   399 965
   014   COLLINS DC            ANN SURG                        95   715 932
   015   DOROSHOW LW           UROLOGICAL SURVEY               11   219 961
   016   GUIZZETTI P           CURR MED LIT                    71  1867 918
   017   HUTCH JA              JAMA                           219  1762 972
   018   MICHELSON L           J UROL                          61   384 949
   019   OCHSNER MG            JAMA                           222  1055 972
   020   WHITEHORN C           J UROL                          72   685 954
   021   YOUNG D               BR J SURG                       36   417 949
   022   GILCHRIST FG          SURVEY OF EMBRYOLOGY                 385 968
   023   VALMAN HB             LANCET                           2   566 969
   024   EL-ITREBY AA          INT J FERTIL                     6   409 961
CT   1   PRIEBE CJ             J PEDIATR SURG                  14   834 979
     2   PIROTH P              UROLOGE (A)                     18   276 979
     3   MACMAHON RA           J PEDIATR SURG                  15    92 980
     4   CHRISTENSON PJ        J ANDROL                         3   326 982
     5   DEANE AM              BR J UROL                       54   298 982
     6   SHAPIRO SR            JAMA                           247   517 982
     7   FLACH A               LANGENBECKS ARCH CHIR          361   343 983

PN 75109
RN 00275
AN 76097542
AU Brungard-K.  Moser-G.  Athreya-B-H.
TI Size distribution of lymphocytes in juvenile rheumatoid arthritis.
SO J-Rheumatol. 1975 Dec. 2(4). P 359-62.
MJ ARTHRITIS-JUVENILE-RHEUMATOID: bl.  LYMPHOCYTES: cy.
MN ASTHMA: bl.  CHILD-PRESCHOOL.  COMPARATIVE-STUDY.
   CYSTIC-FIBROSIS:  bl.  HUMAN.
AB The diameters of circulating peripheral lymphocytes were measured in
   28 children with juvenile rheumatoid arthritis. These were compared
   with lymphocyte measurements in 68 normal children, 19 children with
   asthma, and 12 children with cystic fibrosis. The average diameter of
   lymphocytes in normal children was found to be 11.2 microns. In
   contrast, the average diameter of lymphocytes in juvenile rheumatoid
   arthritis was 12.7 microns (P less than 0.0001). There were more
   lymphocytes with a diameter of 13 to 15 microns in children with
   juvenile rheumatoid arthritis than in normal children.
RF 001   HEYN RM               AM J DIS CHILD                 125   789 973
   002   ANON                  BULL RHEUM DIS                  23   712 972
   003   CARTWRIGHT GE         DIAG LAB HEMATOL                     141 968
   004   WILLIAMS WJ           HEMATOLOGY                            19 972
   005   CLEMENTS RJ           ARTHRITIS RHEUM                 17   347 974
   006   WILLIAMS RC JR        J CLIN INVEST                   52   283 973

PN 75110
RN 00276
AN 76098876
AU Boon-W-H.
TI Cystic fibrosis in a Chinese girl.
SO J-Singapore-Paediatr-Soc. 1975 Oct. 17(2). P 96-102.
MJ CYSTIC-FIBROSIS: di.
MN BLACKS.  CASE-REPORT.  CHILD-PRESCHOOL.  CHINA: eh.
   CYSTIC-FIBROSIS:  fg, oc.  FEMALE.  HUMAN.  INDIANS-NORTH-AMERICAN.
   INFANT.  INFANT-NEWBORN.  JAPAN: eh.  KOREA: eh.  LUNG-DISEASES: di.
   SINGAPORE.
EX A four year old Chinese girl of parents who emigrated to Singapore
   from South China was found to be suffering from bronchiectasis as a
   result of repeated chest infections, and failure to thrive.
   Investigations confirmed the bronchiectasis, and, in the course of
   attempting to elucidate the course, sweat Cl and sweat Na were found
   to be raised.  The patient occasionally passed soft bulky stools and
   the Vitamin A absorption test was abnormal.  The pathogenesis,
   problems in diagnosis and the genetics are briefly reviewed.  This is
   the first proved case of cystic fibrosis occurring in a child of pure
   Chinese stock, and the first to be described in South-East Asia.
   Cystic fibrosis occurring in non-Caucasians in reviewed.
RF 001   AHARI H               J TROP PEDIATR                  11    14 965
   002   ANDERSEN DH           AM J DIS CHILD                  56   344 938
   003   BHAKOO ON             INDIAN J PEDIATR                35   183 968
   004   BRUNECKY Z            J MED GENET                      9    33 972
   005   DANES BS              BIRTH DEF ORIG ART SER           8   114 972
   006   DANKS DM              ANN HUM GENET                   28   323 965
   007   DI SANTAGNESE PA      PEDIATRICS                      22   507 958
   008   DI SANTAGNESE PA      ANN NY ACAD SCI                 93   555 962
   009   GARROD AE             Q J MED                          6   242 913
   010   HARRIS RL             PEDIATRICS                      41   733 968
   011   IKAI K                ACTA PAEDIATR JAP                7    23 965
   012   KULCZYCKI LL          CLIN PEDIATR                     3   692 964
   013   MARTINEZ JR           PEDIATR RES                      9   463 975
   014   ROBERTS GBS           ANN HUM GENET                   24   127 960
   015   SCHULZ IJ             FED PROC                        26   287 967
   016   SPOCK A               PEDIATR RES                      1   173 967
   017   WANG CI               N ENGL J MED                   279  1216 968
   018   WRIGHT SW             AM J HUM GENET                  20   157 968

PN 75111
RN 00277
AN 76009445
AU Schwachman-H.  Araki-H.  Field-M.
TI Letter: Detection of cystic fibrosis and heterozygotes.
SO Lancet. 1975 Aug 23. 2(7930). P 372-3.
MJ CYSTIC-FIBROSIS: fg.
MN CYSTIC-FIBROSIS: di.  HETEROZYGOTE.  HUMAN.  METHODS.
EX During the past year, we have developed a new assay for cystic
   fibrosis by utilising the Ussing chamber technique and measuring the
   electrical properties of rat jejunum in the presence of the sera to
   be tested.  The potential difference (P.D.) and resistance (R.) are
   measured with a sensitive electrometer at 5-minute intervals over 60
   minutes.  We were able to detect 90% of the heterozygotes.  The
   possibility of detecting the remaining 10% is present, and can, we
   feel, be achieved by using a more concentrated specimen.
RF 006   WOOD RE               LANCET                           2  1452 973
CT   1   BURDICK AB            HUM HERED                       27   366 977

PN 75112
RN 00278
AN 76029161
AU McEvoy-F-A.
TI Letter: Essential fatty acids and cystic fibrosis.
SO Lancet. 1975 Aug 2. 2(7927). P 236.
MJ CYSTIC-FIBROSIS: bl.  FATTY-ACIDS-ESSENTIAL: bl.
MN ADULT.  CELL-MEMBRANE: me.  CHILD.  ERYTHROCYTES: me.  HUMAN.
   OXIDATION-REDUCTION.
EX I have measured the fatty-acid profile of C.F. erythrocyte membranes
   in view of the fact that some variations in membrane activity have
   been observed with this system.  The results show that there was a
   lowered content of linoleate (18:2) and arachidonate (20:4) in C.F.
   erythrocyte membranes, and the total essential-fatty-acid content
   was significantly lower than either control group.  There was no
   significant difference in the concentrations of the other major
   fatty acids (palmitate, stearate, and oleate) and we could not
   observe any striking alteration in the concentration of any of the
   minor fatty-acid components of the membrane.  It would thus appear
   that the overall fatty-acid pattern in C.F. erythrocyte membranes is
   altered only by a diminution in those fatty acids which are of
   dietary origin.  The fact that there was considerable overlap
   between the C.F. and control data makes it rather unlikely that the
   fatty-acid profile closely reflects the biochemical lesion of the
   disease.  When the essential-fatty-acid levels of the C.F. samples
   were compared with the Schwachman clinical scores of the patients,
   there was a surprisingly poor correlation (r = 0.49) which was not
   statistically significant.  The correlation with the nutritional
   part of the clinical score was equally low.  Diminished
   essential-fatty-acid content is often observed in many acute
   illnesses.  In addition, the possibility exists that C.F. patients
   may be particularly susceptible to essential-fatty-acid depletion
   due to their pancreatic dysfunction.  Further research on fatty-acid
   transport and metabolism in C.F. is clearly needed to establish the
   role of essential fatty acids in the disease.
RF 002   ROSENLUND ML          NATURE                         251   719 974
   003   ELLIOTT RB            ARCH DIS CHILD                  50    76 975
   004   EMERY AEH             LANCET                           2    80 975
   005   MCEVOY FA             CLIN CHIM ACTA                  54   195 974
   006   GURR MI               LIPID BIOCHEMISTRY                    70 971
   007   LOVE WC               BR MED J                         3    18 974
CT   1   WATTS R               LANCET                           2   983 975
     2   HUBBARD VS            LANCET                           2  1302 977
     3   DAVIS PB              PEDIATR RES                     12   703 978
     4   KUTTY KM              CLIN BIOCHEM                    12    98 979
     5   RIORDAN JR            BIOCHIM BIOPHYS ACTA           574    39 979
     6   HUBBARD VS            CLIN CHIM ACTA                 102   115 980
     7   ROGIERS V             CLIN CHIM ACTA                 105   105 980
     8   ROGIERS V             PEDIATR RES                     16   761 982
     9   PARNHAM MJ            AGENTS ACTIONS                  14   223 984
    10   ROGIERS V             PEDIATR RES                     18   704 984

PN 75113
RN 00279
AN 75099183
AU Conover-J-H.  Conod-E-J.
TI Letter: Complement in cystic fibrosis.
SO Lancet. 1975 Jan 4. 1(7897). P 47-8.
MJ COMPLEMENT.  CYSTIC-FIBROSIS: im.
MN CYSTIC-FIBROSIS: et.  FEMALE.  HISTAMINE-LIBERATION.  HUMAN.
   IGG:  an.  IMMUNE-COMPLEX-DISEASE.  MALE.  SEX-RATIO.
EX Lieberman reported that there was considerable overlap in
   quantitative C3 levels between all of the C.F. subjects tested, and
   the control group.  His control group, however, was composed of
   subjects with bronchiectasis or chronic bronchitis, in whom C.F. had
   been ruled out.  The use of a more proper control group by
   Lieberman, either in place of or in parallel with his "diseased"
   control groups, would have provided a more meaningful interpretation
   concerning the role of complement in cystic fibrosis.  We agree that
   there is a tendency for C3 to be higher in C.F. females than in C.F.
   males.  Although Lieberman was quick to dispel any notion of C3a
   being implicated in the aetiology of C.F., he overlooked the one
   facet of our initial study that still makes our hypothesis feasible
   - raised C3 levels in C.F. obligate heterozygotes.  Hann et al.
   reported that serum-C5 was raised in both C.F. patients and their
   parents.  Our initial data on C5 levels by radial immunodiffusion
   and haemolytic studies do not confirm this finding.  We are
   supporting the hypothesis that C.F. is either a complement-caused or
   complement-mediated disorder, in which a C3a-like molecule (C3a,
   bradykinin) either alone or by complexing with IgG gives rise to the
   physiological and pathological state of C.F.
RF 001   CONOVER JH            LANCET                           2  1501 973
   002   LIEBERMAN J           LANCET                           1  1230 974
   003   CONOVER JH            PEDIATR RES                      7   220 973
   004   CONOVER JH            LANCET                           1  1194 973
   005   HANN S                LANCET                           2   520 974
   006   CONOVER JH            LIFE SCI                        14   253 974
   007   DANES BS              J EXP MED                      137  1538 973
   008   MOLENAAR J            J IMMUNOL                      112  1444 974
   009   WILSON GB             LIFE SCI                        15   551 974
   010   CONOVER JH            CLIN RES                        21   531 973
CT   1   WILSON GB             PEDIATR RES                     10    87 976
     2   WEEKE B               DAN MED BULL                    23   155 976
     3   LEDERBERG S           AM J HUM GENET                  28   597 976
     4   WILSON GB             TEX REP BIOL MED                34    51 976
     5   GOTZ M                EUR J PEDIATR                  127   133 978
     6   JAKEL HP              BIOL ZENTRALBL                  98    55 979
     7   SANDERSON MJ          PEDIATR RES                     15   219 981

PN 75114
RN 00280
AN 75081159
AU Stephan-U.  Brauning-C.  Busch-E-W.
TI Letter: Screening for cystic fibrosis.
SO Lancet. 1975 Jan 18. 1(7899). P 167.
MJ CYSTIC-FIBROSIS: di.  MASS-SCREENING.
MN ALBUMINS: an.  GEL-DIFFUSION-TESTS.  HUMAN.  INFANT-NEWBORN.
   MECONIUM: an.  SPECIMEN-HANDLING.
EX We read with interest Dr Raine's paper but would like to stress that
   Hellsing and Kollberg used a single radial immunodiffusion method
   not radioimmunoassay.  Prosser et al. demonstrated quite clearly
   that similar results were obtained in cystic-fibrosis (C.F.)
   screening with test-strips and with more elaborate methods of
   albumin detection in meconium.  Using both radial immunodiffusion as
   well as test-strips, Kollberg's group noticed a decreased albumin
   content in C.F. meconium stored at room temperature and mailed for
   several days.  Diminished albumin concentration might have been
   brought about by remaining proteolytic activity.  Prosser et al.
   found no change in albumin content during refrigerator storage.
   Approximately 10% of C.F. cases have no raised albumin content in
   meconium and this problem has not yet been solved.
RF 004   HELLSING K            SCAND J CLIN LAB INVEST         33   333 974
   005   PROSSER R             ARCH DIS CHILD                  49   597 974

PN 75115
RN 00281
AN 75081158
AU Crawfurd-M-D.
TI Letter: Frequency of cystic-fibrosis gene.
SO Lancet. 1975 Jan 18. 1(7899). P 167.
MJ CYSTIC-FIBROSIS: fg.  GENES.
MN CAUCASOID-RACE.  COMPARATIVE-STUDY.  HETEROZYGOTE.  HOMOZYGOTE.
   HUMAN.
EX Mr Stuart and Dr Burdon speculate on the possibility that the high
   frequency of the cystic-fibrosis gene among Caucasians may be due to
   the heterozygotes having some advantage in biological fitness over
   normal homozygotes.  They suggest that this might be due to
   increased resistance to typhus, once endemic in Europe, on the basis
   of the well-known immunological cross-reactivity between the
   causative organism, Rickettsia prowazeki, and certain strains of the
   species Proteus vulgaris, which is agglutinated by sera from
   cystic-fibrosis patients and heterozygotes.  However, there is no
   evidence that this agglutination is an immunological reaction.  It
   appears microscopically to be associated with disorganisation and
   inhibition of the bacterial flagellae leading to clumping of the
   organisms.  As such it is probably analogous to the effect on cilia
   of rabbit trachea and oyster or mussel gills.  The cilia factor,
   although associated with IgG, is now known not to be IgG itself and
   may well be the C3a component of complement.  These and other
   observations, such as those on salivary and sweat gland secretions
   and on sodium flux, suggest that all these phenomena are membrane
   rather than immunological effects.  Although it is possible that a
   Proteus flagella antigen could also be the binding site for the
   cilia factor, this seems improbable.  An alternative hypothesis is
   that heterozygotes for the cystic-fibrosis gene have increased
   resistance to tuberculosis.  This would meet the requirement of a
   common disease recently endemic in Europe at least as well as
   typhus, and is suggested by indirect evidence from a family study
   demonstrating a significantly lower incidence of tuberculosis among
   the parents of cystic-fibrosis patients than among parents of
   controls.
RF 006   COHEN FL              J MED GENET                     11   253 974
   008   BOWMAN BH             PROC NAT ACAD SCI USA           70   548 973
   009   CONOVER JH            LANCET                           1  1194 973
   010   CRAWFURD MDA          HEREDITY                        29   126 972
CT   1   SHIER WT              MED HYPOTHESES                   5   661 979
     2   JAKEL HP              BIOL ZENTRALBL                  98    55 979
     3   HOLLANDER DH          MED HYPOTHESES                   8   191 982

PN 75116
RN 00282
AN 75193605
TI Editorial: Pseudomonas vaccines.
SO Lancet. 1975 Jul 26. 2(7926). P 168.
MJ BACTERIAL-VACCINES.  PSEUDOMONAS-AERUGINOSA.
   PSEUDOMONAS-INFECTIONS:  pc.
MN ACUTE-DISEASE.  BACTERIAL-VACCINES: tu.  CYSTIC-FIBROSIS: co.  HUMAN.
   IMMUNITY-ACTIVE.  LEUKEMIA: co.  PSEUDOMONAS-INFECTIONS: co.
EX Few antibiotics have therapeutic value against Pseudomonas
   aeruginosa, and each of them has shortcomings.  It is therefore
   important to try and prevent pseudomonas infection in patients with
   severe burns, immunodeficiency, cystic fibrosis, and other conditions
   or methods of treatment that make them particularly susceptible to
   invasion by these bacteria.
RF 026   MILLICAN RC           J INFECT DIS                   107   389 960
   027   JONES RJ              BR J PLAST SURG                 19    43 966
   028   JONES CE              SURG FORUM                      21   238 970
   029   FELLER I              IN: WALLACE AB                       470 966
   030   ALEXANDER JW          IN: URBASCHEK B                      489 975
   031   MARKLEY K             J BACTERIOL                     96   867 968
   032   JONES RJ              BR J EXP PATHOL                 53   659 972
   033   JONES RJ              IMMUNOLOGY                      23   889 972
   034   ALEXANDER JW          ARCH SURG                       99   249 969
   035   HANESSIAN S           NATURE NEW BIOL                229   209 971
   036   JONES RJ              J HYG CAMB                      70   343 972
   038   YOUNG LS              ANN INTERN MED                  79   518 973
   039   HAGHBIN M             CANCER                          32   761 973
   040   PENNINGTON JE         AM J MED                        58   629 975
CT   1   MUNSTER AM            AM J SURG                      133   710 977

PN 75117
RN 00283
AN 75193529
AU Emery-A-E.  Farrell-K.  Keay-A-J.  McCrae-W-M.
TI Letter: Fatty-acid oxidation in cystic fibrosis.
SO Lancet. 1975 Jul 12. 2(7924). P 80-1.
MJ CYSTIC-FIBROSIS: me.  FATTY-ACIDS: me.
MN ADOLESCENCE.  ADULT.  CYSTIC-FIBROSIS: bl.  FATTY-ACIDS: df.  HUMAN.
   LEUKOCYTES: me.  MIDDLE-AGE.  OXIDATION-REDUCTION.
EX The nature of the metabolic defect in cystic fibrosis (C.F.) is
   unknown.  We therefore undertook to study fatty-acid oxidation
   (Beta-oxidation) in patients with C.F.  There was no significant
   difference in the results obtained in controls and either affected
   individuals or heterozygous carriers.  All the values in the
   affected individuals lay within the normal range.  Unless for some
   special reason the defect is not expressed in leukocytes, these
   results indicate that the metabolic pathway involved in fatty-acid
   oxidation (Beta-oxidation) is intact in C.F.  It therefore seems
   unlikely that the reported deficiency of certain essential fatty
   acids in C.F. is the result of a defect in fatty-acid metabolism.
RF 001   ROSENLUND ML          NATURE                         251   719 974
   002   KUO PT                J CLIN INVEST                   44  1924 965
   003   HSIA DYY              CLIN GENET                       1     5 970
   004   EMERY AEH             J NEUROL SCI                    14   463 971
   005   KING B                J NEUROL SCI                    20   297 973
CT   1   HUBBARD VS            LANCET                           2  1302 977

PN 75118
RN 00284
AN 75173958
AU Scanlin-T-F-Jr.  Norman-M-E.  Rosenlund-M-L.
TI Letter: C3 in cystic fibrosis.
SO Lancet. 1975 Jun 21. 1(7921). P 1382.
MJ COMPLEMENT-3: an.  COMPLEMENT: an.  CYSTIC-FIBROSIS: im.
MN ADOLESCENCE.  AGE-FACTORS.  CHILD.  CHILD-PRESCHOOL.  HUMAN.
   INFANT.
EX We believe that serum-levels of individual complement components in
   children cannot be meaningfully interpreted unless they are compared
   with normal values obtained from age-matched controls.  In a study
   of 163 healthy infants and children we found a statistically
   significant correlation of C3 levels with age, but not with sex or
   race, and we also found a wide range of values within any given
   age-group.  In contrast to previous reports, we did not find raised
   C3 levels in the majority of our C.F. patients when the values were
   compared with projected group mean values for the appropriate age,
   and we did not find a significant elevation of the mean C3 level for
   the C.F. patients in any of the age-groups tested.
RF 001   CONOVER JH            LANCET                           2  1501 973
   002   HANN S                LANCET                           2   520 974
   004   MANCINI G             IMMUNOCHEMISTRY                  2   235 965
CT   1   HOLZHAUER RJ          AM J HUM GENET                  28   602 976
     2   ANON                  J PEDIATR                       88   711 976
     3   HODSON ME             THORAX                          35   801 980
     4   MOSS RB               AM REV RESPIR DIS              121    23 980
     5   SCHIOTZ PO            ACTA PAEDIATR SCAND SUPPL 301 1982    55 982
     6   WISNIESKI JJ          AM REV RESPIR DIS              132   770 985

PN 75119
RN 00285
AN 75117984
AU Dodge-J-A.  Burton-L.
TI Letter: Heterozygote advantage in cystic fibrosis.
SO Lancet. 1975 Mar 8. 1(7906). P 572-3.
MJ CYSTIC-FIBROSIS.  HETEROZYGOTE.  PERSONALITY.
MN ADAPTATION-PSYCHOLOGICAL.  ADULT.  CHILD.  CHILD-PRESCHOOL.  FEMALE.
   HUMAN.  INFANT.  MALE.  PERSONALITY-INVENTORY.
EX In a recent study, we attempted to assess the personality
   characteristics of both mothers and fathers of children with cystic
   fibrosis.  In all, more than 150 such parents were interviewed.
   During the course of the interview, the Taylor manifest anxiety
   scale, Fouldes' personality inventory, and the 16 PF test form A
   were used.  It was apparent that these parents represented a wide
   range of personality types, and differed in no way from the general
   population.
RF 001   GAIRDNER D            LANCET                           1   279 975
CT   1   SHIER WT              MED HYPOTHESES                   5   661 979
     2   JAKEL HP              BIOL ZENTRALBL                  98    55 979

PN 75120
RN 00286
AN 76074281
AU Watts-R.  Taylor-S.  Postuma-R.  Smalley-C-A.
TI Letter: Essential-fatty-acid metabolism in cystic fibrosis.
SO Lancet. 1975 Nov 15. 2(7942). P 983.
MJ CYSTIC-FIBROSIS: me.  FATTY-ACIDS-ESSENTIAL: me.
MN CHILD.  CYSTIC-FIBROSIS: bl.  FATTY-ACIDS-ESSENTIAL: bl, df.  HUMAN.
   INFANT.  INFANT-NEWBORN.
EX 6 patients with proven cystic fibrosis and a wide variety of
   Schwachman clinical scores were studied and the controls were 10
   healthy children undergoing minor elective surgical procedures.  The
   results show that for children with cystic fibrosis there are not
   only decreased proportions of essential fatty acids but that 20:3
   omega-9 is found in all cases.  Our results suggest that there is no
   intrinsic defect of the desaturating system in cystic fibrosis and
   that the pattern of essential-fatty-acid deficiency is entirely
   similar to that found in dietary deficiency of essential fatty
   acids.  A further significant finding is the occurance if 20:3
   omega-9 in apparently healthy children, particularly the very young.
   This is probably diet-related and emphasises the young child's very
   large requirement for essential fatty acids for membrane synthesis.
   The need for adequate polyunsaturated fatty acids in childhood
   cannot be overstated, whether they be for normal membrane synthesis
   or lowering of serum-lipids, giving possible protection against
   cardiovascular disease.
RF 001   SMITH S               J LIPID RES                      9    52 968
   002   BENNETT MJ            AM J CLIN NUTR                  20   415 967
   003   AAES-JORGENSEN E      PHYSIOL REV                     41     1 961
   004   COLLINS FD            NUTR METAB                      13   150 971
   005   PRESS M               BR MED J                         2   247 974
   006   MCEVOY FA             LANCET                           2   236 975
   007   LOVE WC               BR MED J                         3    18 974
   008   PAULSRUD JR           AM J CLIN NUTR                  25   897 972
   009   WOODRUFF CW           AM J CLIN NUTR                  14    83 964
   010   GLUECK CJ             METABOLISM                      21  1181 972
   011   MCBEAN LD             PEDIATR RES                      8   837 974
   012   KINGSBURY KJ          POSTGRAD MED J                  50   425 974
CT   1   HUBBARD VS            LANCET                           2  1302 977
     2   BOHLES H              Z ERNAHRUNGSWISS                18    81 979

PN 75121
RN 00287
AN 76074205
AU Robinson-P-G.
TI Letter: Essential fatty acids in cystic fibrosis.
SO Lancet. 1975 Nov 8. 2(7941). P 919.
MJ CYSTIC-FIBROSIS: me.  FATTY-ACIDS-ESSENTIAL: me.
MN CYSTIC-FIBROSIS: et.  FATTY-ACIDS-ESSENTIAL: df.  HUMAN.
EX In three literature reports the linoleic acid (L.A.) levels for
   cystic fibrosis (C.F.) compared to controls are always more
   significantly lower than arachidonic acid (A.A.).  Similarly the
   percentage lowering is also more for L.A. than A.A.  There is, thus,
   no "overwhelming" evidence for a blocked or absent desaturase and
   the cause of the E.F.A. deficiency must be elsewhere.  We have found
   up to 2.5% of the total fatty acids in both serum and red cells to
   be C20:3-omega-9.  All of our C.F. patients have shown this acid at
   some stage and, for most, it is a permanent feature of their fatty
   acid profile.  It has been reported that C20:3-omega-9 would
   probably act as an inhibitor of prostaglandin formation from A.A.
   and it is interesting to conjecture on whether this could account
   for some of the symptoms of C.F.  C20:3-omega-9 would also be
   incorporated into P.I. and could then alter membrane properties.
RF 001   CAREN R               J CLIN ENDOCRINOL METAB         26   470 966
   002   KUO PT                J CLIN INVEST                   44  1924 965
   003   ROSENLUND ML          NATURE                         251   719 974
   004   BENNETT MJ            AM J CLIN NUTR                  20   415 967
   006   ANON                  NUTR REV                        32    19 974
   007   ELLIOTT RB            ARCH DIS CHILD                  50    76 975
CT   1   LLOYDSTILL JD         AM J CLIN NUTR                  34     1 981

PN 75122
RN 00288
AN 76074167
AU Press-M.
TI Letter: Essential-fatty-acid metabolism in cystic fibrosis.
SO Lancet. 1975 Nov 1. 2(7940). P 871-2.
MJ CYSTIC-FIBROSIS: me.  FATTY-ACIDS-ESSENTIAL: me.
MN FATTY-ACIDS-ESSENTIAL: df.  HUMAN.
EX In an investigation of the effects of intestinal malabsorption on
   plasma-lipids, we compared the fatty-acid composition of the
   serum-lecithin of 23 patients with malabsorption from a variety of
   different causes and found similar changes irrespective of the
   underlying cause of the malabsorption.  The only exception to this
   was that classical E.F.A. deficiency was found only in patients
   whose malabsorption was due to massive small-bowel resection.  All
   other causes of malabsorption gave rise to changes identical to
   those found by other workers in C.F.; there is thus no reason to
   postulate an additional metabolic abnormality specific to C.F.  The
   relatively normal amounts of arachidonic acid reported in some
   E.F.A. deficient patients may not be entirely due to arachidonic
   acid.
RF 001   RIVERS JPW            LANCET                           2   642 975
   002   CALDWELL MD           J PEDIATR                       81   894 972
   003   PRESS M               LANCET                           1   597 974
   004   SHIMOYAMA T           GUT                             14   716 973
   005   PRESS M               BR MED J                         2   247 974
   006   CLARK SB              J LIPID RES                     14   581 973
   007   ACKMAN RG             IN: HOLMAN RT                   12   165 972
CT   1   HUBBARD VS            LANCET                           2  1302 977

PN 75123
RN 00289
AN 76074202
AU Barnes-G-L.  Ekert-H.  Dowling-S-V.
TI Letter: Cystic fibrosis: detection of heterozygotes.
SO Lancet. 1975 Nov 8. 2(7941). P 918.
MJ CYSTIC-FIBROSIS: fg.  HETEROZYGOTE.
MN ADENOSINE-DIPHOSPHATE: pd.  ADULT.  CHILD.  CYSTIC-FIBROSIS: bl.
   HUMAN.  PLATELET-AGGREGATION: de.  PROSTAGLANDINS-E: pd.
EX Samuels and Elliott have described a new technique for detecting
   cystic fibrosis (C.F.) and the heterozygote for C.F.  We have tested
   this technique in detail on a smaller number of patients.  Although
   the number of samples tested in our study is small, results suggest
   that this technique is not likely to be successful in detection of
   heterozygotes for C.F.
RF 001   SAMUELS CE            LANCET                           2   607 975
   002   EKERT H               J THORAC CARDIOVASC SURG        67   184 974
CT   1   HAMDI I               MONOGR PAEDIATR                 10    84 979
     2   BOROVIKOVA TM         TER ARKH                        52   125 980

PN 75124
RN 00290
AN 76050225
AU Thompson-G.
TI Letter: Defective essential-fatty-acid metabolism in cystic fibrosis.
SO Lancet. 1975 Oct 18. 2(7938). P 769.
MJ CYSTIC-FIBROSIS: me.  FATTY-ACIDS-ESSENTIAL: me.
MN HUMAN.  PHOSPHOLIPIDS: me.
EX Mr Rivers and Mr Hassam propose that the subnormal levels of
   linoleic acid (18:2) found in the plasma-phospholipids of patients
   with cystic fibrosis are due to malabsorption.  To substantiate
   their hypothesis they deduce that the remarkable remission observed
   in a cystic-fibrosis patient given intravenous 'Intralipid' was due
   not to the 18:2 content of the 20% triglyceride component of the fat
   emulsion but to the 20:4 content of its 1.2% phospholipid component
   (not 6% as they state).  This explanation seems unlikely in view of
   the relatively small proportion of 20:4 in intralipid phospholipid,
   especially since intravenous administration of intralipid
   phospholipid to healthy subjects decreases both the 18:2 and 20:4
   content of their plasma-phospholipids.  Comparison of the effects of
   complete intralipid versus intralipid phospholipid on the level of
   20:4 in the plasma-phospholipids of patients with cystic fibrosis
   would soon determine whether they lack the ability to desaturate
   18:2 to 20:4.
RF 001   RIVERS JPW            LANCET                           2   642 975

PN 75125
RN 00291
AN 78198472
AU Robinson-P-G.  Elliott-R-B.
TI Pancreatic supplementation for premature babies [letter].
SO Lancet. 1975 Oct 25. 2(7939). P 817-8.
MJ INFANT-PREMATURE-DISEASES: th.  PANCREATIC-EXTRACTS: tu.
MN CYSTIC-FIBROSIS: dh, dt.  FECES.  HUMAN.  INFANT-NEWBORN.
   INFANT-PREMATURE-DISEASES: dh, dt.  TRYPSIN: an.
EX For some time now we have been using a screening test for cystic
   fibrosis based on levels of stool trypsin and chymotrypsin on the
   fourth day of life.  One interesting observation is the number of
   premature babies who have little or no pancreatic trypsin or
   chymotrypsin at this time.  For example, of the babies tested from
   St. Helen's Maternity Hospital between June, 1974, and April, 1975,
   84 were classified as premature in the birth-records book.  Samples
   were received for only 65 of these babies.  Of these 65 babies, 26
   (40%) had stool-trypsin levels of <100 microg. per g. compared with
   only 2.5% of the other babies tested during this period.  As may be
   expected, the lower-birth-weight babies tend to have lower
   stool-enzyme concentrations.  We feel that our data indicate that at
   least some premature babies would benefit from pancreatic-enzyme
   supplementation or predigested foods in the first few days after
   birth.
RF 001   ROBINSON PG           NZ MED J                        79  1024 974
   002   HAVERBACK BJ          GASTROENTEROLOGY                44   588 963
CT   1   MERRITT AD            ADV HUM GENET                    8   135 977

PN 75126
RN 00292
AN 76029171
AU Rivers-J-P.  Hassam-A-G.
TI Defective essential-fatty-acid metabolism in cystic fibrosis.
SO Lancet. 1975 Oct 4. 2(7936). P 642-3. (REVIEW).
MJ CYSTIC-FIBROSIS: me.  FATTY-ACIDS-ESSENTIAL: me.
MN ANIMAL.  DIETARY-FATS: me.  FATTY-ACID-DESATURASES: me.
   FATTY-ACIDS-ESSENTIAL: df.  HUMAN.  PARENTERAL-FEEDING.
   PHOSPHOLIPIDS: me.  REVIEW.
AB Cystic fibrosis (C.F.) is characterised by low serum levels of
   essential fatty acids (E.F.A.). However, the fatty-acid pattern does
   not totally resemble that of dietary E.F.A. deficiency. The
   differences suggest a reduction in the desaturation of E.F.S. It is
   not known whether this defect is the primary lesion in C.F. or is the
   result of tissue damage in the disease. It is proposed that C.F.
   patients might have increased linoleic-acid requirements, and
   possibly specific requirements for its desaturation products.
RF 001   ROSENLUND ML          NATURE                         251   719 974
   002   DODGE JA              BR MED J                         2   192 975
   003   BENNETT MJ            AM J CLIN NUTR                  20   415 967
   004   CAREN R               J CLIN ENDOCRINOL METAB         26   470 966
   005   KUO PT                J PEDIATR                       60   394 962
   006   KUO PT                J CLIN INVEST                   44  1924 965
   007   COLLINS FD            NUTR METAB                      13   150 971
   008   ELLIOTT RB            ARCH DIS CHILD                  50    76 975
   009   HOLMAN RT             PROG CHEM FATS OTHER LIPIDS      9   607 970
   010   WENE JD               J CLIN INVEST                   56   127 975
   013   BRENNER RR            MOL CELL BIOCHEM                 3    41 974
   014   BRENNER RR            LIPIDS                           6   567 971
   015   BRENNER RR            AM J PHYSIOL                   215    63 968
   016   NINNO RE              BIOCHIM BIOPHYS ACTA           360   124 974
   017   HUBBLE DV             CYSTIC FIBROSIS                       55 964
CT   1   HUBBARD VS            EUR J PEDIATR                  141    68 983
     2   FOGERTY AC            AM J CLIN NUTR                  39   201 984
     3   MCKENNA MC            J PEDIATR GASTROENTEROL NUTR     4    45 985
     4   FARRELL PM            PEDIATR RES                     19   104 985
     5   MISCHLER EH           PEDIATR RES                     20    36 986
     6   FRIEDMAN Z            PROG LIPID RES                  25   355 986
     7   CRAIGSCHMIDT MC       AM J CLIN NUTR                  44   816 986
     8   CARLSTEDTDUKE J       PROC NAT ACAD SCI USA           83  9202 986

PN 75127
RN 00293
AN 76009694
AU Samuels-C-E.  Elliott-R-B.
TI Letter: Cystic fibrosis: detection of heterozygotes.
SO Lancet. 1975 Sep 27. 2(7935). P 607-8.
MJ CYSTIC-FIBROSIS: fg.  HETEROZYGOTE.
MN HUMAN.
EX We have developed a new technique for detecting cystic fibrosis
   (C.F.) and the heterozygote of C.F.  The assay can be done by any
   laboratory having an aggregometer for measuring platelet aggregation.
   Quantitation of the results is obtained by comparing the
   transmittance recorded when only A.D.P. is added to platelet-rich
   plasma (P.R.P.). In C.F. patients and known heterozygotes, this ratio
   is 4 - 9 times higher than in healthy subjects.  We have tested
   P.R.P. from 40 healthy people, 25 patients with C.F., and 40 known
   heterozygotes.  We could detect all C.F. patients and 95% of the
   known heterozygotes.
CT   1   BURDICK AB            HUM HERED                       27   366 977
     2   HAMDI I               MONOGR PAEDIATR                 10    84 979
     3   MANCUSO G             RIV ITAL PEDIATR                 8   665 982
     4   DAVIS PB              AM J MED SCI                   288   104 984

PN 75128
RN 00294
AN 76218737
AU Johns-M-K.
TI Skin wrinkling in cystic fibrosis.
SO Med-Biol-Illus. 1975 Nov. 25(4). P 205-10.
MJ CYSTIC-FIBROSIS: di.  SKIN-MANIFESTATIONS.
MN CHILD-PRESCHOOL.  HUMAN.  INFANT-NEWBORN.  PHOTOGRAPHY.
EX It had been noticed that in cases of cystic fibrosis the palmar skin
   of the fingers and the plantar skin of the toes wrinkled very quickly
   when immersed in water.  Almost without exception, the children with
   cystic fibrosis had noticeable wrinkling of the fingers within 2 min
   of immersion in hand-hot water, whereas normal children showed no (or
   minimal) wrinkling after 10 min.  This wrinkling is due to an excess
   of salt in the skin, which increases water-binding capacity of
   keratin.  The test would thus appear to provide a simple and cheap
   screening method for cystic fibrosis, but one that may not be
   absolutely reliable.
RF 001   ELLIOTT RB            LANCET                           2   108 974
   002   NORMAN AP             LANCET                           2   358 974
   003   LUNNON RJ             MEDICAL AND BIOLOGICAL ILLUST    9   150 959
   004   MOYNAHAN EJ           LANCET                           2   399 974

PN 75129
RN 00295
AN 76009233
AU Vagenakis-A-G.  Braverman-L-E.
TI Adverse effects of iodides on thyroid function.
SO Med-Clin-North-Am. 1975 Sep. 59(5). P 1075-88. (REVIEW).
MJ IODIDES: ae.  THYROID-DISEASES: ci.  THYROID-GLAND: de.
MN CYSTIC-FIBROSIS: co.  DRUG-SYNERGISM.  GOITER: ci.
   GOITER-EXOPHTHALMIC: co.  HUMAN.  HYPERTHYROIDISM: ci, dt.
   HYPOTHYROIDISM: ci, co.  INFANT-NEWBORN.
   INFANT-NEWBORN-DISEASES: ci.  IODINE: me, pd, tu.  LACTATION.   
   MATERNAL-FETAL-EXCHANGE.  PREGNANCY.  REVIEW.  THYROID-DISEASES: di.
   THYROID-GLAND: me.  THYROID-HORMONES: me.
   THYROIDITIS-LYMPHOMATOUS: co.  SUPPORT-U-S-GOVT-P-H-S.
AB The administration of pharmacologic quantities of iodine such as
   iodides for the treatment of pulmonary disease, organic iodine
   present in medications and x-ray contrast dyes, and the ingestion of
   iodine-rich natural foods, may result in goiter, hypothyroidism, or
   hyperthyroidism, especially in patients with underlying thyroid
   disease. Medications containing iodide may induce hypothroidism in
   euthyroid patients with Hashimoto's thyroiditis, 131I or surgically
   treated Graves' disease, or following hemithyroidectomy for nodules;
   and they may induce hyperthyroidism in patients with endemic iodine-
   deficient goiter, autonomous nodules or nontoxic nodular goiter, or
   in patients recently treated with antithyroid drugs for Graves'
   disease. Rarely, hypothyroidism or hyperthyroidism may develop in
   patients with completely normal thyroid function during
   administration of iodide. The etiology of iodide-induced goiter and
   hypothyroidism in patients with cystic fibrosis remains obscure.
   Iodide-induced myxedema may also occur in patients receiving drugs
   which alter thyroid function, such as lithium, phenazone, and
   sulfisoxazole. Finally, iodides do have a role in the treatment of
   hyperthyroidism but their use should probably be restricted to
   thyroid storm, preoperative preparation of the hyperthyroid patient,
   and following 131I treatment.
RF 001   AHMED M               J CLIN ENDOCRINOL METAB         38   574 974
   002   ALEXANDER WD          Q J MED                         31   281 962
   002   ALEXANDER WD          LANCET                           2   866 965
   003   ANDERSON FB           ACTA ENDOCRINOL                 73    35 973
   005   BEGG TB               Q J MED                         32   351 963
   006   BELL CO               TRANS AM GOITER ASSOC                 28 952
   007   BIERWALTER WH         BULL ALL INDIA INST MED SCI      3   145 969
   008   BOYLE JA              J CLIN ENDOCRINOL METAB         25  1255 965
   009   BLUM M                N ENGL J MED                   291    24 974
   010   BRAVERMAN LE          J CLIN INVEST                   42  1216 963
   011   BRAVERMAN LE          J CLIN ENDOCRINOL METAB         32   515 971
   012   BRAVERMAN LE          TRANS ASSOC AM PHYSICIANS       84   130 971
   013   BRAVERMAN LE          N ENGL J MED                   281   816 969
   014   DEODHAR SD            ENDOCRINOLOGY                   85   629 969
   014   CONNOLLY RJ           LANCET                           1   500 970
   015   EMERSON CH            J CLIN ENDOCRINOL METAB         40    33 975
   016   ERMANS AM             ACTA ENDOCRINOL                 70   463 972
   017   FEINBERG WD           J CLIN ENDOCRINOL METAB         19   567 959
   018   FISHER DA             J CLIN ENDOCRINOL METAB         33   667 971
   019   GALTON VA             ENDOCRINOLOGY                   64   835 959
   019   HAGEN GA              N ENGL J MED                   277   559 967
   020   HALL R                CLIN EXP IMMUNOL                 1   205 966
   021   HAMILTON CR JR        MEDICINE (BALTIMORE)            52   195 973
   022   HURXTHAL LE           LAHEY CLIN BULL                  4    73 945
   023   INGBAR SH             ENDOCRINOLOGY                   53   171 953
   024   INGBAR SH             IN: WILLIAMS RH                      119 974
   025   JACKSON AS            BOSTON MED SURG J              193  1138 925
   026   KOUTRAS DA            J CLIN ENDOCRINOL METAB         24   867 964
   027   MILNE K               ENDOCRINOLOGY                   71   580 962
   028   MORTON ME             J BIOL CHEM                    154   381 944
   029   NAGATAKI S            ENDOCRINOLOGY                   74   731 964
   030   PASTERNAK DP          ENDOCRINOLOGY                   84   769 969
   031   RABEN MS              ENDOCRINOLOGY                   42   107 948
   033   SHOPSIN B             AM J MED                        55   695 973
   034   STANLEY MD            J CLIN ENDOCRINOL METAB          9   941 949
   035   SUZUKI H              ACTA ENDOCRINOL                 50   161 965
   036   SUZUKI H              J CLIN ENDOCRINOL METAB         34   332 972
   037   TIMMERMANS J          CONGENITALE JODIDEKROP MOCAND   31   308 963
   038   VAGENAKIS AG          J CLIN INVEST                   52   528 973
   039   VAGENAKIS AG          ENDOCRINOLOGY                   94  1669 974
   040   VAGENAKIS AG          J CLIN INVEST                   54   913 974
   041   VAGENAKIS AG          N ENGL J MED                   287   523 972
   042   VIDOR GI              J CLIN ENDOCRINOL METAB         37   901 973
   043   WARTOFSKY L           J CLIN ENDOCRINOL METAB         33   488 971
   044   WARTOFSKY L           J CLIN INVEST                   49    78 970
   044   WARTOFSKY L           JAMA                           226  1083 973
   045   WOLFF J               AM J MED                        47   101 969
   046   WOLFF J               J BIOL CHEM                    174   555 948
CT   1   RODESCH F             AM J OBSTET GYNECOL            126   723 976
     2   COOPER DS             CLIN ENDOCRINOL METAB            7   199 978
     3   EMRICH D              CLIN ENDOCRINOL                  8   257 978
     4   TORTOROLO G           MINERVA PEDIATR                 30   659 978
     5   COBB WE               AM J HOSP PHARM                 35    51 978
     6   RODESCH F             ANN ENDOCRINOL PARIS            39   145 978
     7   PEKONEN F             ANN CHIR GYNAECOL               67   165 978
     8   REINWEIN D            LANGENBECKS ARCH CHIR          347   145 978
     9   BRAVERMAN LE          CLIN ENDOCRINOL METAB            8   621 979
    10   BEKAERT J             COEUR MED INTERNE               18   241 979
    11   JACKSON R             CANCER TREAT REP                63  1393 979
    12   BREUEL HP             MED KLIN                        74  1492 979
    13   THEODOROPOULOS T      SCIENCE                        205   502 979
    14   BAJORUNAS DR          CLIN ENDOCRINOL METAB            9   405 980
    15   RABER JH              DRUG INTEL CLIN PHARM           14   344 980
    16   REINER RG             DIG DIS SCI                     25   379 980
    17   BECROFT DMO           ARCH DIS CHILD                  55   213 980
    18   DOSREMEDIOS LV        ARCH INTERN MED                140  1045 980
    19   STERNTHAL E           N ENGL J MED                   303  1083 980
    20   VOLF V                ATOMKERNENERG KERNTECH          37    50 981
    21   OBER KP               ARCH INTERN MED                141  1225 981
    22   KLEINMANN RE          CATHET CARDIOVASC DIAGN          8   261 982
    23   EMANUELE  R           RIC CLIN LAB                    12   589 982
    24   WEMEAU JL             THERAPIE                        37    95 982
    25   SAFRAN M              OBSTET GYNECOL                  60    35 982
    26   COYLE PJ              ANN R COLL SURG ENGL            64   334 982
    27   PONT A                WEST J MED                     136   255 982
    28   FRADKIN JE            MEDICINE                        62     1 983
    29   CHEN BX               CHIN MED J                      96   235 983
    30   DAHLBERG PA           ACTA ENDOCRINOL                104   195 983
    31   MCGOVERN B            CLIN CARDIOL                     7   131 984
    32   ROBUSCHI G            ACTA DIABETOL LAT               21   357 984
    33   FABRE JL              ANN CARDIOL ANGEIOL (PARIS)     33   175 984
    34   MAZONSON PD           AM J MED                        77   751 984
    35   RAJATANAVIN R         AM J MED                        77   378 984
    36   BECKER DV             JAMA                           252   659 984
    37   WILKIN JK             CUTIS                           36   335 985
    38   JANSSON R             J CLIN ENDOCRINOL METAB         60   168 985
    39   MARIGOLD JH           BR J SURG                       72    45 985
    40   HAWTHORNE GC          ARCH INTERN MED                145  1016 985
    41   DRALLE H              LANGENBECKS ARCH CHIR          365    79 985
    42   ABALOVICH MS          MED (BUENOS AIRES)              46     9 986
    43   MARTINO E             J CLIN ENDOCRINOL METAB         63  1233 986
    44   TAJIRI J              J CLIN ENDOCRINOL METAB         63   412 986
    45   SAFRAN M              AM J MED SCI                   292   136 986
    46   ROBUSCHI GV           J ENDOCRINOLOGICAL INVEST       10   183 987
    47   MECHLIS S             AM J CARDIOL                    59   833 987

PN 75130
RN 00296
AN 75216046
TI Vitamin E.
SO Med-Lett-Drugs-Ther. 1975 Aug 15. 17(17). P 69-70.
MJ HEART-DISEASES: dt.  VITAMIN-E-DEFICIENCY.  VITAMIN-E: tu.
MN ADULT.  ANEMIA-HEMOLYTIC: et.  CYSTIC-FIBROSIS: co.  HUMAN.  INFANT.
   LIVER-CIRRHOSIS-BILIARY: co.  PORPHYRIA: dt.
   VITAMIN-E-DEFICIENCY:  co.  VITAMIN-E: ad, ae.
EX Vitamin E has been claimed to prevent, ameliorate, or cure skin
   disease, warts, ulcers, strabismus, baldness, frostbite, arthritis,
   jaundice, muscular dystrophy, diabetes, liver dysfunction, thyroid
   disease, sexual impotence, and aging.  The vitamin has recently been
   added to cosmetics, used as a deodorant, and alleged to be an
   effective antidote to air pollution.  There is no evidence that large
   doses of vitamin E are effective for the prevention or treatment of
   heart disease or any other human disorder, except in premature
   infants and possibly in patients with diseases that impair fat
   absorption.  Adverse effects, though rare, have resulted from
   ingestion of large doses of vitamin E.
RF 001   HORWITT MK            AM J CLIN NUTR                  27  1182 974
   002   BIERI JG              NUTR REV                        33   161 975
   003   OSKI FA               J PEDIATR                       70   211 967
   004   WILLIAMS ML           N ENGL J MED                   292   887 975
   005   HORWITT MK            AM J CLIN NUTR                  12    99 963
   006   VOGELSANG A           NATURE                         157   772 946
   007   SHUTE WE              VITAMIN E FOR AILING AND HEAL            970
   008   BAILEY H              VITAMIN E YOUR KEY TO A HEALT            966
   009   LEVY H                ANN INTERN MED                  28  1117 948
   010   RAVIN IS              N ENGL J MED                   240   331 949
   011   MAKINSON DH           LANCET                           1   102 948
   012   RINZLER SH            CIRCULATION                      1   288 950
   013   ANDERSON TW           CAN MED ASSOC J                110   401 974
   014   HAEGER K              AM J CLIN NUTR                  27  1179 974
   015   ANON                  BR MED J                         4   251 971
   016   SHARMAN IM            BR J NUTR                       26   265 971
   017   LAWRENCE JD           AM J CLIN NUTR                  28   205 975
   018   NAIR PP               ARCH INTERN MED                128   411 971
   019   WATSON CJ             ARCH INTERN MED                131   698 973
   020   ANDERSON TW           CAN MED ASSOC J                110   401 974
   021   CORRIGAN JJ JR        JAMA                           230  1300 974
CT   1   STEWART JA            SOUTH MED J                     73  1297 980

PN 75131
RN 00297
AN 75156136
AU Woodruff-C.  Barbero-G-J.
TI The challenges of cystic fibrosis.
SO Mo-Med. 1975 Mar. 72(3). P 129-33.
MJ CYSTIC-FIBROSIS.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: di, th.  FEMALE.  HOSPITALS.  HUMAN.  INFANT.
   INFANT-NEWBORN.  MALE.  MISSOURI.
EX Cystic fibrosis (CF) is a generalized disorder of the exocrine glands
   inherited as a recessive genetic trait.  The disease was more fully
   described as a specific entity in 1939 with a pathology of dilated
   ducts and fibrotic changes in the pancreas and copious secretory
   intraluminal obstruction of the bronchial tree.  The symptoms
   predominately involve the gastrointestinal tract as more frequent,
   bulky, malformed and malodorous stools and the respiratory system as
   cough, wheezing and signs of chronic respiratory obstruction.  In
   certain instances, only one of these two systems will have manifest
   symptoms and signs.  An increased concentration of sodium and
   chloride in the sweat was discovered in 1953.  The elevated salt
   concentration of the sweat has proven to be a reliable diagnostic
   tool to confirm the presence of the disease.  Few diseases present in
   so many different forms, degrees of severity and at different ages as
   does CF.  All present treatments for cystic fibrosis are essentially
   symptomatic.  Since the study of families having a child with cystic
   fibrosis has shown an incidence of the disease in one fourth of their
   siblings, classification of the disease as an autosomal recessive
   genetic disorder suggests that the concept of an abnormal gene
   related to alteration in a single enzyme should apply.  The diagnosis
   of cystic fibrosis in childhood is an overwhelming even to the
   patient and his family.
RF 001   BLACKFAN KD           J PEDIATR                       13   627 938
   002   ANDERSEN DH           AM J DIS CHILD                  56   344 938
   003   DI SANTAGNESE PA      AM J MED                        15   777 953
   004   GIBSON LE             PEDIATRICS                      23   545 959
   005   SEKELJ P              AM REV RESPIR DIS              108   603 973
   006   BARBERO GJ            AM J DIS CHILD                 112   536 966
   007   MANGOS JA             PEDIATR RES                      2   378 968
   008   SPOCK A               PEDIATR RES                      1   173 967
   009   BOWMAN BH             SCIENCE                        164   325 969
   010   MANGOS JA             FUNDAMENTAL PROB CF AND RELAT            973
   011   DANES BS              J EXP MED                      136  1313 972
   012   MARTINEZ JR           CF CLUB ABST                             974

PN 75132
RN 00298
AN 75176450
AU Kuzemko-J-A.
TI Recurrent diarrhoea in children.
SO Nurs-Mirror. 1975 Jul 10. 141(2). P 55-8.
MJ DIARRHEA: et.  DIARRHEA-INFANTILE: et.  INTESTINAL-DISEASES: co.
MN CELIAC-DISEASE: co.  CHILD.  CHILD-PRESCHOOL.
   COLITIS-ULCERATIVE:  co.  CYSTIC-FIBROSIS: co.  ENTERITIS: co.   
   FOOD-HYPERSENSITIVITY: co.  GIARDIASIS: co.  HUMAN.  INFANT.   
   INTESTINAL-DISEASES-PARASITIC.  RECURRENCE.
EX Diarrhoea can be defined as the passage of loose stools and increased
   bowel frequency above the accepted norm for the individual and
   resulting in excess loss of water and electrolytes in the faeces.  It
   may or may not be associated with steatorrhea (fatty stools).
   History plays a vital part in the diagnosis of gastro-intestinal
   disease in children.  Time spent here is often more rewarding than a
   battery of specialised investigations.  One must be clear what the
   parent means by diarrhoea, as terminology among doctors, nurses, and
   parents is often confusing.  When dealing with children one must
   always adopt a comprehensive approach and consider the whole child
   and his family.  Common causes, mechanisms, and consequences are
   discussed.  Some of the common causes of diarrhoea are cystic
   fibrosis, gluten-induced enteropathy (coeliac disease), Giardia
   lamblia, sugar intolerance, gastro-intestinal allergy, and irritable
   bowel syndrome.

PN 75133
RN 00299
AN 75176353
AU Noakes-S.
TI Nursing care study: Sally--a child with cystic fibrosis.
SO Nurs-Times. 1975 Jun 5. 71(23). P 876-7.
MJ CYSTIC-FIBROSIS: nu.  PEDIATRIC-NURSING.
MN CHILD-PRESCHOOL.  FEMALE.  HUMAN.
EX Fibrocystic disease is a common disease of childhood and the pancreas
   is abnormal in 90% of these cases.  There is fibrosis with atrophy of
   the exocrine parenchymal tissue, but islet cell tissue is rarely
   involved.  Mucous glands throughout the body are grossly distended
   and they secrete an abnormal viscid mucus.  Sweat glands appear
   normal, but they secrete sweat with an abnormally high concentration
   of electrolytes.  A characteristic feature of the disease is the
   widespread chronic bronchiolitis.  This is due to the Staphylococcus
   aureus which grow best in a salt-rich medium.

PN 75134
RN 00300
AN 76031006
AU Craig-J-M.
TI The pathology of infertility.
SO Pathol-Annu. 1975. 10. P 299-328. (REVIEW).
MJ INFERTILITY-FEMALE: pa.  INFERTILITY-MALE: pa.
MN ADNEXITIS: co.  CHROMOSOME-ABNORMALITIES: pa.  CRYPTORCHISM: pa.
   CYSTIC-FIBROSIS: co.  DIABETES-MELLITUS: co.  ENDOCRINE-DISEASES: co.
   ENDOMETRIOSIS: co.  FEMALE.  GENITAL-DISEASES-FEMALE: co.  HUMAN.
   IATROGENIC-DISEASE.  INFANT.  INFANT-NEWBORN.
   KLINEFELTERS-SYNDROME:  pa.  MALE.  METABOLISM-INBORN-ERRORS: co.
   MYOCLONUS: co.  ORCHITIS:  pa, et.  PREGNANCY.  REVIEW.
   SALPINGITIS: pa.  SCLEROSIS.  SEMINIFEROUS-TUBULES: pa.
   SPERM-MATURATION.  INFERTILITY-FEMALE: et.  INFERTILITY-MALE: et, fg.   
   UTERINE-DISEASES: co.  VARICOCELE: co, pa.
EX In most series of infertility patients, approximately 40 to 60
   percent have no discernible cause for infertility.  No wonder that
   those working with this condition tend to seize upon any demonstrable
   tissue abnormality as related to the infertility.  The use of
   fallible diagnostic tools may lead to misdiagnosis and inappropriate
   treatment.  In studies of the accuracy of dye injections to
   demonstrate tubal patency by roentgenogram the large errors
   introduced by these methods were emphasized.  Between 30 to 40
   percent of tubes found blocked by using a single dye examination and
   using the criterion of "filling but not spilling" into the peritoneal
   cavity, or with apparent obstruction at the uterotubal junction, were
   subsequently found to be patent.  Similar data were offered by
   others.  Lesions with less obvious and demonstrable causal
   relationship to infertility, such as pelvic adhesions and
   endometriosis, are more difficult to judge as to their etiologic
   relation.  These are assessed in discussions of male and female
   infertility.
RF 001   ACOSTA AA             OBSTET GYNECOL                  42    19 973
   002   ARRONET CH            FERTIL STERIL                   20   903 969
   003   BAEYERTZ JD           AUST NZ J OBSTET GYNAECOL        7   284 967
   004   BOYD IA               J OBSTET GYNAECOL BR COMMONW    80   142 973
   005   BROGGEN A             ACTA ENDOCRINOL                 48   490 965
   006   CARSWELL F            POSTGRAD MED J                  42   277 966
   007   CHANDLEY AC           CYTOGENETICS                    10   295 971
   008   CHANG MD              FERTIL STERIL                   15    97 964
   009   CHAMY CW              JAMA                           204  1165 968
   010   CLARKE BG             JAMA                           198  1121 966
   011   COOK ID               J OBSTET GYNAECOL BR COMMONW    79   697 972
   012   COOPER HE             AM J OBSTET GYNECOL            100   371 968
   013   CRAIG JM              AM J OBSTET GYNECOL             97   100 967
   014   DEKRETSER DM          J ENDOCRINOL                    40   107 968
   015   DEKRETSER DM          J CLIN ENDOCRINOL METAB         35   392 972
   016   DE LA BALZE FA        J CLIN ENDOCRINOL METAB         22  1251 962
   017   DE LA BALZE FA        J CLIN ENDOCRINOL METAB         12  1426 952
   018   DENNING CR            PEDIATRICS                      41     7 968
   019   DI POALA GR           INT J FERTIL                    16   189 971
   020   DORING GK             GEBURTSHILFE FRAUENHEILKD       30   302 970
   021   DUBIN L               FERTIL STERIL                   20    50 969
   022   ETRIBY A              FERTIL STERIL                   18   666 967
   023   FAIRLY KF             LANCET                           1   568 972
   024   GALL EA               AM J PATHOL                     23   637 947
   025   GRANT A               INT J FERTIL STERIL              9   503 964
   026   GRANT A               AUST NZ J OBSTET GYNAECOL        9   224 969
   027   HEDBERG E             ACTA OBSTET GYNECOL SCAND       37   131 958
   028   HECKER WC             DTSCH MED WSCHR                 97  1325 972
   029   HORTLING H            J CLIN ENDOCRINOL METAB         27   120 967
   030   HOWARD JE             J CLIN ENDOCRINOL METAB         10   121 950
   031   JENSEN PA             AM J OBSTET GYNECOL            113   150 972
   032   KAPLAN E              N ENGL J MED                   279    65 968
   033   KOZAK GP              IN: MARBLE A                             971
   034   LANDING BH            ARCH PATHOL                     88   569 969
   035   LEE PA                AM J DIS CHILD                 127   530 974
   036   LILIEQUIST B          ACTA OBSTET GYNECOL SCAND       43   240 964
   037   MACKEY RA             FERTIL STERIL                   22   504 971
   038   MACLEOD J             FERTIL STERIL                   20   545 969
   039$  MACLEOD J             OBSTET GYNECOL                  26   335 971
   040   MORAES-RUEHSEN M      FERTIL STERIL                   18   440 968
   041   NEU RL                FERTIL STERIL                   24   811 973
   042   NOYES RW              IN: ENDERS AC                        197 963
   043   PAREKH M              CLIN OBSTET GYNECOL             15     1 972
   044   PARR EL               J EXP MED                      126   523 967
   045   PETERSOHN L           ACTA OBSTET GYNECOL SCAND       49   331 970
   046   PHADKE AN             FERTIL STERIL                   24   802 973
   047   PLONUM L              ACTA OBSTET GYNECOL SCAND       39   143 960
   048   PRINZ W               GYNAECOLOGIA                   167    23 968
   049   QUAN A                OBSTET GYNECOL                  22    96 963
   050   RANNEY B              AM J OBSTET GYNECOL            107   743 970
   051   RICHTER P             CANCER                          25  1026 970
   052   RIMOIN DL             AM J MED                        44   225 968
   053   ROGERS SF             FERTIL STERIL                   19   529 968
   054   RUBIN IC              SURG GYNECOL OBSTET            103   469 956
   055   RUBIN IC              TRANS NJ OBSTET SOC              2    77 957
   056   RYAN G                AM J OBSTET GYNECOL             90   715 964
   057   SAEZ JM               J CLIN ENDOCRINOL METAB         32   604 971
   058   SARTO E               CLIN OBSTET GYNECOL             15   183 972
   059   SCHENKER JF           SURG GYNECOL OBSTET            135    74 972
   060   SIMPSON JL            CLIN OBSTET GYNECOL             15   157 972
   061   SKAKKEBAEK NE         FERTIL STERIL                   21   652 970
   062   SKAKKEBAEK NE         ACTA PATH MICROBIOL SCAND (A)   81    97 973
   063   SKAKKEBAEK NE         ACTA PATH MICROBIOL SCAND (A)   81   112 973
   064   SOHVAL AR             PHYSIOL REV                     43   263 963
   065   SOUTHAM AC            FERTIL STERIL                    8    25 957
   066   VALMAN HB             LANCET                           2   566 969
   067   VAN DEN BERGH H       J CLIN ENDOCRINOL METAB         28  1370 968
   068   VARE AM               FERTIL STERIL                   24   793 973
   069   WARREN SL             PATHOLOGY OF DIABETES                    966
   070   WILSON JD             N ENGL J MED                   290  1097 974
   071   WONG TW               ARCH PATHOL                     95   151 973
   072   WONG TW               ARCH PATHOL                     95   160 973
CT   1   HONORE LH             FERTIL STERIL                   29   164 978
     2   NEWBOLD RR            AM J PATHOL                    117   333 984
     3   NEWBOLD RR            TERATOGEN CARCINOGEN MUTAGEN     5   473 985
     4   PESCE CM              ARCH ANDROL                     15   193 985
     5   WIEDEMANN R           GEBURTSHILFE FRAUENHEILKD       47    96 987

PN 75135
RN 00301
AN 76076809
AU Shwachman-H.
TI Gastrointestinal manifestations of cystic fibrosis.
SO Pediatr-Clin-North-Am. 1975 Nov. 22(4). P 787-805. (REVIEW).
MJ CYSTIC-FIBROSIS: co.  INTESTINAL-DISEASES: co.
MN ADOLESCENCE.  ADULT.  APPETITE.  CHILD.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: dh, di.  DIABETES-MELLITUS: co.  FEMALE.
   GROWTH-DISORDERS: co.  HUMAN.  HYPERTENSION-PORTAL: co.  INFANT.
   INFANT-NEWBORN.  INTESTINAL-OBSTRUCTION: co.  INTUSSUSCEPTION: co.
   LACTOSE-INTOLERANCE: co.  LIVER-CIRRHOSIS: co.  MALE.  MECONIUM.
   PANCREAS: pp.  PANCREATITIS: co.  RECTAL-PROLAPSE: co.  REVIEW.
EX From a historical view cystic fibrosis (CF) has been considered a
   disease of the pancreas which results in maldigestion and loss of
   fat, and nitrogen in the stool.  A number of early synonyms included
   congenital steatorrhea, pancreatic infantilism, and pancreatic
   fibrosis.  The concern of the pediatrician in the late 1930's and
   early 1940's was to distinguish nonfatal celiac disease from fatal
   cystic fibrosis.  In 1954, Shwachman presented clinical and
   laboratory features that distinguish these two entities.  Today one
   is not justified in making a diagnosis of celiac disease without a
   confirmatory small intestinal biopsy coupled with a normal sweat
   test.  A number of gastrointestinal complications in cystic fibrosis
   are examined: meconium ileus, intestinal obstruction, pancreatic
   insufficiency, lactase deficiency, intestinal impaction,
   intussusception, rectal prolapse, growth retardation, excessive
   appetite, cirrhosis and portal hypertension, gallbladder problems,
   and diabetes.  The article closes by recording the indications for
   the sweat test.
RF 001   ANDERSEN DH           AM J DIS CHILD                  56   344 938
   002   ANTONOWICZ I          PEDIATRICS                      49   847 972
   003   ANTONOWICZ I          PEDIATRICS                      42   492 968
   004   BERK RN               RADIOLOGY                      106   377 973
   006   COZZETTO FJ           PEDIATRICS                      32   228 963
   007   DONNISON AB           PEDIATRICS                      37   833 966
   008   GRAND RJ              CLIN PEDIATR                     9   588 970
   009   GREEN MN              PEDIATRICS                      21   635 958
   010   GREEN MN              AM J DIS CHILD                 100   365 960
   011   GREEN MN              PEDIATRICS                      41   989 968
   012   HADORN B              J PEDIATR                       73    39 968
   013   HANDWERGER S          N ENGL J MED                   281   451 969
   014   HOLSCLAW DS           J PEDIATR SURG                   9   867 974
   015   HOLSCLAW DS           PEDIATRICS                      48    51 971
   017   KOPEL FB              GASTROENTEROLOGY                62   483 972
   018   KOPITO L              J PEDIATR                       68   313 966
   019   KULCZYCKI LL          N ENGL J MED                   259   409 958
   020   LEBENTHAL E           AM J CLIN NUTR                  28   595 975
   021   LEBENTHAL E           GASTROENTEROLOGY                67   807 974
   022   LLOYD-STILL JD        PEDIATRICS                      53   678 974
   023   MADDOCK CL            AM J DIS CHILD                  66   370 943
   024   NEUHAUSER EBD         AM J ROENTG RAD THER            51   421 944
   025   NOBLETT HR            J PEDIATR SURG                   4   190 969
   026   OPPENHEIMER EH        J PEDIATR                       86   683 975
   027   OPPENHEIMER EH        PEDIATR RES                      7   339 973
   028   PARKINS RA            LANCET                           2   851 963
   029   ROSAN RC              AM J DIS CHILD                 104   625 962
   030   SHWACHMAN H           PEDIATR CLIN NORTH AM            1   389 954
   031   SHWACHMAN H           IN: SLEISENGER MH                   1206 973
   032   SHWACHMAN H           N ENGL J MED                   286  1300 972
   033   SHWACHMAN H           PEDIATRICS                      55    86 975
   034   SHWACHMAN H           PEDIATRICS                      46     3 970
   035   STEPHAN U             PEDIATRE                        10    63 974
   036   TUCKER AS             AM J ROENTG RAD THER NUCL MED   89  1048 963
   037   WATKINS JB            GASTROENTEROLOGY                68  1087 975
   038   WEBER AM              N ENGL J MED                   289  1001 973
   039   WILMSHURST EG         PEDIATRICS                      55    75 975
CT   1   ROY CC                N ENGL J MED                   297  1301 977
     2   ANGERPOINTNER T       Z KINDERCHIR GRENZGEB           24    99 978
     3   SCHWARZ HP            HELV PAEDIATR ACTA              33   351 978
     4   LAMBRECHT W           CHIRURG                         49   410 978
     5   ROSENSTEIN BJ         AM J DIS CHILD                 132  1043 978
     6   BRADLEY JA            BR MED J                         1   167 979
     7   BARRY MM              J AM DIET ASSOC                 75   446 979
     8   CUNNINGHAM DG         J COMPUT ASSIST TOMOGR           4   151 980
     9   LEDESMAMEDINA J       PEDIATR RADIOL                   9    61 980
    10   ARBORGH B             SCAND J GASTROENTEROL           15    73 980
    11   PSACHAROPOULOS HT     LANCET                           2    78 981
    12   CONGDEN PJ            ARCH DIS CHILD                  56   708 981
    13   MABOGUNJE OA          SURGERY                         90   114 981
    14   CHURCHILL RJ          JAMA                           245    72 981
    15   ROY CC                J PEDIATR GASTROENTEROL NUTR     1   469 982
    16   STAFFORD RJ           CLIN GASTROENTEROL              11   141 982
    17   BASS S                GASTROENTEROLOGY                84  1592 983
    18   ROSENSTEIN BJ         J PEDIATR                      103   667 983
    19   HODSON ME             POSTGRAD MED J                  60   225 984
    20   GILLARD BK            AM J DIS CHILD                 138   577 984
    21   PASCALI VL            EUR J PEDIATR                  143   133 984
    22   TAL A                 CLIN PEDIATR                    24   460 985
    23   GRAHAM N              CLIN RADIOL                     36   199 985
    24   NOUSIAARVANITAKIS S   ARCH PATHOL LAB MED            109   722 985
    25   VINOCUR CD            AM J SURG                      149   182 985
    26   RUBINSTEIN S          PEDIATRICS                      78   473 986
    27   DODGE JA              J ROY SOC MED                   79    27 986
    28   ROSENSTEIN BJ         AM J DIS CHILD                 140   966 986

PN 75136
RN 00302
AN 76076877
AU Araki-H.  Field-M.  Shwachman-H.
TI A new assay for cystic fibrosis factor: effects of sera from
   patients with cystic fibrosis in the in vitro electrical properties
   of rat jejunum.
SO Pediatr-Res. 1975 Dec. 9(12). P 932-4.
MJ CYSTIC-FIBROSIS: bl.  JEJUNUM: de.
MN ANIMAL.  BIOLOGICAL-ASSAY.  FRUCTOSE: pd.  GLUCOSE: pd.  HUMAN.
   IN-VITRO.  JEJUNUM: ph.  RATS.  TEMPERATURE.
AB The in vitro electrical properties of rat jejunum were utilized to
   assay a factor or factors in serum from patients with cystic fibrosis
   (CF). Sera from patients with CF were found to decrease short circuit
   current (SCC) and the SCC response to glucose, and to increase
   electrical resistance. These effects were present in all 24 patients
   with CF and 10 of 14 parents of CF patients and absent from the serum
   of 21 control subjects. This quantitative technique provides an
   alternative to the ciliostatic assays for the detection of the CF
   factor or factors.
RF 001   ASANO T               AM J PHYSIOL                   207   415 964
   002   BERATIS NG            PEDIATR RES                      7   958 973
   003   BOWMAN BH             SCIENCE                        164   325 969
   004   BOWMAN BH             SCIENCE                        167   871 970
   005   BROWN GA              LANCET                           2   639 971
   006   KAISER D              PEDIATR RES                      5   167 971
   007   LOCKHART LH           TEX REP BIOL MED                31   631 973
   008   MANGOS JA             SCIENCE                        158   135 967
   009   MORIN CL              BIOMEDICINE EXPRESS             19   133 973
   010   SCHULTZ SG            J GEN PHYSIOL                   47   567 964
   011   SPOCK A               PEDIATR RES                      1   173 967
   012   TAUSSIG LM            LANCET                           1  1367 972
   013   USSING HH             ACTA PHYSIOL SCAND              23   110 951
   014   WOOD RE               LANCET                           2  1452 973
CT   1   WOOD RE               AM REV RESPIR DIS              113   833 976
     2   DISANTAGNESE PA       N ENGL J MED                   295   534 976
     3   SHWACHMAN H           MEDICINE                        56   129 977
     4   ARAKI H               LANCET                           1   793 978
     5   IMPERO JE             PEDIATR RES                     12   108 978
     6   GILMORE JP            PROC SOC EXP BIOL MED          157    70 978
     7   MORRISSEY SM          MONOGR PAEDIATR                 10   102 979
     8   NAGY EC               PEDIATR RES                     13   729 979
     9   TUCKER RD             PEDIATR RES                     13  1371 979
    10   WILL PC               PEDIATR RES                     13  1129 979
    11   TUCKER RD             IEEE TRANS BIOMED ENG           26   607 979
    12   SCANLIN TF            CLIN CHEST MED                   1   424 980
    13   WILL PC               PEDIATR RES                     14  1245 980
    14   BANCHINI G            PEDIATR RES                     15  1073 981
    15   RUDIN DO              BIOL PSYCHIAT                   16   373 981
    16   ALBAZZAZ FJ           RESPIRATION                     46    88 984

PN 75137
RN 00303
AN 76052122
AU Cole-C-H.  Sella-G.
TI Inhibition of ouabain-sensitive ATPase by the saliva of patients
   with cystic fibrosis of the pancreas.
SO Pediatr-Res. 1975 Oct. 9(10). P 763-6.
MJ ADENOSINE-TRIPHOSPHATASE: ai.  CYSTIC-FIBROSIS: me.  OUABAIN: pd.
   SALIVA: an.
MN ADOLESCENCE.  CELL-MEMBRANE: en.  CHILD.  COMPARATIVE-STUDY.
   ERYTHROCYTES: en.  FEMALE.  HUMAN.  MAGNESIUM: pd.  MALE.
   PHOSPHORUS: ip.  POTASSIUM: pd.  SODIUM: pd.
AB A study has been made of the effect of saliva from children with
   cystic fibrosis of the pancreas (CFP) on various components of the
   ATP hydrolyzing enzyme system. The ouabain-sensitive ATPase activity
   of erythrocyte membranes prepared from intact erythrocytes
   preincubated with CFP saliva was 35 +/- 4 nmol Pi/mg fry wt membrane
   suspension/hr, compared with 48 +/- 7 nmol Pi/mg dry wt membrane
   suspension/hr when the erythrocytes were preincubated with control
   saliva. A calcium-activated component of ATPase was decreased from
   202 +/- 30 nmol Pi/mg dry wt membrane suspension/hr in erythrocytes
   preincubated with control saliva, to 151 +/- 17 nmol Pi/mg dry wt
   membrane suspension/hr when the incubation was carried out with CFP
   saliva. In a second series of experiments, ultrafiltered saliva was
   added directly to an ATPase assay. The saliva from children with CFP
   brought about a mean decrease in ouabain-sensitive ATPase of 16%
   compared with control saliva.
RF 001   BALFE JW              SCIENCE                        162   689 968
   002   BARNETT DR            TEX REP BIOL MED                31   703 973
   003   BESLEY GTN            IN: LAWSON D PROC 5TH INT CF          14 969
   004   COLE CH               PEDIATR RES                      6   616 972
   005   COLE CH               CLIN SCI MOL MED                45   775 973
   006   DUFFY MJ              CLIN CHIM ACTA                  50    97 974
   007   FEIG SA               PEDIATR RES                      8   594 974
   008   HANAHAN DJ            BIOCHIM BIOPHYS ACTA           255   413 972
   009   HORTON CR             BIOCHEM BIOPHYS RES COMMUN      40   505 970
   010   KAISER D              PEDIATR RES                      5   167 971
   011   KATZ AI               N ENGL J MED                   278   253 968
   012   KREUSSER W            EUR J CLIN INVEST                2   398 972
   013   LOWRY OH              J BIOL CHEM                    162   421 946
   014   MANGOS JA             PEDIATR RES                      1   436 967
   015   SCHATZMANN HJ         J PHYSIOL (LOND)               201   369 969
   016   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   017   SPOCK A               PEDIATR RES                      1   173 967
   018   TAYLOR A              PEDIATR RES                      8   861 974
   019   WIESMANN UN           LANCET                           2   510 972
CT   1   BOWMAN BH             TEX REP BIOL MED                34     1 976
     2   WARD JB               TEX REP BIOL MED                34    11 976
     3   WOOD RE               AM REV RESPIR DIS              113   833 976
     4   JAKEL HP              BIOL ZENTRALBL                  98    55 979
     5   BANCHINI G            PEDIATR RES                     15  1073 981
     6   ALADJEM M             NEPHRON                         34    84 983
     7   VONEULER AM           LIFE SCI                        37  2399 985

PN 75138
RN 00304
AN 75217264
AU Wilson-G-B.  Fudenberg-H-H.
TI Studies on cystic fibrosis using isoelectric focusing.  I. An assay
   for detection of cystic fibrosis homozygotes and heterozygote
   carriers from serum.
SO Pediatr-Res. 1975 Aug. 9(8). P 635-40.
MJ CYSTIC-FIBROSIS: fg.  HETEROZYGOTE.  HOMOZYGOTE.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: bl.
   FEMALE.  GELS.  HUMAN.  HYDROGEN-ION-CONCENTRATION.  IGG: an.
   INFANT.  ISOELECTRIC-FOCUSING.  MALE.  MIDDLE-AGE.
AB We have developed a standardized biophysical assay for the rapid
   detection of individuals homozygous or heterozygous for cystic
   fibrosis (C/F). The assay employs isoelectric focusing in thin layer
   polyacrylamide gels to analyze microliter quantities of whole serum
   for the presence of a C/F factor protein and for deletions in a group
   of proteins called proteins B, C, and D (Fig, 1). A pH 5-10 gradient
   is used (Fig. 2) and each sample is screened using a serum volume
   which contains 300 g immunoglobulin G (IgG). Individuals homozygous
   or heterozygous for C/F are distinguished from normal unaffected
   individuals on the basis of the presence of a C/F factor protein band
   (Table 1). Heterozygous carriers for C/F are distinguished from C/F
   homozygotes 75 percent of the time, on the basis of a deletion in
   either band B, C, or D (Table 2). On the basis of screening 65
   patients with cystic fibrosis, 61 heterozygous carriers for C/F, and
   105 normal control subjects, it was concluded that no obvious
   correlation existed between either sex, age, or severity of the
   disease in the individual C/F patient, and the absolute presence or
   absence of the C/F factor. In addition, no correlation existed
   between sex or age and the presence of the C/F factor or deletions in
   proteins B, C, and D in the individual heterozygous carrier for C/F
   or normal control subjects. Analysis of serum samples from 68
   patients with a variety of other diseases, many with clinical
   symptoms resembling those seen in the patient with cystic fibrosis
   (Table 3), indicated that the C/F factor protein described in this
   study appears to be diagnostic for C/F genotypes, with the possible
   exception of patients with certain types of leukemia.
RF 001   BARNETT DR            TEX REP BIOL MED                31   697 973
   002   BARNETT DR            TEX REP BIOL MED                31   703 973
   003   BERATIS NG            PEDIATR RES                      7   958 973
   004   BESLEY GTN            J MED GENET                      6   278 969
   005   BOWMAN BH             TEX REP BIOL MED                31   611 973
   006   BOWMAN BH             IN: MANGOS JA                         29 973
   007   BOWMAN BH             PROC NAT ACAD SCI USA           70   548 973
   008   BOWMAN BH             SCIENCE                        164   325 969
   009   BOWMAN BH             SCIENCE                        167   871 970
   010   CONNEALLY PM          TEX REP BIOL MED                31   639 973
   011   CONOVER JH            PEDIATR RES                      7   224 973
   012   CONOVER JH            CLIN RES                        21   531 973
   013   CONOVER JH            PEDIATR RES                      7   220 973
   014   CONOVER JH            LANCET                           1  1194 973
   015   CONOVER JH            LANCET                           2  1501 973
   016   CONOVER JH            LIFE SCI                        14   253 974
   017   DANES BS              J EXP MED                      137  1538 973
   018   DANKS DM              ANN HUM GENET                   28   323 965
   019   FAHEY JL              J IMMUNOL                       94    84 965
   020   GIBSON LE             PEDIATRICS                      23   545 959
   021   LOBECK CC             IN: STANBURY JB                     1605 972
   022   MANCINI G             IMMUNOCHEMISTRY                  2   235 965
   023   MANGOS JA             PEDIATR RES                      2   378 968
   024   MCCOMBS ML            TEX REP BIOL MED                31   615 973
   025   MCCOMBS ML            CLIN GENET                       1   171 970
   026   SCHMOYER IR           BIOCHEM BIOPHYS RES COMMUN      46  1923 972
   027   SHWACHMAN H           IN: KENDIG EL JR                     541 967
   029   SPOCK A               PEDIATR RES                      1   173 967
   030   WILLIAMSON AR         IN: WEIR DM                              973
   032   WILSON GB             DISSERT ABST INTERNAT           35   479 974
   034   WILSON GB             LIFE SCI                        15   551 974
   035   WILSON GB             CLIN CHIM ACTA                  49    79 973
CT   1   WILSON GB             SCAND J IMMUNOL                  5   828 976
     2   WILSON GB             PEDIATR RES                     10  1001 976
     3   WILSON GB             PEDIATR RES                     10    87 976
     4   WILSON GB             TEX REP BIOL MED                34    51 976
     5   ANON                  J PEDIATR                       88   711 976
     6   CHANGUS JE            ARCH PATHOL LAB MED            100     7 976
     7   WOOD RE               AM REV RESPIR DIS              113   833 976
     8   DISANTAGNESE PA       N ENGL J MED                   295   534 976
     9   THOMAS JM             PEDIATR RES                     11   138 977
    10   THOMAS JM             PEDIATR RES                     11  1148 977
    11   WILSON GB             PEDIATR RES                     11   139 977
    12   WILSON GB             PEDIATR RES                     11   317 977
    13   WILSON GB             PEDIATR RES                     11   986 977
    14   WILSON GB             PEDIATR RES                     11   143 977
    15   ARNAUD P              J IMMUNOL METH                  16   221 977
    16   BURDICK AB            HUM HERED                       27   366 977
    17   WILSON GB             NATURE                         266   463 977
    18   IMPERO JE             PEDIATR RES                     12   108 978
    19   SCHOLEY J             PEDIATR RES                     12   800 978
    20   WILSON GB             PEDIATR RES                     12   801 978
    21   WILSON GB             J LAB CLIN MED                  92   463 978
    22   ALLEN RC              J CHROMATOGR                   146     1 978
    23   TULLY GW              PEDIATR RES                     13  1078 979
    24   WILSON GB             PEDIATR RES                     13  1079 979
    25   MANSON JC             LANCET                           1   330 980
    26   WILSON GB             LANCET                           2   313 980
    27   MAYO BJ               CLIN GENET                      18   379 980
    28   WANG A                ARCH DIS CHILD                  55   130 980
    29   HALLINAN F            MED HYPOTHESES                   7   793 981
    30   NEVIN GB              HUM GENET                       56   387 981
    31   HALLINAN FM           CLIN CHIM ACTA                 117   103 981
    32   BOGART BI             PEDIATR RES                     16   223 982
    33   MCNEELY MC            PEDIATR RES                     16    21 982
    34   BULLOCK S             CLIN GENET                      21   336 982
    35   BROCK DJH             HUM GENET                       60    30 982
    36   HEELEY AF             CLIN CHEM                       29  2011 983
    37   WILSON GB             THYMUS                           6   167 984
    38   GRATAROLI R           PEDIATR RES                     18   130 984
    39   WILSON GB             CLIN GENET                      26   331 984
    40   GEDDES D              THORAX                          39   721 984
    41   PASCALI VL            EUR J PEDIATR                  143   133 984
    42   ANON                  LANCET                           2   249 985
    43   VANHEYNINGEN V        CYTOGENET CELL GENET            40   767 985
    44   SCAMBLER  P           HUM GENET                       69   250 985
    45   QURESHI AR            J PEDIATR                      106   913 985
    46   VANHEYNINGEN V        NATURE                         315   513 985
    47   HAYWARD C             J IMMUNOL METH                  91   117 986

PN 75139
RN 00305
AN 76076889
AU Rao-G-J.  Nadler-H-L.
TI Deficiency of arginine esterase in cystic fibrosis of the pancreas:
   demonstration of the proteolytic nature of the activity.
SO Pediatr-Res. 1975 Sep. 9(9). P 739-41.
MJ ARGININE: df.  CYSTIC-FIBROSIS: me.  ESTERASES: df.
MN ADOLESCENCE.  ARGININE: ai.  CHILD.  CHILD-PRESCHOOL.
   ENZYME-INHIBITORS: pd.  ESTERASES: ai.  HETEROZYGOTE.  HUMAN.
   HYDROLYSIS.  HYDROXYMERCURIBENZOATES: pd.  LUNG-DISEASES: me.
   PANCREATIC-DISEASES: me.  PEPTIDES: me.  PROTAMINES.
   TOSYLLYSINE-CHLOROMETHYL-KETONE: pd.  TRYPSIN-INHIBITORS: pd.
AB Proteolytic activity, defined as the hydrolysis of peptide bonds
   involving the carboxyl group of L-arginine, in plasma of patients
   with cystic fibrosis, heterozygotes, and control subjects has been
   assayed using a fluorometric method with protamine as the substrate
   and fluorescamine as the reagent. The mean total proteolytic activity
   in plasma of patients with cystic fibrosis was approximately one-half
   the mean total activity in control subjects and heterozygotes. The
   mean proteolytic activity inhibited by soybean trypsin inhibitor in
   plasma of patients with cystic fibrosis was approximately one-third
   that of control subjects and heterozygotes. The relationship of
   arginine esterase activity to proteolytic activity was investigated.
   The pH optimum and action of reversible and irreversible inhibitors
   were similar for both activities, suggesting that the arginine
   esterase activity and proteolytic activity represent similar
   catalytic entities. These findings are consistent with our hypothesis
   that the basic defect in cystic fibrosis may reside in the deficiency
   of a proteolytic enzyme which results in the accumulation of the
   various cationic macromolecular "factors" described by other
   investigators in serum of patients with cystic fibrosis. The
   demonstration of a deficiency of proteolytic activity as assayed by
   the hydrolysis of protamine, a cationic polypeptide, could explain
   the presence of ciliotoxic cationic protein or polypeptide factors in
   serum of patients with cystic fibrosis and may, in some unknown
   manner, be related to the clinical manifestations of the disease.
RF 001   BARNETT DR            TEX REP BIOL MED                31   697 973
   002   BARNETT DR            TEX REP BIOL MED                31   703 973
   003   BARRETT AJ            BIOCHEM J                      131   809 973
   004   BOWMAN BH             SCIENCE                        167   871 970
   005   BROWN F               BIOCHEM BIOPHYS RES COMMUN      53    75 973
   006   CHASE T JR            BIOCHEMISTRY                     8  2212 969
   007   COLMAN RW             J CLIN INVEST                   48    23 969
   008   CONOVER JH            LIFE SCI                        14   253 974
   009   GLOVER G              J BIOL CHEM                    246  4594 971
   010   GROSKOPF WR           J BIOL CHEM                    244   359 969
   011   LIEBERMAN J           PEDIATR RES                      3   571 969
   012   LOBECK CC             IN: STANBURY JB                     1605 972
   013   RAO GJS               J PEDIATR                       80   573 972
   014   RAO GJS               PEDIATR RES                      8   684 974
   015   RAO GJS               SCIENCE                        177   610 972
   016   SPOCK A               PEDIATR RES                      1   173 967
   017   TALAMO RC             PEDIATR RES                      6   430 972
   018   UDENFRIEND S          SCIENCE                        178   871 972
CT   1   SHAPIRA E             PEDIATR RES                     10   812 976
     2   BOWMAN BH             LIFE SCI                        19  1289 976
     3   BOWMAN BH             TEX REP BIOL MED                34     1 976
     4   SHAPIRA E             BIOCHEM BIOPHYS RES COMMUN      71   864 976
     5   CALLAHAN JW           PEDIATR RES                     11  1166 977
     6   RAO GJS               PEDIATR RES                     11   981 977
     7   BARRETT AJ            ACTA BIOL MED GER               36  1959 977
     8   COLMAN RW             THROMB HAEMOST                  38   751 977
     9   GOLDSMITH GH          J LAB CLIN MED                  89   131 977
    10   DANN LG               LANCET                           2   405 978
    11   PLATT MW              PEDIATR RES                     12   874 978
    12   SCHAAP T              ISR J MED SCI                   14   201 978
    13   RAO GJS               ENZYME                          23   314 978
    14   GUY GJ                CLIN CHIM ACTA                  87    63 978
    15   RAO GJS               BIOCHIM BIOPHYS ACTA           541   435 978
    16   BOAT TF               ACS SYMPOSIUM SERIES          1978   108 978
    17   DANN LG               LANCET                           2   907 979
    18   WALSHPLATT M          ENZYME                          24   224 979
    19   WALSH MMJ             PEDIATR RES                     14   353 980
    20   LASZLO A              ACTA PAEDIATR ACAD SCI HUNG     21    69 980
    21   NADLER HL             PEDIATRICS                      66   690 980
    22   WALSH MMJ             AM J OBSTET GYNECOL            137   978 980
    23   BURY AF               PEDIATR RES                     16   613 982
    24   SCHWARTZ M            CLIN CHIM ACTA                 124   213 982
    25   TUMMLER B             CLIN CHIM ACTA                 125   219 982
    26   BROCK DJH             PRENAT DIAGN                     3     1 983
    27   BRANCHINI BR          PEDIATR RES                     17   850 983
    28   HEELEY AF             CLIN CHEM                       29  2011 983
    29   SLOMIANY A            J BIOL CHEM                    258  8535 983
    30   BRIDGES MA            ANN NY ACAD SCI                421   360 983
    31   SEYMOUR CA            BIOESSAYS                        1    38 984

PN 75140
RN 00306
AN 76076886
AU Conod-E-J.  Conover-J-H.  Hirschhorn-K.
TI Demonstration of human leukocyte degranulation induced by sera from
   homozygotes and heterozygotes for cystic fibrosis.
SO Pediatr-Res. 1975 Sep. 9(9). P 724-9.
MJ CYSTIC-FIBROSIS: bl.  CYTOPLASMIC-GRANULES.  GLUCURONIDASE: an.
   MYELOPEROXIDASE: an.  NEUTROPHILS: en.  PEROXIDASES: an.
MN AMINOCAPROIC-ACIDS: pd.  ANIMAL.  CARRIER-STATE.  CILIA: de.
   CYSTIC-FIBROSIS: en.  CYTOCHALASIN-B: pd.
   CYTOPLASMIC-GRANULES: en, de.  GLUCURONIDASE: ai.  HETEROZYGOTE.
   HOMOZYGOTE.  HUMAN.  IGG: me.  NEUTROPHILS: de.  TRACHEA: cy.
AB The ability of epsilon-amino caproic acid (EACA)-treated normal serum
   and of cystic fibrosis (CF)-affected and carrier sera to promote the
   release of lysosomal enzymes from sensitized human polymorphonuclear
   leukocytes (PMN) was assessed through the measurement of beta-
   glucuronidase and myeloperoxidase activity after exposure of these
   cells to the various test sera. This study was initiated to extend
   the analogies between preciliary dyskinesia factor (pre-CDF),
   separated from the cell-free media of cultures derived from CF
   homozygous and heterozygous individuals, and C3a anaphylatoxin. The
   extent of lysosomal degranulation of human PMN exposed to fresh
   untreated sera of each of five controls, seven CF homozygotes, and
   eight heterozygotes, as expressed by the amount of beta-glucuronidase
   releases, was 7.84% (+/- 0.934) for control sera, 14.01% (+/- 1.79)
   for CF-affected sera, and 10.61% (+/- 1.43) for heterozygous sera.
   The difference between CF homozygotes and control subjects is
   significant (P less than 0.0001), as is the difference between CF-
   affected and carrier individuals (0.001 less than P less than 0.005)
   and between control subjects and carriers (0.001 less than P less
   than 0.005), when beta-glucuronidase. However, the differences
   between control subjects and CF heterozygous individuals are not
   significant. Treatment of these sera with 1 M EACA gave values for
   beta-glucuronidase and myeloperoxidase release which are slightly
   reduced when compared with those obtained with fresh, untreated
   samples. EACA apparently reduces the activity of beta-glucuronidase
   released from PMN. Amicon filtration studies of these serum samples
   demonstrated that degranulating ability and the presence of cilicary
   dyskinesia, as assessed by rabbit tracheal bioassay, are not always
   associated. Therefore, the relationship between pre-CDF and the
   degranulator activity in native CF-affected and carrier sera is
   unclear, in part because of the limitations inherent in the test
   systems employed.
RF 001   BECKER EL             J IMMUNOL                      112  2047 974
   002   BERATIS NG            PEDIATR RES                      7   958 973
   003   BOWMAN BH             SCIENCE                        164   325 969
   004   BRITTINGER G          J CELL BIOL                     37   394 968
   005   CARTER SB             NATURE                         213  8261 967
   006   COCHRANE CG           J EXP MED                      127   371 968
   007   CONOVER JH            PEDIATR RES                      7   224 973
   008   CONOVER JH            PEDIATR RES                      7   220 973
   009   CONOVER JH            LIFE SCI                        14   253 974
   010   DANES BS              J EXP MED                      136  1313 972
   011   DAVIES P              LAB INVEST                      28    16 973
   012   DAVIS AT              PROC SOC EXP BIOL MED          137   161 971
   013   ESTENSEN RD           PROC NAT ACAD SCI USA           69  1430 972
   014   GOLDSTEIN IM          J IMMUNOL                      111    33 973
   015   GOLDSTEIN I           PROC NAT ACAD SCI USA           70  2916 973
   016   MULLER-EBERHARD HJ    HARVEY LECTURES                 66    75 971
   017   MULLER-EBERHARD HJ    IN: LEPOW IH                          83 972
   018   SPOCK A               PEDIATR RES                      1   173 967
   019   VALLOTA EH            J EXP MED                      137  1109 973
CT   1   BOWMAN BH             LIFE SCI                        19  1289 976
     2   BOWMAN BH             TEX REP BIOL MED                34     1 976
     3   HARPER BL             TEX REP BIOL MED                34    73 976
     4   WARD JB               TEX REP BIOL MED                34    11 976
     5   SCHNEYER CA           CELL TISSUE RES                169   111 976
     6   DISANTAGNESE PA       N ENGL J MED                   295   534 976
     7   WILSON GB             J LAB CLIN MED                  92   463 978
     8   PEARSON RD            PEDIATR RES                     13   834 979
     9   JAKEL HP              BIOL ZENTRALBL                  98    55 979
    10   SEALE TW              PEDIATR RES                     14  1398 980
    11   HUGHES WT             PEDIATR RES                     16   874 982
    12   ANON                  LANCET                           2   249 985
    13   VANHEYNINGEN V        NATURE                         315   513 985
    14   KEMP T                PEDIATR RES                     20   520 986

PN 75141
RN 00307
AN 76076866
AU Shapiro-B-L.  Smith-Q-T.  Warick-W-J.
TI Serum glutathione reductase and cystic fibrosis.
SO Pediatr-Res. 1975 Dec. 9(12). P 885-8.
MJ CYSTIC-FIBROSIS: en.  GLUTATHIONE-REDUCTASE: bl.
MN BLOOD-PROTEINS: an.  COMPARATIVE-STUDY.  CYSTIC-FIBROSIS: fg.
   FEMALE.  HEPARIN: pd.  HETEROZYGOTE.  HUMAN.
   LUNG-DISEASES-OBSTRUCTIVE: en.  MALE.  METHODS.  TIME-FACTORS.
AB Serum glutathione reductase (NADPH-GSSG oxidoreductase, EC. 1.6.4.2
   (GR)) has been examined in cystic fibrosis subjects (CF), obligate CF
   heterozygotes, and control subjects. Serum protein concentration was
   similar in the three groups. Regardless of the units used to express
   activity (milligrams of protein or milliliters of serum) or whether or
   not samples were dialyzed against water or phosphate buffer, mean
   serum GR in CF was greater than in control subjects (P less than or
   equal to 0.002) in all series over several years. Under the above
   assay conditions no difference in serum GR between control subjects
   and carriers was detected. Calculated and assayed values of combined
   control and CF sera agreed as did expected and observed 50% activity
   in 1:2 sera dilutions in CF, control subjects, and carriers. Addition
   of FAD to incubation media did not effect enzyme activity in the
   three groups. Differences between CF and control subjects persisted
   after dialysis in membranes permitting passage of molecules of
   approximately 12,000 mol wt or less. These findings would tend to
   exclude the effect of extraneous serum factors in explaining the
   differences between CF and control subjects. The percentage of
   initial GR activity after four days storage (0-4 degrees) was
   significantly greater in CF than in control subjects (P less than
   0.025). The effect of heparin on serum GR was recorded as the
   percentage of activity after incubation with heparin vs. activity in
   the standard assay for individual subjects. The effect of incubation
   with 5 mug/ml heparin on serum GR activity was greater in control
   subjects than in carriers (P less than 0.0005) and CF (P less than
   0.0005). Mean serum GR activity in CF and carriers was unaffected by
   heparin, whereas mean activity in control subjects was decreased. In
   no control was the percentage of initial activity with heparin
   greater than the mean of CF and carrier groups. Only 3 of 20 CF and 4
   of 20 carrier individuals had percentages lower than the control
   mean. The CF and carrier distributions were clearly different from
   the control distribution. Serum GR was determined in seven non-CF
   individuals with chronic obstructive pulmonary disease (COPD).
   Activity in the COPD was different from CF and no different from
   control subjects. In none of these controls or COPD was serum GR as
   great as the CF mean. Serum GR in no CF was as low as the mean of
   control subjects or COPD. It is concluded that serum GR activity is
   greater in CF than in control subjects, carriers, and non-CF COPD
   subjects; that the difference in activity is not attributable to an
   extraneous serum factor, that the activity difference is not
   secondary to chronic respiratory disease; that in comparison with
   control subjects, GR from CF serum behaves differently after storage;
   and that serum GR from CF and carriers behaves differently from
   control GR in the presence of heparin.
RF 001   BEUTLER E             SCIENCE                        165   613 969
   002   BREWER GJ             IN: YUNIS JJ                         139 969
   003   DOGGETT RG            NATURE NEW BIOL                243   250 973
   004   HARRIS H              PRIN OF HUMAN BIOCHEMICAL GEN            975
   005   HORN HD               IN: BERGMEYER HU                     876 965
   006   HORN HD               BIOCHEM Z                      331    58 958
   007   CAUDILL M             LANCET                           2   307 973
   008   LOBECK CC             IN: STANBURY JB                     1605 972
   009   LOWRY OH              J BIOL CHEM                    193   265 951
   010   MANGOS JA             PEDIATR RES                      2   378 968
   011   SHAPIRO BL            PROC IADR 47TH GENERAL MTG     503       969
   012   SHAPIRO BL            ANAT REC                       166    87 970
   013   SHAPIRO BL            BIOCHEM BIOPHYS RES COMMUN      39   816 970
   014   SHAPIRO BL            LANCET                           2  1020 974
   015   SHAPIRO BL            PROC SOC EXP BIOL MED          144   181 973
CT   1   STEPHAN U             INTERNIST                       17   336 976
     2   WILL PC               PEDIATR RES                     13  1129 979
     3   PRUSINER SB           ANNU REV MED                    32   521 981

PN 75142
RN 00308
AN 76052133
AU Hodes-M-E.  Thomas-J.  Morgan-S.  Merritt-A-D.
TI Do brine shrimp diagnose cystic fibrosis?.
SO Pediatr-Res. 1975 Nov. 9(11). P 812-6.
MJ CYSTIC-FIBROSIS: di.  SHRIMP.
MN ANIMAL.  BIOLOGICAL-ASSAY: mt.  CYSTIC-FIBROSIS: fg, bl.  GENOTYPE.
   HUMAN.  OXYGEN-CONSUMPTION.  SALIVA.  SHRIMP: me.
   SODIUM-CHLORIDE:  pd.
AB The nauplii of the brine shrimp Artemia salina are dependent upon the
   function of their salt gland to maintain osmotic pressure within
   narrow limits. A number of drugs interfere with this function and are
   lethal to the nauplii. Saliva and serum from normal persons, patients
   with cystic fibrosis, and obligate heterozygotes were tested for
   lethal effect against brine shrimp nauplii. At salt concentrations
   between 100 mM and 2.5 no difference was found among the phenotypes.
   At lower concentrations a difference was noted occasionally between
   some normal subjects and some individuals carrying one or two genes
   for cystic fibrosis. Data from an independent series of experiments
   indicate that the naupliar deaths result from distorted ratios of
   Na+/K+ and not from a specific gene product. No difference was noted
   in the O2 uptake of nauplii treated with saliva or serum obtained
   from normal subjects, patients with cystic fibrosis, or obligate
   heterozygotes.
RF 001   BARGMAN GJ            PEDIATR RES                      8   464 974
   002   CONNEALLY PM          TEX REP BIOL MED                31   639 973
   003   CONTE FP              J COMP PHYSIOL                  80   239 972
   005   EWING RD              J COMP PHYSIOL                  80   247 972
   006   HODES ME              PEDIATR RES                      8   212 974
   007   HOOTMAN SR            J COMP PHYSIOL                  79    97 972
   008   LOBECK CC             IN: STANBURY JB                     1605 972
   009   MANGOS JA             PEDIATR RES                      1   436 967
   010   SHWACHMAN H           HOSP PRACT                       9   143 974
CT   1   JAKEL HP              BIOL ZENTRALBL                  98    55 979

PN 75143
RN 00309
AN 75176050
AU Martinez-J-R.  Adelstein-E.  Quissel-D.  Barbero-G-J.
TI The chronically reserpinized rat as a possible model for cystic
   fibrosis.  I. Submaxillary gland morphology and ultrastructure.
SO Pediatr-Res. 1975 May. 9(5). P 463-9.
MJ CYSTIC-FIBROSIS: ci.  DISEASE-MODELS-ANIMAL.  RATS.  RESERPINE.
   SUBMANDIBULAR-GLAND: ul.
MN ANIMAL.  BODY-WEIGHT.  CELL-NUCLEUS: ul.  CYTOPLASM: ul.
   ENDOPLASMIC-RETICULUM: ul.  INJECTIONS-INTRAPERITONEAL.
   ISOPROTERENOL: pd.  MALE.  MICROSCOPY-ELECTRON.  MUCINS: me.
   MUCOPROTEINS: me.  NEURAL-TRANSMISSION: de.  ORGAN-WEIGHT.
   PILOCARPINE: pd.  RESERPINE: ad.  STIMULATION-CHEMICAL.
   SUBMANDIBULAR-GLAND: me, pa.
AB Rats treated for 7 days with reserpine develop structural changes in
   the submaxillary gland that resemble those that have been reported in
   cystic fibrosis. The salivary exocrinopathy is characterized by
   increased amounts of PAS-reactive mucoprotein in the acinar cells and
   by obstruction and dilatation of ducts by precipitated material with
   the same staining characteristics as those found in the acinar
   elements.
RF 001   BARBERO GJ            IN: DI SANTAGNESE PA                 208 964
   002   BENMILOUD M           ACTA PHYSIOL SCAND              59    34 963
   003   BLOMFIELD J           GUT                             14   558 973
   004   CHERNICK WS           ANN NY ACAD SCI                106   698 963
   005   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   006   DI SANTAGNESE PA      N ENGL J MED                   277  1344 967
   007   DI SANTAGNESE PA      N ENGL J MED                   277  1399 967
   008   DOGGETT RG            J CLIN PATHOL                   24   270 971
   009   JOHANSEN PG           ANN NY ACAD SCI                106   755 963
   010   LEESON CR             HANDBOOK OF PHYSIOLOGY SECT 6    2   463 967
   011   LEV R                 AM J PATHOL                     46    23 965
   012   MANGOS JA             SCIENCE                        158   135 967
   013   PREECE A              MANUAL FOR HISTOLIC TECHNIC              972
   014   SCOTT BL              AM J ANAT                      104   115 959
   015   SHACKLEFORD JM        J HISTOCHEM CYTOCHEM            12   512 964
   016   SHACKLEFORD JM        IN: DI SANTAGNESE PA                  51 966
   017   SPICER SS             ANN NY ACAD SCI                106   379 963
   018   SPICER SS             IN: DI SANTAGNESE PA                  26 966
   019   TAMARIN A             ANN NY ACAD SCI                106   609 963
   020   TAYLOR PW JR          J PHARMACOL EXP THER           156   483 967
   021   WAGNER BM             AM J DIS CHILD                  99    61 960
CT   1   MARTINEZ JR           J PHARMACOL EXP THER           194   384 975
     2   THOMPSON FE           PEDIATR RES                     10   632 976
     3   RENNERT OM            TEX REP BIOL MED                34   187 976
     4   MARTINEZ JR           MO MED                          73   173 976
     5   WOOD RE               AM REV RESPIR DIS              113   833 976
     6   DISANTAGNESE PA       N ENGL J MED                   295   597 976
     7   WOOD DL               PEDIATR RES                     11   827 977
     8   DAVIS PB              PEDIATR RES                     12   703 978
     9   PERLMUTTER J          PEDIATR RES                     12   188 978
    10   FORSTNER JF           DIGESTION                       17   234 978
    11   SIMSON JAV            LAB INVEST                      39   157 978
    12   SIMSON JAV            J MICROSC                      113   185 978
    13   DISANTAGNESE PA       MONOGR PAEDIATR                 10    66 979
    14   MARTINEZ JR           PEDIATR RES                     13  1156 979
    15   MAWHINNEY TP          PEDIATR RES                     13   760 979
    16   QUISSELL DO           ARCH ORAL BIOL                  24   639 979
    17   SORDELLI DO           LIFE SCI                        24  2003 979
    18   SETSER ME             EXP MOL PATH                    31   413 979
    19   MARTINEZ JR           EXPERIENTIA                     35  1343 979
    20   SETSER ME             LAB INVEST                      41   256 979
    21   LEE JA                ANN CLIN LAB SCI                10   227 980
    22   BUCHWALD M            ADV CYCLIC NUCLEO RES           12   243 980
    23   MAWHINNEY TP          PEDIATR RES                     14   872 980
    24   MORTON D              PEDIATR RES                     14    18 980
    25   ROSCHER AA            PEDIATR RES                     14   261 980
    26   BYLUND DB             NATURE                         285   229 980
    27   MCCURDY RE            PEDIATR RES                     15  1308 981
    28   GALANT SP             J CLIN INVEST                   68   253 981
    29   ROSCHER AA            J PHARMACOL EXP THER           216   419 981
    30   FORSTNER J            AM J PHYSIOL                   241  G443 981
    31   CUTLER LS             VIRCHOWS ARCH PATHOL ANAT HIS  392   185 981
    32   ROOMANS GM            ULTRASTRUCTURAL PATHOL           3   285 982
    33   SHIFFMAN ML           PEDIATR RES                     16   104 982
    34   FORSTNER G            ADV EXP MED BIOL               144   199 982
    35   JONES CJ              J PHYSIOL (LOND)               332  P 65 982
    36   ROOMANS GM            SCANN ELECTRON MICROSC        1982   229 982
    37   MARTINEZ JR           PEDIATR RES                     17   523 983
    38   SHIFFMAN ML           PEDIATR RES                     17   486 983
    39   DAVIS PB              J CHRON DIS                     36   269 983
    40   WERLIN SL             EXP MOL PATH                    39    24 983
    41   CEDER O               ACTA PAEDIATR SCAND SUPPL 309 1983     1 983
    42   ROOMANS GM            SCANN ELECTRON MICROSC        1983   697 983
    43   BOYD RL               PEDIATR RES                     18  1028 984
    44   MULLER RM             EXP MOL PATH                    40   391 984
    45   MULLER RM             EXP MOL PATH                    41   363 984
    46   SPICER SS             ENVIRON HEALTH PERSPECT         55   193 984
    47   WATSON E              J DENT RES                      63    82 984
    48   SATO K                J CLIN INVEST                   73  1763 984
    49   BRADY RC              EXP CELL RES                   150   141 984
    50   ROOMANS GM            ANN NY ACAD SCI                428   121 984
    51   BARDON A              BIOCHEM MED                     33    99 985
    52   MULLER RM             EXP MOL PATH                    43    97 985
    53   MULLER RM             ACTA PHYSIOL SCAND             123   383 985
    54   BRADY RC              AM J PHYSIOL                   248  G 54 985
    55   MULLER RM             SCANN ELECTRON MICROSC        1985  1583 985
    56   SMITH AC              CLIN GASTROENTEROL              15   815 986
    57   DAVIS PB              HORM METAB RES                  18   217 986
    58   HAZLETT D             PEDIATR RES                     20  1236 986
    59   KLEIN RM              ARCH ORAL BIOL                  31   133 986
    60   ROOMANS GM            SCANN ELECTRON MICROSC        1986   165 986

PN 75144
RN 00310
AN 75176052
AU Beratis-N-G.  Turner-B-M.  Weiss-R.  Hirschhorn-K.
TI Arylsulfatase B deficiency in Maroteaux-Lamy syndrome: Cellular
   studies and carrier identification.
SO Pediatr-Res. 1975 May. 9(5). P 475-80.
MJ ARYLSULFATASES: df.  MUCOPOLYSACCHARIDOSIS-6: en.
   MUCOPOLYSACCHARIDOSIS: en.  SULFATASES: df.
MN AMNIOTIC-FLUID: en.  ARYLSULFATASES: an.  CELL-LINE.  CELLS-CULTURED.
   CHILD-PRESCHOOL.  CHONDROITIN.  CYSTIC-FIBROSIS: en.  FEMALE.
   FIBROBLASTS: en.  GALACTOSEMIA: en.  GAUCHERS-DISEASE: en.
   GLYCOGENOSIS-2: en.  HETEROZYGOTE.  HOMOZYGOTE.  HUMAN.
   LEUKOCYTES:  en.  LEUKODYSTROPHY-METACHROMATIC: en.
   LIPOCHONDRODYSTROPHY: en.  LYMPHOID-TISSUE: en.  LYSOSOMES: en.  MALE.
   METABOLISM-INBORN-ERRORS: en.  MUCOPOLYSACCHARIDOSIS-6: fg.
   PREGNANCY.  SKIN.
AB Arylsulfatase B deficiency was demonstrated in peripheral leukocytes,
   cultured skin fibroblasts, and a lymphoid line derived from a patient
   with MLS. The patient's parents demonstrated levels of arylsulfatase
   B that were intermediate between those found in patient and those in
   control subjects. The activity (mean plus or minus SD) in leukocytes
   from normal subjects, the patient's parents, and the patient was
   113.7 plus or minus 36.2, 31.0, and 5.2 nmol 4-nitrocatechol/mg
   protein/hr, respectively. In skin fibroblasts of the same subjects
   the activity was 145.2 plus or minus 41.6, 58.5, and 7.0,
   respectively. Nine other lysosomal enzymes were normal in skin
   fibroblasts of the patient. No arylsulfatase B activity was detected
   in a lymphoid line established from the patient with MLS. The
   arylsulfatase B activity in cultured amniotic fluid cells from 10
   normal pregnancies was 203.2 plus or minus 49.9.
RF 001   BARTON RW             J PEDIATR                       80   114 972
   002   BAUM H                CLIN CHIM ACTA                   4   453 959
   003   BERATIS NG            ANN HUM GENET                   38   485 975
   004   BERATIS NG            BIRTH DEF ORIG ART SER           9   247 973
   005   BERATIS NG            MAMM CHROM NEWSL                14   114 973
   006   CHOI KW               SCIENCE                        170    89 970
   007   CONOVER JH            PEDIATR RES                      7   224 973
   008   FLEISHER LD           PEDIATR RES                      8   388 974
   009   FLUHARTY AL           BIOCHEM BIOPHYS RES COMMUN      59   455 974
   010   GLASSER JH            J LAB CLIN MED                  82   969 973
   011   HALL CW               ARCH BIOCHEM BIOPHYS           158   817 973
   012   HO MW                 AM J HUM GENET                  24    37 972
   013   KABACK MM             N ENGL J MED                   282  1336 970
   014   KINT JA               SCIENCE                        167  1268 970
   015   LOWRY OH              J BIOL CHEM                    193   265 951
   016   MAROTEAUX P           B PRESSE MED                    71  1849 963
   017   MCKUSICK VA           HERITABLE DISORDERS OF CONNEC            972
   018   NITOWSKY HM           J LAB CLIN MED                  69   472 967
   019   OBRIEN J              BIOCHEM BIOPHYS RES COMMUN      60  1170 974
   020   PERCY AK              SCIENCE                        161   594 968
   021   SPECTOR EB            PEDIATR RES                      7   700 973
   022   SPRANGER JW           HELV PAEDIATR ACTA              25   337 970
   023   STUMPF DA             TRANS AMER SOC NEUROCHEM         3   125 972
   024   STUMPF DA             AM J DIS CHILD                 126   747 973
   025   ZIELKE K              J EXP MED                      136   197 972
CT   1   BERATIS NG            CYTOGENET CELL GENET            15   195 975
     2   KIM HJ                AM J HUM GENET                  27   755 975
     3   KLEIJER WJ            LANCET                           2    50 976
     4   CORTNER JA            PEDIATR RES                     10   927 976
     5   BERATIS NG            CYTOGENET CELL GENET            17   236 976
     6   CANTZ M               HUM GENET                       32   233 976
     7   ROY AB                AUST J EXP BIOL MED SCI         54   111 976
     8   DORFMAN A             PROC NAT ACAD SCI USA           73   630 976
     9   DELVIN EE             BIOCHEM J                      157   353 976
    10   DYGGVE HV             NEUROPADIATRIE                   8   429 977
    11   BERATIS NG            PEDIATR RES                     11   862 977
    12   ZUFFARDI O            ANN GENET (PARIS)               20   191 977
    13   MACPHEE GB            J CLIN PATHOL                   30   278 977
    14   VANBIERVLIET JPGM     ARCH FR PEDIATR                 34   362 977
    15   RASTOGI SC            ACTA NEUROL SCAND               56   389 977
    16   FAROOQUI AA           CLIN CHIM ACTA                  74    93 977
    17   CHRISTOMANOU H        CLIN CHIM ACTA                  79   527 977
    18   JEZYK PF              SCIENCE                        198   834 977
    19   TURNER BM             BIOCHIM BIOPHYS ACTA           480   442 977
    20   BERATIS NG            J CLIN INVEST                   62  1264 978
    21   MOFFITT KD            ARCH BIOCHEM BIOPHYS           190   247 978
    22   JOLLY RD              AM J MED GENET                   4   293 979
    23   PILZ H                ANN NEUROL                       6   315 979
    24   HULTBERG B            J CLIN CHEM CLIN BIOCHEM        17   795 979
    25   GONCERZEWICZ M        GENET POLON                     20   265 979
    26   TALLAN HH             BIOCHEM MED                     21   129 979
    27   KAIBARA N             HUM GENET                       53    37 979
    28   HABUCHI H             J BIOL CHEM                    254  7570 979
    29   BERATIS NG            DEVELOP PHARM THER               1   305 980
    30   LEVY LA               AM J CLIN PATHOL                73   416 980
    31   FAROOQUI AA           CLIN CHIM ACTA                 100   285 980
    32   VANDYKE DL            AM J MED GENET                   8   235 981
    33   MCGOVERN MM           ENZYME                          26   206 981
    34   SHAFITZAGARDO B       AM J HUM GENET                  33   564 981
    35   VINE DT               AM J HUM GENET                  33   916 981
    36   DANESINO C            HUM GENET                       56   371 981
    37   RAPRAEGER AC          DEVELOP BIOL                    88   269 981
    38   PATTERSON DF          ADV HUM GENET                   12   263 982
    39   GRABOWSKI GA          METH CELL BIOL                  26    95 982
    40   GLEW RH               AM J CLIN NUTR                  35   236 982
    41   GLEW RH               COMP BIOCHEM PHYSIOL (B)        72   581 982
    42   GRAVEL RA             ANAL BIOCHEM                   119   360 982
    43   MCGOVERN MM           J BIOL CHEM                    257  2605 982
    44   BERATIS NG            ISOZYMES                        11    25 983
    45   BERATIS NG            AM J HUM GENET                  35    21 983
    46   BERATIS NG            CLIN CHIM ACTA                 134    11 983
    47   DANESINO C            CLIN GENET                      26   462 984
    48   DANESINO C            ANN GENET (PARIS)               27   162 984
    49   KRIVIT W              N ENGL J MED                   311  1606 984
    50   BETREMIEUX P          ANN PEDIATR (PARIS)             32   639 985
    51   MCGOVERN MM           GENETICS                       110   733 985
    52   BERATIS NG            CLIN GENET                      29   129 986

PN 75145
RN 00311
AN 75176051
AU Martinez-J-R.  Adshead-P-C.  Quissell-D-O.  Barbero-G-J.
TI The chronically reserpinized rat as a possible model for cystic
   fibrosis.  II.  Comparison and cilioinhibitory effects of
   submaxillary saliva.
SO Pediatr-Res. 1975 May. 9(5). P 470-5.
MJ CYSTIC-FIBROSIS: ci.  DISEASE-MODELS-ANIMAL.  RATS.  RESERPINE.
   SALIVA.  SUBMANDIBULAR-GLAND: se.
MN ANIMAL.  BIOLOGICAL-ASSAY.  CALCIUM: an.  CARBOHYDRATES: an.
   CILIA:  de.  GUANETHIDINE: pd.  INJECTIONS-INTRAPERITONEAL.
   ISOPROTERENOL:  pd.  MUSSELS.  PILOCARPINE: pd.  PROTEINS: an.
   SALIVA: se, an.  SODIUM: an.  STIMULATION-CHEMICAL.
   SUBMANDIBULAR-GLAND: me, de.
AB Submaxillary saliva from reserpine-treated rats was found to have
   alterations in composition similar to those reported in the same
   secretion from patients with cystic fibrosis. Changes included
   elevated concentrations of Na+, Ca++, protein, and carbohydrate. In
   addition, this saliva was found to have ciliotoxic properties similar
   to those of CF serum. The similarities in cilioinhibitory effects
   salivary composition, and histologic appearance justify the use of
   the chronically reserpinized rat as a model for cystic fibrosis.
RF 002   BENMILOUD M           ACTA PHYSIOL SCAND              59    34 963
   003   BESLEY GTN            J MED GENET                      6   278 969
   004   BOWMAN BH             SCIENCE                        164   325 969
   005   CARLSON A             PHARMACOL REV                   18   541 966
   006   CHERNICK WS           J PEDIATR                       59   890 961
   007   CHERNICK WS           ANN NY ACAD SCI                106   698 963
   008   CHERNICK WS           MOD PROBL PEDIATR               10   125 967
   009   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   010   DI SANTAGNESE PA      N ENGL J MED                   277  1344 967
   011   DI SANTAGNESE PA      N ENGL J MED                   277  1399 967
   012   DISCHE Z              PEDIATRICS                      24    74 959
   013   DOGGETT RG            NATURE NEW BIOL                243   251 973
   014   DREISBACH RH          PROC SOC EXP BIOL MED          126   279 967
   015   DUBOIS M              ANAL CHEM                       28   350 956
   016   EKFORS T              LAB INVEST                      24   197 971
   017   GUGLER EC             J PEDIATR                       71   585 967
   018   IWAYAMA T             J PHARMACOL EXP THER           184    95 973
   019   JOHANSEN PG           ANN NY ACAD SCI                106   755 963
   020   LOWRY OH              J BIOL CHEM                    193   265 951
   021   MANDEL ID             AM J DIS CHILD                 113   431 967
   022   MANGOS JA             SCIENCE                        158   135 967
   023   MANGOS JA             PEDIATR RES                      1   436 967
   024   MANGOS JA             IN: LAWSON D PROC 5TH INT CF          25 969
   026   MENAKER L             LAB INVEST                      24   197 971
   027   SCHNEYER CA           AM J PHYSIOL                   203   232 962
   028   SCHWARTZ A            NATURE                         188   948 960
   029   SHORE PA              PHARMACOL REV                   22   209 972
   030   SPICER SS             IN: DI SANTAGNESE PA                  26 966
   031   SPOCK A               PEDIATR RES                      1   173 967
   032   SPOCK A               GAP CONF REP CILIARY INHIBITO            973
   033   TAKAHAMA M            J ULTRASTRUCT RES               17   452 967
   034   WILCKEN DEL           SCIENCE                        157  1332 967
CT   1   MARTINEZ JR           J PHARMACOL EXP THER           194   384 975
     2   THOMPSON FE           PEDIATR RES                     10   632 976
     3   RENNERT OM            TEX REP BIOL MED                34   187 976
     4   BUCHWALD M            PROC NAT ACAD SCI USA           73  2899 976
     5   MARTINEZ JR           MO MED                          73   173 976
     6   WOOD RE               AM REV RESPIR DIS              113   833 976
     7   MAYO JW               ARCH BIOCHEM BIOPHYS           175   507 976
     8   HAUBRICH J            ARCH OTO RHINO LARYNGOL        213     1 976
     9   DISANTAGNESE PA       N ENGL J MED                   295   597 976
    10   WOOD DL               PEDIATR RES                     11   827 977
    11   SCHNEYER CA           PROC SOC EXP BIOL MED          156   132 977
    12   DANN LG               LANCET                           2   405 978
    13   DAVIS PB              PEDIATR RES                     12   703 978
    14   PERLMUTTER J          PEDIATR RES                     12   188 978
    15   SIMSON JAV            LAB INVEST                      39   157 978
    16   SIMSON JAV            J MICROSC                      113   185 978
    17   MARTINEZ JR           PEDIATR RES                     13  1156 979
    18   MAWHINNEY TP          PEDIATR RES                     13   760 979
    19   QUISSELL DO           ARCH ORAL BIOL                  24   639 979
    20   SETSER ME             EXP MOL PATH                    31   413 979
    21   MARTINEZ JR           EXPERIENTIA                     35  1343 979
    22   SETSER ME             LAB INVEST                      41   256 979
    23   JAKEL HP              BIOL ZENTRALBL                  98    55 979
    24   POINTON SE            BIOCHIM BIOPHYS ACTA           584   231 979
    25   BLOMFIELD J           MICRON                          11   459 980
    26   BUCHWALD M            ADV CYCLIC NUCLEO RES           12   243 980
    27   MAWHINNEY TP          PEDIATR RES                     14   872 980
    28   ROSCHER AA            PEDIATR RES                     14   261 980
    29   BYLUND DB             NATURE                         285   229 980
    30   MCCURDY RE            PEDIATR RES                     15  1308 981
    31   COMPTON J             ARCH ORAL BIOL                  26   555 981
    32   ROSCHER AA            J PHARMACOL EXP THER           216   419 981
    33   BYLUND DB             J PHARMACOL EXP THER           218   134 981
    34   FORSTNER J            AM J PHYSIOL                   241  G443 981
    35   CUTLER LS             VIRCHOWS ARCH PATHOL ANAT HIS  392   185 981
    36   ROOMANS GM            ULTRASTRUCTURAL PATHOL           3   285 982
    37   SHIFFMAN ML           PEDIATR RES                     16   104 982
    38   ABE K                 J DENT RES                      61    52 982
    39   ROOMANS GM            SCANN ELECTRON MICROSC        1982   229 982
    40   SCHNEYER CA           J AUTONOM NERV SYST              8   171 983
    41   JIRAKULSOMCHOK D      J ORAL PATHOL                   12   491 983
    42   MARTINEZ JR           PEDIATR RES                     17   523 983
    43   SHIFFMAN ML           PEDIATR RES                     17   486 983
    44   MARTINEZ JR           ARCH ORAL BIOL                  28  1101 983
    45   BLOMFIELD J           EXP MOL PATH                    38   170 983
    46   MARTINEZ JR           J DENT RES                      62   543 983
    47   BODNER L              COMP BIOCHEM PHYSIOL (A)        74   829 983
    48   MARTINEZ JR           AM J PHYSIOL                   245  G711 983
    49   ROOMANS GM            SCANN ELECTRON MICROSC        1983   697 983
    50   KATZ S                CELL CALC                        5   421 984
    51   BOYD RL               PEDIATR RES                     18  1028 984
    52   JIRAKULSOMCHOK D      ARCH ORAL BIOL                  29    39 984
    53   MULLER RM             EXP MOL PATH                    40   391 984
    54   MULLER RM             EXP MOL PATH                    41   363 984
    55   WATSON E              J DENT RES                      63    82 984
    56   BRADY RC              EXP CELL RES                   150   141 984
    57   ROOMANS GM            ANN NY ACAD SCI                428   121 984
    58   MARTINEZ JR           PEDIATR RES                     19   711 985
    59   BARDON A              BIOCHEM MED                     33    99 985
    60   MULLER RM             EXP MOL PATH                    43    97 985
    61   MULLER RM             ACTA PHYSIOL SCAND             123   383 985
    62   BRADY RC              AM J PHYSIOL                   248  G 54 985
    63   MULLER RM             SCANN ELECTRON MICROSC        1985  1583 985
    64   HAZLETT D             PEDIATR RES                     20  1236 986
    65   ROOMANS GM            SCANN ELECTRON MICROSC        1986   165 986

PN 75146
RN 00312
AN 76076880
AU Welch-D-W.  Roberts-R-M.
TI Complex saccharide metabolism in cystic fibrosis fibroblasts.
SO Pediatr-Res. 1975 Sep. 9(9). P 698-702.
MJ CYSTIC-FIBROSIS: me.  FIBROBLASTS: me.  MUCOPOLYSACCHARIDES: me.
MN AUTORADIOGRAPHY.  CELL-LINE.  CHILD.  CHILD-PRESCHOOL.
   CHONDROITIN-SULFATES: me.  DERMATAN-SULFATE: me.  FIBROBLASTS: an.
   GLUCOSAMINE: me.  GLYCOSAMINOGLYCANS: ip.  HEPARITIN-SULFATE: me.
   HUMAN.  HYALURONIC-ACID: me.  SKIN.  SULFATES: me.  TIME-FACTORS.
   SUPPORT-U-S-GOVT-P-H-S.
AB There are several reports of secretory and other abnormalities
   present in cultured fibroblasts from patients with cystic fibrosis
   (CF). We have, therefore, investigated aspects of complex saccharide
   synthesis and secretion by such cells compared with fibroblasts
   derived from heterozygous (HZ) parents and from normal (N) children.
   The main glycosaminoglycans produced by skin fibroblasts  during in
   vitro culture were hyaluronic acid, heparan sulfates, and dermatan
   sulfate-like materials. Using double-label experiments with D-[3H]-
   or [14c]glucosamine and analyzing the products by ion exchange
   chromatography, it was shown for five CF, two HZ, and four N lines
   that these polysaccharides were secreted into the medium in
   approximately similar proportions to each other. Moreover,
   experiments in which three CF, nine HZ, and three N lines were grown
   in log phase for up to 5 days in the presence of [35S]sulfate and
   [3H]glucosamine indicate that, during such a period, CF fibroblasts
   do not secrete complex carbohydrates at rates significantly different
   from N or HZ cells. Neither do such cells shown an abnormal
   intracellular accumulation of complex carbohydrates. The latter
   observation was further confirmed by preparing whole cell
   autoradiographs during growth of six CF, two HZ, and three N lines in
   the presence of D-[3H]glucosamine and, subsequently, after addition
   of unlabeled medium.
RF 001   BADER JP              BIOCHIM BIOPHYS ACTA           264    73 972
   002   BARTMAN J             J PEDIATR                       76   430 970
   003   DANES BS              LANCET                           1  1061 968
   004   DANES BS              BIOCHEM BIOPHYS RES COMMUN      36   919 969
   005   DANES BS              J EXP MED                      129   775 969
   006   DANES BS              NATURE                         222   685 969
   007   DI SANTAGNESE PA      PEDIATRICS                      12   549 953
   008   DI SANTAGNESE PA      N ENGL J MED                   277  1344 967
   009   FITZPATRICK DF        NATURE NEW BIOL                235   173 972
   010   GIBSON LE             PEDIATRICS                      48   695 971
   011   GUGLER EC             J PEDIATR                       71   585 967
   012   KRAEMER PM            BIOCHEMISTRY                    10  1437 971
   013   KRAEMER PM            BIOCHEMISTRY                    10  1445 971
   014   KRAEMER PM            IN: MANSON LA                    1    67 971
   015   KONDO K               BIOCHIM BIOPHYS ACTA           244   513 971
   016   LOBECK CC             IN: STANBURY JB                     1605 972
   017   MATALON R             BIOCHEM BIOPHYS RES COMMUN      33   954 968
   018   MILUNSKY A            N ENGL J MED                   281  1128 969
   019   NADLER HL             LANCET                           2    84 969
   020   PALLAVICINI JC        J PEDIATR                       77   280 970
   021   RENNERT OM            CLIN PEDIATR                    11   351 972
   022   RENNERT OM            IN: MANGOS JA                         41 973
   023   SATOH C               PROC NAT ACAD SCI USA           70    54 973
   024   SCHUBERT M            J HISTOCHEM CYTOCHEM             4   159 956
   025   SPIRO RG              J BIOL CHEM                    240  1603 965
   026   TAYSI K               N ENGL J MED                   281  1108 969
   027   TURNER JC             INT J APPL RADIAT ISOTOP        19   557 968
   028   WESSLER E             ANAL BIOCHEM                    26   439 968
   029   WIESMANN UN           J PEDIATR                       77   685 970
CT   1   STEIN GS              NATURE                         258   639 975
     2   WARD JB               TEX REP BIOL MED                34    11 976
     3   ANDERSON LC           CLIN CHIM ACTA                  73    63 976
     4   DISANTAGNESE PA       N ENGL J MED                   295   534 976
     5   SULLIVAN JL           BIOCHEM GENET                   15  1125 977
     6   CONRAD GW             J BIOL CHEM                    252  6861 977
     7   OWEN E                J MOL MED                        3   203 978
     8   ALHADEFF JA           CLIN GENET                      14   189 978
     9   JAKEL HP              BIOL ZENTRALBL                  98    55 979
    10   SHAPIRO BL            SCIENCE                        203  1251 979
    11   SPICER SS             EXP MOL PATH                    33   104 980
    12   ROOMANS GM            ULTRASTRUCTURAL PATHOL           2    53 981
    13   MAPLESON JL           J CELL PHYSIOL                 109   215 981
    14   MASTERS RA            J REPROD FERTIL                 66   571 982
    15   CEDER O               SCANN ELECTRON MICROSC        1982   723 982
    16   RUDICK VL             J CELL PHYSIOL                 115   143 983
    17   CEDER O               ACTA PAEDIATR SCAND SUPPL 309 1983     1 983

PN 75147
RN 00313
AN 76076885
AU McEvoy-F-A.  Hartley-C-B.
TI Polyamines in cystic fibrosis.
SO Pediatr-Res. 1975 Sep. 9(9). P 721-4.
MJ CYSTIC-FIBROSIS: bl.  POLYAMINES: bl.
MN BILE: an.  DUODENUM.  HUMAN.  INTESTINAL-SECRETIONS: an.
   POLYAMINES:  an.  SALIVA: an.  SPERMIDINE: an.  SPERMINE: an.
   SWEAT: an.
AB Polyamine concentrations have been measured in blood samples from a
   series of cystic fibrosis (CF) patients and control subjects.
   Analyses were made by a fluorometric method, in which the amines were
   reacted with dansyl chloride and separated by thin layer
   chromatography on Kieselguhr. There was no significant difference
   between the polyamine concentrations of blood samples from CF
   patients and control subjects. Also, the spermidine-spermine ratio
   was similar in both groups. Polyamines were also analyzed in exocrine
   fluids, and although none could be detected in either CF or control
   sweat or saliva, significant amounts of spermine and spermidine were
   present in all samples of bile and duodenal fluids. It thus seems
   likely that the biliary route is a significant pathway in the human
   for excretion of polyamines. The observation that polyamines are
   excreted in considerable concentrations via the bile in children may
   be of interest in view of the reports of elevated urinary polyamine
   concentrations in neoplastic states. Since measurable amounts of
   spermine and spermidine were detected in all six bile preparations
   available for this study, analysis of these substances in bile may be
   of benefit in particular cases.
RF 001   NOUSIA-ARVANITAKIS S  PEDIATR RES                      7   336 973
   002   BACHRACH U            BIOCHEM BIOPHYS RES COMMUN      55  1035 973
   003   COHEN SS              INTRODUCTION TO POLYAMINES               971
   004   DAVENPORT HW          PHYSIOLOGY OF THE DIGESTIVE T            966
   005   DI SANTAGNESE PA      PEDIATRICS                      22   507 958
   006   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   007   DREYFUS G             CLIN CHIM ACTA                  49    65 973
   008   GIBSON LE             PEDIATRICS                      23   545 959
   009   HAMMOND JE            ANAL BIOCHEM                    22   474 968
   010   HARRIS R              BR J HAEMATOL                   18   229 968
   011   HERBST EJ             ANN NY ACAD SCI                171     3 970
   012   JOHANSEN PG           LANCET                           1   455 968
   013   RAINA AA              SCAND J CLIN LAB INVEST         14   318 962
   014   RAINA A               ACTA PHYSIOL SCAND SUPPL 218    60     1 963
   015   RENNERT OM            IN: MANGOS JA                         41 973
   016   RUSSELL DH            POLYAMINES IN NORMAL AND NEOP            973
   017   RUSSELL DH            NATURE                         233   144 971
   018   SEILER N              METHODS BIOCHEM ANAL            18   259 970
   019   STEVENS L             BIOL REV                        45     1 970
   020   TABOR H               PHARMACOL REV                   16   245 964
CT   1   ANON                  J PEDIATR                       88   711 976
     2   DISANTAGNESE PA       N ENGL J MED                   295   534 976
     3   KELLY JC              BIOCHEM GENET                   15   695 977
     4   ALHADEFF JA           CLIN GENET                      14   189 978
     5   SCHRODER CP           EUR J PEDIATR                  128    49 978
     6   BAYLIN SB             PEDIATR RES                     14   921 980

PN 75148
RN 00314
AN 75083182
AU Shwachman-H.  Lebenthal-E.  Khaw-K-T.
TI Recurrent acute pancreatitis in patients with cystic fibrosis with
   normal pancreatic enzymes.
SO Pediatrics. 1975 Jan. 55(1). P 86-95.
MJ AMYLASES.  CHYMOTRYPSIN.  CYSTIC-FIBROSIS: co.  LIPASE.
   PANCREAS: en.  PANCREATITIS: et.  TRYPSIN.
MN ACUTE-DISEASE.  ADOLESCENCE.  ADULT.  AMYLASES: bl, ur, se.
   CHLORIDES: an.  CHYMOTRYPSIN: an.  CYSTIC-FIBROSIS: en, pa.  FEMALE.
   GLUCOSE-TOLERANCE-TEST.  HUMAN.  INTUBATION-GASTROINTESTINAL.
   LIPASE: bl, se.  MAGNESIUM: an.  MALE.  METHIONINE: du.  PAIN.
   PANCREAS: pa.  PANCREATITIS: en, pa.  CHOLECYSTOKININ: du.
   POTASSIUM: an.  RECURRENCE.  SECRETIN: du.  SELENIUM: du.
   SODIUM: an.  TRYPSIN: an.  SUPPORT-U-S-GOVT-P-H-S.   
   SUPPORT-U-S-GOVT-NON-P-H-S.
AB Ten adolescent and young adults with cystic fibrosis (CF) have had
   well-documented recurrent attacks of acute pancreatitis. The
   diagnosis of CF in each patient was delayed because they did not have
   pancreatic insufficiency. The diagnosis of CF was documented by the
   typical pulmonary involvement and elevated sweat sodium and chloride
   levels in all cases and a positive family history in six of the ten
   patients. Two patients were diagnosed as having acute pancreatitis
   before the diagnosis of CF was made, thus indicating that acute
   pancreatitis may be the presenting complaint in the young adult with
   CF. The diagnosis of acute pancreatitis was based on the presence of
   severe abdominal pain, usually with vomiting, tenderness in the mid-
   epigastrium, elevated serum and urinary amylase and serum lipase.
   Attacks were precipitated by fatty meals, alcohol ingestion;
   postcholecystectomy and tetracycline administration. In some patients
   no precipitating event could be elicited. Intravenous secretin-
   pancreozymin stimulation tests revealed a diminished bicarbonate
   secretion with little effect on the secretion of the zymogen enzymes.
   A mild attack of pancreatitis occurred after secretin-pancreozymin
   stimulation. The endocrine pancreatic function tested in four
   patients was normal as revealed by the glucose tolerance tests and
   determinations of serum insulin, growth hormone and free fatty acid.
   Transduodenal pancreatograms were performed in three patients; one
   showed a normal pancreatic duct, one showed duct obstruction and in
   the third patient a beady type of narrowing was found. The
   selenomethionine Se 75 uptake of the pancreas was noted only in the
   head of the pancreas. This suggests that loss of function occurs
   initially to a greater extent in the tail and body of the pancreas.
   Three patients died and showed characteristic lesions of CF.
RF 001   FARBER S              J MICH MED SOC                  44   587 945
   002   DI SANTAGNESE PA      PEDIATRICS                      15   683 955
   003   SHWACHMAN H           AM J DIS CHILD                  92   347 956
   004   RICK W                MED WELT                        42  2158 963
   005   HADORN B              J PEDIATR                       73    39 968
   006   DI SANTAGNESE PA      GASTROENTEROLOGY                40    64 961
   007   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   008   FARBER S              ARCH PATHOL                     37   238 944
   009   LAGERLOF HO           ACTA MED SCAND SUPPL           128     1 942
   010   HENRY RJ              CLIN CHEM                        6   434 960
   011   NAGEL W               PHYSIOL CHEM                   340     1 965
   012   ERLANGER BF           ARCH BIOCHEM BIOPHYS            95   271 961
   013   COTTON PB             LANCET                           1    53 972
   014   KASUGAI T             GASTROENTEROLOGY                63   217 972
   015   BACHRACH WH           GASTROENTEROLOGY                63   890 972
   016   DOLE VP               J CLIN INVEST                   35   150 956
   017   SOELDNER JS           DIABETES                        14   771 965
   018   SHWACHMAN H           N ENGL J MED                   286  1300 972
   019   SNYDER WH JR          PEDIATRICS                      34    72 964
   020   HOLSCLAW DS           PEDIATRICS                      48    51 971
   021   SHWACHMAN H           IN: KENDIG EL JR                 1   524 972
   022   SHWACHMAN H           BIRTH DEF ORIG ART SER           8   102 972
   023   SHWACHMAN H           PEDIATRICS                      30   389 962
   024   KULCZYCKI LL          N ENGL J MED                   259   409 958
   025   HOLSCLAW DS           PEDIATRICS                      48   442 971
   026   KAPLAN E              N ENGL J MED                   279    65 968
   027   RENDLE-SHORT J        ARCH DIS CHILD                  31    28 956
   028   POPPEL MH             SEMIN ROENTGENOL                 3   227 968
   029   GEORGE PK             GASTROENTEROLOGY                60   858 971
   030   HANSSON K             ACTA CLIN SCAND SUPPL          375     1 967
   031   KALANT H              GASTROENTEROLOGY                56   380 969
   032   DWORKIN B             PHYSIOLOGIST                     8   158 965
   033   OPPENHEIMER EH        ARCH PATHOL                     29   790 940
   034   KORNBLITH BA          AM J PATHOL                      5   249 929
   035   ANDERSEN DH           AM J DIS CHILD                  56   344 938
   036   ZUELZER WW            PEDIATRICS                       4    53 949
   037   BANKS PA              GASTROENTEROLOGY                61   382 971
CT   1   SHWACHMAN H           PEDIATR CLIN NORTH AM           22   787 975
     2   LESEC G               NOUV PRESSE MED                  5  2470 976
     3   HOLSCLAW DS           J PEDIATR SURG                  11   217 976
     4   WOOD RE               AM REV RESPIR DIS              113   833 976
     5   LEBENTHAL E           CLIN GASTROENTEROL               6   397 977
     6   ANDORSKY M            AM J DIG DIS                    22    56 977
     7   SIBERT JR             ARCH DIS CHILD                  52   658 977
     8   SHWACHMAN H           MEDICINE                        56   129 977
     9   STERN RC              ANN INTERN MED                  87   188 977
    10   SCHWACHMAN H          N ENGL J MED                   296  1519 977
    11   BOURRY J              GASTROENTEROL CLIN BIOL          2   139 978
    12   DAVIDSON GP           PEDIATR RES                     12   967 978
    13   BOURRY J              AM J DIG DIS                    23   423 978
    14   HUBBARD VS            J PEDIATR                       92   685 978
    15   STERN RC              JAMA                           239  2676 978
    16   FEIGELSON J           NOUV PRESSE MED                  8  3029 979
    17   SWAN HAP              S AFR J SURG                    17    51 979
    18   SAHEL J               DIG DIS SCI                     24   897 979
    19   SIBERT JR             POSTGRAD MED J                  55   171 979
    20   NEZELOF C             PEDIATRICS                      63   361 979
    21   SANTAGNESE PAD        AM J MED                        66   121 979
    22   GILLARD BK            PEDIATR RES                     14  1168 980
    23   BURLINA A             SCAND J GASTROENTEROL           15    35 980
    24   DURIE PR              PEDIATR RES                     15  1351 981
    25   MENEELY RL            PEDIATRICS                      67   136 981
    26   PARK RW               GASTROENTEROLOGY                81  1143 981
    27   STERN RC              LANCET                           1  1401 982
    28   STAFFORD RJ           CLIN GASTROENTEROL              11   141 982
    29   POCKNEE RC            BR J OBSTET GYNAECOL            89   142 982
    30   BARBERO GJ            J PEDIATR                      100   914 982
    31   ROSENSTEIN BJ         JOHNS HOPKINS MED J            150   113 982
    32   KARP MP               J PEDIATR GASTROENTEROL NUTR     2   324 983
    33   MASARYK TJ            DIG DIS SCI                     28   874 983
    34   GHISHAN FK            J PEDIATR                      102   514 983
    35   GILLARD BK            AM J DIS CHILD                 138   577 984
    36   SCOTT HW              ANN SURG                       199   610 984
    37   HUBBARD VS            SEM RESPIR MED                   6   299 985
    38   ORENSTEIN DM          SEM RESPIR MED                   6   252 985
    39   ISAACS JD             J CLIN GASTROENTEROL             7   533 985
    40   OCONNOR KW            ARCH INTERN MED                145   153 985
    41   RUSH PJ               SEM ARTHRITIS RHEUM             15   213 986
    42   BRAGANZA JM           MED HYPOTHESES                  20   233 986
    43   DURIE PR              PEDIATR RES                     20   209 986
    44   LIU P                 J CAN ASSOC RADIOL              37   279 986
    45   SARNELLI  R           AM J MED                        80   541 986
    46   HUNSINGER RN          CLIN CHIM ACTA                 156   165 986

PN 75149
RN 00315
AN 75176126
AU David-S.
TI Letter: Comment on outpatient intravenous therapy.
SO Pediatrics. 1975 Jun. 55(6). P 896-7.
MJ AMBULATORY-CARE.  DRUG-THERAPY.  INJECTIONS-INTRAVENOUS.
   PEDIATRICS.
MN ADOLESCENCE.  ANTIBIOTICS: ad, tu.  CHILD.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: dt.  FOLLOW-UP-STUDIES.  HEMOPHILIA: dt.  HUMAN.
   INFANT.  PATIENT-COMPLIANCE.  PUBLIC-HEALTH-NURSING.
   RESPIRATORY-TRACT-INFECTIONS: dt.
EX There has been a recent trend to treating more and more pediatric
   patients with chronic diseases on an ambulatory basis.  This is true
   of both hemophilia and cystic fibrosis.  Despite their success in
   keeping slightly more than two thirds of their patients out of the
   hospital, I think that they might be more successful in the future if
   the following points are considered.  First, many of those initially
   selected for intravenous medications due to their nonresponsiveness
   to oral therapy and again later considered failures of intravenous
   treatment might actually be noncompliers.  My second point concerns
   the lack of follow-up within the patient's home.  It would seem to me
   that this would be an ideal place for a public health nurse to check
   on the patient's condition, ensure that the procedure was being
   properly followed under actual field conditions, and that the correct
   amount of medicine has been utilized. - Dr. David's letter regarding
   potential problems of noncompliance and home follow-up in the use of
   outpatient intravenous antibiotics points out the need for this type
   of therapy to be instituted only in those centers in which these
   facets can be well controlled. Public health nurses are utilized by
   some centers to supervise and assist in the home management of cystic
   fibrosis with good success.
RF 001   RABINER SF            N ENGL J MED                   283  1011 970
   002   STRAWCZYNSKI H        PEDIATRICS                      51   986 973
   003   RUCKER RW             PEDIATRICS                      54   358 974
   004   LASAGNA L             N ENGL J MED                   289   267 973

PN 75150
RN 00316
AN 75083181
AU Whitman-V.  Stern-R-C.  Bellet-P.  Doershuk-C-F.  Liebman-J.
   Boat-T-F.  Borkat-G.  Matthews-L-W.
TI Studies on cor pulmonale in cystic fibrosis: I. Effects of diuresis.
SO Pediatrics. 1975 Jan. 55(1). P 83-5.
MJ CYSTIC-FIBROSIS: co.  DIURESIS.  ETHACRYNIC-ACID: tu.
   PULMONARY-HEART-DISEASE: et.
MN ACID-BASE-EQUILIBRIUM.  ADOLESCENCE.  ADULT.  BLOOD-PRESSURE.
   CARBON-DIOXIDE: bl.  CARDIAC-OUTPUT.  CYSTIC-FIBROSIS: pp.
   DRUG-EVALUATION.  ETHACRYNIC-ACID: ad, ae.  HEART-CATHETERIZATION.
   HEART: pp.  HUMAN.  HYDROGEN-ION-CONCENTRATION.  OXYGEN: bl.
   PARTIAL-PRESSURE.  PULMONARY-CIRCULATION.
   PULMONARY-HEART-DISEASE:  dt, pp.  SUPPORT-U-S-GOVT-NON-P-H-S.
AB The effects of acute diuresis in patients with cor pulmonale
   secondary to cystic fibrosis were studied. Both hemodynamic
   parameters and arterial blood gas changes were investigated. The
   major effect noted was a significant reduction of systemic venous
   pressure. Pulmonary artery and pulmonary artery wedge pressure either
   remained constant or declined slightly. No consistent changes were
   noted in cardiac output or arterial blood gases. Acute diuresis of
   moderate degree appears to be a safe and effective manner in which to
   treat the systemic venous congestion of cor pulmonale in this
   situation.
RF 001   FISHMAN AP            HOSP PRACT                       6   101 971
   002   KINSMAN JM            AM J PHYSIOL                    89   322 929
   003   MOSS AJ               J PEDIATR                       67   797 965
   004   GOLDRING RM           J PEDIATR                       65   501 964
   005   BERNE RM              CARDIOVASCULAR PHYSIOLOGY                967
   006   NOBLE MIM             LANCET                           2   257 966
CT   1   WOOD RE               AM REV RESPIR DIS              113   833 976
     2   ROSENTHAL A           PEDIATRICS                      59   919 977
     3   TANG SC               CHIN MED J                      93   779 980
     4   MOSS AJ               PEDIATRICS                      70   728 982

PN 75151
RN 00317
AN 75083179
AU Wilmshurst-E-G.  Soeldner-J-S.  Holsclaw-D-S.  Kaufmann-R-L.
   Shwachman-H.  Aoki-T-T.  Gleason-R-E.
TI Endogenous and exogenous insulin responses in patients with cystic
   fibrosis.
SO Pediatrics. 1975 Jan. 55(1). P 75-82.
MJ BLOOD-GLUCOSE.  CARBOHYDRATES: me.  CYSTIC-FIBROSIS: pp.  INSULIN.
MN ADMINISTRATION-ORAL.  ADOLESCENCE.  ADULT.  BLOOD-GLUCOSE: an.
   FATTY-ACIDS-NONESTERIFIED: bl.  GLUCOSE-TOLERANCE-TEST.  GLUCOSE: ad.
   HUMAN.  INJECTIONS-INTRAVENOUS.  INSULIN: se, bl, du.  MALE.
   NITROGEN: bl.  TOLBUTAMIDE: du.  SUPPORT-U-S-GOVT-NON-P-H-S.
AB Eight male patients with cystic fibrosis, normal nutrition, normal
   physical activity, relatively mild pulmonary disease, no evidence of
   liver disease and no family history of diabetes mellitus underwent a
   series of carbohydrate tolerance tests in comparison with a group of
   18 normal male subjects matched for age and body weight. Compared
   with the normal group, the patients with cystic fibrosis had
   significantly impaired glucose tolerance and significantly lower
   serum immunoreactive insulin levels during oral and intravenous
   glucose tolerance tests; serum insulin levels were also significantly
   lower after intravenous administration of tolbutamide in the patients
   with cystic fibrosis, but the reduction in blood glucose
   concentration in each group was not significantly different. During
   an intravenous insulin test, the decrease in blood glucose
   concentration was the same for both groups, in spite of significantly
   lower serum insulin levels in the patients with cystic fibrosis .The
   percentage fall in plasma free fatty acids was at least as great in
   the patients with cystic fibrosis as in normals during the test
   procedures; while a significant decrease in plasma alpha-amino
   nitrogen after intravenously administered insulin was seen only in
   the patients with cystic fibrosis. These studies suggest that the
   carbohydrate intolerance of cystic fibrosis is consequent upon an
   impaired insulin response to glucose, but that this insulin
   deficiency is partly compensated for by increased peripheral tissue
   sensitivity to insulin.
RF 001   ANON                  GUIDE TO DIAGNOSIS AND MANAGE            971
   002   TALAMO RC             CALIF MED                      110   432 969
   003   MCKUSICK VA           MENDELIAN INHERIT IN MAN             167 966
   004   ROSAN RC              AM J DIS CHILD                 104   625 962
   005   WANG CI               CF CLUB ABST                     8     1 967
   006   MILNER AD             ARCH DIS CHILD                  44   351 969
   007   HOLSCLAW DS           PROC AM PEDIATR SOC ANNU MTG          59 970
   008   HANDWERGER S          N ENGL J MED                   281   451 969
   009   SHWACHMAN H           PEDIATRICS                      36   689 965
   010   HOFFMAN WS            J BIOL CHEM                    120    51 937
   011   SOELDNER JS           DIABETES                        14   771 965
   012   BODEN G               DIABETOLOGICA                    3   413 967
   013   DOLE VP               J BIOL CHEM                    235  2595 960
   014   RUSH RL               ADV AUTOMATED ANALYSI                503 970
   015   MOORE S               J BIOL CHEM                    211   907 954
   016   KAHN CB               N ENGL J MED                   281   343 969
   017   MILUNSKY A            AM J DIS CHILD                 121    15 971
   018   KAISER G              HELV PAEDIATR ACTA              25   135 970
   019   PERLEY MJ             DIABETES                        15   867 966
   020   SELTZER HS            J CLIN INVEST                   46   323 967
   021   BIERMAN EL            DIABETES                         6   475 957
   022   HALES CN              LANCET                           1   790 963
   023   SHAFRIR E             DIABETES                        14    77 965
   024   WILMSHURST EG         DIABETES SUPPL                  21   383 972
   025   KAHN CB               DIABETES SUPPL                  21   365 972
CT   1   SHWACHMAN H           PEDIATR CLIN NORTH AM           22   787 975
     2   WOOD RE               AM REV RESPIR DIS              113   833 976
     3   DISANTAGNESE PA       N ENGL J MED                   295   597 976
     4   SHWACHMAN H           MEDICINE                        56   129 977
     5   LIPPE BM              J PEDIATR                       90   751 977
     6   GUYTON JR             DIABETES                        27  1027 978
     7   WOOD RE               SOUTH MED J                     72   189 979
     8   LIPPE BM              PEDIATRICS                      65  1018 980
     9   ADRIAN TE             GASTROENTEROLOGY                79   460 980
    10   ROSS SA               PEDIATRICS                      67   252 981
    11   BISTRITZER T          ISR J MED SCI                   19   600 983
    12   HILLEMEIER C          YALE J BIOL MED                 56   195 983
    13   PEDERSEN PS           ACTA PAEDIATR SCAND             72   757 983
    14   IANNUCCI A            HUM PATHOL                      15   278 984
    15   MATTHEWS LW           PEDIATR CLIN NORTH AM           31   133 984
    16   GEFFNER ME            AM J DIS CHILD                 138   677 984
    17   MOHAN V               DIABETE METAB                   11   376 985
    18   KNOPFLE G             KLIN PAEDIATR                  197    13 985
    19   RODMAN HM             MEDICINE                        65   389 986
    20   DOLAN TF              N ENGL J MED                   314   991 986
    21   WINTER WE             N ENGL J MED                   316   285 987

PN 75152
RN 00318
AN 75083169
AU Stephan-U.  Busch-E-W.  Kollberg-H.  Hellsing-K.
TI Cystic fibrosis detection by means of a test-strip.
SO Pediatrics. 1975 Jan. 55(1). P 35-8.
MJ ALBUMINS: an.  CYSTIC-FIBROSIS: di.  INDICATORS-AND-REAGENTS.
   INFANT-NEWBORN-DISEASES: di.  MASS-SCREENING: mt.  MECONIUM: an.
   REAGENT-STRIPS.
MN EVALUATION-STUDIES.  FALSE-NEGATIVE-REACTIONS.
   FALSE-POSITIVE-REACTIONS.  GEL-DIFFUSION-TESTS.  HUMAN.  INFANT.
   INFANT-NEWBORN.  IONTOPHORESIS.  MASS-SCREENING: is.  METHODS.
   PHENOLPHTHALEINS.  PILOCARPINE.
AB The effectiveness of meconium screening for albumin as an indication
   of cystic fibrosis is examined. BM-Test Meconium was applied to
   69,000 investigations. In 60 positive tests, cystic fibrosis was
   confirmed later. No increased albumin content was observed in four
   cases of cystic fibrosis.
RF 001   GEORGE L              ARCH DIS CHILD                  46   139 971
   002   WARWICK WJ            MINN MED                        52  1567 969
   003   SHWACHMAN H           PEDIATRICS                      46   335 970
   004   KOCH G                IN: VON WINDORFER A                   30 968
   005   WRIGHT SW             AM J HUM GENET                  20   157 968
   006   KULCZYCKI LL          AM J DIS CHILD                 127    64 974
   007   GLANZMANN E           ANN PAEDIATR                   175    33 950
   008   BUCHANAN DJ           PEDIATRICS                       9   304 952
   009   GREEN MN              PEDIATRICS                      21   635 958
   010   WISER WC              PEDIATRICS                      33   115 964
   011   GREEN MN              PEDIATRICS                      41   989 968
   012   SCHUTT WH             ARCH DIS CHILD                  43   178 968
   013   BRAY PT               PROC EWGCF 3RD ANNU MTG                  972
   014   PROSSER R             PROC EWGCF 4TH ANNU MTG                  973
   015   CAIN ARR              ARCH DIS CHILD                  47   131 972
   016   GIBBS GE              PAEDIATRICIAN                    1   133 972
   017   HOBBS JR              PROTIDES BIOL FLUIDS            17   517 969
   018   KOLLBERG H            ARCH DIS CHILD                  47   836 972
   019   SHWACHMAN H           IN: MANGOS JA                        277 973
   020   HELLSING K            SCAND J CLIN LAB INVEST         33   333 974
   022   PROSSER R             ARCH DIS CHILD                  49   597 974
   023   STEPHAN U             IN: MANGOS JA                        281 973
   024   STEPHAN U             PADIATRISCHE PRAXIS             12   487 973
   025   STEPHAN U             PEDIATRE                        10    63 974
   026   STEPHAN U             KLIN PAEDIATR                  186    79 974
   027   STEPHAN U             CF CLUB ABST                    15       974
   028   KAISER D              HELV PAEDIATR ACTA              29    51 974
   030   THORNER RM            PUBLIC HEALTH MONOGRAPH DHEW    10       967
   031   PRITCHARD JA          OBSTET GYNECOL                  25   289 965
   032   RULE AH               PEDIATRICS                      45   847 970
   033   EGGERMONT E           BIOL NEONATE                    10   266 966
   034   SHWACHMAN H           HOSP PRACT                       9   143 974
   036   GOTTSCHALK B          DTSCH GESUNDHEITSW              28  2049 973
   037   LAWSON D              ARCH DIS CHILD                  47     1 972
CT   1   CHILDS B              ANNU REV GENET                   9    67 975
     2   BERRY HK              FED PROC                        34  2134 975
     3   ANTONOWICZ I          LANCET                           1   746 976
     4   ANON                  LANCET                           2   614 976
     5   RYLEY HC              LANCET                           2   365 976
     6   STEPHAN U             INTERNIST                       17   336 976
     7   LANZA I               MINERVA PEDIATR                 28  1510 976
     8   EGGERMONT E           ARCH DIS CHILD                  51   901 976
     9   GRAND RJ              GASTROENTEROLOGY                70   790 976
    10   ANON                  J PEDIATR                       88   711 976
    11   WOOD RE               AM REV RESPIR DIS              113   833 976
    12   ANON                  BR MED J                         1   596 977
    13   TENKATE LP            INT J EPIDEMIOL                  6    23 977
    14   CARTER CO             J MED GENET                     14   316 977
    15   ANDORSKY M            AM J DIG DIS                    22    56 977
    16   TENKATE LP            ANN HUM GENET                   40   287 977
    17   KRAEMER R             SCHWEIZ MED WOCHENSCHR         107  1105 977
    18   BRUNS WT              AM J DIS CHILD                 131    71 977
    19   KATZNELSON D          ISR J MED SCI                   14   204 978
    20   FIFI AR               MINERVA PEDIATR                 30   597 978
    21   ANTONOWICZ I          BIOL NEONATE                    34   225 978
    22   WATTS RWE             EXPERIENTIA                     34   143 978
    23   RETIEF AE             S AFR MED J                     54   849 978
    24   SCHUTTRINGER G        CLIN CHIM ACTA                  83   109 978
    25   GOTZ M                EUR J PEDIATR                  127   133 978
    26   ROSENSTEIN BJ         AM J DIS CHILD                 132   167 978
    27   SHWACHMAN H           AM J DIS CHILD                 132  1112 978
    28   HOSLI P               LANCET                           2   543 979
    29   KAISER D              AKTUEL ERNAHRUNGSMED             4    26 979
    30   RYLEY HC              MONOGR PAEDIATR                 10   151 979
    31   GURWITZ D             PEDIATR CLIN NORTH AM           26   603 979
    32   RYLEY HC              ARCH DIS CHILD                  54    92 979
    33   DOYLE EE              IR MED J                        72    93 979
    34   WOOD RE               SOUTH MED J                     72   189 979
    35   JAKEL HP              BIOL ZENTRALBL                  98    55 979
    36   HOSLI P               FEBS LETTERS                   104   271 979
    37   ANON                  CAN MED ASSOC J                121  1193 979
    38   BERRY HK              AM J DIS CHILD                 134   930 980
    39   MASTELLA G            RIV ITAL PEDIATR                 7   581 981
    40   HSIEH MC              CLIN CHEM                       27   388 981
    41   EVANS RT              J CLIN PATHOL                   34   911 981
    42   FORREST DC            ARCH DIS CHILD                  56   151 981
    43   SHWACHMAN H           ARCH DIS CHILD                  56   137 981
    44   BORGSTROM A           ACTA PAEDIATR SCAND             70   619 981
    45   CAVELL B              ACTA PAEDIATR SCAND             70   635 981
    46   PARK RW               GASTROENTEROLOGY                81  1143 981
    47   MACHILL G             BIOL ZENTRALBL                 100   449 981
    48   ANON                  LANCET                           1  1000 982
    49   KOLLBERG H            ACTA PAEDIATR SCAND             71   197 982
    50   ROSENSTEIN BJ         JOHNS HOPKINS MED J            150   113 982
    51   ROSENSTEIN BJ         JAMA                           247  3313 982
    52   MOHRENWEISER HW       ISOZYMES                        10    51 983
    53   HEELEY AF             CLIN CHEM                       29  2011 983
    54   POSSELT HG            ATEMWEGS LUNGENKRANKH           10   345 984
    55   HSIEH MC              CLIN CHIM ACTA                 138   221 984
    56   NAYLOR EW             SEM PERINATOL                    9   232 985
    57   PERINI JM             BULL EUR PHYSIOPATH RESP        21   569 985
    58   GRUTTNER R            MONATSSCHR KINDERHEILKD        133    54 985
    59   STOLLINGER O          WIEN MED WOCHENSCHR            135   307 985
    60   KNOPFLE G             KLIN PAEDIATR                  197    13 985
    61   KNOPFLE G             KLIN PAEDIATR                  197   481 985
    62   NAZER H               TRANS R SOC TROP MED HYG        80   348 986

PN 75153
RN 00319
AN 76076929
AU Antonowicz-I.  Ishida-S.  Shwachman-H.
TI Studies in meconium: disaccharidase activities in meconium from
   cystic fibrosis patients and controls.
SO Pediatrics. 1975 Nov. 56(5). P 782-7.
MJ CYSTIC-FIBROSIS: en.  DISACCHARIDASES: an.  MECONIUM: en.
MN CYSTIC-FIBROSIS: di.  HUMAN.  INFANT-NEWBORN.
   SUPPORT-U-S-GOVT-P-H-S.
AB Meconium ileus represents the earliest clinical manifestation of
   cystic fibrosis. The differences found in the composition and amount
   of protein, mucoprotein, mucopolysaccharides, and reducing sugars in
   meconium from newborns with cystic fibrosis might be of significance
   relative to the pathogenesis and early diagnosis of this disease. We
   studied the enzymatic activity of disaccharidases (lactase, sucrase,
   maltase, and palatinase) in meconium of infants with cystic fibrosis
   and controls. We found an increase in the specific activity of these
   enzymes in the meconium from infants with cystic fibrosis as compared
   to the specific activity in meconium from normal infants. The
   increase in the activities, expressed as micromols per gram of
   protein per minute was: lactase, 100 times higher; sucrase, 18 times;
   maltase, 4.8 times, and palatinase, 8.9 times.
RF 001   BUCHANAN DJ           PEDIATRICS                       9   304 952
   002   GREEN MN              PEDIATRICS                      21   635 958
   003   SCHACHTER H           CAN J BIOCHEM                   43   381 965
   004   GREEN MN              PEDIATRICS                      41   989 968
   005   KNAUFF RE             PROC SOC EXP BIOL MED          127   801 968
   006   SCHUTT WH             ARCH DIS CHILD                  43   178 968
   007   RULE AH               PEDIATRICS                      45   847 970
   008   RULE AH               PEDIATRICS                      48   601 971
   009   DONNISON AB           PEDIATRICS                      37   833 966
   010   CAIN ARR              ARCH DIS CHILD                  47   131 972
   011   STEPHAN U             CF CLUB ABST                    15       974
   012   EGGERMONT E           BIOL NEONATE                    10   266 966
   013   GRUNDIG CA            ACTA BIOL MED GER               19   193 967
   014   HERNANDEZ-JODRA M     ENZYME                          12   682 971
   015   STEPHAN U             CF CLUB ABST                    15       974
   016   SHWACHMAN H           ANN NY ACAD SCI                 93   600 962
   017   DAHLQVIST A           ANAL BIOCHEM                     7    18 964
   018   TOWNLEY RRW           PEDIATRICS                      36   911 965
   019   LOWRY OH              J BIOL CHEM                    193   265 951
   020   EGGSTEIN M            KLIN WOCHENSCHR                 33   879 955
   021   KOPITO L              J PEDIATR                       68   313 966
   022   OPPENHEIMER EH        ARCH PATHOL                     96   149 973
   023   CRANE RK              IN: CODE CF                      5  2535 968
   024   HAEMMERLI UP          IN: DOWLIN HF                          7 966
   025   AURICCHIO S           PEDIATRICS                      35   944 965
   026   DAHLQVIST A           CLIN SCI                        30   517 966
   027   SHEEHY TW             AM J DIS CHILD                 121   464 971
   028   ANTONOWICZ I          GASTROENTEROLOGY                67    51 974
   029   KARLSON P             INTRODUCTION TO MODERN BIOCHE        314 968
   030   SIEGAL S              NONPARAMETRIC STATISTICS                 956
   031   ERLANGER BF           ARCH BIOCHEM BIOPHYS            95   271 961
   032   NAGEL W               PHYSIOL CHEM                   340     1 965
   033   HADORN B              LANCET                           1   812 969
CT   1   ANTONOWICZ I          LANCET                           1   746 976
     2   GRAND RJ              GASTROENTEROLOGY                70   790 976
     3   ANTONOWICZ I          BIOL NEONATE                    32   280 977
     4   KRAEMER R             SCHWEIZ MED WOCHENSCHR         107  1105 977
     5   RYLEY HC              J CHROMATOGR                   143   411 977
     6   ANTONOWICZ I          BIOL NEONATE                    34   225 978
     7   HARRIES JT            BR MED BULL                     34    75 978
     8   KARLSSON KA           FEBS LETTERS                    87   283 978
     9   ANTONOWICZ I          J PEDIATR                       92   214 978
    10   SHWACHMAN H           AM J DIS CHILD                 132  1112 978
    11   RYLEY HC              MONOGR PAEDIATR                 10   151 979
    12   MORIN PR              CLIN GENET                      18   217 980
    13   BERRY HK              AM J DIS CHILD                 134   930 980
    14   MASTELLA G            RIV ITAL PEDIATR                 7   581 981
    15   LAMBOTTE C            J GENET HUM                     29    85 981
    16   EVANS RT              J CLIN PATHOL                   34   911 981
    17   RYLEY HC              J CLIN PATHOL                   34   179 981
    18   LEBENTHAL E           DIGESTION                       23    39 982
    19   POTIER M              BIOL NEONATE                    45   257 984
    20   BROCK DJH             BR J OBSTET GYNAECOL            91   449 984
    21   KLEIJER WJ            PRENAT DIAGN                     5   135 985
    22   SMITH T               CELL TISSUE RES                242   197 985

PN 75154
RN 00320
AN 76076954
AU Jusko-W-J.  Mosovich-L-L.  Gerbracht-L-M.  Mattar-M-E.  Yaffe-S-J.
TI Enhanced renal excretion of dicloxacillin in patients with cystic
   fibrosis.
SO Pediatrics. 1975 Dec. 56(6). P 1038-44.
MJ CYSTIC-FIBROSIS: dt.  DICLOXACILLIN: ur.
MN ADOLESCENCE.  ADULT.  BIOLOGICAL-AVAILABILITY.  CHILD.
   COMPARATIVE-STUDY.  CYSTIC-FIBROSIS: ur, bl.  DICLOXACILLIN: tu, bl.
   FEMALE.  HUMAN.  KIDNEY: me.  MALE.  PROTEIN-BINDING.
   SUPPORT-U-S-GOVT-P-H-S.
AB Single oral doses of 6.25 mg/kg of dicloxacillin suspension were
   given to ten cystic fibrosis (CF) patients and eight normal subjects.
   Peak serum concentrations and areas under the concentration versus
   time curves for dicloxacillin were variable and, on average, were 2
   1/2 times lower in the CF patients. The time of occurrence of the
   peak serum concentration was similar in both groups and the total
   urinary recovery of dicloxacillin was normal or increased in the CF
   patients, suggesting that the intestinal absorption of the drug was
   unaffected by the disease. The low serum concentrations in the CF
   patients were caused by unusually high renal clearances of
   dicloxacillin which average 282 +/- 135 compared to 95 +/- 28
   ml/min/1.73 sq m in the normal subjects. Creatinine clearances were
   also elevated in the CF patients by 55% on average, while urea
   clearances were normal. The serum protein binding of dicloxacillin
   was similar in both groups of subjects. Because the rapid excretion
   results in low and variable serum concentrations of the antibiotic,
   treatment of CF patients with dicloxacillin may warrant use of
   increased or more frequent doses and monitoring of serum antibiotic
   levels.
RF 001   LOWE CU               IN: BARNETT HL                       413 972
   002   HARRIS R              ARCH DIS CHILD                  30   424 955
   003   DEREN JJ              N ENGL J MED                   288   949 973
   004   WEBER AM              N ENGL J MED                   289  1001 973
   005   DIEM K                DOCUMENTA GEIGY SCIENTIFIC TA            970
   006   BENNETT JV            APPL MICROBIOL                  14   170 966
   007   HEINEGARD D           CLIN CHIM ACTA                  43   305 973
   008   CROCKER CL            AM J MED TECHNOLOGY             33   361 967
   009   JUSKO WJ              J PHARM SCI                     58    57 969
   010   BENNETT JV            J LAB CLIN MED                  66   721 965
   011   STROBER W             PEDIATRICS                      43   416 969
   012   WILSON GB             CLIN CHIM ACTA                  49    79 973
   013   DOLUISIO JT           ANTIMICROB AGENTS CHEMOTHER      9    49 969
   014   DITTERT LW            ANTIMICROB AGENTS CHEMOTHER      9    42 969
   015   ROSENBLATT JE         ARCH INTERN MED                121   345 968
   016   JUSKO WJ              J PHARM SCI                     61  1270 972
   017   AGUSTA VE             J UROL                         110   113 973
   018   RENNICK BR            AM J PHYSIOL                   212  1131 967
   019   MOGENSEN CE           DIABETES                        22   706 973
CT   1   WOOD RE               AM REV RESPIR DIS              113   833 976
     2   YAFFE SJ              ANN NY ACAD SCI                281    90 976
     3   YAFFE SJ              J INFECT DIS                   135   828 977
     4   SOUICH PD             CLIN PHARMACOKINET               3   257 978
     5   GUGGENBICHLER JP      MONOGR PAEDIATR                 10    34 979
     6   BERGAN T              ARZNEIMITTEL FORSCH DRUG RES  29-2  1955 979
     7   BRYSON YJ             J PEDIATR                       94   673 979
     8   FINKELSTEIN E         J PEDIATR                       94   163 979
     9   SOLDIN SJ             THER DRUG MONITOR                2   417 980
    10   PRINCE AS             J PEDIATR                       97   148 980
    11   BAGGOT JD             J AM VET MED ASSOC             176  1085 980
    12   MICHALSEN H           ANTIMICROB AGENTS CHEMOTHER     19  1029 981
    13   STRANDVIK B           LANCET                           1   800 982
    14   BINS JW               BR J CLIN PHARMACOL             14  P611 982
    15   SOLDIN SJ             ADV CHROMATOGR                  20   139 982
    16   NEU HC                MED CLIN NORTH AM               66    51 982
    17   KEARNS GL             J PEDIATR                      100   312 982
    18   EICHENWALD HF         PEDIATR PHARMACOL                3   181 983
    19   PADOAN R              DRUGS UNDER EXP CLIN RES         9   661 983
    20   HUANG NN              J ANTIMICROB CHEMOTHER          11   205 983
    21   KAMPF D               J ANTIMICROB CHEMOTHER          11    25 983
    22   ASSAEL BM             J ANTIMICROB CHEMOTHER          12   341 983
    23   KERCSMAR CM           J ANTIMICROB CHEMOTHER          12   289 983
    24   LEFF RD               PEDIATR CLIN NORTH AM           30    93 983
    25   ARVIDSSON A           ACTA PAEDIATR SCAND             72   293 983
    26   THIRUMOORTHI MC       J PEDIATR                      102   941 983
    27   MACDONALD NE          J PEDIATR                      103   985 983
    28   PADOAN R              J PEDIATR                      103   320 983
    29   ISLES A               AM REV RESPIR DIS              127   417 983
    30   NAHATA MC             DEVELOP PHARM THER               7   221 984
    31   MARTINI N             J CLIN HOSP PHARM                9   303 984
    32   TURNER A              J ANTIMICROB CHEMOTHER          14   521 984
    33   KELLY HW              DRUG INTEL CLIN PHARM           18   772 984
    34   SCHOFIELD DH          DRUG INTEL CLIN PHARM           18   153 984
    35   BOSSO JA              ANTIMICROB AGENTS CHEMOTHER     25   630 984
    36   REED MD               ANTIMICROB AGENTS CHEMOTHER     25   579 984
    37   LEEDER JS             CLIN PHARMACOL THER             36   355 984
    38   REED MD               J PEDIATR                      104   303 984
    39   SPINO M               J PEDIATR                      105   829 984
    40   ANON                  LANCET                           1  1020 985
    41   KUHN RJ               CLIN PHARMACY                    4   555 985
    42   WOOLF RA              CLIN PHARMACY                    4   664 985
    43   HARRISON CJ           PEDIATR PHARMACOL                5     7 985
    44   PRANDOTA J            DEVELOP PHARM THER               8   311 985
    45   REED MD               ANTIMICROB AGENTS CHEMOTHER     27   583 985
    46   BLUMER JL             AM J MED                        79    37 985
    47   HORREVORTS AM         CHEST                           88   260 985
    48   JACOBS RF             J PEDIATR                      106  1001 985
    49   WILSON CB             J PEDIATR                      106  1049 985
    50   SPINO M               J PEDIATR                      107    64 985
    51   REED MD               PEDIATR PULMONOL                 2   282 986
    52   ASSAEL BM             INT J PEDIATR NEPHROL            7   213 986
    53   MICHALSEN H           METH FIND EXP CLIN PHARMACOL     8   685 986
    54   MICHALSEN H           METH FIND EXP CLIN PHARMACOL     8   727 986
    55   BENDER SW             INFECTION                       14    17 986
    56   BRAGANZA JM           MED HYPOTHESES                  20   233 986
    57   WRIGHT DB             DRUG INTEL CLIN PHARM           20   845 986
    58   GOLDFARB J            J CLIN PHARMACOL                26   222 986
    59   LEBEL M               ANTIMICROB AGENTS CHEMOTHER     30   260 986
    60   LITTLEWOOD JM         J ROY SOC MED                   79    55 986
    61   BLUMER JL             J PEDIATR                      108   854 986
    62   KEARNS GL             J PEDIATR                      108   847 986

PN 75155
RN 00321
AN 75083184
AU Dietzsch-H-J.  Gottschalk-B.  Heyne-K.  Leupoid-W.  Wunderlich-P.
TI Cystic fibrosis: comparison of two mucolytic drugs for inhalation
   treatment (acetylcysteine and arginine hydrochloride).
SO Pediatrics. 1975 Jan. 55(1). P 96-100.
MJ ACETYLCYSTEINE: ad.  ARGININE: ad.  CYSTIC-FIBROSIS: dt.
   EXPECTORANTS: ad.
MN ACETYLCYSTEINE: tu.  AEROSOLS.  ARGININE: tu.  BRONCHOSCOPY.
   CARBON-DIOXIDE: bl.  CHILD.  CHILD-PRESCHOOL.  COUGH.
   CYSTIC-FIBROSIS: pp.  DRUG-EVALUATION.  EXPECTORANTS: tu.  FEMALE.
   HUMAN.  MALE.  MUCUS: se.  OXYGEN: bl.  RADIONUCLIDE-IMAGING.
   RESPIRATION.  RESPIRATORY-FUNCTION-TESTS.  SPIROMETRY.  SPUTUM: mi.
AB Clinical, bronchoscopic, spirographic, scintigraphic, and chemical
   analyses were done in 24 children with cystic fibrosis to assess the
   mucolytic effects of acetylcysteine inhalations versus L-arginine
   hydrochloride aerosols. The latter drug is less active than
   acetylcysteine and should not be used to treat children with cystic
   fibrosis.
RF 001   WEBB WR               POSTGRAD MED                    36   449 964
   002   DENTON R              AM REV RESPIR DIS               95   643 967
   003   DIETZSCH HJ           BRONCHES                        20   383 970
   004   DIETZSCH HJ           Z ERKR ATMUNGSORGANE           134   445 971
   005   DIETZSCH HJ           MEDICAMENTUM                    13   299 972
   006   GOTTSCHALK B          DTSCH GESUNDHEITSW              25   700 970
   007   GOTTSCHALK B          DTSCH GESUNDHEITSW              27  1121 972
   008   HUANG NN              GUIDE TO DRUG THERAPY IN PATI            972
   009   MILLER WF             ARCH INTERN MED                131   148 973
   010   REAS HW               J PEDIATR                       65   542 964
   011   SHEFFNER AL           BIOCHEM PHARMACOL               15  1523 966
   012   WEBB WR               J THORAC CARDIOVASC SURG        44   330 962
   013   WEBB WR               CLIN MED                        71  1531 964
   014   LEUPOLD W             DTSCH GESUNDHEITSW              25  1400 970
   015   MATTHEWS LW           MINN MED                        52  1483 969
   016   DIETZSCH HJ           DTSCH GESUNDHEITSW              28   842 973
   017   SOLOMONS CC           PEDIATRICS                      47   384 971
   018   DIETZSCH HJ           PAEDIATR GRENZGEB                6   195 967
CT   1   DIETZSCH HJ           PEDIATRICS                      57   166 976
     2   SOLOMONS C            PEDIATRICS                      57   166 976
     3   RICHARDSON PS         PHARMACOL THER (B)               3   441 978
     4   TABACHNIK E           AM REV RESPIR DIS              122    97 980
     5   WANNER A              AM REV RESPIR DIS              122    79 980

PN 75156
RN 00322
AN 75157451
AU Oppenheimer-E-H.  Esterly-J-R.
TI Pathology of cystic fibrosis review of the literature and comparison
   with 146 autopsied cases.
SO Perspect-Pediatr-Pathol. 1975. 2. P 241-78.
MJ CYSTIC-FIBROSIS: pa.
MN AUTOPSY.  CARDIOVASCULAR-SYSTEM: pa.  CYSTIC-FIBROSIS: co.  EAR: pa.
   GALLBLADDER: pa.  GENITALIA-FEMALE: pa.  GENITALIA-MALE: pa.  HUMAN.
   INTESTINES: pa.  KIDNEY: pa.  LIVER: pa.  LUNG: pa.
   MALABSORPTION-SYNDROMES: et, pa.  NOSE: pa.  PANCREAS: pa.
   PHARYNX:  pa.  SWEAT-GLANDS: pa.
EX This review of pathologic findings in cystic fibrosis includes a
   survey of morphologic changes from the original descriptions of CF
   and the numerous subsequent reports, and an analysis of 146 cases
   autopsied at the Johns Hopkins Hospital and Billings Hospital.
   Achylia occurs in 85 to 90% of patients.  Approximately 1 of 7
   patients with CF presents with meconium ileus.  In 1962 we described
   gallbladder abnormalities in 24 of 72 cases of CF (33%).  In
   Anderson's original description of CF, hemosiderosis was present in
   nearly every liver, and fatty infiltration was a frequent finding.
   The respiratory tract is invariably involved in CF.  The heart has
   never been considered a primary target organ in CF.  Bodian described
   a higher incidence of nephrocalcinosis in CF than in routine
   pediatric autopsies (31% compared to 11%).  With the increased
   longevity of patients with CF male sterility has become a recognized
   complication.  Increased electrolyte concentrations in sweat are the
   most diagnostic manifestation of CF, although an occasional patient
   has escaped this defect.  Nasal polyps are frequent and often
   recurrent problems in patients with CF.  Malabsorption due to
   pancreatic exocrine deficiency was originally described as the main
   manifestation of CF.  The autopsy diagnosis of CF is usually based on
   a combination of lesions rather than on the changes in a single
   organ.
RF 001   ANDERSEN DH           AM J DIS CHILD                  56   344 938
   002   LANDSTEINER K         ZENTRALBL ALLG PATHOL           16   903 905
   003   FARBER S              ARCH PATHOL                     37   238 944
   004   BODIAN M              FIBROCYSTIC DIS OF THE PANCRE            952
   005   KESSLER WR            PEDIATRICS                       8   648 951
   006   DI SANTAGNESE PA      PEDIATRICS                      12   549 953
   007   DANKS DM              ANN HUM GENET                   28   323 965
   008   HARRIS RL             PEDIATRICS                      41   733 968
   009   OPPENHEIMER EH        PEDIATRICS                      42   547 968
   010   REDDY CR              J TROP MED HYG                  73    59 970
   011   ARTHAUD JB            ARCH PATHOL                     90   433 970
   012   KULCZYCKI LL          AM J DIS CHILD                 127    64 974
   013   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   014   SPOCK A               PEDIATR RES                      1   173 967
   015   BOWMAN BH             SCIENCE                        164   325 969
   016   DANES BS              J EXP MED                      129   775 969
   017   REED GB               J PATHOL                       101   251 970
   018   MANGOS JA             PEDIATR RES                      2   378 968
   019   GIBSON LE             PEDIATRICS                      48   695 971
   020   GRAND RJ              CLIN PEDIATR                     9   588 970
   021   DI SANTAGNESE PA      PEDIATRICS                      15   683 955
   022   OPPENHEIMER EH        ARCH PATHOL                     96   149 973
   023   OPPENHEIMER EH        IN: MCKUSICK VA                  7   108 972
   024   ALLEN RA              AM J PATHOL                     31   337 955
   025   KORNBLITH BA          AM J PATHOL                      5   249 929
   026   DI SANTAGNESE PA      GASTROENTEROLOGY                40    64 961
   027   WANG CI               CF CLUB ABST                             968
   028   OPPENHEIMER EH        JOHNS HOPKINS MED J            131   351 972
   029   LARSSON Y             PEDIATRICS                      21   893 958
   030   BROWN RE              ARCH PATHOL                     92    53 971
   031   HANDWERGER S          N ENGL J MED                   281   451 969
   032   KOPEL FB              GASTROENTEROLOGY                62   483 972
   033   HOLSCLAW DS           AM J DIS CHILD                 109   101 965
   034   SHWACHMAN H           N ENGL J MED                   286  1300 972
   035   DONNISON AB           PEDIATRICS                      37   833 966
   036   THOMAIDIS TS          J PEDIATR                       63   444 963
   037   PARKINS RA            LANCET                           2   851 963
   038   OPPENHEIMER EH        BULL JOHNS HOPKINS HOSP        111     1 962
   039   BERNSTEIN JG          AM J DIS CHILD                  99   804 960
   040   LOUW JH               LANCET                           2  1065 955
   041   SANTULLI TV           ANN SURG                       154   939 961
   042   HOLSCLAW DS           PEDIATRICS                      48    51 971
   043   KISSANE JM            PATHOLOGY OF INFANCY AND CHIL        165 965
   044   BERDON WE             N ENGL J MED                   277   585 967
   045   SHWACHMAN H           AM J DIS CHILD                  91   223 956
   046   RICKHAM PP            AM J SURG                      109   173 965
   047   HUNTON DB             GASTROENTEROLOGY                50    99 966
   048   MULLINS F             JAMA                           192   741 965
   049   LLOYD-STILL JD        BR MED J                         1   110 971
   050   KULCZYCKI LL          N ENGL J MED                   259   409 958
   051   BARBERO GJ            PEDIATRICS                      29   788 962
   052   BOLANDE RP            ARCH PATHOL                     95   172 973
   053   WARWICK WJ            PEDIATRICS                      34   621 964
   054   SWENEY LR             ARCH PATHOL                     86   413 968
   055   ALTERMAN K            AM J DIS CHILD                 101   210 961
   056   MCPARTLIN JF          ARCH DIS CHILD                  47   207 972
   057   ESTERLY JR            BULL JOHNS HOPKINS HOSP        110   247 962
   058   ROVSING H             NORD MED                        86  1136 971
   059   VICHI GF              RIV CLIN PEDIATR                82   239 969
   063   CRAIG JM              AM J DIS CHILD                  93   357 957
   064   LANDING B             GAP CONF REP PATHOL OF CF                972
   065   SHARP HL              GAP CONF REP PATHOL OF CF                972
   066   DI SANTAGNESE PA      PEDIATRICS                      18   387 956
   067   ROBERTS WC            AM J MED                        32   324 962
   069   TAYLOR WF             AM J DIS CHILD                 123   161 972
   070   WENTWORTH P           THORAX                          23   582 968
   071   ESTERLY JR            THORAX                          23   670 968
   072   ESTERLY JR            JOHNS HOPKINS MED J            122    94 968
   073   MELLINS RB            PEDIATRICS                      44   315 969
   074   LEV R                 AM J PATHOL                     46    23 965
   075   ESTERLY JR            J NATL CANCER INST              40     1 968
   076   BOAT TF               JAMA                           209  1498 969
   077   REID L                IN: HUBBLE D                          21 964
   077A  NADAS AS              PEDIATRICS                      10   319 952
   077B  GOLDRING RM           J PEDIATR                       65   501 964
   077C  BOWDEN DH             AM J MED                        38   226 965
   078   MCGIVEN AR            ARCH DIS CHILD                  37   656 962
   079   BARNES GL             AUST PAEDIATR J                  6    81 970
   080   OPPENHEIMER EH        JOHNS HOPKINS MED J            133   252 973
   081   OPPENHEIMER EA        AM J MED                        48   637 970
   083   MILUNSKY A            PEDIATRICS                      42   501 968
   084   HOLMAN RL             PEDIATRICS                      24    34 959
   085   OPPENHEIMER EH        LAB INVEST                      30   411 974
   086   PAULSON DF            J UROL                         108   811 972
   087   GHAZALI S             ARCH DIS CHILD                  48   291 973
   088   KUHN JP               RADIOLOGY                       97    59 970
   089   SPEAR GS              NEPHRON                          1   238 964
   090   DENNING CR            PEDIATRICS                      41     7 968
   091   KAPLAN E              N ENGL J MED                   279    65 968
   092   OPPENHEIMER EH        J PEDIATR                       75   806 969
   093   LANDING BH            ARCH PATHOL                     88   569 969
   094   DI SANTAGNESE PA      N ENGL J MED                   279   103 968
   095   VALMAN HB             LANCET                           2   566 969
   096   JOCKIN H              AM J PATHOL                     62   22A 971
   097   WANG CI               AM J DIS CHILD                 119   236 970
   098   HOLSCLAW DS           PEDIATRICS                      48   442 971
   099   RULE AH               FERTIL STERIL                   21   515 970
   100   TAUSSIG LM            LANCET                           1   850 972
   101   FEIGELSON J           ARCH FR PEDIATR                 26   937 969
   102   FEIGELSON J           LYON MED                       226   839 971
   103   TAUSSIG LM            N ENGL J MED                   287   586 972
   104   BUMBALO TS            PEDIATRICS                      43   468 969
   105   GRAND RJ              JAMA                           195   993 966
   106   ROSENOW EC 3RD        JAMA                           203   227 968
   107   OPPENHEIMER EA        AM J OBSTET GYNECOL            108   673 970
   108   OPPENHEIMER EH        J PEDIATR                       77   991 970
   109   KOPITO LE             FERTIL STERIL                   24   512 973
   110   WARD AM               J CLIN PATHOL                   25   119 972
   111   GIBSON LE             J PEDIATR                       81   193 972
   112   MACLEAN WC JR         J PEDIATR                       83    86 973
   113   MUNGER BL             J PEDIATR                       59   497 961
   114$  BARTMAN J             J CLIN PATHOL                   45   455 966
   115   GIBBS GE              J INVEST DERMATOL               51   200 968
   116   ESTERLY NB            AM J DIS CHILD                 123   200 972
   117   KOPITO L              PEDIATR RES                      6   427 972
   118   KOPITO L              N ENGL J MED                   272   504 965
   119   LEONARD PJ            ARCH DIS CHILD                  47   495 972
   120   TAYLOR BW             ARCH DIS CHILD                  49   133 974
   121   NEELY JG              TRANS AM ACAD OPHTHALMOL OTOL   76   313 972
   122   HENKIN RI             SCIENCE                        138  1107 962
   123   PETERSEN RA           AM J DIS CHILD                 116   662 968
   124   KEATING JP            PEDIATRICS                      46    41 970
   125   BOTELHO SY            J PEDIATR                       83   601 973
   126   FOLLIS RH JR          PATHOLOGY OF NUTRITIONAL             163 948
   127   OPPENHEIMER EH        BULL JOHNS HOPKINS HOSP         98   353 956
   128   BLANC WA              PEDIATRICS                      22   494 958
   129   KERNER I              AM J DIS CHILD                  99   597 960
   130   BOREL DM              ARCH PATHOL                     96   269 973
   131   SIMOPOULOS AP         CF CLUB ABST                          13 971
   132   PARK EA               ARCH DIS CHILD                  29   269 954
   133   TORSTENSON OL         PEDIATRICS                      45   857 970
   134   WALTERS TR            AM J DIS CHILD                 124   641 972
   135   KOMP DM               CHEST                           58   501 970
   136   ESTERLY JR            J PEDIATR                       69     3 966
   137   OPPENHEIMER EH        COMPAR PATHOL BULL             111     3 971
   138   PENTSCHEW A           AM J PATHOL                     66   11A 972
   139   OLSON C               ADV VET SCI                     13   101 969
CT   1   SANTAGNESE PAD        N ENGL J MED                   295   481 976
     2   COHN D                MED J AUST                       1   101 977
     3   TOS M                 J LARYNGOL OTOL                 91   827 977
     4   SCHWACHMAN H          N ENGL J MED                   296  1519 977
     5   NEUTRA MR             GASTROENTEROLOGY                75   701 978
     6   VITULLO BB            J PEDIATR                       93  1060 978
     7   VAUGHAN WJ            SCIENCE                        199   783 978
     8   KAISER D              AKTUEL ERNAHRUNGSMED             4    26 979
     9   SWAN HAP              S AFR J SURG                    17    51 979
    10   GURWITZ D             PEDIATR CLIN NORTH AM           26   603 979
    11   SANTAGNESE PAD        AM J MED                        66   121 979
    12   LLOYDSTILL JD         AM J CLIN PATHOL                71   444 979
    13   IMRIE JR              AM J PATHOL                     95   697 979
    14   MISCHLER EH           AM J DIS CHILD                 133   632 979
    15   FINBERG L             N ENGL J MED                   300   420 979
    16   HOLSCLAW DS           CLIN CHEST MED                   1   407 980
    17   ARBORGH B             SCAND J GASTROENTEROL           15    73 980
    18   LOPEZCORELLA E        PATOLOGIA (MEXICO CITY)         18   167 980
    19   WILLI UV              AM J ROENTGENOL                134  1005 980
    20   BLUSTEIN PK           PEDIATRICS                      68   387 981
    21   LAMBERT JR            GASTROENTEROLOGY                80   169 981
    22   PARK RW               GASTROENTEROLOGY                81  1143 981
    23   HULTBERG B            CLIN CHIM ACTA                 112   167 981
    24   FRIEDMAN PJ           AM J ROENTGENOL                136  1131 981
    25   COLTEN HR             N ENGL J MED                   304   831 981
    26   ROY CC                J PEDIATR GASTROENTEROL NUTR     1   469 982
    27   ABDULKARIM FW         GASTROENTEROLOGY                82   758 982
    28   CHOW CW               EUR J PEDIATR                  139   240 982
    29   GUIDOTTI TL           AM J MED SCI                   283   157 982
    30   SHAWKER TH            J ULTRASOUND MED                 2   439 983
    31   MUKAI K               PATHOL ANNU                     18    87 983
    32   JEFFREY I             J CLIN PATHOL                   36  1292 983
    33   WERLIN SL             EXP MOL PATH                    39    24 983
    34   GUIDOTTI TL           RESPIRATION                     44   351 983
    35   BASS S                GASTROENTEROLOGY                84  1592 983
    36   HOLMES R              J PEDIATR                      103   491 983
    37   DANEMAN A             AM J ROENTGENOL                141   653 983
    38   ROOMANS GM            SCANN ELECTRON MICROSC        1983   697 983
    39   PHELAN P              ARCH DIS CHILD                  59    71 984
    40   BRACHLOW M            FORTSCHR GEB RONTG NUKL        140   145 984
    41   MICHALSEN H           PATHOL RES PRACT               178   261 984
    42   SPEERT DP             SURV SYNTH PATHOL RES            4    14 985
    43   HUBBARD VS            SEM RESPIR MED                   6   299 985
    44   SWOBODNIK W           J CLIN ULTRASOUND               13   469 985
    45   ABRAMOWSKY C          HUM PATHOL                      16  1243 985
    46   HIBON D               ANN RADIOL (PARIS)              28   469 985
    47   SZEIFERT GT           CLIN GENET                      28   561 985
    48   AKIMOTO N             HIROSHIMA J MED SCI             34   189 985
    49   GRAHAM N              CLIN RADIOL                     36   199 985
    50   EISENBURG J           FORTSCHR MED                   103   133 985
    51   ROSENBLUM JL          J PEDIATR                      107   149 985
    52   FIEDOREK SC           CLIN PEDIATR                    25   243 986
    53   LIU P                 J CAN ASSOC RADIOL              37   279 986
    54   RUBINSTEIN S          PEDIATRICS                      78   473 986
    55   ABDULKARIM FW         ARCH PATHOL LAB MED            110   602 986
    56   MCGLENNEN RC          ARCH PATHOL LAB MED            110   879 986
    57   ROSENSTEIN BJ         AM J DIS CHILD                 140   966 986
    58   HERNANZSCHULMAN M     RADIOLOGY                      158   629 986
    59   VARMA RR              SEM LIVER DIS                    7    59 987
    60   MCHUGO JM             BR J RADIOL                     60   137 987

PN 75157
RN 00323
AN 76012241
AU Tecklin-J-S.  Holsclaw-D-S.
TI Evaluation of bronchial drainage in patients with cystic fibrosis.
SO Phys-Ther. 1975 Oct. 55(10). P 1081-4.
MJ BRONCHI.  CYSTIC-FIBROSIS: su.  DRAINAGE.
MN ADOLESCENCE.  ADULT.  BRONCHIAL-SPASM: pp.  CHILD.
   CYSTIC-FIBROSIS:  pp.  HUMAN.  LUNG: pp.  RESPIRATORY-FUNCTION-TESTS.
   SUPPORT-U-S-GOVT-P-H-S.
AB Examined in this study are the results of six tests of pulmonary
   function immediately preceding and following bronchial drainage in
   twenty-six patients with cystic fibrosis. Highly significant
   increases averaging 5.67, 4.13, 13.47, and 6.98 percent occurred in
   peak expiratory flow rate, forced vital capacity, expiratory reserve
   volume, and inspiratory capacity respectively. Significant increases
   in peak expiratory flow rate, forced vital capacity, and inspiratory
   capacity were observed in a subgroup of six of the above patients who
   had evidence of bronchospasm. The authors conclude that bronchial
   drainage will produce significant increases in routine pulmonary
   function values. The results suggest that this treatment is most
   effective in clearing the larger, more proximal, airways and is of
   benefit even in the presence of clinical bronchospasm.
RF 001   ANON                  GUIDE TO DIAGNOSIS AND MANAGE            971
   002   STURGESS JM           IN: LAWSON D PROC 5TH INT CF         368 969
   003   SPOCK A               PEDIATR RES                      1   173 967
   004   DOYLE B               PHYS THER REV                   39    24 959
   005   JACKSON CD            AM J MED SCI                   186   849 933
   006   BUSHNELL GE           AM REV TUBERC                    2   259 918
   007   KNIES PT              PHYS THER REV                   18   239 938
   008   MAY E                 PHYS THER REV                   32   121 952
   009   GASKELL DV            BROMPTON HOSP GUIDE TO CHEST             973
   010   THACKER EW            POSTURAL DRAINAGE AND RESPIRA            971
   011   ZAUSMER E             PHYS THER                       48   586 968
   012   ANTHONISEN P          ACTA MED SCAND                 175   715 964
   013   MARCH H               ARCH PHYS MED REHABIL           52   528 971
   014   KANG B                J ALLERGY CLIN IMMUNOL          53     2 974
   015   HUBER AL              J ALLERGY CLIN IMMUNOL          53   109 974
   016   LORIN MI              AM J PHYS MED                   50   215 971
   017   MOTOYAMA EK           IN: MANGOS JA                        335 973
   018   POLGAR G              PULMONARY FUNCTION TESTING IN            971
   019   BRYANT EC             STATISTICAL ANALYSIS                     966
   020   MACKLEM PT            ARCH ENVIRON HEALTH             14     5 967
   021   REAS HW               J PEDIATR                       65   556 964
CT   1   WOOD RE               AM REV RESPIR DIS              113   833 976
     2   TECKLIN JS            AM REV RESPIR DIS              114  1038 976
     3   FRYDMAN MI            J CHRON DIS                     32   211 979
     4   FELDMAN J             AM REV RESPIR DIS              119   239 979
     5   MURRAY JF             N ENGL J MED                   300  1155 979
     6   HOLSCLAW DS           CLIN CHEST MED                   1   407 980
     7   WELLER PH             RESPIRATION                     40    53 980
     8   MACKENZIE CF          ANESTH ANALG CLEVE              59   207 980
     9   ROCHESTER DF          AM REV RESPIR DIS              122   133 980
    10   MALONEY FP            ARCH PHYS MED REHABIL           62   452 981
    11   HOLODY B              AM REV RESPIR DIS              124   372 981
    12   MALONEY FP            ARCH PHYS MED REHABIL           63   423 982
    13   SUTTON PP             EUR J RESPIR DIS                63   188 982
    14   REDDING GJ            AM REV RESPIR DIS              126    31 982
    15   DESMOND KJ            J PEDIATR                      103   538 983
    16   FALK M                EUR J RESPIR DIS                65   423 984
    17   MARINI JJ             AM REV RESPIR DIS              129   101 984
    18   ANDERSON J            BR J DIS CHEST                  79   272 985
    19   MOHSENIFAR Z          CHEST                           87   483 985
    20   KIRILOFF LH           CHEST                           88   436 985
    21   MAZZOCCO MC           CHEST                           88   360 985
    22   VERBOON JML           EUR J RESPIR DIS                69   169 986
    23   CURRIE DC             BR J DIS CHEST                  80   249 986
    24   WEBBER BA             BR J DIS CHEST                  80   353 986

PN 75158
RN 00324
AN 75218113
AU Hertz-J.  Cain-W-S.  Bartoshuk-L-M.  Dolan-T-F-Jr.
TI Olfactory and taste sensitivity in children with cystic fibrosis.
SO Physiol-Behav. 1975 Jan. 14(1). P 89-94.
MJ CYSTIC-FIBROSIS: pp.  SMELL.  TASTE.
MN ADAPTATION-PHYSIOLOGICAL.  ADOLESCENCE.  ADULT.  ALCOHOLS-BUTYL.
   CHILD.  DIFFERENTIAL-THRESHOLD.  FEMALE.  HUMAN.  MALE.
   SODIUM-CHLORIDE.  SUPPORT-U-S-GOVT-P-H-S.
AB Psychophysical experiments measured both olfactory sensitivity to 1-
   butanol and sodium chloride and taste sensitivity to sodium chloride
   in normal children and in children with cystic fibrosis. The
   sensitivity of the children with cystic fibrosis fell within the
   normal range. These results stand in contrast to those of Henkin and
   Powell, who found children with cystic fibrosis to be hypersensitive
   to both olfactory and taste stimuli. Apparent hypersensitivity to
   taste stimuli could have resulted from the adapting effects of the
   relatively high level of sodium in the saliva of children with cystic
   fibrosis. If the contaminating effects of saliva are removed,
   children with cystic fibrosis yield, on the average, a taste
   threshold identical to that of normal children. There appears to be
   no simple explanation for why Henkin and Powell found
   hypersensitivity to odorants. The present results indicate that, in
   fact, children with cystic fibrosis display a slight hyposensitivity
   to odorants.
RF 001   ALTMAN PL             BLOOD AND OTHER BODY FLUIDS              961
   002   BARTOSHUK LM          PERCEPT PSYCHOPHYS               3    69 968
   003   BARTOSHUK LM          J COMP PHYSIOL PSYCHOL          87   310 974
   004   BARTOSHUK LM          SCIENCE                        143   967 964
   005   CAIN WS               PERCEPT PSYCHOPHYS               9   478 971
   006   CAIN WS               ANN NY ACAD SCI                237   427 974
   007   DAVIES JT             BIOL BULL                      117   222 959
   008   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   008   DI SANTAGNESE PA      N ENGL J MED                   277  1344 967
   009   FRAWLEY TF            IN: MOTE JR                          115 951
   010   GREEN DM              SIGNAL DETECTION THEORY AND P            966
   011   HENKIN RI             SCIENCE                        138  1107 962
   012   HENKIN RI             J CLIN INVEST                   42   727 963
   013   MCBURNEY DH           J GEN PHYSIOL                   48  1145 965
   014   MONCRIEFF RW          ANN NY ACAD SCI                 58    73 954
   016   PFAFFMAN C            J EXP PSYCHOL                   65   523 963
   017   WOTMAN S              AM J DIS CHILD                 108   372 964
CT   1   BARTOSHUK LM          AM J CLIN NUTR                  31  1068 978
     2   SHERMAN AH            OTOLARYNGOL HEAD NECK SURG      87   717 979
     3   HYDE RJ               J DENT RES                      60  1730 981
     4   COWART BJ             PSYCHOL BULL                    90    43 981
     5   POLLACK MS            IMMUNOGENETICS                  15   579 982
     6   CAIN WS               YALE J BIOL MED                 55   515 982
     7   WEIFFENBACH JM        CHEM SENSES                      8   151 983
     8   ESKENAZI B            NEUROPSYCHOLOGIA                21   365 983
     9   RUSSELL RM            ANN INTERN MED                  99   227 983
    10   SCHIFFMAN SS          N ENGL J MED                   308  1275 983
    11   WEIFFENBACH JM        CHEM SENSES                      9   193 984
    12   WYSOCKI CJ            PROC NAT ACAD SCI USA           81  4899 984
    13   LAWLESS H             J AM DIET ASSOC                 85   577 985

PN 75159
RN 00325
AN 76012347
AU Holzel-A.
TI The quest for the basic defect in cystic fibrosis.
SO Physiotherapy. 1975 Aug 10. 61(8). P 238-9.
MJ CYSTIC-FIBROSIS: et.
MN CYSTIC-FIBROSIS: fg.  HUMAN.  METABOLISM-INBORN-ERRORS: co.
EX The search for the basic defect in cystic fibrosis has so far been
   singularly disappointing.  There is no doubt that it is a disease
   recessively inherited, ie that the parents carry the cystic fibrosis
   gene without showing any signs of ill health (heterozygous) but when
   transmitted from both of them to an offspring this child manifests
   the disease, having acquired the abnormal gene in double dose
   (homozygote).  Cystic fibrosis is the most common of the genetically
   determined diseases.  Two types of cultured cells, fibroblasts and
   white cells from affected individuals and heterozygous carriers for
   cystic fibrosis, showed characteristic changes of metachromasia that
   seemed to allow for a classification of patients and carriers to be
   distributed into separate classes.  Serum from patients with cystic
   fibrosis of the pancreas disorganises the movement of cilia of the
   isolated rabbit tracheal mucosa.  One of the early and also most
   constant observations is the 'viscosity' of secretions of the mucosal
   glands in the respiratory tract, in the alimentary apparatus, in the
   biliary system and in the pancreas.  A striking increase in the
   levels of sodium and chloride, and to a lesser extent of potassium,
   is present in the sweat of practically all sufferers of cystic
   fibrosis.  However frustrating and tantalising the outcome of
   research into the basic defect has been so far, the ultimate answer
   is likely to be astonishing in it simplicity.
RF 001   BARBERO GJ            IN: PORTER R                    32       968
   002   BEARN AG              IN: MANGOS JA                         21 973
   003   DANES BS              IN: LAWSON D PROC 5TH INT CF          67 969
   004   DANES BS              J EXP MED                      123     1 966
   005   DI SANTAGNESE PA      PEDIATRICS                      12   549 953
   006   MANGOS JA             PEDIATR RES                      1   436 967
   007   SPOCK A               PEDIATR RES                      1   173 967

PN 75160
RN 00326
AN 76012350
AU Mearns-M-B.
TI Inhalation therapy in cystic fibrosis.
SO Physiotherapy. 1975 Aug 10. 61(8). P 245-6.
MJ CYSTIC-FIBROSIS: dt.  RESPIRATORY-THERAPY.
MN ACETYLCYSTEINE: ad.  ALBUTEROL: ad.  ANTIBIOTICS: ad.  HUMAN.
   PENICILLINS: ad.  SODIUM-CHLORIDE: ad.
EX Inhalation therapy can be divided into two types, intermittent
   aerosol therapy which is used to administer medications over brief
   periods and mist tent therapy which is used for prolonged periods of
   treatment.  The present state of knowledge of the basic defect of
   cystic fibrosis makes it impossible to give hard and fast guide lines
   for the use of inhalation therapy.  Much depends on the individual
   experience of the physician and the degree of pulmonary involvement
   of the individual patient.  Response to bronchodilators can be
   assessed relatively easily, assessment of mucolytics and antibiotics
   is difficult.  Antibiotics can be useful in helping to clear
   infection in those patients with early disease, as judged by clearing
   of pathogens from the cough swab or sputum.  In patients with chronic
   cough and large volumes if purulent sputum with positive culture from
   gram negative bacteria, the cultures never become negative and only
   in the occasional patient can definite clinical benefit be claimed.
   A few severely ill patients have dramatically improved when this
   therapy has been introduced, and the patients are convinced of the
   benefit of this treatment.  It is of course impossible in this
   disease, with such a varying clinical course, to prove scientifically
   that the inhalation therapy was the reason for this improvement.
RF 001   ANDERSEN DH           AM J DIS CHILD                  56   344 938
   002   ANDERSEN DH           PROC R SOC MED                  42    25 949
   003   ANDERSEN DH           J CHRON DIS                      7    58 958
   004   BAU SK                PEDIATRICS                      48   605 971
   005   CHANG N               AM REV RESPIR DIS              107   672 973
   006   DENTON R              DIS CHEST                       28   123 955
   007   DOERSHUK CF           PEDIATRICS                      36   675 965
   008   DOERSHUK CF           PEDIATRICS                      41   723 968
   009   FARBER S              J MICH MED SOC                  44   587 945
   010   MOTOYAMA EK           PEDIATRICS                      50   299 972
   011   NORMAN AP             IN: LAWSON D PROC 5TH INT CF         155 969
   012   SHWACHMAN H           PEDIATRICS                      36   689 965
   013   WOLFSDORF J           PEDIATRICS                      43   799 969
CT   1   MITCHELL EA           AUST PAEDIATR J                 18    40 982

PN 75161
RN 00327
AN 76012353
AU Gaskell-D.
TI Physiotherapy for adolescents and adults with cystic fibrosis.
SO Physiotherapy. 1975 Aug 10. 61(8). P 250-2.
MJ CYSTIC-FIBROSIS: th.  PHYSICAL-THERAPY.
MN ADOLESCENCE.  ADULT.  AEROSOLS.  BREATHING-EXERCISES.
   CYSTIC-FIBROSIS: co.  DRAINAGE.  HEMOPTYSIS: co.  HUMAN.
   PNEUMOTHORAX: co.  POSTURE.
EX Physiotherapy for adolescents and adults with cystic fibrosis is
   continued along the same lines as for younger patients, but certain
   modifications may be necessary to fit in with their changing needs.
   When patients are transferred from the care of the paediatrician to
   the thoracic physician it may be helpful for them to be admitted to
   hospital for reassessment.  During this admission, the opportunity
   can be taken to review the daily physiotherapy regimen with the
   patients and their parents.  Postural drainage, the use of aerosols,
   breathing exercises, long-term follow-up, complications (haemoptysis
   and spontaneous pneumothorax), the use of intermittent positive
   pressure breathing, and terminal care are discussed.
RF 001   MATTHEWS LW           J PEDIATR                       65   558 964
   002   PLUMSTEAD AJ          PHYS THER                       52   178 972

PN 75162
RN 00328
AN 76012348
AU Carter-C-O.
TI Genetics and incidence of cystic fibrosis.
SO Physiotherapy. 1975 Aug 10. 61(8). P 240-2.
MJ CYSTIC-FIBROSIS: oc.
MN CHILD.  CYSTIC-FIBROSIS: fg.  EUROPE.  FEMALE.  GENE-FREQUENCY.
   GENES-RECESSIVE.  GENETIC-COUNSELING.  HUMAN.  MALE.  MUTATION.
EX Cystic fibrosis is a genetically determined disorder.  The evidence
   that cystic fibrosis is inherited in this way comes from several
   sources.  The birth frequency of cystic fibrosis is unexpectedly high
   in Britain for such a serious illness.  It is easy to calculate the
   proportion of the population who are carriers from the birth
   frequency of the disease.  The explanation of the unlikely high birth
   frequency of cystic fibrosis in Europe is not known.  An attempt to
   reduce substantially the birth frequency of cystic fibrosis will
   become possible once it is practicable to detect reliably the carrier
   of the gene.
RF 001   HALL BD               J MED GENET                      5   262 968
CT   1   WARWICK WJ            HELV PAEDIATR ACTA              33   117 978
     2   POSSELT HG            ATEMWEGS LUNGENKRANKH           10   345 984

PN 75163
RN 00329
AN 76012352
AU Hodge-G-J.
TI Physiotherapy for children with cystic fibrosis.
SO Physiotherapy. 1975 Aug 10. 61(8). P 248-9.
MJ CYSTIC-FIBROSIS: th.  PHYSICAL-THERAPY.
MN CHILD.  CHILD-PRESCHOOL.  COUGH: et.  DRAINAGE.  HUMAN.  INFANT.
   INFANT-NEWBORN.  POSTURE.  RESPIRATORY-TRACT-INFECTIONS: pc.
EX The importance of regular efficient postural drainage cannot be
   emphasised too strongly.  Most parents of pre-school and primary
   school children are young enough to be physically able to play a
   major role in the routine physiotherapy treatment.  The parents will
   require a great deal of support and encouragement from the
   physiotherapist, who must be ready to organise professional
   physiotherapy at crisis times in the family as well as in the event
   of an exacerbation.

PN 75164
RN 00330
AN 76012349
AU Norman-A-P.
TI Medical management of cystic fibrosis.
SO Physiotherapy. 1975 Aug 10. 61(8). P 242-4.
MJ CYSTIC-FIBROSIS: th.
MN CHILD.  CHILD-PRESCHOOL.  COUGH.  DIET.  DRAINAGE.  HUMAN.  INFANT.
   INFANT-NEWBORN.  INTESTINAL-ABSORPTION.  INTESTINAL-OBSTRUCTION: su.
   LIVER-CIRRHOSIS: et.  MECONIUM.  PSYCHOLOGY.
   RESPIRATORY-TRACT-INFECTIONS: et.
EX The manifestations of cystic fibrosis make it a complex disease, in
   the management of which the respiratory physician, the
   microbiologist, the gastroenterologist and last but not least, the
   psychologist, all are or should be involved.  About 1 in 10 babies
   with cystic fibrosis are born with acute intestinal obstruction due
   to plugging of the small intestine with very sticky meconium.
   Diagnosis is made by the test for excess salt in the sweat, and
   although possible very soon after birth, it is easier to carry out at
   about three weeks of age when the baby sweats more freely.  The great
   majority of children, if not treated, tend to suffer progressively
   more frequent chest infections or chronic chest infections.  The
   reason for the tendency of the lungs of children with cystic fibrosis
   to become colonised by harmful bacteria is not known.  Most cystic
   fibrosis children absorb carbohydrate normally, but only about 50%
   (range 45% to 80%) of the protein and fats they eat.  The only other
   major problem for which any active measures may be required is the
   occurrence of fibrosis of the liver in about 5% of these children.
   Children with cystic fibrosis should be brought up from the beginning
   to be like other children.

PN 75165
RN 00331
AN 76012351
AU Batten-J.
TI Cystic fibrosis in adolescents and adults.
SO Physiotherapy. 1975 Aug 10. 61(8). P 247-8.
MJ CYSTIC-FIBROSIS: th.
MN ADOLESCENCE.  ADULT.  COUGH: et.  FEMALE.  HUMAN.  MALE.
   PHYSICAL-THERAPY.  PNEUMOTHORAX: co.  SPUTUM: an.
EX With improvement in the treatment of children suffering from cystic
   fibrosis and increase in the average survival to about 17 years of
   age, many more patients with this disease are now coming under the
   care of thoracic physicians.  In nearly every patient,
   broncho-pulmonary disease is the major problem.  Pneumothorax is
   encountered in about 15% of the older patients and some of these
   occur bilaterally.  A few patients develop refractory airways
   obstruction and then a trial of steroids is justifiable.  Most
   patients with cystic fibrosis also require treatment for their
   pancreatic insufficiency.  Diabetes mellitus is more common in cystic
   fibrosis than in the normal population.  Analysis of sweat is
   essential for diagnosis.  The psychological stresses imposed upon
   patients and their families are very great.

PN 75166
RN 00332
AN 76012354
AU McCrae-W-M.
TI Emotional problems in cystic fibrosis.
SO Physiotherapy. 1975 Aug 10. 61(8). P 252-4.
MJ CYSTIC-FIBROSIS: co.  STRESS-PSYCHOLOGICAL.
MN ADULT.  CHILD.  CYSTIC-FIBROSIS: fg.  FAMILY.  FEMALE.
   GENETIC-COUNSELING.  HUMAN.  PARENT-CHILD-RELATIONS.
   PROFESSIONAL-PATIENT-RELATIONS.
EX The emotional distress associated with cystic fibrosis is
   considerable.  From the moment of diagnosis, delayed or not, the
   parents' problems multiply and for the most part these problems are
   at first only vaguely comprehended.  Many parents embark on the long
   haul of caring for their child in almost total ignorance of the
   disease and its implications.  The fact that the disease is inherited
   is of outstanding importance to the parents.  The basis of genetic
   counseling in the disease is the explanation of recessive
   inheritance.  Even when genetic counseling has been given effectively
   and the parents have decided to have no further children, the family
   planning problem is not yet solved.  The physiotherapist is also
   necessarily concerned with the emotional state and behaviour of the
   child.  Except in the latest stages of this disease the child's
   emotional distress is not directly related to the discomfort of his
   symptoms.  Over-protection by parents is understandable but it is
   important to persuade them that it is undesirable.  Perhaps the most
   difficult questions of protection arise in relation to the child's
   knowledge of his own disorder.  Cystic fibrosis is a miserable
   disease and the cause of much distress, emotional and otherwise.
RF 001   GASKELL DV            BROMPTON HOSP GUIDE TO CHEST             973
   002   BATTEN JC             MEDICINE 1974                   14   877 974
   003   MEARNS MB             BR J HOSP MED                   12   497 974
   004   PORTER R              CIBA FOUND STUDY GROUP 32                968
CT   1   GOLDBERG RT           ARCH PHYS MED REHABIL           60   369 979

PN 75167
RN 00333
AN 75196313
AU Holzel-A.
TI Cystic fibrosis.
SO Practitioner. 1975 Jun. 214(1284). P 776-85.
MJ CYSTIC-FIBROSIS.
MN ADOLESCENCE.  ADULT.  ANIMAL.  CARBENICILLIN: tu.  CHILD.
   CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: et, di, th.
   DIAGNOSIS-DIFFERENTIAL.  GENTAMICINS: tu.  HUMAN.  INFANT.
   INFANT-NEWBORN.  INTESTINAL-OBSTRUCTION: et.  LIPASE: tu.
   PEPTIDE-HYDROLASES: tu.  PHYSICAL-THERAPY.  PROGNOSIS.  RABBITS.
   RATS.  RESPIRATORY-TRACT-DISEASES: et.  CELIAC-DISEASE: et.
EX Cystic Fibrosis (fibrocystic disease of the pancreas) is a common
   inherited disease which, to date, still has a fatal outcome.  The
   diversity of clinical manifestations and pathological findings has
   added further to the mysterious nature of the disease, as have the
   tantalizingly conflicting results of biochemical, physical and
   experimental studies in many laboratories of the western world.  One
   of the most constant clinical observations is the viscosity of the
   secretion of the mucosal glands in the respiratory and alimentary
   tracts, in the ducts of the biliary system and in the pancreas.  In
   approximately 10 to 15 per cent of all patients with cystic fibrosis
   of the pancreas the earliest manifestation, meconium ileus, occurs in
   the neonatal period.  In the remaining 85 to 90 per cent of affected
   infants the symptoms generally become evident within the course of
   the first year of life.  The lung symptoms tend to dominate the
   clinical picture in the vast majority of untreated patients and will
   ultimately decide the outcome.  The lower respiratory tract is not
   the only part involved: nasal polyps and the accumulation of viscous
   secretions in the paranasal sinuses with subsequent bacterial
   infection are not unusual.  Pancreatic deficiency is present in the
   vast majority of patients with cystic fibrosis and consists of a
   gross reduction or complete absence of exocrine secretion.  Although
   some histological damage has been seen in the neonatal period in
   infants suffering from meconium ileus, in general the full-blown
   picture of extensive cirrhosis, with portal hypertension,
   hepatosplenomegaly, and severe and sometimes fatal haemorrhages from
   oesophageal varices, is seen in the older child and adolescent.
   Screening of the newborn to enable the institution of protective
   measures before lung complications arise has been attempted with
   various techniques.  Management includes diet and pancreatic enzyme
   replacement.  The treatment of pulmonary disease is the most
   important aspect of care in patients with cystic fibrosis, and its
   prevention is priority number one in the over-all management.  The
   outlook for the child born with cystic fibrosis depends to a large
   extent upon the avoidance, or delay until adult life, of the two
   complications that threaten his existence: cor pulmonale and
   cirrhosis of the liver.
RF 001   KULCZYCKI LL          JAMA                           175   358 961
   002   MANGOS JA             SCIENCE                        158   135 967
   003   MCCARTHY DS           CLIN ALLERGY                     1   261 971
   004   MEARNS MB             BR J HOSP MED                   12   497 974
   005   MEARNS MB             LANCET                           1   538 967
   006   RACHELEFSKY GS        AM J DIS CHILD                 128   355 974
   007   VAN METRE TE JR       J ALLERGY CLIN IMMUNOL          31   141 960
CT   1   HARTUNG J             SOC BIOL                        24   192 977

PN 75168
RN 00334
AN 76052758
AU Chamberlain-J.
TI Screening for the early detection of diseases in Great Britain.
SO Prev-Med. 1975 Sep. 4(3). P 268-81.
MJ DIAGNOSTIC-SERVICES.
MN AGED.  BREAST-NEOPLASMS: pc.  BRONCHITIS: pc.  CERVIX-NEOPLASMS: pc.
   CHILD.  CORONARY-DISEASE: pc.  CYSTIC-FIBROSIS: oc.  FEMALE.
   GLAUCOMA: pc.  GREAT-BRITAIN.  HUMAN.  HYPERTENSION: pc.
   CHILD-HEALTH-SERVICES.  INFANT.  INFANT-NEWBORN.  LUNG-NEOPLASMS: pc.
   MENTAL-DISORDERS: pc.  MULTIPHASIC-SCREENING.
   OCCUPATIONAL-HEALTH-SERVICES.  PHENYLKETONURIA: bl.  PREGNANCY.
   PRENATAL-CARE.  SCHOOL-HEALTH-SERVICES.  STATE-MEDICINE.
   TUBERCULOSIS-PULMONARY: pc.
AB An account is given of screening for the early detection of disease
   in Great Britain today.  The organisation of screening programmes
   provided nationally for the whole population is described.  These
   include programmes for prenatal care, screening of infants,
   screening of schoolchildren, and screening of women for carcinoma in
   situ of the uterine cervix.  Selective screening programmes for
   tuberculosis and for various industrial diseases are mentioned.
   Experience in provision of these services on a national scale has
   emphasised the importance of evaluating future screening programmes,
   before they are implemented, by research studies on their
   effectiveness, their possibly harmful side effects, and their cost.
   Evidence from research in screening for a number of diseases is very
   briefly summarized, and it is concluded that there may be some
   development of programmes for the early detection and treatment of
   hypertension and of breast cancer, but for other diseases and for
   multiphasic screening, evidence so far available is insufficient to
   warrant any immediate extension from research towards service.
RF 001   ALLMAN ST             HEALTH TRENDS                    6    39 974
   002   BEST L                IN: MCLACHLAN G                  2   339 973
   003   BRETT GZ              THORAX                          23   414 968
   004   BRIMBLECOMBE FSW      LANCET                           2  1428 973
   005   BUTLER NR             PERINATAL MORTALITY                      963
   007   CHAMBERLAIN J         PROC R SOC MED                  66   888 973
   008$  COCHRANE AL           IN: SCREENING IN MEDICAL CARE         81 968
   009   DAVIE R               FROM BIRTH TO SEVEN                      972
   010   ELWOOD PC             BR MED J                         3   254 970
   011   GOLDBERG DP           DETECTION OF PSYCHIATRIC ILLN            972
   013   KEEN H                PROC INT SYMP ON ATHE 2ND            435 970
   014   ANON                  BR MED J                         1  1317 966
   015   MORRIS JN             AM J MED                        46   674 969
   016   OSBORN GR             LANCET                           1   256 966
   017   RAMCHARAN S           PREV MED                         2   207 973
   018   ROSE GA               TRANS SOC OCCUP MED             20   109 970
   019   SHAPIRO S             PROC NAT CANCER CONF 7TH             663 973
   020   ANON                  INT J EPIDEMIOL                  2   219 973
   021   ANON                  RAPP                             9       972
   022   ANON                  HEALTH OF THE SCHOOL CHIL                972
   023   TREVELYAN H           PREV MED                         2   278 973
   024   ANON                  JAMA                           213  1143 970
   025   WILLIAMSON J          LANCET                           1  1117 964
   026$  WILSON JMG            IN: SCREENING IN MEDICAL CARE         15 968
CT   1   HARMAN D              J AM GERIATR SOC                24   452 976
     2   SCHWARTZ FW           MED KLIN                        71  1248 976
     3   KRISTEIN MM           SCIENCE                        195   457 977
     4   WERNER M              CLIN CHEM                       25   509 979

PN 75169
RN 00335
AN 75120418
AU Siwinska-Golebiowska-H.
TI Studies on immunoglobulins in healthy children in various stages of
   development and in the chosen illnesses.
SO Probl-Med-Wieku-Rozwoj. 1975. 4. P 207-14.
MJ ATAXIA-TELANGIECTASIA: im.  CYSTIC-FIBROSIS: im.
   DWARFISM-PITUITARY:  im.  IMMUNOGLOBULINS: bi.  PHENYLKETONURIA: im.
MN ADOLESCENCE.  AGE-FACTORS.  CHILD.  CHILD-PRESCHOOL.
   COMPARATIVE-STUDY.  HUMAN.  IGA: bi.  IGG: bi.  IGM: bi.
   IMMUNOELECTROPHORESIS.  INFANT.  INFANT-NEWBORN.
AB The studies were carried out with view to evaluate development of
   immunoglobulins biosynthesis in children from birth through first
   year of life and up to age of 15 years as well as to establish the
   normal values of each immunoglobulin class in healthy children of
   different age in our conditions of investigations and in our
   geografical, social and economical situation.  There was also under
   consideration the evaluation of body reaction on antigenic
   stimulation and administration of gammaglobulin preparations.  In
   order to determine more broadly the development of these humoral
   immunity parameters in children qualitative and quantitative
   investigations of immunoglobulins were undertaken also in same
   chosen illnesses where changes in biosynthesis and metabolism of
   immunoglobulins may be connected with pathogenesis of illness or
   with type of treatment (cystic fibrosis) (C.F.),
   Ataxia-Telangiectasia syndrome (A-T), pituitary dwarfism,
   fenyloketonuria (PKU).  In some groups of children investigations
   were systematically repeated to evaluate the dynamism of changes.
RF 001   ANON                  CLIN EXP IMMUNOL                 9   695 971
   002   GOLEBIOWSKA H         CLIN EXP IMMUNOL                 2   275 967
   003   GOLEBIOWSKA H         ACTA HAEMATOL POL                1   363 970

PN 75170
RN 00336
AN 75217882
AU Farrell-P-M.  Pallavicini-J-C.  Ulane-M-M.
TI Growth characteristics and protein content of tissue-cultured
   fibroblasts from cystic fibrosis patients.
SO Proc-Soc-Exp-Biol-Med. 1975 Jun. 149(2). P 340-3.
MJ CELL-DIVISION.  CYSTIC-FIBROSIS: me.  DNA: an.  PROTEINS: an.
MN BIOPSY.  CELL-COUNT.  CYSTIC-FIBROSIS: pa.  FIBROBLASTS: ph, me, an.
   GROWTH.  HUMAN.  PROTEINS: bi.  SKIN: me.  TISSUE-CULTURE.
AB Proliferation rates and cellular protein content have been measured
   in cultured fibroblasts derived from the skin of normal volunteers
   and cystic fibrosis patients. Three methods of measuring growth
   indicated that under our conditions, CF fibroblasts divide normally
   with a  mean doubling time of 29 hr. During the logarithmic growth
   phase, however, lower cell protein/DNA ratios were observed
   consistently in CF cultures. This difference was not present in
   contact-inhibited, confluent fibroblasts. The finding of an apparent
   reduction in protein synthesis during rapid division, coupled with an
   observation by others that CF fibroblasts fail to normally induce
   collagen formation, suggests the possibility of a disturbance in the
   biochemical regulation of protein synthesis.
RF 001   SEEGMILLER JE         SCIENCE                        155  1682 967
   002   NEUFELD EF            SCIENCE                        169   141 970
   003   DANES BS              J EXP MED                      129   775 969
   004   DANES BS              BIOCHEM BIOPHYS RES COMMUN      36   919 969
   005   PALLAVICINI JC        J PEDIATR                       77   280 970
   006   BOWMAN BH             PROC NAT ACAD SCI USA           70   548 973
   007   HOUCK JC              PROC SOC EXP BIOL MED          135   369 970
   008   HOUCK JC              CF CLUB ABST                    15    51 974
   009   JACOBSON CB           CF CLUB ABST                    15    23 974
   010   BURTON K              BIOCHEM J                       62   315 956
   011   LOWRY OH              J BIOL CHEM                    193   265 951
   012   TODARO GJ             J CELL COMP PHYSIOL             62   257 963
   013   RUBIN H               IN: DEFENDI V                         51 967
   014   FLETCHER DS           CLIN CHIM ACTA                  44     5 973
   015   MELLMAN WJ            IN: ROTHBLAT GH                  1   327 972
   016   RAFF EC               J CELL PHYSIOL                  74   235 969
   017   WIEBEL F              J CELL PHYSIOL                  74   191 969
   018   TEMIN HM              IN: ROTHBLAT GH                  1    49 972
CT   1   WARD JB               TEX REP BIOL MED                34    11 976
     2   ANON                  J PEDIATR                       88   711 976
     3   DISANTAGNESE PA       N ENGL J MED                   295   534 976
     4   LUNDGREN DW           J PEDIATR                       90  1034 977
     5   OWEN E                J MOL MED                        3    49 978
     6   HOSLI P               ACTA PAEDIATR SCAND             67   617 978
     7   SHAPIRO BL            CLIN CHIM ACTA                  82   125 978
     8   FEIGAL RJ             PEDIATR RES                     13   764 979
     9   SHAPIRO BL            SCIENCE                        203  1251 979
    10   DAVIS PB              PEDIATR RES                     14   863 980
    11   GAHL WA               PEDIATR RES                     14   118 980
    12   LIMBOSCH S            CLIN CHIM ACTA                 102    11 980
    13   JAKEL HP              BIOL ZENTRALBL                 100   273 981
    14   LIEDTKE C             N ENGL J MED                   304   975 981
    15   THOMPSON KVA          GERONTOLOGY                     29    97 983

PN 75171
RN 00337
AN 75196736
AU Shapiro-B-L.  Pence-T-V.  Warwick-W-J.  Smith-Q-T.
TI Insulin iontophoresis in cystic fibrosis.
SO Proc-Soc-Exp-Biol-Med. 1975 Jul. 149(3). P 592-3.
MJ CYSTIC-FIBROSIS: me.  INSULIN: me.  IONTOPHORESIS.
MN CHLORIDES: an.  CYSTIC-FIBROSIS: fg, pp.  HETEROZYGOTE.  HUMAN.
   INSULIN: ad.  PILOCARPINE: me, ad.  SWEAT: an.
AB Insulin and its vehicle without insulin were administered separately
   by iontophoresis to patients with cystic fibrosis (CF), obligate
   heterozygotes, and healthy controls. The resultant sweat chloride
   concentration after treatment with both preparations was compared in
   each individual. No difference after the two treatments was found in
   the control sample. A decrease in sweat chloride concentration after
   insulin iontophoresis in comparison with the vehicle was observed in
   both the CF (P smaller than 0.005) and heterozygote (P smaller than
   0.01) samples. These observations suggest an involvement of insulin
   in CF and a possible role of insulin in sweat gland function.
RF 001   CAUDILL M             LANCET                           2   307 973
   002   LOBECK CC             IN: STANBURY JB                     1605 972
   003   KAISER D              PEDIATR RES                      5   167 971
   004   MANGOS JA             PEDIATR RES                      2   378 968
   005   MILNER AD             ARCH DIS CHILD                  44   351 969
   006   HANDWERGER S          N ENGL J MED                   281   451 969
   007   STAHL M               J PEDIATR                       84   821 974
   008   GOODCHILD MC          ARCH DIS CHILD                  47   152 972
   009   GIBSON LE             PEDIATRICS                      23   545 959
   010   HANSEN L              MINN MED                        50  1191 967
   011   SHAPIRO BL            BIOCHEM BIOPHYS RES COMMUN      39   816 970
   012   BROWN GA              LANCET                           2   639 971
   013   ZIERLER KL            AM J MED                        40   735 966
   014   KAISER D              IN: MANGOS JA                        247 973
   015   SWEENEY EA            VOX SANG                        13    54 967
   017   TOMIZAWA HH           J BIOL CHEM                    240  3191 965
   018   SHAPIRO BL            PROC SOC EXP BIOL MED          144   181 973
   019   SHAPIRO BL            LANCET                           2  1020 974
CT   1   BANK S                AM J DIG DIS                    23   178 978
     2   GLASS JM              INT J DERMATOL                  19   519 980
     3   SLOAN JB              J AM ACAD DERMATOL              15   671 986
     4   KARI B                DIABETES                        35   217 986

PN 75172
RN 00338
AN 76079679
AU Samuels-C-E.  Robinson-P-G.  Elliott-R-B.
TI Decreased inhibition of platelet aggregation by PGE1 in children
   with cystic fibrosis and their parents.
SO Prostaglandins. 1975 Oct. 10(4). P 617-21.
MJ CYSTIC-FIBROSIS: bl.  PLATELET-AGGREGATION: de.
   PROSTAGLANDINS-E:  pd.
MN ADENOSINE-DIPHOSPHATE: pd.  ADULT.  CARRIER-STATE: bl.  CHILD.
   CLINICAL-TRIALS.  CYSTIC-FIBROSIS: di.  DEPRESSION-CHEMICAL.  HUMAN.
   PROSTAGLANDINS-E: du.
AB PGE1 inhibited ADP-induced platelet aggregation in children with
   cystic fibrosis and their parents to a much lesser extent than in
   normal controls. We suggest that this may be a reliable test for
   heterozygote carriers of cystic fibrosis.
RF 001   KLOEZE JE             PROC NOBEL SYMP 2ND                  241 966
   002   KINLOUGH-RATHBONE RL  BR J HAEMATOL                   19   559 970
   003   SMITH JB              J CLIN INVEST                   52   965 973
   004   SCHOENE NW            PROSTAGLANDINS                   5   387 974
   005   CLAUSEN J             LIPIDS                           7   246 972
   006   VAN DORP D            ANN NY ACAD SCI                180   181 971
   007   VINCENT JE            PROSTAGLANDINS                   5   369 974
   008   KUO PT                J PEDIATR                       60   394 962
CT   1   ELLIOTT RB            PEDIATRICS                      57   474 976
     2   ROSENLUND ML          PEDIATRICS                      59   428 977
     3   MANCUSO G             RIV ITAL PEDIATR                 8   665 982
     4   DAVIS PB              J LAB CLIN MED                 104   203 984
     5   STEAD RJ              PROSTAGLANDINS LEUKOTR MED      26    91 987

PN 75173
RN 00339
AN 76032664
AU Griscom-N-T.  Capitanio-M-A.  Wagoner-M-L.  Culham-G.  Morris-L.
TI The visibly fatty liver.
SO Radiology. 1975 Nov. 117(2). P 385-9.
MJ FATTY-LIVER: ra.
MN CASE-REPORT.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: co.
   FATTY-LIVER: co.  HUMAN.  INFANT.  LIVER-CIRRHOSIS: co.  MALE.   
   TOMOGRAPHY-X-RAY.
AB Fatty infiltration of the liver has been identified
   roentgenographically in several young children. Awareness of this
   possibility will sometimes allow a radiologist to contribute to the
   understanding of the patient's metabolic and nutritional state. If a
   child's liver is shown to be abnormally radiolucent, cystic fibrosis
   should be considered.
RF 001   AMBROSE J             PROC R SOC MED                  66   833 973
   004   FLETCHER K            AM J CLIN NUTR                  19   170 966
   005   ISSELBACHER KJ        IN: SCHIFF L                         672 969
   007   LOMBARDI B            LAB INVEST                      15     1 966
   008   MELHEM RE             PROC EUR SOC PED RAD ANN MTG             975
   009   NEW PFJ               RADIOLOGY                      110   109 974
   010   STEINBACH HL          RADIOLOGY                       62   858 954
   012   SWISCHUK LE           AM J ROENTG RAD THER NUCL MED  122   159 974
   014   TER-POGOSSIAN MM      RADIOLOGY                      113   515 974
   015   WOLF BS               IN: MARGULIS AR                      233 967
CT   1   SWISCHUK LE           J PEDIATR                       88   452 976
     2   GIBSON B              PEDIATRICS                      59   778 977
     3   FAURE C               ARCH FR PEDIATR                 35   887 978
     4   WORLEY L              J PEDIATR                       94  1005 979
     5   YOUSEFZADEH DK        RADIOLOGY                      131   351 979
     6   MINDELZUN R           RADIOL CLIN NORTH AM            18   221 980
     7   ZAMMIT AA             BR J RADIOL                     53  1018 980
     8   ROY CC                J PEDIATR GASTROENTEROL NUTR     1   469 982
     9   SCATARIGE JC          J ULTRASOUND MED                 3     9 984

PN 75174
RN 00340
AN 75120914
AU Fellows-K-E.  Stigol-L.  Shuster-S.  Khaw-K-T.  Shwachman-H.
TI Selective bronchial arteriography in patients with cystic fibrosis
   and massive hemoptysis.
SO Radiology. 1975 Mar. 114(3). P 551-6.
MJ ANGIOGRAPHY.  BRONCHIAL-ARTERIES: ra.  CYSTIC-FIBROSIS: ra.
   HEMOPTYSIS: ra.
MN ADOLESCENCE.  ADULT.  BRONCHIAL-ARTERIES: su.  BRONCHOSCOPY.
   CYSTIC-FIBROSIS: di, pa.  FEMALE.  HEMOPTYSIS: di, pa.  HUMAN.  MALE.
   PULMONARY-ARTERY: su.  PULMONARY-CIRCULATION.
   SUPPORT-U-S-GOVT-P-H-S.
AB Massive hemoptysis is a potentially fatal complication of long-
   standing cystic fibrosis. Lobectomy may prevent a hemorrhagic death
   if the hemorrhage source can be identified and if involvement of the
   remaining lung tissue is mild. Selective bronchial arteriography was
   performed in six patients with cystic fibrosis to localize a lobar
   source of bleeding. Arteriographic findings correlated with
   bronchoscopic observations. Bronchial arteriography may be helpful
   when bronchoscopy cannot be done because of continuous hemorrhage or
   because the severity of the lung disease precludes general
   anesthesia, but it is not an adequate substitute for bronchoscopy in
   most patients.
RF 001   BOTENGA ASJ           AM J ROENTG RAD THER NUCL MED  104   829 968
   002   BOTENGA ASJ           RADIOL CLIN                     38   309 969
   003   EARL GM JR            AM REV RESPIR DIS              106   898 972
   004   FEIGELSON HH          RADIOLOGY                       85   663 965
   005   HAROUTUNIAN LM        CHEST                           62   587 972
   006   HOLSCLAW DS           J PEDIATR                       76   829 970
   007   LIEBOW AA             AM J PATHOL                     25   211 949
   008   MACK JF               BR J RADIOL                     38   422 965
   009   MOSS AJ               PEDIATRICS                      41   438 968
   010   NEWTON TH             RADIOLOGY                       84  1043 965
   011   NORTH LB              AM J ROENTG RAD THER NUCL MED  107   328 969
   012   SCHUSTER SR           J THORAC CARDIOVASC SURG        48   750 964
   013   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   015   WAGENVOORT CA         PATHOLOGY OF PULMONARY VASCUL            964
   016   WENTWORTH P           THORAX                          23   582 968
CT   1   WOOD RE               AM REV RESPIR DIS              113   833 976
     2   SCHUSTER SR           J PEDIATR SURG                  12   889 977
     3   SHWACHMAN H           MEDICINE                        56   129 977
     4   BOOKSTEIN JJ          CHEST                           72   658 977
     5   REMY J                RADIOLOGY                      122    33 977
     6   WOLFE JD              WEST J MED                     127   383 977
     7   HARLEY JD             AM J ROENTGENOL                128   302 977
     8   WEBB WR               AM J ROENTGENOL                129   233 977
     9   SELECKY PA            CHEST                           73   741 978
    10   BREDIN CP             AM REV RESPIR DIS              117   969 978
    11   STERN RC              AM REV RESPIR DIS              117   825 978
    12   JONES RSW             CATHET CARDIOVASC DIAGN          5   145 979
    13   BABO HV               RADIOLOGE                       19   506 979
    14   LAMARQUE JL           RADIOLOGE                       19   514 979
    15   CULHAM JAG            PEDIATR CLIN NORTH AM           26   661 979
    16   SWERSKY RB            ANN THORAC SURG                 27   262 979
    17   ASPELIN P             SCAND J RESPIR DIS              60    20 979
    18   SANTAGNESE PAD        AM J MED                        66   121 979
    19   WOOD RE               SOUTH MED J                     72   189 979
    20   HARGROVE WC           CHEST                           76   234 979
    21   FELLOWS KE            J PEDIATR                       95   959 979
    22   SENAC JP              ANN CHIR                        34   542 980
    23   FAIRFAX AJ            BR J DIS CHEST                  74   345 980
    24   WISEMAN NE            J PEDIATR SURG                  16   457 981
    25   REES S                CLIN RADIOL                     32     1 981
    26   FELLOWS KE            RADIOLOGY                      140   249 981
    27   MOSS AJ               PEDIATRICS                      70   728 982
    28   KELLER FS             CHEST                           81   407 982
    29   VUJIC I               RADIOLOGY                      143    19 982
    30   GONG H                RESPIRATION                     44   225 983
    31   PORTER DK             J THORAC CARDIOVASC SURG        86   409 983
    32   PORTER DK             ARCH INTERN MED                143   287 983
    33   SAPIRE DW             CLIN CARDIOL                     7   673 984
    34   LESTER LA             SEM RESPIR MED                   6   285 985
    35   IMGRUND SP            CRIT CARE MED                   13   438 985
    36   STANKIEWICZ JA        EAR NOSE THROAT J               64   180 985
    37   OSADA H               ANN THORAC SURG                 41   440 986

PN 75175
RN 00341
AN 75121373
AU Haluszka-J.  Scislicki-A.
TI Bronchial lability in children suffering from some diseases of the
   bronchi.
SO Respiration. 1975. 32(3). P 217-26.
MJ BRONCHI: pp.  BRONCHITIS: pp.  CYSTIC-FIBROSIS: pp.  RESPIRATION.
MN AIRWAY-RESISTANCE: de.  CHILD.  COMPARATIVE-STUDY.  HISTAMINE: du.
   HUMAN.  PLETHYSMOGRAPHY-WHOLE-BODY.  RESPIRATORY-FUNCTION-TESTS.
AB The authors studied bronchial reactivity in children with cystic
   fibrosis and with deformative bronchitis. The reaction of the bronchi
   was studied both by inhalatory and exercise provocation. Inhalatory
   tests were monitored by means of a whole body plethysmograph. Free-
   range run was used for the exercise test, and the peak expiratory
   flow rate was measured. The described technique of inhalatory tests
   was accurate, safe, and not tiring for the patient. No distinct
   difference in bronchial reaction between the two groups of patients
   could be stated. The bronchial reaction to the inhalatory and
   exercise tests was stronger in both groups than in normals but not as
   strong as in asthmatics. The nature of bronchial hyperreactivity in
   those patients is still unknown. The inhalatory test seems to be more
   sensitive than the exercise test in detecting that hyperreactivity.
RF 001   ANDERSON SD           THORAX                          26   396 971
   002   CADE JF               LANCET                           2   186 971
   003   CONNOLLY NM           J ASTHMA RES                     8    31 970
   005   GAVALOV S             PROC EWGCF 4TH ANNU MTG               61 973
   006   HEIMLICH EM           J ALLERGY CLIN IMMUNOL          37   103 966
   007   JONES RS              BR J DIS CHEST                  56    78 962
   008   KONIG P               ARCH DIS CHILD                  47   578 972
   009   MASTELLA G            PROC EWGCF 4TH ANNU MTG               51 973
   010   SILVERMAN M           ARCH DIS CHILD                  47   882 972
   011   WILLIAMS HE           BR MED J                         4   321 969
CT   1   VARPELA E             CLIN ALLERGY                     8   273 978
     2   HALUSZKA J            ARCH IMMUNOL THER EXP           26   731 978
     3   MELLIS CM             PEDIATRICS                      61   446 978
     4   LEUPOLD W             MONOGR PAEDIATR                 10   119 979
     5   TOBIN MJ              THORAX                          35   807 980
     6   DAVIS PB              N ENGL J MED                   302  1453 980
     7   HOLZER FJ             ARCH DIS CHILD                  56   455 981
     8   LEMANSKE RF           AM REV RESPIR DIS              123   622 981
     9   GEORGITIS JW          ANN ALLERGY                     48   175 982
    10   GOTZ M                WIEN KLIN WOCHENSCHR            94     3 982
    11   DAVIS PB              J CHRON DIS                     36   269 983
    12   DAVIS PB              AM REV RESPIR DIS              129   911 984
    13   DAVIS PB              SEM RESPIR MED                   6   261 985
    14   HORDVIK NL            AM REV RESPIR DIS              131   889 985
    15   DARGA LL              PEDIATR PULMONOL                 2    82 986
    16   DAVIS PB              HORM METAB RES                  18   217 986
    17   BERDEL D              KLIN PAEDIATR                  198    71 986

PN 75176
RN 00342
AN 75219305
AU Super-M.
TI Cystic fibrosis in the South West African Afrikaner.  An example of
   population drift, possibly with heterozygote advantage.
SO S-Afr-Med-J. 1975 May 10. 49(20). P 818-20.
MJ CAUCASOID-RACE.  CYSTIC-FIBROSIS: oc.  GENE-FREQUENCY.
   HETEROZYGOTE.
MN AFRICA-SOUTHERN.  CHILD.  CYSTIC-FIBROSIS: fg, di.  HUMAN.  INFANT.
   INFANT-NEWBORN.  INFANT-NEWBORN-DISEASES: di.
   INTESTINAL-OBSTRUCTION: di.  MALE.  MASS-SCREENING.  MECONIUM.
AB An incidence of the genetic recessive disease cystic fibrosis
   (mucoviscidosis) far in excess of that reported recently from other
   countries, has been encountered in the South West African Afrikaner.
   This has probably resulted from the immigration of a segment of the
   South African Afrikaner population rich in the gene, into South West
   Africa, where, for religious reasons and reasons of geographical
   isolation, the gene has persisted and, perhaps, increased in
   frequency. Malaria, which killed many of the early settlers, might
   have selectively spared carriers of the gene, thus enriching its
   occurrence in the population. Details of patients, particularly with
   regard to the criteria of diagnosis, are given with the relevant
   population and birth figures, from which an estimate of the incidence
   of the disease and of its carrier rate has been made. Screening of
   the newborn for the condition and the compiling of a register of
   potential and obligatory carriers are also discussed.
RF 001   GOODMAN HO            AM J HUM GENET                   4    59 952
   002   STEINBERG AG          AM J HUM GENET                  12   416 960
   003   KRAMM ER              AM J PUBLIC HEALTH              52  2041 962
   004   HONEYMAN MS           AM J HUM GENET                  17   461 965
   005   DANKS DM              ANN HUM GENET                   28   323 965
   006   PUGH RJ               ARCH DIS CHILD                  42   544 967
   007   HALL BD               J MED GENET                      5   262 968
   008   SELANDER P            ACTA PAEDIATR SCAND             51    65 962
   009   CARTER CO             ABC OF MEDICAL GENETICS                  969
   010   HSIA DYY              INBORN ERRORS OF METABOLISM              959
   011   GEORGE L              ARCH DIS CHILD                  46   139 971
   012   DI SANTAGNESE PA      AM J MED                        15   777 953
   013   TAUSSIG LM            N ENGL J MED                   287   586 972
   014   SORSBY A              TRANS R SOC MED HYG             57    15 963
   015   DEAN G                S AFR MED J                     34   745 964
   016   MYRIANTHOPOULOS NC    AM J HUM GENET                  24   341 972
   017   VEDDER H              SOUTH WEST AFRICA IN EARLY TI        420 966
   018   CAIN ARR              ARCH DIS CHILD                  47   131 972
CT   1   BEIGHTON P            S AFR MED J                     50  1125 976
     2   SUPER M               S AFR MED J                     50   238 976
     3   WOOD RE               AM REV RESPIR DIS              113   833 976
     4   SUPER M               LANCET                           2  1288 977
     5   TENKATE LP            INT J EPIDEMIOL                  6    23 977
     6   SUPER M               S AFR MED J                     52   390 977
     7   SCHAAP T              ISR J MED SCI                   14   201 978
     8   WARWICK WJ            HELV PAEDIATR ACTA              33   117 978
     9   RETIEF AE             S AFR MED J                     54   849 978
    10   SUPER M               S AFR MED J                     54    18 978
    11   SUPER M               CLIN GENET                      16    65 979
    12   JAKEL HP              BIOL ZENTRALBL                  98    55 979
    13   HOLLANDER DH          MED HYPOTHESES                   8   191 982
    14   BOTHA MC              S AFR MED J                     64   609 983
    15   KOESLAG JH            S AFR MED J                     66    87 984
    16   GRUTTNER R            MONATSSCHR KINDERHEILKD        133    54 985
    17   RUBIO TT              AM J MED                        81    73 986
    18   LIVINGSTONE FB        HUM BIOL                        59    59 987

PN 75177
RN 00343
AN 75219297
TI Editorial: Cystic fibrosis.
SO S-Afr-Med-J. 1975 May 10. 49(20). P 800-1.
MJ CYSTIC-FIBROSIS: fg.
MN AFRICA-SOUTHERN.  CYSTIC-FIBROSIS: oc.  HUMAN.  MALE.
   SELECTION-GENETICS.
EX Cystic fibrosis, sometimes known as mucoviscidosis, is a generalised
   disorder of the exocrine glands which affects children, adolescents
   and young adults.  No biochemical abnormality may be regarded as the
   primary cause, although at various times it has been suggested that
   the defect lies in ion transport, in glycoprotein structure or in
   membrane permeability.  Cystic fibrosis is inherited as a Mendelian
   recessive, and is the commonest of all such genetic diseases in the
   Caucasoid populations of Western Europe and North America.  Super
   has detected and documented a frequency of the disease among
   Caucasoids in South West Africa which is considerably higher than
   that found anywhere else in the world.  An investigation of the ways
   in which the disease in South West Africa may differ, clinically or
   pathologically, from that found elsewhere, is necessary.
RF 001   SUPER M               S AFR MED J                     49   818 975

PN 75178
RN 00344
AN 75159629
AU Skude-G.
TI Electrophoretic separation, detection, and variation of amylase
   isoenzymes.
SO Scand-J-Clin-Lab-Invest. 1975 Jan. 35(1). P 41-47.
MJ AMYLASES: an.  ISOENZYMES: an.
MN ACUTE-DISEASE.  AMYLASES: bl.  CHRONIC-DISEASE.  CYSTIC-FIBROSIS: en.
   ELECTROPHORESIS-AGAR-GEL.  HUMAN.  PANCREATITIS: en.  SALIVA: en.
   STAINS-AND-STAINING.
AB An electrophoretic technique for demonstrating amylase isoenzymes is
   described. After separation in an agarose gel containing a linear
   polyacrylamide polymer to reduce electroendosmotic flow, the amylase
   fractions are visualized by incubation with a commercially available
   dye-starch polymer (Phadebas Amylase Test). The technique detects
   amylase fractions with activities below 10 U/l. Some characteristic
   changes in such diseases as acute and chronic pancreatitis, cystic
   fibrosis of the pancreas, macroamylasemia and inherited variants as
   well as after maxillofacial surgery are mentioned.
RF 001   AFONSE E              CLIN CHIM ACTA                  14   195 966
   002   AW SE                 NATURE                         209   298 966
   003   AW SE                 GUT                              8   402 967
   004   BAKER RWR             SCAND J CLIN LAB INVEST          6    94 954
   005   DAVIES TJ             J CLIN PATHOL                   25   266 972
   006   GOETZ H               CLIN CHIM ACTA                  19   235 968
   007   GOT R                 CLIN CHIM ACTA                  22   545 968
   008   HILL C                NATURE                         235   162 972
   009   HOBBS JR              IN: DUBACK UC                        281 968
   010   JOHANSSON BG          SCAND J CLIN LAB INVEST SUPPL  124     7 972
   012   KAMARYT J             HUMANGENETIK                     1   579 965
   013   MEITES S              CLIN CHEM                       14  1176 968
   014   MEITES S              CRC CRIT REV CLIN LAB SCI        2   103 971
   015   MERRITT AD            NATURE NEW BIOL                239   243 972
   016   MUUS J                NATURE                         204   283 964
   017   NORBY S               EXP CELL RES                    36   663 964
   018   OGITA S               MED J OSAKA UNIV                16   271 966
   019   PIMSTONE NR           CLIN CHEM                       10   891 964
   020   ROSALKI SB            J CLIN PATHOL                   23   373 970
   021$  SCHIWARA HW           ARZTL LAB ?                     19    38 973
   022   SCHIWARA HW           Z KLIN CHEM KLIN BIOCHEM        11   319 973
   023   SKUDE G               HEREDITAS                       65   277 970
   025   SKUDE G               SCAND J PLAST RECONSTR SURG      7   105 973
   026   SOMOGYI M             CLIN CHEM                        6    23 960
   027   SPIEKERMAN AM         CLIN CHEM                       20   324 974
   028   WIEME RJ              IN: DUBACK UC                        293 968
   029   WILDING P             CLIN CHIM ACTA                  12    97 965
   030   WOLF RO               NATURE                         213  1128 967
CT   1   ODONNEL MD            BIOL GASTROENTEROL               8   354 975
     2   SKUDE G               SCAND J GASTROENTEROL           10   577 975
     3   SKUDE G               SCAND J GASTROENTEROL           11    21 976
     4   SKUDE G               SCAND J GASTROENTEROL           11    17 976
     5   SKUDE G               SCAND J GASTROENTEROL           11   525 976
     6   SKUDE G               GUT                             17   127 976
     7   SKUDE G               ACTA PAEDIATR SCAND             65   145 976
     8   SKUDE G               AM J OBSTET GYNECOL            126   652 976
     9   HAUBRICH J            ARCH OTO RHINO LARYNGOL        213     1 976
    10   AMADOR E              ACS SYMPOSIUM SERIES          1976   175 976
    11   MERRITT AD            ADV HUM GENET                    8   135 977
    12   SCHIOTZ PO            CLIN GENET                      11    43 977
    13   DONALDSON LA          SCAND J GASTROENTEROL           12   637 977
    14   IHSE I                SCAND J GASTROENTEROL           12   629 977
    15   MAGID E               SCAND J GASTROENTEROL           12   621 977
    16   SKUDE G               SCAND J GASTROENTEROL           12    53 977
    17   SKUDE G               SCAND J GASTROENTEROL           12     3 977
    18   SKUDE G               SCAND J GASTROENTEROL           12   673 977
    19   TAKACS O              ACTA PAEDIATR ACAD SCI HUNG     18    21 977
    20   SKUDE G               ACTA MED SCAND                 201    53 977
    21   BIRKHED D             SCAND J DENT RES                86   248 978
    22   JENSEN SL             AM J PHYSIOL                   235  E381 978
    23   BORULF S              SCAND J GASTROENTEROL           14   151 979
    24   KANNO T               J JAPAN SOC STARCH SCI          26    96 979
    25   NAEIJE R              ACTA OBSTET GYNECOL SCAND       58   531 979
    26   JAKEL HP              BIOL ZENTRALBL                  98    55 979
    27   MINAIRE Y             LYON MED                       241   213 979
    28   MAGID E               J CLIN CHEM CLIN BIOCHEM        18   669 980
    29   SKUDE G               J CLIN CHEM CLIN BIOCHEM        18   680 980
    30   FAHRENKRUG J          CLIN CHEM                       26  1573 980
    31   JACOBSON G            SCAND J CLIN LAB INVEST         40    77 980
    32   HUETHER G             HISTOCHEM J                     13   207 981
    33   SORENSEN S            SCAND J GASTROENTEROL           16   885 981
    34   DERIJKE D             J CLIN CHEM CLIN BIOCHEM        19   815 981
    35   BOSSUYT PJ            CLIN CHEM                       27   451 981
    36   FAHRENKRUG J          CLIN CHEM                       27  1655 981
    37   JONES JB              J PEDIATR GASTROENTEROL NUTR     1    43 982
    38   RAMMELOO T            CLIN CHEM                       28   145 982
    39   LINDBERG T            PEDIATRICS                      70   235 982
    40   KOLLBERG H            ACTA PAEDIATR SCAND             71   321 982
    41   MAGID E               SCAND J RHEUMATOL               12   129 983
    42   RASMUSSEN SN          SCAND J GASTROENTEROL           18   353 983
    43   NASRALLAH SM          GUT                             24   161 983
    44   VENTRUCCI M           DIGESTION                       28   114 983
    45   DERIJKE D             CLIN CHEM                       29  1100 983
    46   ZIMMERMAN HM          AM J GASTROENTEROL              78   575 983
    47   ZIMMERMAN HM          GASTROENTEROLOGY                85   190 983
    48   HEGARDT P             J PEDIATR GASTROENTEROL NUTR     3   563 984
    49   KJAERGAARD JJ         DIABETE METAB                   10    25 984
    50   KOOP H                CLIN GASTROENTEROL              13   739 984
    51   PANTEGHINI M          RIC CLIN LAB                    14   449 984
    52   PAVESI F              RIC CLIN LAB                    14   443 984
    53   BORGSTROM A           SCAND J GASTROENTEROL           19   220 984
    54   MASSON P              J CLIN CHEM CLIN BIOCHEM        22   427 984
    55   PARVIAINEN MT         J CLIN CHEM CLIN BIOCHEM        22    41 984
    56   BECCIOLINI A          ACTA RADIOL ONCO RAD PHYS BIO   23     9 984
    57   NILSSON PE            ACTA RADIOL DIAGN STOCKH        25   395 984
    58   OKABE H               CLIN CHEM                       30  1219 984
    59   ORBAEK P              SCAND J WORK ENVIRON HEALTH     11     1 985
    60   JENSEN AR             SCAND J GASTROENTEROL           20    83 985
    61   KJAERGAARD J          SCAND J GASTROENTEROL           20   848 985
    62   ZAKOWSKI JJ           CRC CRIT REV CLIN LAB SCI       21   283 985
    63   GERBER M              J CLIN CHEM CLIN BIOCHEM        23   587 985
    64   GERBER M              CLIN CHEM                       31  1331 985
    65   KAMMERAAT C           CLIN CHEM                       31  1078 985
    66   MASSEY TH             CLIN CHEM                       31    70 985
    67   URDAL P               CLIN CHEM                       31   699 985
    68   ECKFELDT JH           ARCH PATHOL LAB MED            109   316 985
    69   HARMOINEN A           J CLIN CHEM CLIN BIOCHEM        24   903 986
    70   GORUS F               CLIN CHEM                       32   398 986

PN 75179
RN 00345
AN 76033530
AU Skude-G.
TI Sources of the serum isoamylases and their normal range of variation
   with age.
SO Scand-J-Gastroenterol. 1975. 10(6). P 577-84.
MJ GLYCOSIDE-HYDROLASES: bl.  ISOAMYLASE: bl.
MN ADOLESCENCE.  ADULT.  AGE-FACTORS.  CHILD.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: en.  FEMALE.  FETUS: en.  GENITALIA-FEMALE: en.
   HUMAN.  INFANT.  INFANT-NEWBORN.  ISOAMYLASE: ur.  KIDNEY: en.
   LIVER: en.  LUNG: en.  MALE.  PANCREAS: en.  SUBMANDIBULAR-GLAND: en.
AB The isoamylases in various human tissue homogenates and body fluids
   were separated by agarose gel electrophoresis. Nothing suggested any
   significant production of amylase in the liver. Minute amounts of
   amylase belonging to the pancreatic group of isoamylases might be
   produced by the glands of the proximal duodenum. The specific group
   of isoamylases produced in the female genital tract could not be
   demonstrated in serum or urine. The activity of amylase in serum was
   derived from two groups of isoenzymes, one group originating from the
   salivary glands, the other from the pancreatic gland. The
   contribution of each of these two sources to the total serum amylase
   was determined from early foetal life to adult age. A very low
   activity of the salivary isoamylases was regularly found in serum
   from 14-week-old foetuses. The activity increased steadily with age
   and reached the normal adult level, about 80 U/l, at the age of 5
   years. The pancreatic group of isoamylases in serum developed later;
   the majority of children below 3 months had no demonstrable
   pancreatic isoamylase activity. The activity rose slowly to reach
   adult level, about 80 U/l, at the age of 10 to 15 years. The activity
   did not vary with sex, and the diurnal variation of the isoamylase
   was negligible. In children with cystic fibrosis of the pancreas the
   activity of pancreatic isoamylases in serum was low.
RF 001   AMMAN RW              ANN INTERN MED                  78   521 973
   002   AW SE                 GUT                              8   402 967
   003   BELFIORE F            CLIN CHEM                       18  1403 972
   004   BELFIORE F            CLIN CHEM                       19   387 973
   005   FARBER S              J CLIN INVEST                   22   827 943
   006   GOT R                 CLIN CHIM ACTA                  22   545 968
   007   GREEN CL              AM J OBSTET GYNECOL             73   402 957
   008   JANOWITZ HD           AM J MED                        27   924 959
   009   KAMARYT J             Z KLIN CHEM KLIN BIOCHEM         8   564 970
   010   KUTTNER M             PROC SOC EXP BIOL MED           32   564 934
   011   LAXOVA R              J MED GENET                      9   321 972
   012   LEVITT MD             ANN INTERN MED                  71   919 969
   013   LILLIBRIDGE CB        J PEDIATR                       82   279 973
   014   MCGEACHIN RL          PROC SOC EXP BIOL MED           99   130 958
   015   MAYER WB              BULL JOHNS HOPKINS HOSP         44   246 929
   016   MEITES S              CRC CRIT REV CLIN LAB SCI        2   103 971
   017   NICORY C              BIOCHEM J                        6   387 922
   018   ROSSITER MA           ACTA PAEDIATR SCAND             63   389 974
   019   SEARCY RL             PEDIATRICS                      39   294 967
   020   SKUDE G               SCAND J CLIN LAB INVEST         35    41 975
   021   SOMOGYI M             ARCH INTERN MED                 67   665 941
   022   TAKEUCHI T            CLIN CHIM ACTA                  54   137 974
   023   VACIKOVA A            J CHROMATOGR                    69   349 972
CT   1   SKUDE G               SCAND J GASTROENTEROL           11    21 976
     2   SKUDE G               SCAND J GASTROENTEROL           11   525 976
     3   SKUDE G               GUT                             17   127 976
     4   SKUDE G               ACTA PAEDIATR SCAND             65   145 976
     5   SKUDE G               AM J OBSTET GYNECOL            126   652 976
     6   WARSHAW AL            LANCET                           1   929 977
     7   MERRITT AD            ADV HUM GENET                    8   135 977
     8   DONALDSON LA          SCAND J GASTROENTEROL           12   637 977
     9   MAGID E               SCAND J GASTROENTEROL           12   621 977
    10   SKUDE G               SCAND J GASTROENTEROL           12    53 977
    11   SKUDE G               SCAND J GASTROENTEROL           12     3 977
    12   WARSHAW AL            J SURG RES                      22   362 977
    13   ODONNELL MD           CLIN CHEM                       23   560 977
    14   WARSHAW AL            J LAB CLIN MED                  90     1 977
    15   DAVIDSON GP           PEDIATR RES                     12   967 978
    16   GILLARD BK            PEDIATR RES                     12   868 978
    17   KAMARYT J             J CLIN CHEM CLIN BIOCHEM        16   539 978
    18   BERK JE               AM J GASTROENTEROL              69   417 978
    19   BERK JE               GASTROENTEROLOGY                74  1313 978
    20   KENNY D               CLIN CHIM ACTA                  89   429 978
    21   HUBBARD VS            J PEDIATR                       92   685 978
    22   FORSTNER GG           PEDIATR RES                     13  1077 979
    23   DONALDSON LA          GUT                             20   216 979
    24   STICKLE JE            AM J VET RES                    41   506 980
    25   AGGETT PJ             ARCH DIS CHILD                  55   236 980
    26   ODONNELL MD           CLIN CHIM ACTA                 104   265 980
    27   KRISTENSEN BO         BR MED J                       281   978 980
    28   HAGGMARK A            GASTROENTEROL CLIN BIOL          5   927 981
    29   ZANNINO L             RIV ITAL PEDIATR                 7   247 981
    30   BOSSUYT PJ            CLIN CHEM                       27   451 981
    31   FAHRENKRUG J          CLIN CHEM                       27  1655 981
    32   JACOBSON G            SCAND J GASTROENTEROL           17   833 982
    33   VONEYBEN FE           J UROL                         128  1195 982
    34   MOLLERPETERSEN J      ACTA MED SCAND                 211   459 982
    35   HICKS JM              BULL MOL BIOL MED                8   105 983
    36   GILLARD BK            CLIN CHEM                       29  1119 983
    37   JACOBS E              CLIN CHEM                       29   887 983
    38   LEBENTHAL E           J PEDIATR                      102     1 983
    39   KOOP H                CLIN GASTROENTEROL              13   739 984
    40   OKABE H               CLIN CHEM                       30  1219 984
    41   MASIAR PJ             NEOPLASMA                       31   351 984
    42   GUERRA EG             REV INVEST CLIN                 36   109 984
    43   MORGENSTERN T         MONATSSCHR KINDERHEILKD        132   661 984
    44   HUBBARD VS            SEM RESPIR MED                   6   299 985
    45   GIBERTINI P           ITAL J GASTROENTEROL            17   211 985
    46   CHO JW                ACTA CHIR SCAND                151   323 985
    47   FOO AY                ANN CLIN BIOCHEM                23   624 986
    48   FUKAYAMA M            DIFFERENTIATION                 31   127 986
    49   TSIANOS EB            HEPATOGASTROENTEROLOGY          33   247 986
    50   TSIANOS EB            J CLIN PATHOL                   39   464 986
    51   BARROS FP             AM J GASTROENTEROL              81   261 986
    52   FJOSNE U              ACTA MED SCAND                 219   301 986

PN 75180
RN 00346
AN 75198186
AU Hoiby-N.  Wiik-A.
TI Antibacterial precipitins and autoantibodies in serum of patients
   with cystic fibrosis.
SO Scand-J-Respir-Dis. 1975 May. 56(1). P 38-46.
MJ ANTIBODIES-BACTERIAL: an.  AUTOANTIBODIES: an.  CYSTIC-FIBROSIS: im.
   PRECIPITINS: an.  RESPIRATORY-TRACT-INFECTIONS: im.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.
   STREPTOCOCCUS-PNEUMONIAE: im.  FEMALE.  FOLLOW-UP-STUDIES.
   HAEMOPHILUS-INFLUENZAE: im.  HUMAN.  IGG: an.  INFANT.  MALE.
   PSEUDOMONAS-AERUGINOSA: im.  RHEUMATOID-FACTOR: an.
   STAPHYLOCOCCUS:  im.
AB Sera from 84 patients with cystic fibrosis, 31 patients with other
   respiratory diseases and 21 control persons have been investigated
   for the occurrence of antibacterial precipitins and autoantibodies.
   Preciptins were studied by means of crossed immunoelectrophoresis,
   antinuclear factors by an indirect immunofluorescence technique and
   rheumatoid factors by the latex fixation slide test. A very
   heterogeneous antibacterial immune response was found in patients
   with cystic fibrosis, notably as regards Ps. aeruginosa. None of the
   other patients or controls had precipitins against this bacterium.
   The occurrence of precipitins against St. aureus and D. pneumoniae
   were more frequent in cystic fibrosis patients as compared with
   controls, but not as compared with other respiratory disease
   patients. No significant differences were found as regards
   precipitins against H. influenzae or the occurrence of rheumatoid
   factors. Antinuclear factors were more frequent in cystic fibrosis
   patients than in the other two groups investigated. A pronounced and
   heterogeneous humoral immune response against Ps. aeruginosa in
   cystic fibrosis patients chronically infected with mucoid strains of
   this bacterium was found to be correlated with poor prognosis and the
   reason for this is discussed.
RF 001   BARTFELD H            ANN NY ACAD SCI                168    30 969
   002   BONOMO L              AM J CLIN PATHOL                45   313 966
   003   DIEM K                DOCUMENTA GEIGY SCIENTIFIC TA            962
   004   DOGGETT RG            IN: LAWSON D PROC 5TH INT CF         175 969
   005   DOGGETT RG            INFECT IMMUN                     6   628 972
   006   GORDON DS             AM REV RESPIR DIS              108   127 973
   007   HALBERT SP            MOD PROBL PEDIATR               10   144 967
   008   HOFF GE               SCAND J INFECT DIS               6   333 974
   009   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   81   298 973
   010   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   541 974
   011   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   551 974
   012   HOIBY N               ACTA PAEDIATR SCAND             63   843 974
   014   JOHNSON KJ            J CLIN INVEST                   54   349 974
   015   KOFFLER D             J EXP MED                      134   169 971
   016   MASS B                AM REV RESPIR DIS              106   384 972
   017   MAY JR                ARCH DIS CHILD                  47   908 972
   018   MEARNS MB             ARCH DIS CHILD                  47   902 972
   019   MUNTHE E              CLIN EXP IMMUNOL                 8   249 971
   020   THUESEN-PEDERSEN J    DAN MED BULL                    21    12 974
   021   TORRIGIANI G          LANCET                           1    14 970
   022   TURNER-WARWICK M      BR MED J                         3   492 970
   023   WALLER M              J INFECT DIS                   125    45 972
   024   WIIK A                IMMUNOLOGY                      23    53 972
   025   WIIK A                ANN RHEUM DIS                   33   515 974
   026   WILLIAMS RC JR        J CLIN INVEST                   41   666 962
   027   WINCHESTER RJ         CLIN EXP IMMUNOL                 6   689 970
CT   1   AXELSON NH            SCAND J IMMUNOL                  5   177 976
     2   WEEKE B               DAN MED BULL                    23   155 976
     3   ANDERSEN V            CLIN EXP IMMUNOL                26   469 976
     4   HOIBY N               SCAND J RESPIR DIS              57    37 976
     5   HOIBY N               SCAND J RESPIR DIS              57   103 976
     6   WOOD RE               AM REV RESPIR DIS              113   833 976
     7   HOIBY N               ACTA PATH MICROBIOL SCAND (C) S262     3 977
     8   CLARKE CW             CLIN ALLERGY                     7   527 977
     9   SORENSEN RU           INFECT IMMUN                    18   735 977
    10   HOIBY N               SCAND J RESPIR DIS              58    65 977
    11   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   85    57 977
    12   NIELSEN HE            ACTA PAEDIATR SCAND             67   443 978
    13   HILTON AM             BR J DIS CHEST                  72   207 978
    14   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   86    37 978
    15   SORENSEN RU           J PEDIATR                       93   201 978
    16   HOIBY N               ACTA PAEDIATR SCAND             68   495 979
    17   WOOD RE               SOUTH MED J                     72   189 979
    18   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (B)   87   345 979
    19   HOLSCLAW DS           CLIN CHEST MED                   1   407 980
    20   WIIK A                ALLERGY                         35   263 980
    21   MIELIVERGANI G        ARCH DIS CHILD                  55   696 980
    22   SAGRANSKY DM          AM J DIS CHILD                 134   319 980
    23   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C) S276     1 981
    24   FEIGELSON J           NOUV PRESSE MED                 10   955 981
    25   SORENSEN RU           PEDIATR RES                     15    14 981
    26   SORENSEN RU           AM REV RESPIR DIS              123    37 981
    27   MOSS RB               CLIN EXP IMMUNOL                47   301 982
    28   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982
    29   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    33 982
    30   SCHIOTZ PO            ACTA PAEDIATR SCAND SUPPL 301 1982    55 982
    31   KLINGER JD            INFECT IMMUN                    39  1377 983
    32   COLLINS MT            J CLIN MICROBIOL                19   757 984
    33   PRESSLER T            ACTA PAEDIATR SCAND             73   541 984
    34   SPEERT DP             SURV SYNTH PATHOL RES            4    14 985
    35   OLIVER AM             CLIN EXP IMMUNOL                59   190 985
    36   RUSH PJ               SEM ARTHRITIS RHEUM             15   213 986
    37   PEDERSEN M            SCAND J INFECT DIS              18   245 986
    38   PHILLIPS BM           J ROY SOC MED                   79    44 986
    39   BRETT MM              ARCH DIS CHILD                  62   357 987

PN 75181
RN 00347
AN 75141326
AU Brogan-T-D.  Ryley-H-C.  Neale-L.  Yassa-J.
TI Soluble proteins of bronchopulmonary secretions from patients with
   cystic fibrosis, asthma, and bronchitis.
SO Thorax. 1975 Feb. 30(1). P 72-9.
MJ ASTHMA: me.  BLOOD-PROTEINS: an.  BRONCHITIS: me.
   CYSTIC-FIBROSIS:  me.  SPUTUM: an.
MN ADULT.  AGED.  ALBUMINS: an.  BETA-GLOBULINS: an.  CHILD.
   CHILD-PRESCHOOL.  COMPARATIVE-STUDY.  FEMALE.  GLYCOPROTEINS: an.
   HAPTOGLOBINS: an.  HUMAN.  IGA: an.  IGG: an.  IMMUNOELECTROPHORESIS.
   LACTOFERRIN: an.  MALE.  MIDDLE-AGE.  MURAMIDASE: an.
   TRANSFERRIN:  an.
AB The concentrations of nine plasma proteins were determined by
   quantitative immunoelectrophoresis in sputum specimens from 29
   patients with cystic fibrosis (CF) and from 24 patients with severe
   asthma and chronic bronchitis. The results suggested that the
   population of CF patients could be divided into two groups in spite
   of an absence of difference in clinical status between the groups.
   Average concentrations of seven plasma proteins in sputum of group I
   CF patients were identical with those in sputum of patients with
   bronchitis, but the average concentrations of six of these proteins
   in sputum from group II CF patients were higher than those in
   specimens from the bronchitic patients and were similar to
   corresponding concentrations in sputum from patients with asthma, all
   of whom were examined while in status asthmaticus. The average
   concentrations of 14 secretory proteins were the same in all sputum
   specimens whether or not they were produced by patients with cystic
   fibrosis, asthma or bronchitis. It was concluded that the
   concentrations in the bronchopulmonary secretions of proteins
   associated with host defence were not diminished in patients with
   cystic fibrosis, and failure to produce adequate concentrations of
   proteins with antimicrobial activity was unlikely to be responsible
   for the above average susceptibility to chest infection in cystic
   fibrosis. It is suggested that there exists a group of CF patients in
   whom a pulmonary allergic reaction generates an inflammatory response
   as severe as that characterizing status asthmaticus and that this
   response could be detrimental.
RF 001   ANDERSEN DH           AM J DIS CHILD                  56   344 938
   002   BROGAN TD             IMMUNOLOGY                       7   626 964
   003   BURNS MW              LANCET                           1   270 968
   004   CLARKE HGM            CLIN SCI                        35   403 968
   005   COOPERMAN EM          CAN MED ASSOC J                105   580 971
   006   HEINER DC             AM J DIS CHILD                 103   634 962
   007   LOPEZ M               IMMUNOCHEMISTRY                  6   513 969
   008   MARTINEZ-TELLO FJ     J IMMUNOL                      101   989 968
   009   MAY JR                IN: OSWALD NC                            958
   010   ANON                  LANCET                           1   775 965
   011   OLITZKI L             BACT REV                        12   149 948
   012   RYLEY HC              BIOCHIM BIOPHYS ACTA           271   300 972
   013   RYLEY HC              BR J EXP PATHOL                 49   625 968
   014   RYLEY HC              J CLIN PATHOL                   26   852 973
   015   SPOCK A               PEDIATR RES                      1   173 967
CT   1   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   83   459 975
     2   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   83   469 975
     3   WEEKE B               DAN MED BULL                    23   155 976
     4   CLARKE CW             THORAX                          31   702 976
     5   LAINE A               CLIN CHIM ACTA                  67   159 976
     6   SANTAGNESE PAD        N ENGL J MED                   295   481 976
     7   HOIBY N               ACTA PATH MICROBIOL SCAND (C) S262     3 977
     8   BROGAN TD             J ANTIMICROB CHEMOTHER           3   247 977
     9   PROCTOR DF            AM REV RESPIR DIS              115   315 977
    10   RUDNIK J              ARCH IMMUNOL THER EXP           26   717 978
    11   LOPEZVIDRIERO MT      BR MED BULL                     34    63 978
    12   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   86    37 978
    13   LOPEZVIDRIERO MT      AM REV RESPIR DIS              117   465 978
    14   ROUSSEL P             LUNG                           154   241 978
    15   SCHIOTZ PO            MONOGR PAEDIATR                 10   131 979
    16   LOPEZVIDRIERO MT      THORAX                          34   512 979
    17   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   87   229 979
    18   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   87     1 979
    19   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (B)   87   345 979
    20   BROGAN TD             THORAX                          35   624 980
    21   HARBITZ O             EUR J RESPIR DIS                61    84 980
    22   KOTLAR HK             EUR J RESPIR DIS                61   233 980
    23   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   88   275 980
    24   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C) S276     1 981
    25   LOPEZVIDRIERO MT      CHEST                           80   799 981
    26   KONSTAN MW            AM REV RESPIR DIS              123   120 981
    27   EMMETT M              J IMMUNOL METH                  50  R 65 982
    28   MOLLER NE             EUR J RESPIR DIS                63   130 982
    29   PEATFIELD AC          AM REV RESPIR DIS              125   210 982
    30   SCHIOTZ PO            ACTA PAEDIATR SCAND SUPPL 301 1982    55 982
    31   JACQUOT J             BULL EUR PHYSIOPATH RESP        19   453 983
    32   WILLIAMS IP           THORAX                          38   682 983
    33   SCHIOTZ  PO           ACTA PAEDIATR SCAND             72   283 983
    34   STELANDER M           EUR J RESPIR DIS                65     5 984
    35   SPEERT DP             SURV SYNTH PATHOL RES            4    14 985
    36   JACQUOT J             INFECT IMMUN                    47   555 985
    37   PERSSON CGA           LANCET                           2  1126 986
    38   MOSS RB               MONOGR ALLERGY                  19   202 986
    39   MOSS RB               CHEST                           91   522 987

PN 75182
RN 00348
AN 75199129
AU Ryland-D.  Reid-L.
TI The pulmonary circulation in cystic fibrosis.
SO Thorax. 1975 Jun. 30(3). P 285-92.
MJ CYSTIC-FIBROSIS: pp.  PULMONARY-CIRCULATION.
   PULMONARY-HEART-DISEASE: pa.
MN ADOLESCENCE.  ADULT.  BODY-HEIGHT.  BODY-WEIGHT.  CHILD.
   CHILD-PRESCHOOL.  CYANOSIS.  ELECTROCARDIOGRAPHY.
   HEART-VENTRICLE:  pp.  HEART: ra.  HEMOGLOBINS: an.  HUMAN.  INFANT.      
   INFANT-NEWBORN.  LUNG-VOLUME-MEASUREMENTS.  LUNG: pa, ra.
   MYOCARDIUM: pa.  ORGAN-WEIGHT.
   OSTEOARTHROPATHY-SECONDARY-HYPERTROPHIC.  PSEUDOMONAS-INFECTIONS.         
   PULMONARY-ARTERY: pa.  PULMONARY-HEART-DISEASE: di.  PULMONARY-VEINS: pa.
AB The hearts and lungs of 36 patients dying of cystic fibrosis have
   been studied to establish the relationship between right ventricular
   hypertrophy (RVH), pathological changes in the pulmonary circulation,
   and the clinical features. The presence and degree of RVH were
   measured by Fulton's technique of weighing the ventricles separately.
   Of the subjects who died after the age of 3 years, one in six had no
   RVH, although the mean age of this group was not significantly
   different from that of the remainder. There was no correlation
   between duration of cyanosis, haemoglobin levels, and RVH. Although
   not statistically significant, the cases without RVH tended to have
   had clubbing of the finger-nails for longer periods before death. The
   electrocardiogram was useful in the diagnosis of RVH. Right
   ventricular hypertrophy was common in children with lungs of large
   volume as judged by the radiographic centile of lung length. Cases
   with RVH show reduced background haze in the arteriogram and fewer
   arteries per unit area of lung. For the first time thickening of the
   medial muscle layer proportional to the degree of RVH has been
   demonstrated, only in the smaller arteries. Arterial subintimal
   fibrosis is more common in cases with RVH, as is thickening of the
   walls of small pulmonary veins. The implications of these findings
   are discussed.
RF 001   ANDERSEN DH           AM J DIS CHILD                  56   344 938
   002   ANDERSEN DH           PEDIATRICS                       3   406 949
   003   BOWDEN DH             CIRCULATION                     28   693 963
   004   CAPLAN AH             J PEDIATR                       73   540 968
   005   DAVIES GM             IN: LAWSON D PROC 5TH INT CF         350 969
   006   DAVIES G              THORAX                          25   669 970
   007   DUNNILL MS            THORAX                          17   329 962
   008   ELLIOTT FM            THESIS                                   964
   009   ESTERLY JR            JOHNS HOPKINS MED J            122    94 968
   010   FULTON RM             BR HEART J                      14   413 952
   011   GOLDRING RM           J PEDIATR                       65   501 964
   012   HISLOP A              THESIS                                   971
   013   HISLOP A              THORAX                          25   682 970
   014   KELMINSON LL          PEDIATRICS                      39    24 967
   015   LAWSON D              IN: LAWSON D PROC 5TH INT CF         225 969
   016   MAY CD                J PEDIATR                       34   663 949
   017   MEARNS MB             ARCH DIS CHILD                  47   902 972
   018   MILLARD FJC           THESIS                                   965
   019   RECAVARREN S          BR HEART J                      26   187 964
   020   ROYCE SW              PEDIATRICS                       8   255 951
   021   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   022   SHINEBOURNE E         MEDICINE                        16   999 973
   023   SIASSI B              J PEDIATR                       78   794 971
   024   SIMON G               ARCH DIS CHILD                  47   373 972
   025   SYMCHYCH PS           ARCH PATHOL                     92   409 971
   026   TANNER JM             ARCH DIS CHILD                  41   454 966
   027   WEIBEL ER             J APPL PHYSIOL                  17   343 962
   028   WIGLESWORTH FW        AM J MED SCI                   212   351 946
   029   ANON                  WHO TECH REP SER NO 213                  961
CT   1   GAULTIER C            SEM HOP PARIS                   52   447 976
     2   HISLOP A              BR J EXP PATHOL                 57   542 976
     3   FISHMAN AP            AM REV RESPIR DIS              114   775 976
     4   HAWORTH SG            BR HEART J                      39    80 977
     5   SHELTON DM            CHEST                           71   303 977
     6   REID L                AM J ROENTGENOL                129   777 977
     7   POUKKULA A            SCAND J RESPIR DIS            1977     7 977
     8   MEYRICK B             LAB INVEST                      38   188 978
     9   GOLDSTEIN JD          AM J CARDIOL                    43   962 979
    10   ALLEN HD              CHEST                           75   428 979
    11   MEYRICK B             AM J PATHOL                     94    37 979
    12   MEYRICK B             AM J PATHOL                     96    51 979
    13   REID LM               AM REV RESPIR DIS              119   531 979
    14   MATTHAY RA            BR HEART J                      43   474 980
    15   LESTER LA             J PEDIATR                       97   742 980
    16   FRANCIS PWJ           AM J DIS CHILD                 134   734 980
    17   MATTHAY RA            MED CLIN NORTH AM               65   489 981
    18   MIGALLY N             J SUBMICROSC CYTOL              14   239 982
    19   HAWORTH SG            CARDIOVASC RES                  16   293 982
    20   RABINOVITCH M         AM J CARDIOL                    50   804 982
    21   REID L                ANN NY ACAD SCI                384     3 982
    22   KUZEMKO JA            LANCET                           1   448 983
    23   COTTON DJ             RESPIR PHYSIOL                  54    19 983
    24   GAULTIER C            EUR J RESPIR DIS                64   319 983
    25   GAULTIER C            AM REV RESPIR DIS              127   527 983
    26   BRIGHAM KL            CIRC RES                        54   623 984
    27   GAULTIER C            EUR J RESPIR DIS                65   460 984
    28   LESTER LA             SEM RESPIR MED                   6   285 985
    29   GAULTIER C            BULL EUR PHYSIOPATH RESP        21    55 985
    30   GAULTIER C            CHEST                           87   168 985
    31   MEYRICK B             CHEST                           88  S268 985
    32   GEGGEL RL             AM REV RESPIR DIS              131   531 985
    33   HAWORTH SG            INT J CARDIOL                   13   207 986
    34   THOMPSON BT           HEART LUNG                      15   457 986
    35   MEYRICK B             LAB INVEST                      55   164 986
    36   PERKETT EA            J APPL PHYSIOL                  61  1875 986
    37   REID LM               CHEST                           89   279 986
    38   HAWORTH SG            WIEN KLIN WOCHENSCHR            98   732 986
    39   BRIGHAM KL            AM REV RESPIR DIS              133   913 986
    40   GAULTIER C            BULL EUR PHYSIOPATH RESP        23    87 987
    41   LEBECQUE P            CHEST                           91   693 987

PN 75183
RN 00349
AN 77237076
AU Gocmen-A.
TI The comparison of peak flow rate with other spirometric measurements
   in cyctic fibrosis patients.
SO Turk-J-Pediatr. 1975 Jul-Aug. 17(3-4). P 92-104.
MJ CYSTIC-FIBROSIS: pp.  LUNG: pp.
MN ADOLESCENCE.  CHILD.  CHILD-PRESCHOOL.  CLINICAL-TRIALS.
   COMPARATIVE-STUDY.  FEMALE.  HUMAN.  MALE.
   RESPIRATORY-FUNCTION-TESTS.
AB This study was done to determine the role of the Wright peak
   flowmeter for evaluation of pulmonary functions in children with
   cystic fibrosis.  Peak expiratory flow rate was measured with the
   use of a Wright peak flowmeter and one second forced expiratory
   volume, maximal mid-expiratory flow rate and maximal voluntary
   ventilation were measured with a spirometer in a total of 55
   children, 25 of whom had cystic fibrosis disease, with the remainder
   being normal.  Measurements were repeated after administration of
   bronchodilating drugs to the cystic fibrosis patients.  All the
   values of the four measurements were decreased significantly in the
   cystic fibrosis patients.  Positive and significant correlation
   co-efficients were obtained by comparing the peak flow rate with
   other spirometric measurements.  It was concluded that peak
   expiratory flow rate is a feasible and useful measurement of
   pulmonary functions in cystic fibrosis patients.  No changes were
   observed after administration of bronchodilating drugs to these
   patients.
RF 001   SHWACHMAN H           PEDIATRICS                      36   689 965
   002   DI SANTAGNESE PA      N ENGL J MED                   277  1399 967
   003   BEIER FR              AM REV RESPIR DIS               94   430 966
   004   WEST JR               PEDIATRICS                      13   155 954
   005   COOK CD               PEDIATRICS                      24   181 959
   006   ZELKOWITZ PS          AM J DIS CHILD                 117   543 969
   007   HARRISON GM           AM J DIS CHILD                 100   530 960
   008   DEMUTH GR             AM J DIS CHILD                 103   129 962
   009   DUBOIS AB             J CLIN INVEST                   35   322 956
   010   WRIGHT BM             BR MED J                         2  1041 959
   011   NAIRN JR              ARCH DIS CHILD                  36   253 961
   012   MURRAY AB             J PEDIATR                       62   186 963
   013   HEAF PJD              BR MED J                         1  1595 962
   014$  LOCKHART MB           BR MED J                         1       960
   015   TINKER CM             BR MED J                         1  1365 961
   016   JACKSON MJ            BR MED J                         1  1760 961
   017   TINKER CM             BR MED J                         2   177 961
   018   FLINT FJ              BR MED J                         2  1231 962
   019   LEINER GC             AM REV RESPIR DIS               88   644 963
   020$  RILEY EA              NY STATE J MED                  40  2656 969
   021   KAMAT SR              AM REV RESPIR DIS               96   545 967
   022   PRIME FJ              BR MED J                         1   423 960
   023   ROSENBLATT G          AM REV RESPIR DIS               87   589 963
   024   RITCHIE B             LANCET                           2   271 962
   025   KAZEMI H              DIS CHEST                       50   500 966
   026   GANDEVIA B            ARCH DIS CHILD                  34   511 959
   027   ROYCE SW              ROSS PAEDIATR RES CONF 18TH           84 956
   028   MATTHEWS LW           MOD PROBL PEDIATR               10   297 967
   029   SHWACHMAN H           MOD PROBL PEDIATR               10   158 967
   030   KORY RC               AM J MED                        30   243 961
   031   SNEDECOR GW           STATISTICAL METHODS                      967
   032   CHERNIACK RM          CAN MED ASSOC J                 87    80 962
   033$  STANG LB              THORAX                          14    39 962
   034   ENGSTROM I            ACTA PAEDIATR SCAND             45   277 956
   035   HELLIESEN PJ          PEDIATRICS                      22    80 958
   036   POLGAR G              PULMONARY FUNCTION TESTING IN            971
   037   WOOD DW               PEDIATR CLIN NORTH AM           16   159 969
   038   DENTRY JM             MED THORAC                      23   358 966
   039   FAIRBAIRN AS          THORAX                          17   168 962
   040   LEUALLEN EC           AM REV TUBERC PULM DIS          72   783 955
   041   COMROE JH JR          LUNG CLINICAL PHYSIOLOGY AND             962
   042   OLSEN HC              BR MED J                         1  1450 960
   043   DOERSHUK CF           IN: GREEN M                          707 968

PN 75184
RN 00350
AN 77237069
AU Tinaztepe-B.  Kural-N.  Tinaztepe-K.  Gocmen-A.
TI Clinico-pathological evaluation of 37 cases of cystic fibrosis of
   the pancreas in infancy at necropsy.
SO Turk-J-Pediatr. 1975 Jul-Aug. 17(3-4). P 108-18.
MJ CYSTIC-FIBROSIS: pa.
MN AUTOPSY.  FEMALE.  HUMAN.  INFANT.  MALE.
EX The clinical and morphological findings of 37 cases of cystic
   fibrosis of the pancreas from 525 full, but non-consecutive
   necropsies are presented.  All of these 37 cases were diagnosed at
   post-mortem examination.  The autopsy incidence was 7% and none of
   the cases was beyond two years of age.  Morphological findings
   revealed varying severities in organ involvement in all cases, with
   absence of fibrosis of the pancreas in some.  In only two cases
   histopathological changes seemed to be confined to the pancreas.
   This study suggests that cystic fibrosis plays a considerable role in
   infant deaths in our country and in most if not all cases the
   diagnosis must necessarily be based on postmortem studies.
RF 001   DI SANTAGNESE PA      IN: NELSON WE                        856 969
   002   ANON                  GUIDE TO DIAGNOSIS AND MANAGE            971
   003   HALL BD               IN: LAWSON D PROC 5TH INT CF          82 969
   004   WRIGHT SW             IN: LAWSON D PROC 5TH INT CF          91 969
   005   WARWICK WJ            PROC INT CONG PEDIATR 13TH           101 971
   006   GURSON CT             HELV PAEDIATR ACTA              28   165 973
   007$  HATEMI N              MEDICINA ROCHE                   2       972
   008   OPPENHEIMER EH        ARCH PATHOL                     96   149 973
   009   DI SANTAGNESE PA      AM FAM PHYSICIAN                 7   102 973
   010   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   011   MORISON JE            FOETAL AND NEONATAL PATHOL           305 963
   012   SAY B                 TURK HALKINDA CESITLI KONGENI         27 971
   013   DANKS DM              ANN HUM GENET                   28   323 965
   014   SMOLLER M             AM J DIS CHILD                  98   277 959
   015   SIASSI B              J PEDIATR                       78   794 971
   016   ESTERLY JR            JOHNS HOPKINS MED J            122    94 968
   017   THOMAIDIS TS          J PEDIATR                       63   444 963
   018   HODSON WJ             BR J SURG                       56   472 969
   019   SELIGER G             DIGESTIVE DIS                   27    10 972
   020   SHWACHMAN H           N ENGL J MED                   286  1300 972
   021   HOLSCLAW DS           PEDIATRICS                      48   442 971
   022   TAYLOR WF             AM J DIS CHILD                 123   161 972
   023   VALMAN HB             ARCH DIS CHILD                  46   805 971
   024   RICKHAM PP            IN: RICKHAM PP                       366 969
   025   MILUNSKY A            PEDIATRICS                      42   501 968
   026   LEE PA                JAMA                           228   585 974
   027   TINAZTEPE K           TURK J PEDIATR                  17    19 975
   028   CASTLEMAN B           N ENGL J MED                   288   570 973
   029   PORTA EA              AM J CLIN PATHOL                42   451 964
   030   ESTERLY NB            AM J DIS CHILD                 123   200 972
   031   FALCHUK ZM            PEDIATRICS                      51    49 973
   032   VALMAN HB             LANCET                           2   566 969
   033   KAPLAN E              N ENGL J MED                   279    65 968
   034   HOLSCLAW DS           BR MED J                         3   356 969

PN 75185
RN 00351
AN 75103651
AU Roth-S-S.  Roth-R-A.
TI Letter: Congenital absence of vasa.
SO Urology. 1975 Jan. 5(1). P 158.
MJ CYSTIC-FIBROSIS.  INFERTILITY-MALE: et.  VAS-DEFERENS: ab.
MN ABNORMALITIES: co.  CYSTIC-FIBROSIS: co.  HUMAN.  MALE.
   TESTICULAR-DISEASES: co.
EX Although it is generally true that most male patients with cystic
   fibrosis are infertile due to congenital atresia or absence of the
   vasal structures, this finding is not invariable.  Taussig et al.
   reported 2 well-studied patients with cystic fibrosis who had normal
   semen analysis, and at this writing both have fathered children.  A
   third patient with normal semen analysis also is known to us.  In
   addition there are many instances of presumed but undocumented
   paternity in these patients.  Cystic fibrosis centers estimate male
   fertility at 2 to 3 per cent; although low, this figure warrants
   semen analysis before assuming sterility.  In view of this, we feel
   that the diagnosis of cystic fibrosis should be considered when the
   vasa are absent, but it is incorrect to exclude the diagnosis on the
   basis of palpable vasa.
RF 001   TAUSSIG LM            N ENGL J MED                   287   586 972
CT   1   AMELAR RD             UROLOGY                          5   430 975

PN 75186
RN 00352
AN 75103652
AU Kornitzer-G-D.  Newton-R-A.
TI Letter: Cystic fibrosis and absence of vas deferens.
SO Urology. 1975 Jan. 5(1). P 158.
MJ CYSTIC-FIBROSIS.  INFERTILITY-MALE: et.  VAS-DEFERENS: ab.
MN ABNORMALITIES: co.  CYSTIC-FIBROSIS: co.  HUMAN.  MALE.
EX Infertility and abnormalities of the mesonephric derivatives are
   common in patients with cystic fibrosis, but it is not a uniform
   finding.  Taussig et al. reported on 2 patients with cystic fibrosis
   who had proved fertility.  Abnormalities of the vas could be
   documented in pathologic studies, but the vas was found to be present
   in some patients who died of cystic fibrosis.  In many patients,
   absence could not be ruled out on physical examination.  In healthy,
   young children the vas is not easily palpable; even when it is, the
   degree of certainty in its identification is less than in the
   post-pubertal male.  Cystic fibrosis is a disease with protean
   manifestations, and it would be a mistake to rule out cystic fibrosis
   just because the vas can be palpated or to have victims of cystic
   fibrosis labeled as infertile.
RF 001   TAUSSIG LM            N ENGL J MED                   287   586 972
   002   HOLSCLAW DS           J UROL                         106   568 971
CT   1   AMELAR RD             UROLOGY                          5   430 975

PN 75187
RN 00353
AN 75199860
AU Dajani-A-M.
TI Obscure bilateral calcified swellings of paratesticular tissues.
SO Urology. 1975 Jul. 6(1). P 101-4.
MJ CALCINOSIS: pa.  SCROTUM: pa.
MN CALCINOSIS: et.  CASTRATION.  CYSTIC-FIBROSIS: co.  HUMAN.  INFANT.
   MALE.  MECONIUM.  PERITONITIS: co.
AB A case of calcified swellings of the paratesticular tissues
   discovered in an infant at different ages is described.  The exact
   cause is obscure; and three pathologic conditions are suggested.
   Possibly it was due to an old reaction to meconium peritonitis
   through a patent processus vaginalis.
RF 004   OERTEL HB             JAMA                            49    32 907
   005   THANNHAUSER SJ        PHYSIOL REV                     26   275 946
   006   WILLIAMS G            BR J UROL                       51   332 969
   007   BERDON WE             N ENGL J MED                   277   585 967
   008   OLNICK HM             CITED IN: N ENGL J MED         277   585 967
   009   THOMPSON RB           J UROL                         110   364 973
CT   1   FOROUHAR F            AM J CLIN PATHOL                78   208 982

PN 75188
RN 00354
AN 75180144
AU Moss-A-J.  Dooley-R-R.  Mickey-M-R.
TI Cystic fibrosis complicated by heart failure.
SO West-J-Med. 1975 Jun. 122(6). P 471-3.
MJ CYSTIC-FIBROSIS: co.  HEART-FAILURE-CONGESTIVE: et.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: mo.
   FEMALE.  HEART-FAILURE-CONGESTIVE: mo.  HUMAN.  INFANT.  MALE.
   PULMONARY-HEART-DISEASE: et, mo.  TIME-FACTORS.
AB Survival studies were done on 36 children with cystic fibrosis and
   heart failure.  Thirty percent did not survive the first four weeks,
   and the median survival for the group was between two and three
   months.  By the end of the first year from the onset of failure, 74
   percent had died and at 30 months, 87 percent had died.
RF 001   WIGLESWORTH FW        AM J MED SCI                   212   351 946
   002   ROYCE SW              PEDIATRICS                       8   255 951
   003   GOLDRING RM           J PEDIATR                       65   501 964
   004   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   005   SIASSI B              J PEDIATR                       78   794 971
   006   MOSS AJ               MOD PROBL PEDIATR               10   187 967
   007   CUTLER SJ             J CHRON DIS                      8   699 958
CT   1   MATTHAY RA            BR HEART J                      43   474 980
     2   FRANCIS PWJ           AM J DIS CHILD                 134   734 980
     3   STERN RC              AM J DIS CHILD                 134   267 980
     4   MATTHAY RA            MED CLIN NORTH AM               65   489 981
     5   MOSS AJ               PEDIATRICS                      70   728 982
     6   LESTER LA             SEM RESPIR MED                   6   285 985

PN 75189
RN 00355
AN 75180411
AU Dominick-H-C.  Husen-N-V.  Hosemann-R.  Gerlach-U.
TI Isoenzymes of alkaline phosphatase in the serum of patients with
   cystic fibrosis.
SO Z-Kinderheilkd. 1975. 119(4). P 261-7.
MJ ALKALINE-PHOSPHATASE: bl.  CYSTIC-FIBROSIS: en.
MN ADOLESCENCE.  BILE-DUCTS: en.  BILIARY-TRACT-DISEASES: et, di.
   BODY-WEIGHT.  BONE-AND-BONES: en.  CHILD.  CHILD-PRESCHOOL.
   ELECTROPHORESIS-POLYACRYLAMIDE-GEL.  ELECTROPHORESIS-STARCH-GEL.
   ENZYME-TESTS.  FEMALE.  HUMAN.  INTESTINES: en.  ISOENZYMES: bl.
   LIVER-DISEASES: et, di.  LIVER: en.  MALE.
AB In 36 children with cystic fibrosis (CF), the isoenzymes of alkaline
   phosphatase (AP) were determined microelectrophoretically in
   polyacrylamide- and starch-gel.  The study was done to evaluate the
   clinical significance of these additional data for the diagnosis of
   liver involvement in CF.  The results lead to the following
   conclusions.  Serum activity of total AP is comparatively
   unsensitive "masking" alterations in the isoenzyme pattern
   contributing to the AP serum activity.  In 17 children resp. 47%
   bile-duct phosphatase was increased indicating a secretostasis
   while other marker enzymes of cholestasis were normal in part.  The
   activity of bone phosphatase in the serum showed a significant
   correlation to the degree of growth retardation in these patients.
   Intestinal phosphatase was present in the serum of only one child
   with cirrhosis of the liver being an indicator for liver
   insufficiency.  Determination of AP isoenzymes in the serum may
   provide additional information about the organs involved for the
   physician in handling CF patients.
RF 001   BAMBERGER CF          ARCH BIOCHEM BIOPHYS           123   195 968
   002   BATSAKIS JG           ARCH SURG                       95   138 967
   003   BAUMFORD KF           LANCET                           1   530 965
   004   BECKMANN R            ACTA HEPATO SPLENOL              6    65 959
   005   BODANSKY O            J BIOL CHEM                    118   341 937
   006   DI SANTAGNESE PA      PEDIATRICS                      18   387 956
   007   FANCONI G             WIEN MED WOCHENSCHR             86   753 936
   008   FEIGELSON J           PROC EWGCF 4TH ANNU MTG                  973
   009   FISHMAN WH            CLIN CHIM ACTA                  12   298 965
   010   GERLACH U             MED WELT                        21  1252 970
   011   HERZ R                ARCH BIOCHEM BIOPHYS            69   506 962
   012   HORNE M               J LAB CLIN MED                  72   905 968
   013   HOSENFELD D           MED KLIN                        67  1301 972
   014   VAN HUSEN N           MED WELT                        24  1510 973
   015   VAN HUSEN N           CLIN CHIM ACTA                  53    91 974
   016   KAPLAN MM             N ENGL J MED                   286   200 972
   017   KATTWINKEL J          J PEDIATR                       82   234 973
   018   KLEIN UE              GASTROENTEROLOGIA SUPPL        107   137 967
   019   KLEIN UE              CLIN CHIM ACTA                  16   163 967
   020   KLEIN UE              LANCET                           2  1396 968
   021   KLEIN UE              DTSCH MED WSCHR                 94   526 969
   022   KREISSL T             Z KINDERHEILK                  113    93 972
   023   MOSSER RH             AM J OBSTET GYNECOL             98   459 967
   024   MUCKE D               DTSCH GESUNDHEITSW              26  2418 971
   025   POSEN S               ANN INTERN MED                  62  1234 965
   026   RONCHI G              BEITR PATHOL ANAT              149   213 973
   027   SHWACHMAN H           PEDIATRICS                      46   335 970
   028   SITZMANN FC           MED KLIN                        67  1183 972
   029   SKILLEN AW            CLIN CHIM ACTA                  40    21 972
   030   SUSSMANN HH           J BIOL CHEM                    243   160 968
   031   SZASZ G               IN: BERGMEYER HU                     733 970
   032   SZASZ G               DTSCH MED WSCHR                 94  1911 969
CT   1   ALHADEFF JA           CLIN GENET                      10    63 976
     2   KRUSE K               EUR J PEDIATR                  126    53 977


